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1. Abstract
Ankylosing Spondylitis (AS) is the second most common form of inflammatory arthropathy 
after rheumatoid arthritis, affecting 1:200 men and 1: 500 women. Age at onset and severity 
are highly variable. The impact of sex and genetic transmission are poorly defined. Herein, a 
series of clinical, epidemiological and genetic studies explore these issues. The Bath 
National AS database (n= 5500) was used. 1) A new scoring system for radiographs was 
validated and implemented in order to examine the nature of progression in AS. 2) The 
influence of a) genetic and b) environmental variables on progression was examined. This 
involved an autosomal genome screen, a two year longitudinal study and control matched 
parent-child / sibling-sibling studies.
The data reveal: 1) Although symptoms begin in the mid twenties, the disease process may 
start as early as the first decade. The more severe the disease in the spine the more likely 
disease is to affect other areas, such as hips, skin, eyes and GI tract. 2 a). Severity is 
determined by genetics (chromosomes 13,18, 20, 21) and these genes are discrete from 
those determining susceptibility to AS (chromosome 6, 16). Furthermore, women carry 
more susceptibility factors and their children are more likely to develop AS and 
inflammatory bowel disease. The results from this study suggest that susceptibility genes 
may determine distribution of affected areas (eg bowel, skin, hip). However, severity genes 
determine the degree of inflammation in these areas. 2 b) Exercise, education and smoking 
may modify the activity of the disease (pain, function etc) but results show that radiological 
change appears to be an inherent phenomenon. These results pave the way for further 
research with the goal of modifying severity of AS. Future work should target the genes 
involved and identify their protein products, leading to improved prognosis for the first 
time.
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2. Explanation of terms used
Susceptibility to disease : Predisposition to disease
Susceptibility genes'. Genes which are associated with development of disease.
Severity o f disease : The impact that the disease has on the patient. This can be measured or 
defined in terms of outcome measures (ie amount of radiological change, function of patient, 
disease activity of patient, need for surgery etc) at a specific point in time.
Severity genes : Genes which may be associated with severity of disease. However, there is no 
current evidence that severity genes exist.
Interaction between severity and susceptibility genes : How these genes overlap or affect one 
another : It is not known 1. If severity genes exist 2. If susceptibility genes work by making 
the disease more severe and therefore are severity genes 3. If severity and susceptibility genes 
are independent and separate entities.
Course o f the disease/ progression o f AS/pathogenesis ofdisease/ evolution o f disease : How 
the disease develops on a population level.
Outcome : The measurement of severity. An end result at a specific time point. Mortality, 
function, disease activity, radiological change, and prevalence of secondary disorders may all 
be used to give outcome of AS.
Secondary Diseases: Iritis, psoriasis and inflammatory bowel disease are all concomitant 
disorders associated with AS.
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3. Outline of proposal
Ankylosing spondylitis is a chronic progressive inflammatory disorder affecting the axial 
skeleton and the peripheral joints. It is a condition which generally begins in the teens / early 
twenties and is unusual in that it is almost totally (95% in Caucasians) associated with one 
specific genetic marker (HLA-B27). However, AS is a polygenic disease. Therefore, there 
could be a great deal of interaction both between the different genetic components as well 
as between the genes and the environmental factors and this is likely to impact on the level 
of disease susceptibility and severity. There is marked individual variation in outcome and 
disease prognosis. Some individuals have minimal symptoms with only pelvic involvement, 
while others have widespread disease resulting in a curved spine and severe disability. There 
is no cure for the disorder. Moreover, it is uncertain if the long-term course of the disease 
can be altered. It is known that sex plays an important role in pathogenesis of disease with 
men having more severe axial disease. However, little is known on how genetic, sex and 
environmental factors interact to influence the disease course. Understanding the effects of 
these interactions will not only aid in the treatment of AS but also provide a model, which 
can be extrapolated to other polygenic inflammatory disorders.
3.1 Structure of investigation
This proposal is divided into two sections :
a) The nature of progression in AS : characteristics and disease evolution.
The validation of an existing radiographic scoring system in order to define the disease 
course in AS.
b) Genetic and environmental factors impacting on progression of disease.
The examination of how interactions between susceptibility and/or severity genes and 
environmental factors influence rate of progression in AS.
3.2 Hypothesis:
AS is an expression of both susceptibility genes and severity genes with environmental 
factors playing little part in disease outcome.
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3.3 Aims and Purpose of the investigation
This study aims to examine the inter-relationship between genetics, sex and the environment
in determining disease pathogenesis. Specifically to:
1. validate the Bath Ankylosing Spondylitis Radiology Index (BASRI).
2. describe the course of AS using BASRI in terms of radiological development and 
progression,
3. examine the relative contribution of genetics in terms of susceptibility and severity of 
disease.
4. to examine the relative contribution of environmental factors in terms of susceptibility 
and severity of disease.
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4. Background
4.1 Ankylosing spondylitis : a historical perspective
The term ankylosing spondylitis (AS) comes from the Greek words ankylos (bent or 
crooked) and spondylos (vertebra)[l]. AS has been with man throughout the ages. 
It has been found in Egyptian mummies [Amenhotep II ( Pharaoh in 1439-1413 
BC), Rameses the Great (1298-1232 BC) and his son and successor Memeptah] [2]
[3] and ancient tribes world wide. It has been identified as the condition which Saint 
Banus (355-395 AD) suffered from (named Father Palm Tree in local language due 
to his stooped posture), forcing him to eat and sleep standing for 18 years [4] .This 
condition was recognized as distinct from Rheumatoid Arthritis by Hippocrates as 
early as the second century [5] . However it was not until 1898 that an accurate 
description of AS was published. Pierre Marie [5] outlined AS both in terms of post­
mortem examinations of fusion and on patients posture and walking. Seventy five 
years later a major advance in understanding of AS occurred when it was shown that 
95% of Caucasian patients all had one gene in common, HLA B27. Yet, AS is not a 
condition only found in man, a disease very much like ankylosing spondylitis has 
also been described in prehistoric crocodiles, monkeys and in horses.
4.2 What is the course of AS
AS is the second most common form of inflammatory arthritis (after rheumatoid 
arthritis) affecting 1 in 200 men (0.5%) and 1 in 500 women (0.2%). In general it 
occurs in patients who are genetically susceptible and exposed to an environmental 
trigger. It is thought to begin in the sacroiliac joints and progress up the spine. 
However, cases of AS without sacroiliac joint involvement have been reported [6] 
[7] [8]. Even so, the diagnosis of AS requires sacroliitis of grade 2 bilaterally or 3-4 
unilaterally plus clinical criteria such as limited movement of lumbar spine, history 
of pain, limited chest expansion. However, 1.5%-10% of patients may be 
asymptomatic [9] . In addition, it could be argued that in the early stages plain 
radiographs are insufficient to detect changes in the sacroiliac joints [and other 
unrelated conditions such as tuberculosis, SAPHO syndrome, systemic lupus 
erythematosus, gout [10] or paraplegia [5] may also cause sacroliitis]. Mild disease
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may never reach the threshold level of damage needed to achieve diagnosis. Women 
have milder disease than men in terms of radiographic change [1] and this may mean 
that it is the women who are less likely to be diagnosed. Thus, reports that the 
disease is less common in women could simply be a fault of the diagnostic criteria. 
All current research uses patients diagnosed under the New York Criteria and this 
might mean that many of the findings on AS are based on moderate and severe cases 
with a higher ratio of men than women. This will not only impact on our estimates 
of the incidence of AS but also presents a biases that research findings may only be 
based on the advanced diseased patients. Mild and early AS may not be studied 
under today’s criteria. More importantly the criteria for classification have been 
developed for Caucasian patients and may not have been applicable to non- 
Caucasians.
The course of the disease differs among individuals but it also differs from country 
to country. It occurs at a younger age in developing countries. Juvenile AS [JAS] 
affects a greater proportion of patients in Mexico [11] , India [12] , and North 
Africa [13] than among European or American patents. JAS in general is associated 
with first symptoms in the knee or lower limbs. [14] Therefore, this means a greater 
proportion of patients in developing counties present with lower peripheral joint 
involvement. Ankylosing spondylitis is indigenous in Mexico and was present before 
European people arrived. [15] The knee, midtarsus and ankle are more frequently 
involved among these Mexican patients, but this condition is rarely associated with 
psoriasis. Yet, psoriatic arthritis is one of the most common forms of spondyarthritis 
(SpA) in Southeast Asia [16] . Thus, the type of clinical symptoms associated with 
AS do differ depending on country, whether this is ethic background or 
environmental differences is not clear. However, a severe outcome is more common 
in developing countries. For example, in Pakistan there was worse disease activity 
and function compared to an equivalent British Cohort [17] and in North Africa a 
higher proportion of patients have juvenile onset and suffer from peripheral arthritis, 
hip involvement, enthesopathies and are less likely to have axial changes than 
western patients [18]. A study in Morocco showed patients have more severe 
disease accompanied by hip involvement [19]. On the other hand in sub-Saharan 
Africa ankylosing spondylitis is extremely rare. In these patients (n=29) there was an 
older age at onset (age 32 years), no family history or psoriasis or iritis or
inflammatory disease [20]. Similarly, the prevalence of AS in Japan is very low at a 
rate of 2 per 100 000 [21] while prevalence in China is 2 per 1000 [22]. Among the 
Chinese patients there was more peripheral involvement but less iritis than in 
western countries and extra-articular manifestations are rare [23]. Patients in Saudi 
Arabia show a mean age of onset of 23.4 years, a positive family history in only 13 
% of patients and iritis in 7% . Thus, the disease appears to be rare and shows a mild 
course with few complications.
Clearly the clinical pattern of disease can be influence by a number of factors 
including race, sex, age at onset, and associated conditions. In addition, differences 
in referral and follow-up practices and availability of rheumatology expertise and 
relevant resources may also explain some of the variation.
In western patients there is lower than normal bone density in early or mild AS. This 
early osteoporosis/osteopenia may result from disease specific inflammatory and 
cytokine-induced changes [24][25][26][27][28] . As the disease progresses greater 
than normal bone density (compared to controls) is observed as fusion takes place 
[28] [30] (although there may be continuing loss of bone from specific areas of the 
skeleton). The fusion will spread from the lumber spine up to the neck. The hips and 
peripheral joints may also become involved. However, it is possible that the fusion 
is in fact a protective mechanism of the body protecting against fractures due to the 
osteoporosis [31]. Although AS is described as a chronic condition it may be 
argued that it is really an acute disease with many changes in the beginning but little 
active inflammation later. There are no reliable inflammatory markers. Erythrocyte 
sedimentation rate (ESR), plasma viscosity and C-reactive protein (CRP) are not 
abnormal in many patients with active disease [32] [33][34]. Other measures, such 
as such as IL-6, are found to be increased in the majority of patients with AS, but 
there is no correlation between IL-6 and disease activity [35] . The main symptoms 
of the condition are pain, fatigue, morning stiffness, tenderness, discomfort which 
can be measured by the Bath Disease Activity Index [BASDAI] [36] [Appendix 1] 
(this consists of 6 questions assessing on a 10 point scale the level of activity of 
disease). In defining outcome various approaches have been taken, culminating in 
the development of an international group (ASAS) formed to evaluate the best end­
points for use in AS [37] [38] . The domains selected for measurement were: 
physical function, pain, spinal mobility, peripheral entheses, spinal radiograph and
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patient global assessment. For function either the Bath functional index (BASFI) [a 
0-10 scale (with 10 being the worst function and 0 being normal) assessing 10 
aspects of daily function)] [39] [Appendix 1] or Dougados functional index (FI 
Dougados)[40] may be used. While for pain measurement two 100mm visual 
analogue scales (VAS) , one for night pain and the other for general pain are 
employed. The patient global assessment would be a VAS such as BAS-G [41] 
[Appendix 1] which consists of two question assessing patients global well-being 
over a 1 week or 6 month period.
These are all aspects of the disease which may only be measured by patients 
subjective reports. There are very few objective and independent measures of the 
activity or severity of AS. For example, when disease activity is reported to decline 
as the disease progresses [42] it is possible that some of this decline may simply be a 
result of patients adaptation to living with the disease. Thus, psychological and 
social factors might affect these self assessment measures of AS.
A more objective approach would be to examine the disease in animals. The 
transgenic rat model develops a spontaneous inflammatory disease involving colitis 
and arthritis. For this condition to occur, T cells, gut bacteria (normal bacterial 
flora) and a high expression of B27 are needed. [43] . The earliest clinical 
manifestation is diarrhea which 100% of rats develop. The rat develops bowel 
disease, which is associated with increased production of cytokines, nitric oxide and 
myeloperoxidase. Most rats then develop peripheral arthritis, sacroiliitis and 
spondylitis with skin and nail changes appearing later. However, rats held in a 
germfree environment showed no evidence of gut or joint inflammation. Once the 
germfree rats are exposed to normal gut flora the entire disease process returns [44], 
Transgenic mice with the HLA-B27 gene are more susceptible to bacterial infection 
than mice without the gene. [45] However most importantly, for the rat or mouse to 
develop any symptoms of AS a large number of copies of B27 are needed (ie gene 
copy number and level of expression of B27 is important for susceptibility). In 
addition, the strain of animal (ie genetic background) exerts a strong influence.
4.3 What causes AS ? : a) Genetics
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A genetic susceptibility to disease is the first major contributor to developing AS. 
The link between HLA B27 and AS has been recognised for 25 years [46] [47]. 
This B27 association is consistent with a dominant or additive mode of inheritance. 
[48] There also exists weaker associations between this antigen and uveitis [49] [50] 
[51] and inflammatory bowel disease [52] [53]. The prevalence of AS world-wide 
varies within the different races, with frequency roughly following the distribution of 
HLA-B27. For example, B27 is absent among the Australian aborigines, and they do 
not suffer from AS. [54] The highest prevalence of both ankylosing spondylitis and 
B27 is found among the native American Indians (Haida, Pima) [54] [55] . It is also 
highly prevalent among the indigenous populations of the circum-polar regions [56]. 
This high frequency of the antigen may be explained by the finding that it is 
advantageous in generating viral specific immunity. For example, HIV infection 
progresses more slowly in HLA-B27 individuals [56]. Thus, it has been suggested 
that the reason the native American Indians have such a high presence of B27 is 
because these are the descendants of the people who survived small pox or other 
European viruses when the Spanish first arrived Moreover, the overrepresentation 
of B27 concordance among dizygotic twin pairs suggests a survival advantage for 
this gene. [57] Approximately 10% of all B27 positive subjects develop AS.[58] 
[59] [60].
Why do only some people with B27 develop AS ?
It has been shown that the risk for developing the disease is 16 times greater in the 
HLA B27(+) relatives of AS patients than HLA-B27 (+) individuals of the 
population at large [58] [60]. In addition, as discussed above, in animal studies of 
B27(+) transgenic rats, the background strain of the rat will influence disease 
penetrance of the arthritis [61]. This indicates that the B27 antigen is important in 
developing AS but it is not sufficient by itself for the development of disease. For 
example, among the Fula ethnic group in The Gambia the gene B27 is nearly as 
common as among Caucasians. However, AS is extremely rare. This population may 
lack additional non-B27 susceptibility factors [62] . Conversely in a Lebanese 
population of 19 AS patients only 5 (26%) were B27 positive [63] and among a 
Zimbabwean population only 1 in 8 (13%) AS patients were B27 positive. [64] [65]
. Therefore, non-B27 disease predisposing factors play a strong role in susceptibility
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to disease in these populations. This suggests that, in Western populations where the 
B27 gene is prevalent there is a strong and characteristic association between this 
gene and AS. However, non- B27 susceptibility factors also exist and can cause 
disease. In populations of low natural prevalence of B27 then these additional 
factors form an important component in predisposition to AS.
Other genes linked to AS
The HLA genes are within the major histocompatibility complex on Chromosome 6 
[see figure 1], they encode molecules involved in recognition within the immune 
system. The class I molecules (such as those encoded by HLA B27) are involved in 
response to virus-infected cells and tumours. Class II molecules are expressed on 
specialised antigen-presenting cells (B lymphocytes, macrophages etc) and they act 
to stimulate antibody production and are involved in cellular responses. In addition, 
other loci within the major histocompatibility complex have immunological functions 
(cytokines, molecular chaperones etc) which potentially may be involved in 
influencing AS.
HLA B60 (a split of B40) increases susceptibility to AS in B27 positive [66] [67] 
and negative subjects [68]. It is believed to act in a synergistic manner with B27, 
increasing risk in the B27 / B60 positive individuals by a factor of three [69] . 
However, this is not confirmed by all studies [69] [70] [71] . Other HLA-B alleles 
which may have a role in susceptibility include HLA-B49 [69] , HLA-B 16 [72] , 
HLA-B39 [73] [74] and HLA-B22 [75]. In addition, the genes of the class II 
molecules are speculated to have a role in susceptibility but again, studies have 
yielded conflicting results. HLA DR1 has been reported to increase risk of AS [71] 
[76] [77] albeit with only a minor effect [57] . DR4 may be associated with 
peripheral arthritis when AS is present [78] and DR2 has been reported to have 
similarities of peptide presentation with B27 [79] and has been associated with 
susceptibility to AS [80]. However, unlike the clear repeatability of the B27 
association, the DR susceptibility effects are not consistently observed. For example, 
DR 8 may be important for the development of uveitis (iritis) in Japanese patients 
with AS [81], while Mexican and Norwegian studies do not support this finding. 
Nevertheless, the gene did influence other aspects of phenotypic expression, such as 
age at onset [82][83]. Another HLA class II gene (LMP2) may be the risk factor for
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uveitis [84][85] and it is known that there is linkage disequilibrium between the DR 
8 and LMP2 genes [86]. However, among a white Caucasian population the role of 
LMP2 in is not supported [87], It is thought that non-HLA B27 alleles play a more 
significant role in the clinical expression of disease in Mexican patients [88] Thus, 
similar genes may have different roles depending on the ethnic background of the 
individual and perhaps environmental factors.
There is evidence of protective effects from certain subtypes of genes. For example, 
tumour necrosis factor encoded within the Class in region of the MHC may have 
alleles (TNF308 and TNF238.2) which have a protective role [89]. In addition, B35 
is found in higher numbers than expected among unaffected relatives of AS patients
[90]. Two subtypes of the B27 genes, B2706 and B2709 appear to be protective
[91][92][93]. However, in the presence of the pathogenic B2704 subtype, the 
protective effects of B2706 are overridden. [94]
The presence of susceptibility (and perhaps protective genes) outside the MHC is 
supported by family and twin studies. The contribution of the MHC genes 
collectively has been calculated to be 50% or less of the total genetic contribution to 
the disease [57][67][95]. The T-cell receptor genes are on chromosome 7 and 14, 
and the T-cell receptor B locus may be involved in susceptibility [96]. In addition, it 
has been suggested since 1973 [97] that the susceptibility genes of the concomitant 
disorders (inflammatory bowel, psoriasis and iritis) associated with spondylitis may 
also act as susceptibility factors for AS. This hypothesis is supported by the finding 
that B27 negative patients suffer more psoriasis and inflammatory bowel disease [98] 
Thus, AS is clearly a polygenic disease, with many of the genes interacting. The 
phenotypic expressions depend presumably on the presence or absence of other 
genes.
Strikingly, a low prevalence of SpA can change abruptly as shown in sub-Saharan 
Africa with the advent of HIV & AIDS. In addition, studies of identical twins reveal 
disease concordance in only 50%-70% of pairs suggesting that not all of the 
susceptibility influences come from the genes, interaction with the environmental 
must also be taken into account.
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b) Environment
Identical twin studies have shown even in patients with susceptibility to AS, the 
disease does not always develop. AS needs to be triggered by an environmental 
stimulus. This trigger is likely to be a bowel or urinary tract infection since many 
reactive arthropathies such as Reiter’s Syndrome which are within the 
spondyarthritis family, are triggered by a bowel or genitourinary infection. [1] In 
addition, over 50% of patients with documented AS who underwent an 
ileocolonoscopy had evidence of inflammation of the bowel. [99]. In fact, gut 
inflammation is frequent in patients with spondylarthropathy, a quarter of whom 
have early features of Crohn’s disease [52] . In addition, recent studies have 
indicated that the gut has a role in the severity of disease [101]. Among patients and 
their first-degree relatives there exists altered small intestine permeability which 
could possibly be genetically determined and may precede the development of bowel 
and joint symptoms. [102] Perhaps the strongest evidence for a environmental 
trigger comes from the HLA transgeneic rat. These animals develop bowel 
inflammation followed by arthritis, but if the rat is maintained in a sterile 
environment neither the inflammatory gastrointestinal disease, nor the arthritis 
develop. However, there is much debate as to which bacteria are involved. For 
example, the role of Kebsiella remains unknown [103]. The isolation of Kebsiella 
from patients with inactive disease was associated with a flare 2-3 months later, and 
it is claimed that bacteria may exacerbate disease [104]. AS patients have also been 
found to have elevated levels of antibodies against bacteria such as Klebsiella [105] 
The connection between the genetic and bacterial triggering agents is thought to lie 
in the way B27 is expressed. B27 is unique in binding poorly with P2-microglobulin 
(normally associated with class I molecules as they are assembled in the endoplasmic 
reticulum to be transported to the cell surface). Thus B27 positive individuals may 
have two forms of the B27 molecule: the normal B27~p2-microglobulin associated 
molecule, and the globulin free molecule. The latter have a low affinity for T cells. 
Thus, during the process of T cell selection, the T cells which recognise this 
molecule will not be identified as self/auto-reacting cells. These self-cells will not be 
deleted and destroyed. Several bacteria have sequences similar to those of
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B27[107]. A bacterial infection will expand the T cells with the specificity for 
recognising self-B27 cells, initiating inflammation [56].
Yet, for every study identifying the role of specific bacteria, there are as many 
studies which have not found a link between gut flora and AS. [108][109] For 
example, it has been shown that when 82 AS patients were compared to 36 healthy 
controls there was no difference in faecal flora in terms of isolation rate of 
Klebsiella or other arthritogenic organisms [110]. However, it could be argued that 
the trigger is present at the beginning of the disease process but there is no reason 
why it should remain after this time. Thus, the absence of Klebsiella or other 
arthritogenic organisms among long term AS patient does not rule out its role as a 
trigger. In addition, the high frequency of juvenile-onset disease in developing 
countries may be a result of high incidence of infection in childhood. [111]. Support 
for this theory comes from findings that hip disease (which is more prevalent among 
juvenile onset patients in Morocco than among patients in France) is associated with 
environmental factors such as ‘no running water in the home* in Moroccan AS 
patients. [112] Therefore, these data suggest that regardless of clinical status, gut 
infection may be the initial trigger for the immune response which leads to 
spondylitis. However, the putative triggers are likely to be common pathogens and 
not easily eliminated from the environment of susceptible individuals. It is also 
possible that there is not one trigger initiating AS, but instead a cascade of different 
bacteria, and each assault is progressively dealt with less well by the susceptible 
individuals. Thus, any gut pathogen with sequences similar to B27 or other 
susceptibility genes (and there are several bacteria of this type) may act as a trigger 
for the inflammation leading to AS.
4.4 Why is the disease in some patients severe and others mild ?
Many interlinking and overlapping variables affect severity of AS. For example some 
of the factors found to influence outcome include: dietary habits and a peripheral 
pattern of arthritis, which impact on the disease activity of AS (pain, fatigue, 
discomfort, morning stiffness etc) [106][113] . Smoking [114] is associated with 
worse clinical, functional and radiological outcome. Patients in the low 
education/occupational group have greater disease severity and poorer prognosis 
than those with higher occupational status [115][116]. Disability is more frequent
15
after heavy physical work or labour involving exposure to cold conditions, while 
sedentary work and vocational rehabilitation programs protect against long-term 
disability. [117] Cessation of work due to AS, before retirement age is associated 
with female sex, low education levels, uveitis and coexistence of non-rheumatic 
diseases. [116] Progression of disease is slowed by daily exercise [118], with women 
and younger patients showing most improvement [119].
However, it is difficult to separate the effects of one variable from another. For 
example, the influence of smoking may actually be a reflection of social status, 
occupation (manual labour) or lack of exercise.
In addition, other predictors of severity such as; hip disease [120], peripheral joint 
involvement and gut inflammation [106] may point to a genetic rather than 
environmental component. One study using clinical entry variables to predict long 
term outcome identified severe disease as being associated with the presence of: hip 
arthritis, ESR>30mm/h, sausage-like finger or toe, oligoarthritis, onset < 16  years, 
limitation of the lumbar spine and poor efficiency of nonsteroidal anti-inflammatory 
drugs. [121] However, clearly here, there is a risk of circular reasoning with those 
already doing badly destined to do less well.
Trauma, or immobilisation due to injury has been implicated in precipitating AS. 
However, it may be that immobilisation might bring the already existing disease to 
the patent’s attention. [122] Associated with this is the realisation that the onset of 
AS symptoms may not necessarily indicate the beginning of AS. Conceivably, the 
time when the trigger is pulled may precede symptoms by years or even a decade. 
Thus, pain, function and progression of AS may be influenced by inter-related 
factors such as education, occupation and exercise. However one of the most 
important factors in determine severity of AS is sex.
Hormones as an environmental effect on severity
There exists an obvious and dramatic difference in susceptibility and severity of AS 
between the sexes. Men are 2.5 times more likely to suffer from AS [123]. Most 
studies suggest that most of the diseases associated with B27 (eg. Reiter’s disease, 
AS, PsAS) occur much more commonly in men. [124] Women have milder disease 
in terms of axial involvement although extra-spinal manifestations such as hip 
involvement and iritis occur in equal frequency to men. [125][126] Pregnancy does
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not influence the overall course of AS. However, peripheral arthritis and anterior 
uveitis occurred less frequently during pregnancy compared to the 6 months post 
delivery. [127]
In general, symptoms of AS are uncommon before puberty, but rapidly increase in 
incidence during the teen and young adult years. Conceivably, testosterone levels 
play a role in AS, male patients have higher testosterone levels than average 
[128][129][130]. Moreover, the MHC of the mouse has been shown to encode 
genes which are responsible for regulating testosterone [131]. HLA susceptibility 
may be modulated by differences in circulating sex hormone levels. However, when 
corrected for confounding variables (serum extraction to eliminate interference with 
water-soluble substance such as phenylbutazone) the elevated testosterone levels are 
no longer seen in AS compared to controls. [132][133] [134] In addition, it is not 
clear what the effect of pain from a chronic disease will have on hormone levels. 
Hormone levels may have an influence in AS but measuring their levels and showing 
their effect on an inflammatory disease such as AS is difficult.
4.5 Aspects of the disease which remain unknown.
It is not know when the disease process of AS actually begins. In some patients at 
least there is asymptomatic radiological change [9] . Thus , the onset of symptoms 
may not actually be the time of onset of the disease for many patients. When the 
disease onset occurs may be at the time of exposure to the trigger. Alternatively 
there may be a latent period between the timing of the trigger and first disease 
specific change. The cascade of environmental triggers may begin as early as in 
utero. If this were the case then a mother with AS may be exposing her genetically 
susceptible child to the triggering agents as an embryo. There may be different 
forms of AS. Women may have a different type of disease (ie less severe axial 
involvement but more peripheral change) which is passed on to her children. Patients 
with hip disease or a family history may have a different expression of disease than 
sporadic or non-hip patients. There may be some predictors (environmental or 
genetic) to suggest which form of AS the person will develop. Most importantly it 
is not known what effect the susceptibility genes such as B27 and B60 have on 
outcome. People who are diagnosed easily may be the most severe and appear the
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most susceptible. Perhaps susceptibility genes also determine severity. These are the 
aspects of the disease which will be specifically targeted within this study.
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Figure 2: Factors affecting Ankylosing Spondylitis
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5. Rational of proposal
The hypothesis that AS is an expression of both susceptibility and severity genes with 
environmental factors playing little part in disease outcome is explored in this project.
1. The natural progression of disease is examined by validating and implementing a 
radiographic scoring system.
2. The extent to which this natural disease course is determined by genetics or 
environmental factors is assessed.
5.1 The nature of progression in AS
A number of measures (ie. metrology, function, global well-being and disease activity 
indices) are used simultaneously by researchers and clinicians to monitor outcome in 
spondylitis. However, the comparison of individuals with AS is often difficult as many of 
the measures are subjective (ie pain, fatigue and movement). To determine the natural 
course of disease it was felt that a fixed and objective measure was needed. Radiographs 
can represent an unbiased, ‘gold standard* for the measurement of disease status. In 
addition, they are generally available on most patients, as they are required within the Rome 
and New York Criteria for the diagnosis of AS. However, to date the existing measures 
using radiographs are time consuming to use, do not include the entire spine or address hip 
involvement and have been shown to be insensitive to change [135][136]. Little work has 
been done to assess disease progression in radiological terms. Mackay et al developed a set 
of criteria for a new radiology score in 1996 [137] but this has not been validated. Thus, 
this study will validate and implement this measure of
(a) assessing spinal and hip disease thereby creating the opportunity to describe the 
progression of AS in an objective way.
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(b) A general description of the disease course and development of spondylitis will be 
presented (eg average change in disease per year [linear or sigmoid progression]) using the 
new radiology measure.
A description of the disease course among subsets of AS patients (ie male/ female and hip/ 
non-hip) will be offered using the new radiology measure.
This section of the work will then allow an investigation into what influence genetic and 
environmental factors have on the rate of this disease development and how they affect the 
natural history of AS.
5.2 (a) The influence of genetic factors:
The hypothesis (see page 4) is that the expression of AS may result from a combination of 
severity and susceptibility genes. The study will explore the relationship and overlap 
between these two types of genes.
(i) Secondary disorders: As reported earlier, B27 negative spondylitis patients are more 
likely to have concomitant disorders (psoriasis or IBD). This suggests that the secondary 
diseases associated with AS (inflammatory bowel disease, psoriasis, iritis) may share 
susceptibility genes with AS. These genetic factors may be additive or have synergistic 
effects on one another. The genes themselves may have effects in modulating disease 
expression of the AS. Thus, the hypothesis, that there are shared over-lapping genes 
between AS and the associated inflammatory conditions (iritis, psoriasis, inflammatory 
bowel disease), will be investigated by the study.
21
(ift Susceptibility genes: The susceptibility genes which have been identified (ie B27, B60 
and DR alleles) may not be ‘pure* susceptibility markers but may also have a severity effect. 
The study will investigate the impact of established susceptibility genes on severity.
(iii) Age of onset: Similarly, patients with a young age at onset who have an increased 
number of genetic susceptibility markers may have a different disease expression than late 
onset patients (who may carry fewer susceptibility genes but more severity genes). These 
cohorts will be compared within the project.
(iv) Sex: It is known that disease prevalence differs between men and women. There are
2.5 men affected for every woman with disease. This difference may be due to genetic 
factors in the sex chromosomes. If this were the case then there should be a difference in the 
sex ratio of children who inherit the disease depending on the sex of the affected parent, (eg 
an X chromosome susceptibility gene will always be passed on by an affected father to the 
daughter but not to their sons). The study will investigate the sex ratio of affected children 
of parents with disease.
(v) Inheritance of phenotypic expression: Assuming that the combination of severity to 
susceptibility genes creates the clinical expression of disease and women develop the disease 
less often (compared to men). Then, women should require more susceptibility factors than 
do men to develop disease. Thus, the children of women with AS should inherit a higher 
proportion of susceptibility genes (and less severity genes) than offspring of men. This 
higher susceptibility may influence outcome. By comparing the expression of disease in 
children inheriting the disease maternally as opposed to paternally, the affect of these 
susceptibility factors can be investigated.
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(vi) Concomitance of disease among affected relatives: Little is known about factors 
influencing outcome. A comparison of the expression of disease in parent-child and sibling- 
sibling pair should aid in understanding the extent to which disease expression is inherited. 
Eighty percent of AS patients have sporadic disease (ie no previous member in their family 
with spondylitis) and 20% have a family history of the condition (ie have other relatives 
with AS). It is feasible that these may represent two slightly different forms of the disease. 
Those with a family history may have more susceptibility factors but milder disease (hence 
its ability to be transmitted). A comparison of familial and sporadic disease will further 
examine the interaction between susceptibility and severity factors.
(vii) Identification of loci associated with severity:
Greater similarity of disease severity is observed in monozygotic compared with dizygotic 
twins, although no individual severity measure achieved statistical significance [57]. 
Collaborative work with The Wellcome Trust, Oxford suggests there may be a recessive 
genetic model for influencing disease activity and function. Further work into forming this 
model will involve identifying the loci which are associated with variation in severity 
measures.
Thus this section of the study investigates the over-lap of severity and susceptibility genes 
and the contribution that genetic factors play in outcome of AS.
5.2 (b) The influence of environmental factors
Little is known about how environmental factors influence severity. Herein factors such as 
entry variables (ie education, area of first symptom, smoker etc) and exercise are explored 
and their impact on outcome is examined.
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(i) Exercise: How much exercise patients do on a regular bases will be evaluated.
Demographic and clinical variables that might influence adherence to exercise will be 
examined.
(in Phvsiotherapv/education: A 2 year longitudinal follow-up of the patients attending the 
Royal National Hospital for Rheumatic Diseases will be performed. The long-term 
improvement gained by exercise therapy will be evaluated.
(iii) Entry variables: The natural history of AS in the individual is poorly defined and there is 
a great deal of individual variation in terms of prognosis. It is possible that demographic 
factors with which the patient presents can be used to predict long term outcome [121]. 
Taking the disease index scores (ie BASRI [radiology], BASDAI [disease activity], BASFI 
[function]) of patients now and correlating with presentation as defined by the patients 
demographic characteristics (such as; smoker, occupation, education level etc.) may give an 
indication of factors associated with a severe prognosis.
(iv) Birth Order: HLA-B27 transgenic mice with a lower birth order have an increased 
prevalence of ankylosing enthesopathy. If the same were true in humans, an environmental 
explanation (such as a lower incidence of childhood diseases among the first bom children) 
would be implied. The study will examine if the AS patient is more likely to be a first bom 
child.
The disease course will be investigated using a newly validated outcome measure. The 
relative overlap and role of the severity vs susceptibility genes in progression of AS will be 
examined along with the effect of environmental variables such as exercise and demographic 
details in the prognosis of disease [Figure 3]
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Figure 3: Genetic and environmental factors influencing susceptibility and outcome in ankylosing spondylitis:
-The validation of an objective measure (BASRI)
-Description of progression in ASGenetic influence Environmental influence
Characteristics and disease progression
Overlap between severity and 
/or susceptibility genes.
- Secondary diseases
- Severity effect o f ‘susceptibility’ genes
- Age at onset 
-Sex and inheritance
- Sex and severity
-Disease concordance among family members






6. Methods and Results
6.1 The nature of progression in AS: characteristics and disease evolution.
In order to determine the history and characteristics of disease development in ankylosing 
spondylitis an objective scoring system was needed. Thus, the Bath Ankylosing Spondylitis 
Radiology Index (BASRI) was validated to provide this measure for this study. However, 
patients with hip disease represent a small and distinct subset of individuals and hip disease 
is more difficult to quantify and validate than spinal disease. This is because of the difficulty 
distinguishing between AS hip changes and those of osteoarthritis. Therefore, the two 
regions of disease (ie the index for spinal disease and the index documenting hip disease) 
were validated and described separately. The BASRI -spine [BASRI-s] describes spinal 
status, BASRI-hip [BASRI-h] describes hip involvement and BASRI-total [BASRI-t] 
describes the combination of these two indices. Using these indices the general disease 
evolution of AS will be determined and the differences between sub-sets of patients such as 
male /female, and those with hip disease/non-hip will be examined.
6.1 (a) The validation of BASRI
(i) The spine :
Objective: To validate the scoring system for spinal involvement devised by MacKay et al. 
[138] This system should be reproducible, simple and quick to use, incorporate the entire 
spine (anteroposterior & lateral) and pelvis and be sensitive to change. The discriminating 
features of each radiological severity group were defined by 3 experienced readers [138] 
[Appendix 2].
Methods: Radiographs of 188 consecutive patients with AS and 89 without AS were scored 
randomly and blindly by 3 readers to validate the BASRI. Two hundred and sixty-three SI 
joint, 160 lumbar spine and 145 cervical spine radiographs from the AS cohort were scored,
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assessing intra and interobserver variation using a kappa statistic (as data tended to cluster 
towards worse disease).
Sensitivity to change over time was determined by scoring serial radiographs of 58 patents, 
assessing 177 time intervals of 1,2,3 and 4 yrs. Radiographs were obtained on 2 occasions 
for each individual. The two time intervals were separated by 12, 24, 36 or 48 months. 
They were available on 20, 31, 28 and 23 individuals respectively. All radiographs were 
blinded as to the date of radiograph and a Wilcoxon signed rank test for nonparametric data 
was used to determine the earliest point at which sensitivity to change became apparent.
The specificity and positive predictive value against other rheumatic conditions was 
assessed using 305 radiographs from the AS cohort and 78 radiographs from 89 non-AS 
patients. Radiographs of non-AS patients were interspersed with the AS patient’s films, 
such that readers were unaware of the diagnosis. A cut-off of grade 2 (definite) disease was 
used and all radiographs were then classified into one of two groups, those with and those 
without AS changes. The SI joints were not viewed at this point.
The non-AS cohort consisted of consecutive outpatients who were attending the Royal 
National Hospital for Rheumatic Disease and who had cervical and lumbar spine 
radiographs obtained for evaluation of symptoms. The mean age was 57.9 +/- 16.8 yrs and 
the sex ratio was 1:3 (males: female). This cohort included 41 patients with rheumatoid 
arthritis, 21 with mechanical back pain, 10 with fibromyalgia, 10 with osteoporosis and 7 
with psoriatic arthritis.
Results: Intraobserver variation. Two hundred blinded SI joint radiographs were assessed 
twice by a single observer, with 86% complete agreement, giving a kappa score of 0.69. 
Results for the lumber and cervical spine showed 75% complete agreement, with kappa
0.65 and 81% complete agreement with kappa 0.73. The main errors were reading the SI 
joint as grade 3 rather than grade 4 on 12/200 (6%) of cases [Figure 4] and distinguishing 
suspicious (grade 1) from mild (grade 2) disease in the cervical spine in 5 cases [Figure 5].
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Figure 4
Plain radiograph o f SI joint demonstrating errors in distinguishing Grade 3 (moderate) from Grade 4 (severe)
Variation of >1 grade occurred only twice when scoring the lumbar spine and never when 
scoring the SI joints or the cervical spine.
Interobserver variation: Reproducibility between two readers was assessed using 
261 SI joint radiographs scored by each assessor on separate occasions. There was 78% 
complete agreement between observers, with kappa score of 0.55. The 160 sets of lumbar 
spine radiographs used reached 73% complete agreement (k = 0.64) and the 145 cervical 
spine radiographs reached 79% complete agreement (k =0.69) Both the lumbar and cervical 
spine scores outperformed the established NY criteria for SI joint assessment. Difficulty in 
separating grades 3 and 4 existed in SI joint assessment (8 occasions)[Figure 4], while 
distinguishing mild from suspicious disease was the main problem for the lumber and 
cervical spine scoring (5 occasions). Discrepancies of >1 grade occurred while scoring the 
SI joints in 3 of 263 films, the lumber spine in 5 of 160 films, and the cervical spine in 10 of 
145 radiographs.
Disease specificity: Specificity for the lumbar spine was 0.89, and that for the 
cervical spine was 0.83. The positive predictive value for the lumbar spine was 0.97 and that 
for the cervical spine was 0.95.
Sensitivity to change: Using Wilcoxon’s signed rank test for nonparametric data, 
the BASRI-s demonstrated a significant change in radiological score (p<0.001) at 24 
months for the SI joints, the lumbar spine, and the cervical spine. Where the time interval 
between radiographs was 12 months, 30% of cases showed changes of at least 1 grade 
within this period, but this is not statistically significant (p<0.07).
Interpretation o f the study: The BASRI was reproducible, with intra- and interobserver 
variations equivalent to those of the NY criteria. The main problem for grading the lumbar 
and cervical spine was distinguishing suspicious disease from mild disease on 5 occasions 
because of difficulty in determining whether squaring of the vertebra was present. A
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Figure 5
Plain radiograph of cervical spine demonstrating errors in distinguishing Grade 1 (suspicious) from Grade 3 (fusion)
potential method of overcoming this problem for the spine would be to measure each 
vertebra individually (in cases where distinguishing the grade is a problem) to determine the 
presence or absence of squaring as done in the method described by Ralston et al [136]. 
The BASRI was found to be sensitive to change over a 2 year period, which suggests that 
radiographs at intervals of <2 yrs for either routine or study purposes are not warranted. To 
maintain simplicity, the BASRI does not pick up minor radiological change. However, by 
not differentiating between grades such as bamboo spine and >3 vertebrae fused, the score 
does suffer from a ceiling effect. Yet, the lack of radiological progression to severe spinal 
disease in the majority of cases suggests that the potential ceiling effect is of little 
consequence. The BASRI fulfils the OMERACT (Outcome Measures in Rheumatoid 
Arthritis Clinical Trials) filter goal: truth, discrimination and feasibility [139].
31
Table 1: Validation ofBASRI-spine
Radiographs (number) Kappa
Intraobserver variation Sacroiliac joints 263 0.69
Lumbar spine 160 0.65
Cervical spine 145 0.73
Interobserver variation Sacroiliac joints 263 0.55
Lumbar spine 160 0.64
Cervical spine 145 0.69
Specificity
Specificity Lumbar spine 188 (AS) vs 89 (non-AS) 0.89
Cervical spine 188 (AS) vs 89 (non-AS) 0.83
Sensitivity Lumber & Cervical spine & 
sacroiliac joints
12 months 20 p<0.07
24 months 31 p<0.001
36 months 28 p<0.001
48 months 23 pO.001
fiH The hip :
Objective: To validate the scoring system for hip involvement devised by MacKay et al. 
Patients developing hip disease represent a small, distinctive subset of patients, developing 
more severe disease, at a younger age (15-19 yrs). Hip disease in AS has not been 
satisfactorily defined. The Larsen score (originally designed for grading radiological change 
in rheumatoid arthritis) has occasionally been applied to the hip radiographs of AS patients. 
However, this score is less reproducible if used for assessing conditions where there is 
increased bony deposition, as occurs in AS. [140]
The Bath Ankylosing Spondylitis Radiology Hip Index, (the BASRI-hip) was designed to 
address these problems. No additional radiographs are required to score the BASRI-hip if 
an antero-posterior (AP) pelvic view has already been taken to review the sacroiliac (SI) 
joints.
Methods: Following definition of the scoring system [141] [Appendix 3], radiographs of 
134 consecutive patients with AS and 100 without AS were chosen to assess the reliability, 
predict sensitivity to change and determine disease specificity. The mean age of the AS 
population was 45.9 [+/- 10.6 yrs and the sex ratio was 4.8 : 1 (males : females)]. The non- 
AS cohort were consecutive outpatients attending the Royal National Hospital for 
Rheumatic Diseases (RNHRD), a tertiary referral centre. Pelvic x-rays, in this group, had 
been taken for the evaluation of symptoms. Their mean age was 54.5 +/- 17.5 yrs and the 
sex ratio was 1:2 (males : females). The cohort included 48 with Rheumatoid Arthritis, 21 
with osteoarthritis or mechanical back pain, 7 with fibromyalgia, 3 with osteoporosis, 12 
with psoriatic arthritis, 4 with polymyalgia rheumatica, 3 with inflammatory bowel disease 
and 2 with trochanteric burstis.
Inter-observer variation: Two independent observers (Sinead Brophy, Michele Doran) 
scored the 234 radiographs in a blinded fashion, on separate occasions, to assess inter-
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observer variation. All sacroiliac joints had been obscured and radiographs from the non-AS 
cohort interspersed such that the readers were unaware of the diagnosis.
Intra-observer variation: One hundred AS radiographs were chosen by a non-reader and 
scored by a single observer (Sinead Brophy) on two consecutive sessions, assessing intra­
observer variation. A Kappa statistic was used to determine the significance of inter- and 
intra-observer variability.
Disease Specificity: The specificity of BASRI-h against other rheumatic conditions was 
assessed using 234 radiographs. A cut off of grade 2 (definite) disease was used and all 
radiographs were then classified into one of two groups: those with and those without AS 
changes.
Sensitivity to change: Sensitivity to change over time was determined by scoring 438 serial 
radiographs of 122 patients, assessed at time intervals of 1,2,3 or 4 years. Patients were 
included if pelvic radiographs were available on two occasions 12,24, 36 or 48 months 
apart. Pairs of x-rays were available in 60, 65, 55 and 55 cases, respectively.
The mean time from diagnosis of these 122 patients was 18 years (range 0-44 years). All 
radiographs were blinded as to the name and date of the radiograph and a Wilcoxon signed 
rank test for non-parametric data was used to determine the earliest point at which 
sensitivity to change became apparent.
Results: One hundred pelvic (AP) radiographs were assessed twice by a single observer 
with 94% complete agreement for the right hip and 96% complete agreement for the left 
hip. The Kappa scores (see table 3) showed good agreement at 0.86 and 0.91 respectively 
for the right and left hips. The main errors were distinguishing between suspicious (grade 1) 
and minimal (grade 2) disease in 4% of cases. As the definition is ‘narrowing of less than 1 
cm* the main difficulty was deciding if narrowing was present when both hips were affected 
(ie normal vs narrowed) [Figure 6]
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/1 - erosion
2 & 3 - possible narrowing
Figure 6
Plain radiograph of hip joint demonstrating errors in distinguishing if narrowing
Inter-observer variation. Reproducibility between two readers was assessed using 134 
pelvic (AP) radiographs scored by each observer on separate occasions, revealing a 83% 
complete agreement between readers for the right hip and 84% complete agreement for the 
left hip. Kappa scores showed good agreement at 0.75 and 0.74 respectively. Distinguishing 
minimal from suspicious disease was again the main problem in 6% of cases.
Sensitivity to change. Using a Wilcoxion signed rank test for non-parametric data, BASRI 
demonstrated a significant change in radiological score (p<0.001) at 1 year for the hip. 
Disease specificity: A B ASRI-hip score of grade 2 was used as the cut off to determine AS 
radiological change. Disease specificity is defined as ‘the proportion of true positives that 
are correctly identified as such and is 1 minus the false negative rate’ [142] . Hence, the 
disease specificity of the BASRI-hip in this study was 1-0.24 = 0.76 (76%). If non-AS 
patients with a total hip replacement (THR) were excluded (because they automatically 
score grade 4, whatever the reason for their THR), disease specificity was 0.83. Hence, 24 
of the 200 hips studied in the non-AS cohort scored more than 2.
Scoring speed. The mean time taken to score a pair of hips, on a single AP pelvic 
radiograph, is 10 seconds
Interpretation o f this study: The only radiological scoring system currently in use for the AS 
hip has been the Larsen score, which was designed primarily to describe the hip in 
Rheumatoid Arthritis. Larsen states in his paper that the score is not as reliable when used 
to grade conditions, such as psoriatic arthritis or AS, where new bone formation is a 
prominent feature [140]. The BASRI-hip, in conjunction with the BASRI-spine, was 
designed to fill a perceived gap in the range of outcome measures for AS.
The BASRI-hip was developed in an identical way to the BASRI-spine score and was 
equally reproducible. During the validation of BASRI-hip, the sacroiliac joints were covered 
prior to scoring because sacroilitis (as part of the NY criteria) was a necessary entry
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requirement for any AS patient in the study. Although BASRI-hip was shown to be disease 
specific it did not perform as well as the BASRI-spine mainly because a hip replacement 
always scores grade 4 whatever its cause. Of the 100 patients included in the non-AS 
cohort, 24 were graded as if they had AS (i.e. they had scores > 2) but 7/24 scored grade 4 
because of a hip replacement. If these 7 were excluded, only 17/100 scored >2 giving a 
specificity of 83%. Of the remaining 17 with scores greater than two, 13 had severe RA. It 
may be that the BASRI-hip is describing certain aspects of inflammatory arthritis eg 
circumferential joint space narrowing which is central to both RA and AS.
Little information is available regarding radiographic sensitivity to disease progression and 
at what frequency repeat radiographs should be performed. The BASRI-hip was found to be 
sensitive to change over a one-year period. By definition, the patients used to study 
sensitivity to change each had more severe hip disease than other patients with only a single 
pelvic x-ray. This could mean that sensitivity to change becomes apparent at one year only 
in those with severe hip disease. However, in an effort to reduce radiation dosage, it is the 
hospital policy to perform a single pelvic radiograph to assess both the sacroiliac joints and 
hips together. Hence, the additional pelvic x-ray may have been taken to assess the 
sacroiliac joints rather than the hips and this was the case in at least half of the patients 
included. The radiographs in the study were blinded for date. This confirms that the 
BASRI-hip can determine ‘forward progression’ (i.e. it can identify the earlier of 2 
radiographs performed on the same individual).
Table 2: Validation of BASRI-hip
Radiographs (number) Kappa
Intraobserver variation Left hip 100 0.91
Right hip 100 0.86
Interobserver variation Left hip 234 0.74
Right hip 234 0.75
Specificity
Specificity 234 (AS) vs 100 (non-AS) 0.76
Sensitivity
12 months 60 p<0.001
24 months 65 p<0.001
36 months 55 p<0.001
48 months 55 p<0.001
6.1 (b) Natural History.
(i) Radiological progression in AS:
Objective: The natural history of AS is poorly understood. However, using BASRI to 
examine the disease history and radiographic progression of AS will allow this study to 
examine the influence of genetic and environmental factors on the rate of this disease 
development and their affect on the course of AS.
Aims: 1) to examine the progression of the disease cross-sectionally and evaluate factors 
associated with hip, lumber or cervical involvement. 2) to examine the longitudinal 
progression of disease among individuals in whom a diagnosis was made and radiographs 
taken within two years of developing first symptoms. 3) to construct a centile chart both for 
reference and to further aid in describing the disease history of AS. 4) to examine the rate 
of radiological change and estimate by extrapolation the age when first radiological change 
may occur. Assuming rate of progression before symptom onset is equal to rate of 
progression after symptom onset, the extrapolation can indicate age of first radiological 
change. [Appendix 4]
These four approaches were designed to reflect the natural history of AS, including first 
radiological change, rate of progression, variation seen among individuals in relation to the 
general AS population and factors determining this variation.
Methods’. All existing radiographs of 571 AS patients attending the Royal National Hospital 
for Rheumatic Diseases (n= 2,284 radiographs) were scored using BASRI by two trained 
independent readers (SB, AA1-S). [Discrepancies between scores were rescored by a third 
trained reader (KM) and a consensus was reached]. Patients were selected if they had been 
diagnosed according to the New York Criteria, had full sets of X rays and complete notes 
(including age of symptom onset, disease duration, family history, etc). Where more than
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one set of radiographs were available on a patient a random number table was used to select 
the set for inclusion in the cross sectional database.
1. Cross sectional progression of AS (n=571 patients): A plot was made of percentage of 
patients with regional involvement (lumbar, cervical and hip) at each year of disease 
duration. A cut off of grade 2 or more (ie mild disease) on the BASRI scale was used to 
define involvement of the joint. Univariate analysis was used to examine factors (ie 
secondary diseases, delay in diagnosis, age, family history, disease activity) associated with 
cervical, hip and lumbar involvement. Multivariate analysis was performed using these 
factors.
2. Longitudinal progression of AS: Patients with radiographs taken within 2 years of 
symptom onset (n=20) and who had more than one set of films were selected. The BASRI 
score was plotted against disease duration.
3. Percentile reference curve for BASRL : The curve was assembled using the method 
described by Altman and Chitty [143]. A quadratic regression model was fitted to the raw 
data with means weighted according to sample number in at each disease duration point. 
Cross sectional data (with each patient included only once) was used to develop the 
reference centiles (n=571).
4. Rate of progression and extrapolation to time of first radiological change: Patients 
with two sets of radiographs taken 10 years apart were selected. Those patients with first 
radiographs taken at 0-2 years, 10(+/-2) years and 20 (+/-2) years from time of symptom 
onset were used to examine rate of progression of disease over any 10 year period. The 
progression rate was calculated not in relation to total score but in relation to remaining 
score, to remove the ceiling effect. The formula to calculate relative progression (ie the 
score change per amount of score available to change [144]) was as follows:
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(the score of the designated year) - (the score of the previous year)
the total score (16) - (the score of the previous year)
Using this estimate of rate of progression of radiological change, an extrapolation to time 
of first radiological change was performed. Assuming rate of progression before symptom 
onset is equal to rate of progression after symptom onset, then extrapolation can indicate 
age of first radiological change.
Statistical methods: SPSS was used for the univariate & multivariate analysis (multiple 
regression) and the percentile estimates using a quadratic regression model.
Results: 1. Progression of disease The cross sectional data of all 571 patients was plotted 
against disease duration [Figure 7]. More patients have lumbar involvement than cervical 
disease at all points in the disease duration (p<0.001) and 86% of those with cervical 
disease had also lumbar spine changes. Patients with cervical changes alone (14%) had a 
shorter disease duration [18 (sd: 10 yrs) vs 23 (sd: 10 yrs) respectively (p=0.006), Cl: 5.2 
(1.5-8.9)] than those with both lumbar and cervical change. After 25 years of disease, 
approximately 75% of patients have cervical spine involvement and 85% have lumbar spine 
involvement. The factors associated with level of cervical involvement include [Table 3]: 
disease duration, degree of hip disease, degree of lumbar spine disease and a history of iritis. 
A model of these factors explains 59% [p<0.0001] of the variation seen in cervical spine 
involvement. The factors associated with level of lumbar spine disease were disease 
duration and level of cervical involvement. A model of these factors explain 36% 
[p<0.0001] of the variation seen in lumbar spine involvement. Only degree of cervical spine 
involvement and disease duration was associated with level of hip disease, describing 19%
[p<0.0001] of the variation seen in level of hip disease. Factors not associated with 
progression to lumbar, cervical or hip disease include disease activity [BASDAI], delay in 
diagnosis, family history, bowel disease and presence of psoriasis.
2. Longitudinal progression: Individual plots of patients confirmed the findings from cross 
sectional study. [Figure 8]. There is a great deal of variation in radiological score among 
patients at time of first symptoms of spondylitis. There is a very slow general rate of 
progression with some individuals having bursts of rapid change. However, these times of 
change can occur at any time in the course of the disease.
3. Percentile reference curve for BASRI: The percentiles of 571 patients were plotted 
against disease duration (defined as years from time of first symptom of AS). Quadratic 
regression models were fitted to the weighted means (weighted for number of observations 
at each time point) at each disease duration point [Figure 9]. The proportions of cases 
falling outside the 10th and 90th centile were calculated and confirmed the goodness of fit. 
[<10th centile range = 7.5%-10.2%, ; >90th centile range 6.2%-l 1.2%].
4. Rate of progression and extrapolation to age of first radiological change: On a 
BASRI scale of 2-16 the change in score was 2.9 (+/-3), 3.2 (+/1.3) and 1.6 (+/-1) for 
disease duration time points of 0-10 yrs, 10-20 yrs and 20-30 yrs respectively. [Table 4]. 
There was no significant difference between rate of radiological progression in these three 
time periods (p=0.163). If progression rate was calculated not in relation to total score but 
to remaining score to remove the ceiling effect, the progression rate was 30% of remain 
change (sd: 0.3), 40% of remaining change (sd:0.3) and 35% remaining change (sd: 0.4) at 
time points 0-10 yrs, 10-20 yrs and 20-30 yrs respectively. Thus, rate of radiological change 
was linear. [Figure 10]
If the change in AS is linear with an average change over any 10 year period of 2.55 (36%), 
then the rate of change is 1 point on the BASRI scale every 4 years. If average BASRI 
score at time of symptom onset is 5 when the patient is aged on average 28 (see table 4)
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then it would have been an estimated 20 years (eg 5 x 4 years =20 yrs) before symptom 
onset that radiological change began or at age 8 (assuming rate of change before symptoms 
is equal to rate of change after symptom onset). [Figure 11]
Interpretation o f the study. In terms of time of first radiological change, rate of progression, 
variation seen among individuals in relation to general AS population and factors 
determining this variation this study shows:
1. In the majority of patients, AS begins in the SI joints and progresses up the spine (the 
thoracic spine is not evaluated within the BASRI score). Thus, spinal involvement is largely 
an expression of disease duration.
2. The hips become involved in about 20-30% of individuals and may predict a more severe 
outcome for the cervical spine.
3. AS is a linearly progressing condition with about 35% change or an increase of 2.5 on the 
BASRI (2-16) scale every 10 years.
4. This rate of change can be extrapolated backwards to estimate time of first radiological 
changes to be at approximately age 8 years.
However, AS is defined as symptomatic sacroiliitis and therefore by definition all our 
patients had sacroiliitis. Conceivably some patients may begin with cervical or thoracic 
disease and then have descending involvement or may indeed have spinal disease without SI 
involvement. However, this is most likely a rare phenomenon [145] [142].
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The patients followed longitudinally from time of onset of first symptoms are those who 
have received an early diagnosis and have been referred to a tertiary referral centre. Thus, 
these subjects probably represent a severe group with perhaps the most rapidly progressing 
disease. Yet, even among this population of patients the radiographic progress of the 
disease appears to be quite slow and gradual.
A reference centile chart for BASRI has been developed based on outpatients from the 
RNHRD and individuals attending an in-patients intensive physiotherapy and education 
course which is comprised of people from across the UK and N Ireland. This population 
should provide a representative sample which may be applied to other patients around the 
world. The centile chart may differ between populations of male vs female, hip vs non-hip 
disease patients and those with and without iritis. With greater numbers the reference 
centile chart may be made more specific to different subgroups of AS patients. Using the 
centile chart showed that there is a great deal of variation and spread among patients with 
AS [ie half of the patients are spread over 40% of the entire BASRI scale at 10 yrs disease 
duration (50% of patients lie between 4 and 9.5 on the BASRI scale)]
This study examined a hospital population and showed linear progression of disease. 
However, this study probably suffers from left censoring and as such it would be expected 
that the most severe cases are referred to this tertiary centre. This would normally imply 
that there would be differential exclusion of patients with mild disease early in the course of 
their illness allowing for their inclusion only later as the disease became more 
problematic. [147]. Thus, patients with inherently milder disease are seen later in their course 
than those with more severe disease. The progression in this case would appear to be rapid 
at the beginning and slower as disease duration progresses. However, this selection bias 
does not appear to be observed in the AS population therefore perhaps lending weight to 
the finding that AS is a linearly progressing condition. Although it is theoretically possible 
that the patients who do continue to attend the hospital visits are the ones who continue to
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have disease and this disease may in fact 'bum out’, there has been has as yet been no 
evidence among non-hospital patients that the disease goes into remission [148]'
The extrapolation to age of first radiological change is based on the assumption that rate of 
change before symptoms (generally SI changes) are equal to change after symptoms 
(generally spinal change). Only by investigating the rate of SI change will we be able to truly 
estimate the timing of first radiological damage. This would require an MRI of young 
individuals who are in the highest risk groups such as those with a family history, iritis etc 
[149].
In summary, radiographic progression appears to be constant over the course of AS. With 
advancing disease duration there is advancing radiographic change, the involvement of the 
lumbar spine increases the chances that the cervical spine will become affected. Hip disease 
and iritis, separately point to worse cervical involvement. There is a great deal of variation 
and spread among patients with AS. However, the disease progresses at an estimated rate 
of 2.5 points on the BASRI scale or 35% every 10 years. This rate can be used to make a 
very crude extrapolation to timing of first radiological change which could be from as young 
as aged 8. However, the time interval between the pulling of the trigger and onset of disease 
remains unknown.
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Table 3: Factors associated with progression to cervical spine, lumbar spine or hip involvement.
Factors associated with Cervical spine Factors associated with Lumbar spine Factors associated with Hip
Correlation Univariant analysis Correlation Univariant analysis Correlation Univariant analysis
Disease Duration 0.3 p<0.0001 0.4 p<0.0001 0.2 p=0.005
Age 0.3 p<0.001 0.4 pO.0001 0.02
BASDAI -0.02 -0.05 0.05
Delay 0.1 0.01 -0.1
Means Univariant analysis Means Univariant analysis Means Univariant analysis
Family history 0 = 2.1, 1= 1.8 0 = 2.4, 1 =2.2 0 = 0.7, 1 = 1.0
Hip disease 0=  1.7, 1 =3.3 p<0.0001 0 = 2.1, 1 =3.0 p<0.0001
Cx disease 0=1.1, 1=2.2 p<0.0001 0 = 0.1, 1 =0.5 pO.0001
ffiD 0 = 2.1, 1 = 1.5 0 = 2.4, 1=2.0 0 = 0.8, 1 = 0.8
Iritis 0=1 .8 ,1= 2 .5 p=0.001 0 = 2.2, 1=2.6 p=0.02 0 = 0.7, 1 = 0.9
Lx 0 = 0.5, 1=2.5 p<0.0001 0 = 0.3, 1 = 0.9 p<0.0001
Psoriasis 0 = 2.0, 1 = 2.3 0 = 2.2, 1 = 2.6 0 = 0.8, 1 = 0.8






Disease duration Age BASRI BASRI Change Percentage change
(Yearl) (Year 10)
0-10 yrs (n=15) 28.3 (+/- 10) 5.0 (+/- 2) 8.0(+/-4) 2.9 (+/-3) 29%
11-20 yrs (n=20) 35.8 (+/-11) 8.2 (+/-4) 11.3 (+/-3) 3.1(+/-2.5) 40%
21-30 yrs (n=19) 43(+/-5) 9.6(+/-3) 11.4(+/-3) 1.6(+/-1) 36%








Figure 7: P ercen ta ge  of patients with regional involvment (hip, cervical spine, lumbar spine) over
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Figure 8: Longitudinal radiographs taken from time of symptom onset [n=20 indiviuals]
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(ii) Subsets of AS patients: variations in disease progression:
Objective: To describe the progression and disease development of ankylosing spondyltis 
among subsets of AS patients (Male vs Female / Hip vs non-hip) [Appendix 5].
Methods: The difference in progression in a) male vs female and b) hip vs non-hip was 
assessed. Sets of radiographs (n=423) of patients with known disease duration were 
selected and scored. Independent t tests or wilcoxon rank sum test and chi-squared were 
used to evaluate mean scores. The SPSS software program was used for analyses.
Results: a) The mean BASRI-t was higher for men than women (8.9 vs 7.2 respectively; 
p<0.001 Figure 12). Disease duration was comparable (21 vs 20 yrs ; p<0.27). More men 
than women had severe disease in the SI joints (odds ratio, 1.74 (1.1-2.7) p<0.016). More 
men than women had severe lumbar spine disease (2.6 (1.4-4.6); p<0.001) More men than 
women had severe cervical spine disease (2.3 (1.3-3.9) p<0.002). The numbers of men and 
women with severe hip disease were comparable at all stages of disease,
b) The BASRI-s was higher for those with hip disease (p<0.001 Figure 13). There was no 
difference in disease duration between the 2 groups (20 and 21 yrs respectively: p<0.2). 
Interpretation o f study: a) Men have more severe disease than women in the SI joints, 
lumbar spine, and the cervical spine, but not in the hips, b) Hip disease is a marker for more 
severe axial progression in AS (in both men and women).
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6.2 The influence of genetic and environmental factors:
i) Genetics
AS is a polygenic disease, therefore it can be expected that there will be overlap and 
interaction between susceptibility and severity factors. Susceptibility is clearly genetically 
determined but as yet there is little knowledge as to what factors influence disease 
progression and outcome. Herein, we examine the overlap between susceptibility and 
severity factors by exploring:
a) Evidence for an overlap of susceptibility genes involved in both AS and the secondary 
disorders (iritis, psoriasis, and inflammatory bowel disease) b) Impact of known 
susceptibility genes on disease activity and function c) Impact of age at onset (ie 
susceptibility factors) on outcome d) Impact of parental sex on transmission of disease to 
the next generation e) Inheritance of phenotypic expression f) Concomitance of disease 
expression among family members and g) Identification of possible loci on the genome 
involved in severity.
This should establish
1. the influence of susceptibility factors on disease expression and
2. if severity genes exist and where in the geneome they might lie.
5.2 (a'l Eve, skin and bowel disease in spondylarthritis : Genotypic, phenotypic and 
environmental factors.
Objective: Patients with ankylosing spondylitis (AS) can develop psoriasis (Ps) or 
inflammatory bowel disease (IBD), whereas those with psoriasis may develop joint 
involvement. The link between these diseases might be genetic, with shared susceptibility 
genes. This hypothesis is supported by the finding that B27 negative spondylitis patients are
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more likely to have secondary forms of disease linked to psoriasis or IBD [98] . Thus, in 
the absence of the B27 susceptibility effect, genes such as those for the other inflammatory 
conditions may be important in predisposing the individual to ankylosing spondylitis. 
Alternatively, these conditions may be linked by environmental factors, the inflamed gut and 
skin allowing the conduit of pathogenic triggers which induce AS. The HLA-B27 transgenic 
rat develops clinical features including: inflammatory gastrointestinal disease (stomach, 
small intestine, colon), skin lesions (psoriasiform dermatitis, nail dystrophy), spinal lesions, 
peripheral arthritis, carditis and some develop anterior uveitis [150] . These rats generally 
develop bowel inflammation which is then followed by arthritis. However, if the HLA B27 
transgenic rat is maintained in a sterile environment neither the inflammatory gastrointestinal 
disease, nor the arthritis develop [151].
Thus there is evidence that the link between these inflammatory conditions could be both 
genetic and environmental. How these diseases are linked will have an important impact on 
our understanding and treatment of AS and the associated risks to relatives of affected 
individuals [143] . This study explores the nature of the inter-relationship between 
inflammatory disease of the spine / joints, skin, eye and bowel [i.e ankylosing spondylitis 
(AS), psoriasis (Ps), iritis (I), inflammatory bowel disease (IBD)]. [Appendix 6]
Methods: The database
The Bath RNHRD AS database consists of 4953 spondylarthritis patients. These subjects 
are defined as those with symptomatic sacroiliitis diagnosed by x-ray, fulfilling the New 
York criteria for AS and meeting the Amor (1991) and the European Spondylarthropathy 
Study Group diagnostic criteria for the Spondylarthropathies. Subjects are either those 
referred to the Royal National Hospital for Rheumatic Diseases or are members of the 
National Ankylosing Spondylitis Society. Among the patients, 1915 (39%) have iritis, 811 
(16%) psoriasis and 404 (8%) inflammatory bowel disease (IBD: 158 Crohn’s disease and
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246 ulcerative colitis). The diagnoses for iritis and psoriasis were ascertained by the GP, 
rheumatologist, ophthalmologist or dermatologist. A gastroenterologist was used for the 
diagnosis of inflammatory bowel disease. In each case the diagnosis was recorded as 
representing one point in time. Two studies have been performed to validate the diagnosis 
of ankylosing spondylitis in those patients recruited through NASS. 146 subjects were 
assessed by a rheumatologist and 100% were confirmed as having AS according to the New 
York Criteria (personal communication, M. Brown, Oxford) The general practitioners of a 
further 240 NASS members were contacted to determine whether their patient’s AS had 
been confirmed radiologically. In 229 (95.4%) cases, AS with radiological evidence of 
sacroliitis was confirmed. The GP’s of 120 Ps-AS patients and 139 IBD-AS patients were 
contacted. Of these, 77 (64%) and 112 (81 %) replied confirming Ps in 65 (84%) of cases 
and IBD in 108 (96%) of cases.
Data processing and statistical methods
1. Of the 4953 subjects on the database, 3287 had a complete data set with full family and 
personal data. The prevalence of the three individual secondary disorders (psoriasis, IBD 
and iritis) was determined. From these data the expected numbers of patients with none, 
one, two or three of these conditions was established assuming independence between the 
diseases. The expected number was compared with the observed number using the %2 test. 
Patients with a secondary disorder were matched with an available and appropriate control 
(without the specific condition) for disease duration, age and sex (ie psoriasis patients were 
matched with those without psoriasis [600 pairs of 811 Ps patients], IBD patients with 
those without IBD [335 pairs of 404 IBD patients], and iritis patients matched with those 
without iritis [735 pairs]. These were compared using McNemar’s %2 for prevalence of 
secondary disorders as outlined above.
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2. Patients with a confirmed diagnosis for the reported secondary conditions and arthritis 
were asked to report when symptoms of each condition first began. Patient recollection was 
verified by GP reports.
3. Patients with a confirmed diagnosis of disease were asked ‘to your knowledge do any 
members of your family have a diagnosis of psoriasis, inflammatory bowel disease, iritis or 
ankylosing spondylitis*.
4. Patients with multiple disease completed disease activity (Bath Ankylosing Spondylitis 
Disease Activity Index [BASDAI]) and function (Bath Ankylosing Spondylitis Functional 
Index [BASFI]) assessments. The radiographs of RNHRD patients were blindly scored by 
two independent observers using the Bath Ankylosing Spondylitis Radiology Index 
[BASRI] and then sub-grouped according to presence of secondary disorders.
Results: 1. Analysis of the prevalence of secondary disorders within the individual: There 
were more people with spondylitis and multiple co-diseases than expected and more with 
pure ankylosing spondylitis (ie without secondary diseases) but there were fewer with 
spondylitis and only one single co-disease than expected. The observed /expected numbers 
for patients with no co-diseases were 2069 /1973, with one co-disease 1722 /1872, with 
two co-diseases 454 /417 and with three co-diseases 42 /25. (x2 =32.2 p<0.001).
Psoriatic patients (n=600, M: F=3.2:l, disease duration=22 yrs, age = 47 yrs) had a 
higher prevalence of iritis. 48% vs 40% [O.R: 1.4 (1.1-1.7)] and more IBD than 
controls [O.R: 1.3 (1.1-2.0)] 12.5% vs 9.4%. (n=600, M:F=3.2:1, disease duration = 22 ys, 
age = 47)
Iritis patients (n=735, M:F=2.3:1, disease duration = 21 yrs, age = 45 yrs) had a higher 
prevalence of psoriasis [OR: 1.4 (1.1-1.8)] 18.2 % vs 14% and IBD [OR: 1.5 (1.1-2.2)] 
10.6% vs 7.3% than controls (n=735, M:F=2.3:1, disease duration = 21yrs, age = 45 yrs).
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IBD patients (n=335, M:F=2.3:1, disease duration =22 yrs, age = 47 yrs) had a higher 
prevalence of iritis [O.R: 1.4 (1.1-2.0)] 45.4% vs 36.7% and psoriasis [O.R: 1.9 (1.3- 
2.8)] 23.9% vs 14.3% than controls (n=335, M:F=2.3:1, disease duration =22 yrs, age = 
47 yrs).
2. Temporal relationship between onset of the different conditions: Patient recollection of 
age of onset and diagnosis was confirmed using GP reports. The GP and patients 
recollection was comparable for age/year in 95% of cases of ankylosing spondylitis, 
inflammatory bowel disease and psoriasis and 100% of those with iritis. Onset of AS 
symptoms occurs significantly before advent of iritis (p<0.001) and IBD (p<0.001). Onset 
of Ps and AS symptoms occurs at comparable ages. Gut, skin and eye symptoms do not 
precede those of AS. [Table 5]
3. The prevalence of disease among first degree relatives: Relatives of patients with IBD-AS 
are at an increased risk of developing psoriasis and iritis. (Tables 6 and 7) Those with 
multiple disease predict the highest prevalence of co-diseases (ie Ps, IBD, I or AS) within 
family members, followed by those with IBD, psoriasis and lastly iritis.
4. The influence of secondary disorders on outcome of AS: Disease activity and function are 
worse for patients with psoriasis and/or IBD. However, those with iritis are comparable to 
those with primary disease. [Table 8] Radiological change was worse for those with iritis 
than for patients with pure AS [Table 9].
Interpretation o f study: The data explore the nature of the inter-relationship between the 
spinal disease, AS, and the extra-spinal co-disorders. Particularly focusing on the relative 
role of environment and genetics in the inter-relationship of these inflammatory disorders:
59
1. in an individual with AS, the presence of one concomitant disorder enhances the 
probability of there being a second or third co-disease.
2. the symptoms of AS precede or are contemporaneous with the concomitant disorders
3. family members are at increased risk of secondary disorders even in the absence of their 
expression in the index case and finally
4. the expression of severity (ie BASRI, BASDAI, BASFI) in AS is influenced by the 
presence of the secondary conditions. Thus, it can be concluded that the susceptibility 
genes of these co-disorders overlap with each other and with AS and impact on disease 
severity.
In terms of the increased prevalence of secondary disorders within the individual, it is 
recognised that patients seen at a tertiary referral clinic may have more co-diseases than 
those seen in the general population. Similarly, patients who join a self-help group (NASS) 
may be more likely to have multiple disorders. This suggests that a bias towards multiple 
disease (Berkson’s Bias) may be observed among the total sample. However, more patients 
than expected were found without a concomitant disease (pure AS) and fewer were found 
with AS and a single secondary disorder. This is not a finding predicted by the bias. In 
addition, the matched data used control and sample patients from the same population 
which were equally likely to have multiple disease as there were no selection differences 
between the subgroups (ie both entered the hospital/self help group system).
A link between the secondary disorders in the absence of AS has been previously described. 
Psoriatic patients suffer from IBD more than controls [152] [153] the prevalence of 
psoriasis is increased in Crohn’s disease [154][155][156] and there is a higher incidence of 
iritis than expected among psoriasis patients [157]. Genes on chromosome 16 are associated 
with iritis [158], psoriasis [159] and Crohn’s disease [160]. These inflammatory disorders 
are linked to chromosome 6, perhaps through HLA-Cw6, in the case of psoriasis [161], 
B62 in IBD [162] and B27 for AS [163] and iritis [164]. Thus, there is evidence to support
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the finding in this study that the genetic susceptibility to inflammatory bowel, skin, eye and 
joint disease overlaps and may be additive.
The suggestion that the triggering agent for AS may enter the body through the inflamed 
gut or skin (as proposed in the HLA transgenic rat) is not supported by our human data. 
There was little overt (symptomatic) inflammation due to IBD prior to the onset of 
symptomatic AS. However, we do appreciate that occult bowel involvement may occur 
early in AS [165] and that the clinical expression of psoriasis varies, very mild disease (ie 
minor scalp involvement) could be overlooked by the patient and GP. In fact, it is not 
known when the actual onset of disease begins in any of these conditions. It is possible that 
the trigger is pulled in the womb and disease begins in the infant with age of symptom onset 
simply a reflection of severity of disease. However, this study has not found evidence that 
overt and symptomatic IBD or Ps are involved in triggering AS (ie allowing the conduit of 
environmental pathogens to induce AS). Conceivably, the results may be different in a 
population chosen from a gastroenterological or dermatological clinic. However, the finding 
that onset of bowel disease and the other inflammatory conditions do not follow a temporal 
pattern but may occur at any time (before or after the onset of arthritis), supports the 
hypothesis that susceptibility genes of inflammatory skin, eye and bowel disease may 
overlap with those for inflammatory joint disease.
The prevalence of disease among family members of the index case represents an estimate 
of the occurrence of disease within this population. The observation of familial aggregation 
has been previously identified. [153]. Herein, we reinforce the previous observations and 
suggest that the strongest genetic load can be seen among the IBD-AS sufferers with the 
least observed among the iritis-AS patients (Table 6). The data from the relatives of the 
pure AS subjects suggest that occult genes associated with IBD & Ps and/or the presence of 
iritis genes may be required for the development of ankylosing spondylitis (see Figure 14)
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Patients with psoriasis and / or IBD had poorer function and greater disease activity. 
Psoriasis/IBD genes may have an additive effect on susceptibility to and severity of AS. 
Alternatively, an inflammatory/immunological response to a sizeable area of body (skin 
surface or bowel) may have an effect of potentiating inflammation elsewhere. Indeed, it is 
recognised that active inflammatory bowel disease can coincide with flares in peripheral 
joint disease [165]. However, this condition does not appear to increase disease specific AS 
changes (ie radiological change). Conversely, iritis appears to be a strong phenotypic 
marker for more severe radiological disease. Moreover, peripheral arthritis in a patient with 
ankylosing spondylitis enhances the likelihood that iritis will develop [166].
The secondary diseases do appear to have a genetic overlap with AS in terms of 
susceptibility genes. The susceptibility factors for these conditions may be additive or have a 
synergistic effect on each other. The presence of these conditions has a pronounced effect 
on the phenotypic expression. The patient is more likely to have multiple disorders, develop 
these disorders after the onset of AS and have a poorer outcome in terms of the spondylitis. 
These findings point to the striking overlap within the patient and their family of 
rheumatological, dermatological and gasteroentrological processes. The impact of a 
relevant family history is clearly demonstrated and the data enhance our understanding of 
how the shared gene hypothesis can have an impact on disease expression.
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Table 5: Mean age of onset of the inflammatory disorders [Iritis (I), psoriasis (Ps), inflammatory bowel (IBD)] compared to onset of AS.
AS (yrs) I (yrs) Ps IBD (yrs) Mean difference (Confidence Intervals)
(yrs)
Pure AS (n=2221) 25
AS I (n=151) 23 33 AS vs 1 :10 (7.4-10.8)
AS Ps (n=40) 27 26 AS vs Ps : none
AS IBD (n=74) 24 30 AS vs IBD : 6 (3.4-9.7)
AS IP s (n = 30) 28 39 32 AS vs 1 :11 (6.6-15.2), AS vs Ps : 4 (0.5-8.8)
AS I IBD (n=66) 22 34 31 AS vs 1 :12 (9.6-15.8), AS vs EBD: 9 (5.1-12.2)
AS Ps IBD (n=18) 23 26 31 AS vs Ps : none, AS vs IBD : 6.6 (1.7-11.6)
AS IP s IBD (n=26) 23 32 33 33 AS vs 1 : 9 (4.5-14.8), AS vs Ps : 10 (2.5-16.9), AS vs IBD : 10 (3.6-16.1)
Table 6 First degree relatives
Ps IBD Iritis AS Order
1. AS pure (n = 138) 10%
2. AS + iritis (n=142) 5%
3. AS + Ps (n=42) 33%
4. AS + iritis + Ps (n= 26) 19%
5. AS + IBD + Ps (n=17) 12%
6. AS + iritis + IBD (n=63) 14%
7. AS + IBD (n=76) 17%
8. AS +IBD + Ps + Iritis (n=23) 17%
Population Rate. 1.1%
Moll et al. Medicine 1974 vol
53 (5) 343-364)
7% 6% 25% 1
3% 13% 29% 2
12% 0% 14% 3
8% 15% 19% 4
24% 6% 24% 5
14% 16% 29% 6
24% 8% 24% 6
17% 26% 30% 8
0.07% 0.19%
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Table 7 : Relatives of AS patients affected with inflammatory diseases not identified in the index
case.
+  IBD 
Relatives with:
Ps Iritis Summary Ps Iritis Summary
AS + IBD 13/76 6/76 16/76 AS pure 14/138 8/138 21/138
AS + iritis + IBD 9/63 9/63 AS + iritis 7/142 7/142







+  Iritis 
Relatives with:
IBD Ps Summary IBD Ps Summary
AS + iritis 4/142 7/142 11/142 AS pure 10/138 14/138 23/138
AS + iritis + IBD 9/63 9/63 AS + IBD 13/76 13/76
AS + iritis + Ps 2/26 2/26 AS + Ps 5/42 5/42
22/231
(10%)






Table 8: Phenotypic expression of secondary disease
AS duration BASDAI BASFI Mean Difference between 1° AS vs 2° AS Mean Difference between 1°AS vs 2° AS
[BASDAI] (confidence interval) [BASFI] (confidence interval)
Pure AS (n=2221) 19.0 yrs 4.1 3.9
AS I (n=1342) 23.7 yrs 3.9 4.0 ns ns
AS Ps (n=389) 19.3 yrs 4.7 4.6 0.5 (0.3-0.7) 0.4 (0.2-0.7)
AS IBD (n=341) 25.7 yrs 4.5 4.8 0.4 (0.05-0.7) 0.6 (0.3-1.0)
AS I Ps (n=323) 25.6 yrs 4.6 4.8 0.4 (0.2-0.6) 0.8 (0.4-1.0)
AS IEBD (n=150) 25.3 yrs 4.3 4.6 ns 06=6 (0.2-1.1)
AS Ps IBD (n=44) 20.5 yrs 5.9 5.4 1.7 (1.2-2.4) 1.6 (0.9-2.4)
AS IP s IBD (n=46) 23 yrs 4.5 5.4 ns 1.5 (0.8-2.3)
Table 9: BASRI in primary vs secondary disease
AS disease duration BASRI Mean difference 1° AS vs 2° 
AS (confidence intervals)
Pure AS (n=151) 19.8 yrs 8.3
AS I (n=121) 23.8 yrs 10.1 1.8 (0.8-2.7)
AS Ps (n=60) 22.3 yrs 9.6 1.3 (0.2-2.4)
AS IBD (n=23) 21.3 yrs 8.7 ns
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Figure 14: Relationship between AS and secondary disorders
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Role of susceptibility in severity (established genes'!
Objective: Studies in diverse populations have demonstrated that HLA B27 [46] and B60 [66] 
both influence susceptibility to ankylosing spondylitis (AS). B60 may increase susceptibility three 
fold in both B27 positive [66] and negative individuals [68], However, this is not confirmed by all 
studies [69] [70][71].
In terms of severity effects, HLA-B27 has no effect on the phenotypic expression of progressive 
ankylosis in ank/ank mice. In patients with HLA B27 there is an earlier onset of disease, more hip 
involvement and peripheral arthritis [49] but no influence on radiological and clinical outcome 
measures. However, B27 (+) patients do suffer less psoriasis and inflammatory bowel disease 
[99].
The role of B60 in severity of disease has not been investigated. Therefore, the present study was 
undertaken specifically to assess the role of B60 and B27 (in patients who have inflammatory 
bowel disease) in determining disease severity of AS as measured by disease activity [BASDAI] 
and function [BASFI].
Methods: Patients and control subjects: AS patients were recruited from the Royal National 
Hospital for Rheumatic disease and the National Ankylosing Spondyltitis Society.
1. Four hundred and three (403) AS patients were typed for B60, DR1 and B27. Many had been 
originally selected and typed for family studies. Therefore, there was a bias towards those with a 
positive family history (ie those with a first degree relative with disease). Thirty five (8.7%) were 
identified as B60 positive (M:F 2.2: 1). These patients were matched with 35 B60 negative 
control subjects for sex, age and disease duration.
2. One hundred and forty three (143) AS patients with bowel disease were typed for B27. 
[Bowel disease patients were selected as they have a higher prevalence of B27 negative disease] 
Thirty three (23%) of these 143 patients were negative for B27. These subjects were matched 
with B27 positive patients (with IBD) for sex, age and disease duration.
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All subjects were assessed for disease activity (BASDAI), Functional Status (BASFI) and Global 
well-being (BAS-G).
Confirmation of diagnosis for AS and all secondary conditions was obtained from the GP for all 
subjects.
Statistical Analysis All matching was performed by identifying all 
random number table to select the appropriate control. McNemars 
matched pairs. The SPSS package was used for the analysis.
Results
1. B60 (+) patients matched for sex, age and disease duration:
There was no difference in age of onset of AS among the B60(+) and (-) patients. [24.2 years & 
22.9 years B60 (+) & B60 (-) respectively, p=0.4,] .Of the 35 B60 positive patients, 20 had 
familial AS (57%). Of the 35 B60(-) patients, 26 had familial AS (74%) (p=0.13). Iritis and 
psoriasis were more prevalent in the B60(-) control group (p<0.041 O.R 3 [1.3-6.7] & p<0.035 
O.R: 4 [1.07-15] respectively). There was a 5.7% prevalence of IBD in the B60(-) group and no 
cases in the B60(+) group. However, the disease activity and functional status were comparable. 
[Table 10]
2. B27(+) patients matched for sex and disease duration (all patients have bowel disease,)
The age of onset of AS was younger among those with HLA B27. [22.3 years & 29 years,
B27(+) & B27(-) respectively, p<0.001,]. Disease activity and function were comparable 
between the two groups [p=0.2]. [Table 11]
possible matches and using a 
X2 test was used to compare
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Interpretation: The susceptibility genes B27 and B60 do not impact on disease activity or 
function.
HLA B60 was only present in 8.7% of patients typed and although sample numbers were 
relatively small but the power for the B60 sample was 95%. These patients were selected from a 
specific population. Most, were originally typed for family studies. This may imply that the AS 
would be inclined to be milder [167] [168] and may increase the prevalence of concomitant 
disorders observed.
It is known that in the HLA B27 negative individual, genes for psoriasis and inflammatory bowel 
disease take on a greater relevance in AS [168]. Patients with ulcerative colitis and ankylosing 
spondylitis are less frequently B27 positive (in this sample 23% were B27 negative) than those 
with ankylosing spondylitis alone [169]. The implication being that genes for psoriasis and IBD 
may be playing a role in the pathogenesis of spondylitis. The susceptibility genes B60 can be seen 
to reflect the findings observed with B27. The susceptibility genes for iritis, and psoriasis may be 
involved in susceptibility to ankylosing spondylitis. Without the influence of B60 and B27, other 
genes such as those for iritis, psoriasis and perhaps IBD may be additional susceptibility factors. 
B60 and B27 negative patients may have a higher frequency of non B60 and B27 pathogenic 
genes.
In conclusion the susceptibility genes HLA B60 and HLA B27 do not influence severity of AS. 
However, the phenotypic expression of AS in terms of prevalence of co-diseseas is significantly 
different for the B60(+)/B27(+) vs the B60(-)/B27(-) individual. AS patients without these 
susceptibility genes may need other pathogenic genes such as those for psoriasis, iritis and bowel 
disease to develop AS.
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Age at onset (years) 24
Disease Duration (years) 22 
Delay in diagnosis 8.8
(years)
BASDAI. Scale 1-10 3.6
BASF! Scale 1-10 3.5













60% p=0.041 OR = 3
37% p=0.035 OR= 4
5.7%
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Table 11: AS-IBD Patients matched for sex, age and disease duration
B27(+) B27(-)
Age (years) 45 years 46 years
Age at onset (years) 25 yrs 27 years
Disease duration (years) 20 yrs 19 years
Delay in diagnosis (years) 4.7 yrs 8.0 years 3.3 [0.2-6.3] p=0.04
BASDAI. Scale 1-10 5.0 4.4 p=0.2
BASFI. Scale 1-10 4.7 4.5 p=0.7
Age onset IBD 30.2 yrs 27.9 yrs p=0.4
(c) Interaction between age of onset and severity:
Objective: In ankylosing spondylitis a juvenile age at symptom onset (less than 16 yrs) has been 
found to correlate with increased disease severity [121][101][171]. In addition, hip involvement 
(and need for total hip replacement) is more often seen in those with juvenile onset [170] [171] 
and hip involvement itself is a marker for more severe axial involvement [101][172], However, 
iate onset, (after age 55) has also been reported to affect the clinical pattern of disease. Such 
patients are said to have more cervical pain, anterior chest wall involvement, aseptic osteitis [173] 
and shoulder involvement [174] . It can be assumed that the expression of AS results from a 
combination of severity and susceptibility genes. Therefore, patients with a younger age at onset 
may have an increased number of susceptibility factors and perhaps a different disease expression 
from those with late onset. Late onset individuals may carry fewer susceptibility and a different 
array of severity genes.
This aspect of the study aims to examine the influence of age at symptom onset on disease 
expression as measured by radiological change (BASRI), disease activity (BASDAI), function 
(BASFI), percentage undergoing AS-related surgery, and prevalence of secondary disorders 
(iritis, psoriasis, inflammatory bowel disease). [Appendix 7]
Methods : The Bath Ankylosing Spondylitis Database consists of 4741 patients (2.5:1 M:F). All 
were out-patients of the Royal National Hospital for Rheumatic Diseases (n=851) or were 
members of the National Ankylosing Spondylitis Society. Patients referred to the RNHRD had 
their diagnosis confirmed according to the New York Criteria. The NASS members are those who 
have received a positive diagnosis of ankylosing spondylitis from a specialist rheumatologist as a 
result of an x ray. To validate the diagnosis in those patients recruited through NASS, one 
hundred and forty-six consecutive subjects were invited to attend an assessment clinic and all 146 
were confirmed as having AS according to the same criteria. In addition, for 240 patients a
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confirmation was sought from the GP, and confirmed in 229 cases (95.4%) [ie AS with 
radiological evidence of sacroliitis]. We contacted the GP’s of 120 Ps(AS) patients and 139 
IBD(AS) patients. Of these, 77 (64%) and 112(81%) replied confirming the diagnosis of Ps and 
IBD in 65 (84%) and 108 (96%) cases.
Patients were divided into cohorts according to age of symptom onset and were controlled for a) 
age now and b) disease duration now (McNemar’s chi-squared). In addition, cohorts of juvenile 
onset (<16 yrs), young onset (17-20 yrs), twenties (21-29 yrs), thirties (30-39) and late onset 
(40+ yrs) were compared. The primary outcome measure was radiological status as determined 
by BASRI. Secondary measures were disease activity (BASDAI), function (BASFI), numbers 
undergoing surgery and percentage with secondary disorders.
Results: Radiological progression [sacroiliac joints, hips, lumbar spine, cervical spine]: BASRI
Age at onset has no significant effect on radiological progression [Table 12 & Figure 15].
Radiological change is a factor of disease duration ie those with a young age at onset have more 
severe disease when compared to like aged late onset patients [Young onset: Late onset; 10.0 :
8.0 respectively (p=0.02)]. However, disease duration matched pairs are comparable for 
radiological change [Young onset: Late onset; 8.0 : 8.6]
Patients with hip disease and a young onset had comparable spinal disease to those with hip
disease and a late onset [Table 12] [Young : Late ; 9.0 : 10.8 p=0.04 (corrected value not 
significant)]. Hip disease patients have more spinal change than non-hip patients [Table 12a] 
[Young onset -  Hip disease : Non-hip disease ; 9.7 : 7.2 respectively (p=0.0001). Late onset -  
Hip disease : Non-hip disease; 10.13 : 7.1 p= 0.0001].
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Secondary outcome measures Age at onset had no significant effect on disease activity, function, 
prevalence of secondary disorders, or need for surgery [Table 13 & Table 14]. At comparable 
age (ie age now [Table 13]), those with longer disease duration (ie young onset) have lower 
disease activity [Young onset : Late onset ; 4.0 : 4.3 respectively p<0.02], more iritis [Young 
onset : Late onset; 50% : 40% p<0.01] and more surgical intervention [14% : 7% respectively 
p<0.01]. However, when matched for disease duration [Table 14], the disease activity [Young 
onset : Late onset ; 4.4 : 4.4] , prevalence of secondary conditions and need for surgery [9% : 
8%] were all comparable for those with a young age at onset vs late age onset. When matched 
for disease duration the function was worse for the delayed onset males (ie older aged men) 
[p<0.01]. However, at equivalent ages [Table 11] the function is comparable regardless of disease 
duration (ie between young age at onset and delayed onset individuals).
Cohorts of juvenile onset (<16 yrs), young onset (17-20 yrs), twenties (21-29 yrs), thirties (30- 
39) and late onset (40+ yrs) were comparable for disease activity [Figure 16], function [Figure 
17] and surgery [Figure 18].
Interpretation o f study: The data suggest that age at onset has no impact on disease severity. 
However, this must be seen in the context that hip disease is more prevalent among patients with 
juvenile onset [THR rate - Juvenile vs non-juvenile : 18% : 8% respectively, p<0.001, Figure 19] 
and this phenomenon is known to be a predictor of more severe spondylitis [101] [131].
This paradox [ie a) there is a link between age at onset and hip disease,
b) hip disease is linked to increased severity but
c) there is no link between age at onset and increased severity] may be explained on the basis that 
only a subgroup of young onset patients develop hip disease and only this cohort is at risk of more 
severe spondylitis. [In our study 21/68 (31%) of the young onset subjects and 13/68 (19%) in of 
the late onset patients had hip involvement as assessed by a radiograph and THR occurred in 9% 
and 4% respectively].
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It is possible that the young developing hip may be more at risk of becoming affected than the 
adult hip. Thus, patients with young onset are more at risk of hip involvement (because of the 
juvenile hip). However, patients with hip disease and a young onset do not have more severe 
disease than subjects with a late onset and hip disease [Figure 20]. Hip involvement per se appears 
to be the relevant factor contributing to outcome.
The trigger for AS is thought to be a ubiquitous bacterium [175] . If this is so, then the age of 
onset of disease should be related to the genetic susceptibility load. Yet, this enhanced genetic 
susceptibly in young onset patients does not influence outcome, implying that the contributing 
genes for susceptibility and severity are independent of one another. If by contrast, the age of 
onset of a patient is governed by the timing of contact with an environmental trigger, the age 
when this happens appears to have no influence on the later disease development. Separate and 
unrelated severity factors must influence disease progression. In conclusion, there are three clearly 
distinct independent factors: the environment and both susceptibility and severity genes.
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Table 12: Young onset compared to Late onset in terms of radiological progression
Age onset 0-21 (young onset) Age onset 30+ (late onset) p value
(corrected)
Age Now (& Sex) Matched n=56 pairs
BASRI-total* 10.0 8.0 p=0.02 (ns)
BASRI-spine** 8.7 7.6 p=0.02 (ns)
With hip involvement (n= 19, 10) 9.7 10.0 ns
Without hip involvement (n=37,46) 8.2 7.1 ns
Disease Duration (& Sex) Matched n=68 pairs
BASRI-total* 8.0 8.6 ns
BASRI-spine** 7.1 8.1 ns
With hip involvement (n=21, 13) 9.0 10.8 p=0.04 (ns)
Without hip involvement (n=47, 55) 6.3 7.5 p=0.06 (ns)
♦including hips **without hips
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Table 12a : Hip disease vs non-hip disease patients : spinal severity score and age at onset 
of AS
Hip disease Non-hip disease P value
(corrected)
Young onset n=81 n=148
Disease duration 22.1 yrs 22.7 yrs
Mean (sd) 9.7 (2.43) 7.2 (3.0) p<0.001
Late onset n=19 n=64
Disease duration 15.2 14.1
Means (sd) 10.13 (2.5) 7.1 (3.0) p<0.001
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Table 13: Influence of age at onset on outcome - Age Now and Sex matched
Age onset 0-21 (young onset) Age onset 30+ (late onset) p value$
BASDAI
Whole group (n=784) 4.0 4.3 p<0.02
Males (n=543 pairs) 3.7 4.2 p<0.01
Females (n=241 pairs) 4.5 4.4 ns
BASFI
Whole group (n=829) 4.4 4.3 ns
Males (n=574 pairs) 4.3 4.3 ns
Females (n=255 pairs) 4.8 4.3 p=0.03
Secondary Disorders
Iritis (n=829 pairs) 50% 40% p<0.01
Ps (n=807) 20% 20% ns
IBD (n=828) 7.5% 7.6% ns
Surgery
Total surgery n=991 140(14%) 67(7%) p<0.01
$ Corrected
Table 14: Influence of age at onset on outcome - Disease Duration and Sex Matched
Age onset 0-21 (young onset) Age onset 30+ (late onset) p valu
BASDA1
Whole group (n=784) 4.4 4.4 ns
Males (n=543 pairs) 4.2 4.1 ns
Females (n=4.5) 4.6 4.5 ns
BASH
Whole group (n=810) 3.7 4.5 p<0.01
Males (n=546 pairs) 3.6 4.5 p<0.01
Females (n=216) 4.1 4.5 ns
Secondary Disorders
Iritis (n=799 pairs) 40% 41% ns
Ps (n=792 pairs) 20% 19% ns
IBD (n=810 pairs) 7.5% 8.9% ns
Surgery
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5.2 (bl . The impact of sex on inheritance of AS
Objective: Disease expression differs in men and women, with about 2.5 men affected for 
every woman with disease [176]. Men develop more severe spinal disease [177]. Women 
have more peripheral joint involvement [178] . These differences may be due to genetic 
factors in the sex chromosomes [179], which would lead to a difference in the sex ratio of 
children and siblings who inherit the disease. The influence of the sex of the index case of 
ankylosing spondylitis on disease inheritance among offspring and siblings, irrespective of 
HLA-B27 status is investigated. [Appendix 8]
Methods: The frequency distributions of age of onset and age of diagnosis of the 4400 
individuals were calculated so that we could identify the ages at which 50% (ie 30 yrs) and 
75% (ie 39 yrs) of patients should have obtained a diagnosis of ankylosing spondylitis 
(Figure 21) The study then focused on 1192 individuals (879 men, 313 women) who had 
children and were older than 50 yrs , and 2222 individuals (1615 men, 607 women) with 
siblings older than 39 yrs. Where there were several family members with ankylosing 
spondylitis, only one sibling per family was selected. All patients who had children older 
than 39 yrs who had ankylosing spondylitis were contacted to ensure the child had a 
radiographicaly validated diagnosis. Of 29 families with a child older than 39 yrs with AS, 
all the affected offspring provided confirmation of diagnosis. 100 (25%) patients who report 
a sibling with ankylosing spondylitis were contacted to provide medical confirmation of 
diagnosis. We selected these patients using a random number table. Of those chosen, 18 
could not be contacted (moved or died). 82 individuals were traced, of whom 78 (95%) had 
AS confirmed, two had no formal diagnosis but were still in the process of being 
investigated for AS, and two did not have the disease.
The age of disease onset of fathers and mothers with AS was compared with the percentage 
of children with disease. To investigate the possibility of a uterine effect (eg passage of 
pathogens or other agents across the placenta) in mothers with AS, we assessed whether the
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affected child was bom before or after disease onset in the parent. The results for affected 
fathers were used as control for when no uterine effect is present.
We analysed the data using %2 tests with Yates’s continuity correction of SPSS (version 
7.0). We used Fisher’s exact test for small entries.
Results: The frequency distribution of age of diagnosis showed a mean 10-year delay from 
onset of symptoms to diagnosis (Figure 21). Men and women did not differ in mean age at 
onset [24.5 (+/- 10.1) vs 24.4 (+/-10.5) years] or mean age at diagnosis [31.7 (+/- 11.5) vs
33.2 (+/- 11.4)]. The sex ratio of sporadic (simplex family) cases (74%) was 2.8, whereas 
the male/female ratio of familial (first degree relatives, multiplex family) cases (22%) was 
1.7 (p<0.0001). Further relatives (ie second and third degree; 4%) had a ratio of 2.3.
The inheritance of ankylosing spondylitis among children of affected parents is shown in 
Table 15. Overall, sons of men with ankylosing spondylitis were 2.5 times more likely than 
daughters of men to inherit the disease. Children of women were more likely to develop 
ankylosing spondylitis than were children of male patients (Table 15). Women with a young 
age at onset were more likely to have children with disease than were men or women with 
older age at disease onset (Table 15). Women aged 21 yrs or less at disease onset had a 
much higher proportion of affected children (38%) than women who were at least 25 years 
at disease onset (13%; odds ratio 4.0 Cl: 1.1-14.0; Figure 22).
For women with an affected child, 74 (43%) mothers had onset of ankylosing spondylitis 
before birth of the affected child, whereas 48 (28%) women had onset of disease after birth 
of child and 26 (15%) had child and onset of disease in the same year (onset unknown in 25 
(15%) cases). For men with an affected child, 205 (58%) had onset of ankylosing 
spondylitis
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before birth of an affected child, and 46 (13%) developed ankylosing spondylitis at the same 
time as the birth of their child (p=0.7).
For siblings older than 39 yrs of men with ankylosing spondylitis, brothers were 1.6 times 
more likely to have inherited the disease than sisters [Table 16]. For siblings older than 39 
years of men with ankylosing spondylitis with young age of onset (<21 yrs), brothers were 
twice as likely to have inherited the disease as sisters. In all cases, siblings of women were 
more likely to have the disease than siblings of men [Table 16].
Interpretation: One bias in the study is patients who have a relative with AS may be more 
likely to join a self help group, resulting in a greater number with a positive family history. 
However, this would apply to patients regardless of the sex of their relative and should not 
influence the comparison of ratios for each sex affected by AS. In addition, the percentage 
of affected relatives in this study (11 %) is comparable to that of published data [180] [181] 
[182]. A further issue relates to the inevitably small size of certain subsets of individuals (ie 
young age at onset maternal cases).
Patients and relatives were not systematically typed for HLA B27 status. Nevertheless, of 
the children randomly reviewed for B27 status used in this study 92% (34/ 37) and 96% 
(113,118) of first degree disease concordant relatives of AS patients were B27 positive. 
Moreover, over 95% of AS patients carry this antigen and B27 is inherited as a co-dominant 
factor [183]. About 50-56% of siblings and children of patients will be B27 positive. Thus, 
the risk for those carrying B27 will be twice that of the given data. The prevalence of AS 
among relatives may be a conservative estimate. Clearly, subjects with AS can not be 
included within the study if they are undiagnosed, misdiagnosed or have clinically silent 
disease. In addition, although we did ascertain that patients had a diagnosis from their 
rheumatologist following a pelvic x-ray, we were not always able to review source material. 
With rheumatoid disease, female susceptibility predominates. The patient’s gender appears 
to be an important risk factor, with relatives of male patients having the greatest cumulative
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risk of RA [184] . We now demonstrate that the reverse appears to be true for ankylosing 
spondylitis, a mainly male susceptibility disease with relatives of female patients being more 
at risk. Women have a greater family history of disease than do men and this finding is 
reflected in data from our database showing the sex ratio of sporadic (simplex family) cases 
compared to the sex ratio of familial disease. Where the index case is male, female relatives 
are less susceptible to AS than are males. By contrast, there is no significant difference in 
prevalence of AS among the relatives of either sex of female AS patients. The genetic load 
passed on by women with a young age at onset appears to be even more dramatic. 
However, this finding is not seen among siblings. There are at least 4 possible explanations 
for these findings, none of which are mutually exclusive:
1. Genetic Load Effect: Generally, females are at less risk of developing AS. Thus, it 
remains possible that those with AS have a higher genetic load in order to develop the 
disease. A woman with AS clearly carries sufficient genetic susceptibility factors for disease 
expression. This could explain why both her male and female children will have an equal 
chance of developing disease. By contrast daughters of AS males may not inherit enough 
genetic material to present with clinical symptoms.
2. A uterine effect: In general, the overall sex ratio for AS is 2.5 :1 (M:F). However, eighty 
percent of these individuals have sporadic disease. For those with familial disease, a similar 
distribution is observed among the offspring of AS fathers. By contrast, the sex ratio for 
offspring of maternal cases is equal. Moreover, children of AS mothers have a higher risk of 
AS than do children of men. AS mothers may pass an environmental disease inducing factor 
across the placenta, given the intimate contact the child has with the mother for nine 
months. Such a uterine effect (ie. environmental overlay) may enhance the risk of disease 
susceptibility in children who would not normally have developed AS. It remains possible 
that this phenomenon is particularly relevant for inducing disease in female offspring. 
Women with a young age at onset may have a greater genetic susceptibility load than
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women developing the disease later in life. Therefore, children exposed to a uterine effect 
and carrying this larger genetic susceptibility factor would have an even higher prevalence 
of disease. Indeed, in the small subset of women with a young age of onset, no less than 
38% of children developed disease (ie approximately 70-80% of B27 positive subjects [see 
Table 17]). Nevertheless, we showed that for 28% of women the onset of AS had not 
occurred before the birth of the AS child. Indeed, there is no difference in numbers of AS 
children bom before/after/during onset of AS among fathers and mothers. However, it 
remains unknown when the triggers for AS development is ‘pulled* given there may be 
many years of latency between precipitation of disease and symptom onset.
3. Influence of cvtoplasmic/mitochondrial DNA: The children of AS fathers inherit disease 
at the ‘normal* rate of 2.5:1 (M:F). That mothers with AS have more diseased offspring 
than do men could be explained in part by additional non-nuclear 
cytoplasmic/mitrochondrial genetic material that is operative only in females. Sons and 
daughters of AS mothers inherit susceptibility to AS equally as they both receive maternal 
mitochondrial DNA
4. Susceptibility genes on X or Y chromosome: The X chromosome may carry
susceptibility or protective genes and influence disease. Regardless of B27 status the sons 
of young disease onset AS mothers have a 50% chance of developing the condition. 
Possibly, the healthy 50% are those who have not inherited their mother’s B27. Of those 
with the antigen, there may be closer to 100% penetrance of disease. These sons have all 
inherited their mothers X chromosome. Daughters who develop disease may receive an X 
chromosome from their healthy father that carries the same recessive susceptibility gene. 
However, with an X-linked disease the daughters of affected fathers should have a higher 
risk than sons but our data do not support this finding.
Alternatively if the Y chromosome was involved this would mean that some of the 
susceptibility to AS may come from the Y chromosome. Therefore males carrying this
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factor have an extra susceptibility gene which can not be inherited by women. The sons of 
males would be more likely to develop disease and the children of affected females would be 
equally likely to develop disease. This suggestion is supported by the finding that in mice 
the Y chromosome has been shown to interact with the HLA B27 gene [185] . Peptides 
encoded by the Y chromosome are believed to be presented by the HLA B27 gene. 
Environmental and genetic factors are required in disease pathogenesis [186] . No doubt 
genes impact on both susceptibility and severity and may influence onset and course of 
disease by way of negative or positive effects (protective genes). Both HLA and non-HLA 
genes are relevant. Herein, we demonstrate an important influence of the sex of the index 
case and suggest that additional factors are operative. These could include a uterine 
(environmental) effect and an influence from either or both the X and Y chromosomes. 
Meanwhile, the role of protective genes, particularly in the female, and the inter-relationship 





















Table 15: Inheritance of AS among sons and daughters of AS patients.
Index case N Sons Daughters Rate of inheritance 
(sons vs daughters)




Odds ratio (95% Cl) P Odds ratio (95% Cl) P
For children > 30 years (50% diagnosis)
Father 354 35/396(8.8%) 13/376(3.5%) 2.6 (1.4-5.2) 0.003 48/772 (6.2%) 2.5
Mother 173 23/185(12.4%) 17/190(8.9%) 1.4 (0.7-2.8) 0.3 40/375 (10.7%) 1,9 (1.2-3.0) 0.005 1.4
For children > 39 years (70% diagnosis)
Father 101 11/90(12%) 5/92(5%) 2.4 (0.8-7.2) 0.17 16/182 (8.8%) 2.25
Mother 53 9/45(20%) 7/48(15%) 1.5 (0.5-4.3) 0.6 16/93 (17%) 2.1 (1.0-4.5) 0.063 1.4
Age of onset <21years and children >30 years
Father 90 11/105(10%) 4/99(4%) 2.8 (0.9-9.0) 0.1 15/204 (7.3%) 2.6
Mother 41 7/49 (14%) 6/44 (14%) 1.0(0.3-3.4) 1.0 13/93 (14%) 2.0 (0.9-4.5) 0.086 1
Age of onset < 21 years and children >39 years
Father 22 2/20 (10%) 1/19 (5%) 2.0(0.2-2.4) 0.58 3/39 (8%) 1.9
Mother 9 4/7 (57%) 2/9 (22%) 4.7 (0.5-40.4) 0.3 6/16 (38%) 7.2 (1.5-34) 0.013 2.6
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Table 16: Inheritance of AS among brothers and sisters of patients.
Index case n Brothers Sisters Rate of inheritance 
(brothers vs sisters)




Odds ratio (95% Cl) P Odds ratio (95% Cl) P
Siblings >39 years
Male 1615 153/168(9.46%) 90/1559 (5.77%) 1.7 (1.3-2.2) <0.0001 243/3177 (7.65%) 1.6
Female 607 85/673(12.6%) 57/613 (9.3%) 1.4(1.0-2.0) 0.62 142/1286 (11.04%) 1.5 (1.2-1.9) 0.0001 1.4
Age of onset <21 and siblings >39 years
Male 598 76/564(13.5%) 40/594(6.7%) 2.2 (1.4-3.2) <0.0001 116/1158 (10.02%) 2.0
Female 220 43/260 (16.5%) 21/201 (10.4%) 1.7 (1.0-3.0) 0.07 64/461 (13.9%) 1.5 (1.0-2.0) 0.029 1.6
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Table 17: Data and extrapolation in inheritance of ankylosing spondylitis to children.
Father to son Father to Mother to son Mother to
daughter daughter
Actual data











100% diagnosis S -15% -6% -30% -20%
HLA-B27 positive O -30% -12% -60% -40%
* Age at which 50% of patients are assumed to have received a diagnosis o f ankylosing spondylitis. + Age at which 
75% of patients are assumed to have received a diagnosis of ankylosing spondylitis. S  Percentage of sons or 
daughters who will develop ankylosing spondylitis eventually based on linear extrapolation from actual data o f 50% 
and 75%. O 100% diagnosis based on HLA-B27 positive and negative cases; 100% diagnosis underestimates the 
value of HLA-B27 positive children by 50%.
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fe) The interrelationship between sex, susceptibility factors and outcome in ankylosing 
spondylitis.
Objective: Men and women are affected with spondylitis differently. A greater number of 
men develop the disease (2.5:1 Males: Females) and they develop more severe spinal 
disease [126]. Women have more disease activity (pain, fatigue, discomfort) [187] and the 
children of female patients get the disease more frequently than children of male patients 
[188] . Also, children of mothers with ankylosing spondylitis with an onset of disease at a 
younger age get ankylosing spondylitis more frequently than children of mothers with later 
onset of disease [188] . One explanation for this is due to a genetic load effect. In general, 
women are less likely than men to develop ankylosing spondylitis. Thus, it remains possible 
that women with ankylosing spondylitis have to have a higher genetic load to develop 
disease. This higher genetic load (ie susceptibility genes) is passed on to the children 
causing them to develop spondylitis. Alternatively, factors like uterine environment and 
breast feeding may impact on susceptibility to disease.
This study is based on the hypothesis that women need a higher susceptibility gene load to 
develop the condition. The son of a father with disease may inherit enough genes to 
predispose a man to the disease, but any daughter of a father with disease who does not 
inherit enough susceptibility factors will not suffer from AS. [Figure 22 (a)].
Any female who develops disease must by definition carry enough susceptibility factors to 
show clinical symptoms of disease. [Figure 22 (b)]. This means that although mothers carry 
more susceptibility genes, the daughter of a man with disease must be comparable to the 
daughter of a women with disease in terms of genetic susceptibility load because by 
definition both daughters must carry enough genetic load to predispose them to develop 
disease.
This study will examine further evidence that families where the mother has disease carry 
more heritable factors (as opposed to environmental factors influencing susceptibility such
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as breast milk of uterine environment) than families where the father has AS. It will 
examine the effect of maternal inheritance of disease on severity (as measured by disease 
activity, function and radiology) as opposed to paternal transmission.
Methods: All patients with a family history were selected from the database and a 
confirmation of the diagnosis was sought from the GP for all these subjects. Only those 
patients with a confirmed diagnosis were used within the study.
1. Susceptibility : The number of affected second generation relatives (ie grandparents, 
aunt/uncle) of AS children with an AS affected mother was calculated and compared to 
number of affected relatives for AS children with and AS affected father. This analysis 
should highlight if mothers do carry more genetic factors related to susceptibility to 
ankylosing spondylitis.
2. Severity: (a) The outcome measures for children with an AS mother compared to an AS 
father were compared. Measures used were disease activity [BASDAI calculated on a 0-10 
scale], function [BASFI calculated on a 0-10 scale] and radiology [BASRI calculated on a 
2-16 scale].
(b) Sons of AS mothers compared to AS affected fathers for prevalence of secondary 
disease (iritis, psoriasis, inflammatory bowel disease [IBD]). This analysis was repeated for 
daughters of AS mothers compared to daughters of AS fathers.
Statistical methods: SPSS was used for all analysis. T-tests or % 2 were used.
Results: There were 328 children of AS parents with a confirmed diagnosis of AS. Of these 
the B27 status was available on 44 (43/44 were positive) and SI joint radiographs were
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requested and scored on 90 subjects, all were found to have evidence of sacroliitis of grade 
2 or more.
1. Susceptibility: The offspring of women with disease had more additional AS relatives 
(grandparents, uncle/aunt) than the offspring of men with disease [p=0.012, odds ratio : 2.3 
(1.2-4.5)]. There were 203 patients with an AS father and 125 patients with an AS mother, 
these cohorts were comparable for disease duration, age and sex [Table 18]. There were 25 
(20%) of patients with an AS mother and 19 (9%) of patients with an AS father who had a 
previous family history. For children of AS mothers, among daughters there were 13/58 
(22%) who had other relatives compared to 12/68 (18%) of sons. For children of AS 
fathers, 10/76 (13%) of daughters and 9/125 (7%) of sons had additional relatives. [Figure 
23]
2. Severity: (a) The children of a mother with AS were comparable in terms of disease 
activity, function and radiology to the children of a father with AS [Table 18]. For children 
of AS mothers, among daughters the average disease activity and function was 4.3 (sd: 2.9) 
and 3.7 (sd:3.2), while among sons it was 3.5 (2.7) and 3.0 (3.4) respectively [Daughter 
compared to son - BASDAI: 0.8 (0.2-1.6) and BASFI: 0.7 (-0.2-1.8)] For children of AS 
fathers, among daughters the average disease activity and function was 4.9 (2.3) and 3.8 
(2.7), while among sons it was 3.2 (3.3) and 2.8 (2.6) respectively [Daughter compared to 
son-BASDAI: 1.7(0.6-1.8) and BASFI: 1.0(0.3-1.8)]
(b).The prevalence of iritis is comparable between children of female AS patients compared 
to male patients [33%-39%]. However, inflammatory bowel disease is more prevalent 
among children of AS mothers [19/123(15%)] than AS fathers [10/196 (5%)] [p=0.009 
OR: 2.9(1.3-6.3)]. Psoriasis is less prevalent among sons of AS mothers than among sons of 
AS fathers [Table 19] [p=0.03 OR 0.4(0.2-0.9)].
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Of the 29 children with IBD the records of the parents were available in 14 (48%) cases. 
Only 1 of the 14 (7%) affected parents of IBD-AS children also suffered from inflammatory 
bowel disease. Of the 38 children with psoriasis and an AS father the records of the parent 
were available in 19 (50%) cases. There were 6/19 (32%) cases of psoriasis among the AS 
affected fathers.
Interpretation o f study: Tne study examines 1. Susceptibility: whether the increased 
inheritance of AS among the children of affected mothers could be due to environmental 
factors (e.g. uterine environment or breast feeding) or whether there is evidence for a higher 
susceptibility gene load within these families.
2. Severity: the effect of maternal transmission of disease compared to paternal 
transmission.
However, the assumption in this study is that AS affected daughters of AS parents (either 
fathers or mothers with disease) carry comparable susceptibility loads. The sons of AS 
fathers should on the whole carry fewer susceptibility genes than sons of AS mothers 
[Figure 22(a)]. If the transmission of AS to sons/daughters from the father is 2:1 then we 
expect that 2 out of 3 sons of men carry fewer susceptibility genes than the sons of women.
Susceptibility: Families where the mother and child have disease do appear to carry more 
heritable factors predisposing the family to disease, than father-child families. 
Approximately 20% of patients with an AS mother compared to 10% of children of AS 
fathers, had second generation relatives with disease.
Impact of susceptibility factors on outcome: In terms of disease activity, function and 
radiology, there is no difference between disease transmitted from the maternal side as 
opposed to that from the paternal side. The level of susceptibility should be comparable 
between daughters of mothers with AS and fathers with AS. However, 2A of the sons of
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AS fathers should carry fewer susceptibility genes than son of AS mothers. The finding that 
AS sons inheriting disease from the maternal side do not differ from sons inheriting disease 
from the paternal side might suggest that susceptibility effects (predisposition to disease) do 
not impact on the outcome or severity of disease. That susceptibility factors are not 
associated with altered severity may be supported by findings that in the transgenic ank/ank 
mouse the susceptibility gene HLA-B27 plays no part in the phenotypic expression of 
ankylosis (ankylosing spondylitis) [189] . Among patients, HLA B27 is associated with 
younger age at onset but not with severity measures as determined by clinical and 
radiological parameters. [190]
Inflammatory bowel disease is inherited more by the children if the mother had AS. 
However, only 7% of the mothers traced of AS-IBD patients had concomitant bowel 
disease. Psoriasis was inherited by the sons of a father with AS more than a mother. 
Among patients with psoriasis it has been previously shown that paternal transmission of 
PsA is higher than maternal transmission [191] [192], In this case, 32% of the fathers also 
had psoriasis. The sex ratio in uncomplicated psoriasis and uncomplicated inflammatory 
bowel disease is virtually the same [193] . However, more women with AS have bowel 
disease than expected and more men with AS have psoriasis. Among this sample of patients 
women do not appear to be protected from psoriasis (as 15%-17% have the disease) but 
male offspring of male AS patients appear more at risk, simply because the father may be 
more likely to have the condition. However, offspring of women with AS do develop more 
IBD even when the mothers do not seem to suffer from the condition. Iritis is inherited 
equally from mother and father, this may be because this disorder is strongly linked to the 
HLA B27 gene and most subjects with AS are carrying this gene.
For women to develop AS some of the susceptibly genes they need may over lap with those 
for inflammatory bowel disease. These genes are passed on the children. Thus, women 
appear to carry more of these occult or expressed bowel disease genes.
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Therefore, the number of susceptibility genes inherited by the children are very strongly 
linked to the sex of the parent. Women carry a higher susceptibility load and this load 
contains factors linked to inflammatory bowel disease. There is a male sex effect on 
susceptibility to psoriasis when AS is present. However, there is no evidence that 
susceptibility load has an effect on outcome and severity of disease (as measured by disease 
activity, function and radiology) or that outcome is influenced if the transmission is maternal 
as opposed to paternal.
In summary, 1. Families where the mother has AS contain more heritable factors than 
families with an AS father. 2. Disease transmitted from the maternal side does not differ 
from disease transmitted from the paternal side in male patients in terms of severity. (In 
terms of susceptibility however, disease among female patients may differ, as there are 
fewer susceptibility genes from the paternal side and daughters are less likely to develop the 
condition). 3. Offspring of AS women develop more inflammatory bowel disease and sons 
of male patients develop more psoriasis. Thus, there is a sex effect on inheritance of 
secondary conditions associated with AS. [Figure 23]
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Table 18: Impact o f sex on inheritance o f disease expression
AS women with AS mother with AS father T test
N= 57 76
Disease duration 15.9 (+/-11.5) 16.2 (+/-9.1) 0.3[-3.0-3.8] ns
Age 38.6 (+/- 11.3) 37.2 (+/-10.8) 1.4[-2.7-4.9] ns
Disease activity [BASDAI] 4.3 +/- 2.9 4.9 (+/-2.3) 0.7[-0.2-1.6] ns
Function [BASFI] 3.7+/-3.2 3.8+/-3.4 0.2[-0.9-1.4] ns
AS man with AS mother with AS father
N= 68 127
Disease duration 18.8 (+/-11.3) 15.9 (+/-9.9) 2.9 [-0.2-6.0] ns
Age 40.5 (+/- 12.7) 38.1 (+/- 11.0) 2.5 [-0.9-6.0] ns
Disease activity [BASDAI] 3.5 +/-2.7 3.2+/-3.3 0.3[-0.7-1.2] ns





n=22, dis.dur=15, age = 37 
5.8
with AS father
n=39, dis.dur=17, age =41 
6.2 0.4[-l.6-2.6] ns
Table 19: Daughters and sons of AS affected mother and AS affected father compared for 
prevalence of secondary disease [iritis, psoriasis and inflammatory bowel disease].
AS woman with AS mother with AS father Odds ratio
Number 57 76
Disease duration 15.9 (sd: 11.5) 16.2 (sd 9.1)
Age 38.6 (sd 11.3) 37.2 (10.8)
Iritis 33% (19) 39% (30) 0.8 [0.4-1.6]
Psoriasis 15% (9) 17% (13) 0.8[0.3-2.1]
Inflammatory bowel disease 18% (10) 6% (4) 3.7 [1.1-12.6] p=0.0
AS man with AS mother with AS father Odds ratio
Number 68 127
Disease duration 18.8(11.3) 15.9 (9.9)
Age 40.5 (12.7) 38.1(11)
Iritis 36 % (24) 34%(43) 1.1 [0.6-2.1]
Psoriasis 9% (6) 22% (28) 0.4[0.2-0.9] p=0.03
Inflammatory bowel disease 13% (9) 5% (6) 2.9[1.0-8.7] p=0.05
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Figure 22: Inheritance of susceptibility factors [If women need a higher susceptibility load 
than men to develop AS ]
(a) AS mother carry enough 
susceptibility to pass on disease 
to son and daughter 
++++
Many AS fathers do not carry enough 




(b) Any female who does develop disease (whether inherited from the father or the mother) 
will carry enough (and equal) susceptibility factors to show disease.
++++ (+)
m i  ++(++) ++++ ++(++)
+++ = susceptibility factors I I Male Female |  Affected
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Figure 23: Percentage of index children (mother/father with disease) with a second degree relative with AS.
AS child with AS father (n=203) AS child with AS mother (n=125)
■
7% 13% 18% 22%
Overall: 9% p = 0 . 0 1 2 20%
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Figure 24 :

















(fl Ankylosing spondylitis: Concomitance of disease among affected relatives
Objective Susceptibility to ankylosing spondylitis depends on two factors. Firstly, a genetic 
background involving many interlinking and overlapping genes and secondly factor is an 
external trigger [1]. However, little is known about factors which influence outcome in this 
condition. It can be expected both in the determination of susceptibility and severity that 
there will be a great deal of interaction both between the different genetic components as 
well as between the genes and environmental factors.
Previous work has suggested that women carry more susceptibility genes than men and 
these translate into a higher prevalence of disease among offspring of AS women [188]. 
Children of a women with disease are more likely to suffer from inflammatory bowel disease 
and sons of a man with disease are more likely to suffer from psoriasis' Thus, number of 
susceptibility genes inherited by the child is very strongly determined by the sex of the 
parent.
However, known susceptibility genes such as HLA B27 have not been found to impact on 
severity. In the transgenic ank/ank mouse the gene B27 plays no part in the phenotypic 
expression of ankylosis (ankylosing spondylitis) [189]. Among human subjects, HLA B27 
is associated with younger age at onset but not with severity measures as determined by 
clinical and radiological parameters [190].It is possible that severity genes exist which are 
independent and separate from susceptibility genes. For example, polymorphism in the 
manganese super oxide dismutase (MnSOD) gene is not associated with susceptibility to 
RA but is associated with more severe radiological outcome [194].
This study aims to explore how genetic, sex and environmental factors interact to influence 
the disease course. 1. A comparison of the expression of disease in parent-child and sibling- 
sibling pairs may provide evidence of a genetic effect on severity. 2. A comparison of
110
familial and sporadic disease will further examine the effect of susceptibility factors (ie those 
carried by familial patients) on determining severity.
Methods The Bath Ankylosing Spondylitis Database consists of 5507 (2.5: 1 M:F) patients. 
All were out-patients of the Royal National Hospital for Rheumatic Diseases or were 
members of the National Ankylosing Spondylitis Society. Patients referred to the RNHRD 
had their diagnosis confirmed according to the New York Criteria. The NASS members are 
those who have received a positive diagnosis of ankylosing spondylitis from a specialist 
rheumatologist as a result of an x ray.
All patients with a family history were selected and a confirmation of the diagnosis was 
sought from the GP for all these subjects. Only those patients with a confirmed diagnosis 
were used within the study:
A. Parent / Child :i] Parent compared to child versus parent compared to control [There 
were 2 control groups : 1 A Familial control ie the affected child of another AS-parent 2. 
A Sporadic control ie a patient with no family history].
A matched pair t-test was carried out on : The absolute difference between each parent and 
child versus the absolute difference between each parent and control.
1) Parent compared to child versus Parent compared to Familial control (ie matched child 
of another AS parent)
2) Parent compared to child versus Parent compared to Sporadic control (ie match patient 
with no family history)
ii] Analysis of variance used univariate analysis and random effects first to establish the 
extent to which the child’s disease expression can be predicted from the parental disease
i l l
level. Then, a model of factors affecting BASDAI and BASFI was established using 
multivariate analysis.
B Sibling/Sibling i] Sibling compared to Sibling versus Sibling compared to Control (1. 
familial control ie affected sibling of another AS-patients, 2. sporadic control ie patient 
with no family history)
A matched pair t-test was carried out on : The absolute difference between each patient 
and sibling versus the absolute difference between each patient and control.
ii] Analysis of variance using univariate analysis and random factors were used to establish 
the extent to which the patients disease expression can be predicted from the siblings 
disease level. Multivariable analysis was then used to examine factors influencing BASDAI 
and BASFI.
Matching was performed by identifying all possible matches [Sex, disease duration and age] 
and using a random number table to select the control.
Results’. All subjects used had a confirmed diagnosis of ankylosing spondylitis from their GP 
[89 % of those typed (293/329) were B27 positive]:
1) i] Parent/child versus parent/control matched pairs: The level of disease activity and 
function was not closer between parent -child pairs than between parent - control pairs. 
[Table 20]. Also, same sex comparisons [mother-daughter & father-son] were not closer 
than opposite sex comparisons [mother-son & father-daughter] (Absolute difference 
between same sex : opposite sex - BASDAI: 2.2 : 2.7 p=0.1, BASFI: 3.1 : 3.5 p=0.3) .
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The parent and child did however had comparable disease in terms of prevalence of iritis 
(p=0.005) and psoriais (p=0.01) [Of the 50% of parents with a history of iritis, [70/141] : 
39% of their children also had iritis, as opposed to 29% of familial and 26% of sporadic 
controls]. Of the 22% of parents who had psoriasis (32/143); 19% of the children also had 
psoriasis as opposed to 9% (Fam and Spor) of controls]. Numbers with IBD were too small 
for analysis.
Finally, the child of the AS parent had lower disease activity [BASDAI ; p=0.005] and 
better function [BASFI; p=0.001] than their sporadic matched control. [Table 21]
ii] Analysis of variance of child disease expression: The functional level [BASFI] of 142 
patients was related to: their disease activity (pO.OOl), educational level (p=0.004), 
presence of bowel disease (p=0.01) and age of patient (p=0.04). These variables together 
explain 64% of the variation seen in BASFI (p<0.001). [BASDAI alone explains 46% of the 
variation seen in BASFI and age, education and bowel disease account for 17% of the 
variation]. Factors which are not related to patients functional level was the functional level 
of the parent (with AS) (p=0.2), the disease activity level of the parent with disease (p=0.8), 
the sex of the patient (p=0.1), the family (p=0.3) [as a random effects variable, patients 
were not closer in severity to members of their family than to non-related individuals].
The level of disease activity [BASDAI] was not related to the level of disease activity in the 
parent (p=0.7), the functional level of the parent (p=0.5), the age of the patient (p=0.4), or 
sex of patient (p=0.12), or the family (p=0.08) [as a random effect]. However, it was 
affected by presence of bowel disease (p=0.041) and educational level (p=0.004). These 
two variables explain 15% of the variation seen in BASDAI (p<0.001).
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2) i] Sibling - Sibling versus Sibling - Control: A patient is closer to their diseased sibling 
in disease activity level and function than to a control matched with their sibling for sex, age 
and disease duration [Table 22].
However, there was no difference between sibling-sibling and sibling-control in terms of 
inheritance of psoriasis or iritis (numbers were too small for bowel disease) [Iritis : 39.9% 
of probands (87/218) had iritis or these 47% (40/84) sibs and 43% (34/79) controls also 
had iritis. Psoriasis: 16.7% (36/215) of probands had psoriasis of these 18% (6/33) of sibs 
(5 Brother / brother, and 1 brother/sister) and 17.6 % of controls (6/34). IBD 9.9% 
(21/212) probands had IBD of these 9.5% (2/21) of the sibs and 5.6% (1/18) of the controls 
had IBD].
The sibling had a trend to lower disease activity [BASDAI : 3.8 versus 4.3 respectively; 
p=0.07 , BASFI : 3.8 versus 4.2; p= 0.1] (but not function) than their sporadic matched 
control. [Table 23]
b] Analysis of variance of disease expression level of siblings: The functional level of 204 
subjects was related to: their siblings functional level (p=0.05 describing 8.8% of the 
variation seen in function), the patients disease activity level (p=0.001) and education 
(p<0.001). This model describes 50% of the variation seen in function (p<0.0001). Family 
(p=0.004) had an effect ie siblings are closer in severity than to individuals outside the 
family [random effects].
The disease activity level is related to the siblings disease activity level (p=0.05) and 
education (p<0.001). A model of these two variables describes 21.4% of the variation seen 
in BASDAI (p<0.0001). Siblings were closer in BASDAI [p=0.005] than to non related 
individuals [random effects].
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Interpretation o f study: This study explores the interaction between sex, environment and 
genetics in determining outcome in ankylosing spondylitis. It suggests that:
1. Severity between parent and child is not comparable.
2. Severity between affected siblings is comparable
3. Children suffer from the same secondary disorders as their parents (iritis and psoriasis) 
but not as their affected siblings.
4. Offspring of AS-parents have milder disease than sporadic AS cases.
5. Important determinants of disease activity [BASDAI] and function [BASFI] were - 
sibling severity measures, education and prevalence of secondary disorders.
Some areas of the study which may be improved in the future relate to measures of 
assessing severity. This study examined disease activity and function in patients but a 
radiological assessment of severity among relatives may provide more subjective results. 
However presently numbers of radiographs are too few to use. The use of radiographs may 
better examine the effect of sex on outcome as axial involvement is more marked among 
men with AS.
However, using disease activity and function as the measure of outcome suggests that there 
is evidence for severity genes in AS. These genes must be carried by both affected and non­
affected parents. Therefore, severity genes in the affected parent are modified by the non­
affected partner. Siblings can inherit the severity genes from both parents and therefore are 
more likely to have comparable disease.
Alternatively, it is also possible that severity is a factor of the environment and that siblings 
share more environmental variables (ie educational level) than perhaps offspring and their 
parents. Prevalence of iritis and psoriasis are clearly genetically determined outcome 
measures and these are inherited directly from the affected parent. However, severity could
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be determined by a range of variables such as uterine environment, nutrition, childhood 
disease and education level which may be closer in siblings than parental-child relationships. 
However, some support that severity genes may play a role in this condition comes from the 
finding that offspring of a diseased parent have milder disease than sporadic controls. 
Patients with milder disease may be more able to stay on in education (hence higher level of 
education associated with milder BASDAI) and perhaps more willing have children. 
[Parents of AS children have milder disease than sporadic controls (Table 21)]. The 
children may inherit some of this milder expression of the disease. The difference between 
familial and sporadic disease is not as clear between siblings. Siblings resemble sporadic 
cases as they do not have a ‘previous’ generation family history. Thus, to some extent 
milder disease may be inherited from the parents.
An alternative explanation could be that offspring of parents with AS are more often 
diagnosed with AS even if symptoms are mild. Sporadic cases with mild symptoms may not 
be diagnosed. However, this hypothesis does not account for the lower BASDAI and 
BASFI scores among the parents of AS children.
Severity in terms of function and disease activity (pain, fatigue etc) may be in part 
genetically determined and may be influenced by heritable factors carried by the non-AS 
affected parent. Familial disease which should carry a higher load of susceptibility factors 
appears to be milder than sporadic disease. This might in part be explained be the 
hypothesis that the most severe ‘sporadic’ patients may choose not to have children and 
therefore do not have the opportunity to become ‘familial disease’ cases.
In summary, this study suggests that siblings have comparable disease activity and 
functional levels but this similarity is not seen between parents and children. Secondary 
disorders are inherited from the parents. Children of affected parents have milder disease 
than sporadic controls. These findings enhance our ability to determine outcome for the
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individual (ie advice to patients that they will not resemble their parent but may follow the 
disease pattern of their sibling), and may provide evidence that severity genes are involved 
in this condition.
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Table 21: Parent-child versus parent-control.
Mean (sd)
Disease activity [BASDAI]
Difference in BASDAI between Parent compared to Child [n=l 50] 2.4 (1.8)
Difference in BASDAI between parent and Familial control [n=137] 2.5 (1,9)
Difference in BASDAI between parent and Sporadic Control [n=150] 2.6 (1.6)
Mean difference [C.I]
Matched paired T-test of difference between parent Familial: 0.1 [-0.3-0.5] Not
and their child versus parent and matched control for Sporadic : 0.2 [-0.1-0.8] signif.
their child
Function [BASFI]
Difference in BASFI between Parent compared to Child [n=150] 3.0 (2.2)
Difference in BASFI between parent and Familial control [n=137] 3.3 (2.3)
Difference in BASFI between parent and Sporadic Control [n=150] 3.1 (2.5)
Mean difference [C.I]
Matched paired T-test of difference between parent and their Familial: 0.3 [-0.3-0.9] Not
child versus parent and matched control for their child Sporadic:.0.1 [-0.4-0.6] signif.
Table 22: Familial vs sporadic disease
BASDAI (sd) BASFI (sd)
Parent [n=195] 3.8 (2.3) 4.6 (2.7)
Sporadic match 4.3 (2.1) 5.2 (2.6)
(for parent) p=0.034 p=0.021
Child [n=150] 3.6 (2.2) 2.9 (2.3)
Sporadic match 4.4 (2.3) 3.9 (2.5)
(for child) p=0.004 p=0.001
Sibling [n=221] 3.8 (2.3) 3.7 (2.8)
Sporadic match 4.2 (2.3) 4.2 (2.6)
(for sibling) p=0.072 p=0.1
Table 23: Sibling-Sibling vs Sibling - Control.
Mean (sd)
Disease activity [BASDA1]
Difference in BASDAI between Sibling compared to Sibling [n=221] 2.2 (1.6)
Difference in BASDAI between Sibling and Familial control [n=137] 2.7 (1.9)
Difference in BASDAI between Sibling and Sporadic Control [n=150] 2.6 (2.0)
Mean difference [C.I] 
Matched paired T-test of difference between parent and Familial: 0.5 [0.1-0.7] 
their child versus parent and matched control for their child Sporadic : 0.4 [0.1-0.7]
Function [BASFI]
Difference in BASFI between Parent compared to Child [n=150] 2.6 (2.2)
Difference in BASFI between parent and Familial control [n=137] 2.9 (2.3)
Difference in BASFI between parent and Sporadic Control [n=150] 3.1 (2.3)
Mean difference [C.I]
Matched paired T-test of difference between parent and Familial: 0.3 [0.004-0.7] 
their child versus parent and matched control for their child Sporadic:.0.4[0.04-0.8]
p=0.05
p=0.045
fg) Identification of severity loci in ankylosing spondylitis:
Objective: Little is known about the genetic control of disease severity in ankylosing 
spondylitis. Greater similarity of disease severity is observed in monozygotic compared to 
dizygotic twins, although no individual severity measure achieved statistical significance 
[57]. In collaborative work with The Wellcome Trust Oxford [Appendix 9] a segregation 
analysis was performed to examine the best model describing the method of inheritance of 
severity in terms of disease activity (BASDAI) and function (BASFI). This analysis 
suggested that environmental factors play little role in determining disease severity, instead 
both BASDAI and BASFI were found to be highly familial. This segregation study suggests 
that a single recessive or codominat locus influences level of BASDAI and BASFI.
Thus, this study aims to perform a genome screen of autosomal factors (ie chromosomes 1- 
22 not examining sex chromosomes X and Y) in order to examine evidence for genetic 
severity loci. A whole genome screening has been performed for genetic susceptibility loci 
[Appendix 10] and this will be used to compare the overlap of possible susceptibility and 
severity loci.
In order to do this study, variance -components analysis will be performed, this assesses the 
relative contribution of random (environmental) factors, major genes and polygenes at 
individual marker locations to the overall trait variance being studied [ie to severity]. The 
major effect in the presence and absence of linkage are compared using the likelihood ratio 
test to provide a measure of linkage of the marker and the trait. Likelihood test ratio is the 
odds ratio that the area (locus with marker) is linked to severity vs the probability it is not 
linked. The LOD score (log of the odds ratio) gives the probability that they are linked (as 
opposed to chance result when not linked). Families are studied as single units resulting in 
significantly greater power.
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Methods: All patients were seen by a qualified rheumatologist to confirm a diagnosis of AS. 
Four hundred and fifty six (456) had been previously genotyped (see appendix 10) of these 
382 individuals from 184 families completed disease activity and functional measures 
(BASDAI, BASFI).
Statistical analysis: Multi-point non-parametric linkage analysis was performed using the 
ALL statistic of the program GENEHUNTER version 2.0 (Pratt et al 2000). This method 
should identify evidence of additive genetic variance (ie effect of individual alleles on 
BASDAI and BASFI). Two-point parametric analysis was then performed assuming a 1. 
co-dominant 2. dominant or 3. recessive interaction between alleles using the LINKAGE 
CONTROL PACKAGE. The parameters used (ie standard deviation for genotype means, 
frequency of major gene alleles etc) were taken from the estimates derived using the 
segregation analysis (appendix 10).
Results: Of the 382 individuals studied, 246 were male and 136 were female (M:F 1.8:1). 
Average disease duration was 24.3 years (sd: 11.7) and age of onset was 22.7 years (sd 7.8 
years).
Disease Activity [BASDAI]: ‘Significant* Linkage (>3.6, ie expected to occur once by 
chance per 20 whole genome screens) was found using multipoint linkage analysis at 
position 18cM from the p-telomere on chromosome 18p [LOD score =4.3].
‘Suggestive* linkage (> 2.2 , ie expected to occur once by chance per whole genome screen) 
was observed in 21 markers on chromosome 18 (ie markers in position 111.9 -123.9 cM all 
had LOD scores of 2.2-2.6] using non-parametric analysis and on one marker in 
Chromosome 20 (position 96.5 cM) and one marker on chromosome 21 (position 8.6 cM) 
using parametric analysis. LOD scores of >1.5 were observed on chromosomes 6 [LOD = 
1.7 (parametric), LOD = 1 .4  (non-parametric) at position 129.8 cM] , chromosome 16
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[LOD =1.6 (parametric) at positions 60 cM and 76 cM]. All chromosomes are represented 
in Figure 25.
Function [BASFI] : LOD scores > 2.2 was observed in one marker on chromosome 2 
[position 248.3 cM (parametric)] and one marker on chromosome 13 [position 7.4 cM 
(parametric)]. LOD scores of >1.5 were observed on chromosomes 8 [5 markers at 
positions 8.4 - 18 cM], chromosome 9 [one marker at position 17.5 cM (parametric)], 
chromosome 11 [23 markers at positions 132.24 - 139.86 cM and 143.04 - 149.8 cM (non- 
parametric) and at position 71.1 (parametric)], and chromosome 18 [one marker at 17.65 
cM (parametric)]. Figure 26.
Interpretation of study:
This study provides strong evidence supporting the existence of genes involved in severity 
of AS, and points to their likely location. One region on chromosome 18 was found to be 
significantly linked to disease activity and regions on chromosomes 18,20,21 & 2, 13, 11 
were identified as having suggestive linkage.
The lack of linkage of the MHC region on chromosome 6 with severity supports the 
hypothesis that susceptibility genes and severity genes are independent and separate. 
However, the LOD score of 1.2 at position 100.66 cM on chromosome 16 is in agreement 
with the susceptibility genome screen (appendix 10) which found a LOD score of 4.7 at 
lOlcM on chromosome 16. This region may be involved in both susceptibility and severity. 
No other genome-wide scans have been performed in severity aspects of disease. A genome 
screen for loci involved in controlling normal variation in bone mineral density and 
osteoporosis identified chromosome 11 (position 12-13) as important in linkage. However, 
this is not the same region as identified on chromosome 11 as affecting BASFI in AS.
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(b) The influence of environmental factors:
Identical twins both suffer from ankylosing spondylitis in only 70 % of cases [57]. Thus, 
30% of pairs are not concordent for disease even though the genetic load carried by both 
twins is comparable. This means that the environment must play role in susceptibility to 
spondylitis. However, very little is known about the role of environmental factors in 
determining outcome and seveirty of disease. Herein, the focus is on treatments for AS, 
specifically (a) exercise and (b) physiotherapy in order to evaluate their effectiveness as 
long term modifiers of disease development, (c) Entry variables such as clinical measures 
and demographic details are analysised to see if they can be used to help predict outcome in 
terms of radiological change and functional ability. Finally (d) to evaluate if birth order has 
an effect in AS as has been reported in mice [195].
(a^Exercise in Ankylosing Spondylitis : How much is optimum ?
Objective: Drug therapy for symptom control in patients with AS has largely been confined 
to the use of NSAIDs and second line agents like sulfasalazine, which have some activity on 
peripheral joints but less effect on the spine itself. Although drug therapy with NSAID can 
be effective, the cornerstone of medical management is therapeutic exercise with the prime 
objective of maintaining normal posture and activity. This is now an essential part of a 
patients* treatment [196]. Many kinds of physical therapy can be considered for AS 
patients: supervised individual therapy, unsupervised self-administered individual exercise, 
and supervised group therapy [197] . Short-term improvement, following in-patient and 
out-patient treatment regimes, has been demonstrated in a number of centres [118][198] 
[199-207]. There remains some doubt whether this improvement is sustained in the longer
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term. In addition there is the bias that the act of follow-up may create the Hawthorne Effect 
[208] encouraging patients to do more exercise.
This study aimed to evaluated how much exercise patients with ankylosing spondylitis (AS) 
perform on a regular basis, to analyse demographic and clinical variables that might 
influence adherence to exercise, and to determine the effect of exercise on disease activity 
and function.
M ethods: Study Population
A self-administered questionnaire regarding physical exercise was completed by 4282 
patients (M:F = 3057:1221) Patients were asked “For how many hours per week on 
average have you taken part in sports, AS exercises or hydrotherapy during the last three 
months ?”. Patients were given five options: 0 hours (Group 0), 1 hour (Group I), 2-4 hours 
(Group II), 5-9 hours (Group III), 10 or more hours (Group IV). Those who did not 
answer the question were excluded from the study (n = 83).
Data processing and statistical methods
To determine the relationship between physical exercise, demographic data and clinical 
variables, patients who exercised 2 to 4 hours and 10 hours were compared to the non­
exercising group. Group II (2 to 4 hours exercise) was matched for sex, age and disease 
duration with Group 0 (n = 553). Group IV (10 or more hours exercise) was matched for 
sex, age and disease duration with Group 0 (n = 272). The matched pairs were analysed for 
demographic and clinical status. This included: marital status, employment status, education 
level, medical follow-up (rheumatologist or general practitioner), delay in diagnosis, 
medication/no medication and family history of AS. Beliefs in the benefits of exercise were 
assessed by asking the patients to record on a separate 10 cm visual analogue scale (VAS) 
the effectiveness which exercise has on reliving their symptoms. Clinical status was assessed 
by self-administered validated instruments: 1) The Bath Ankylosing Spondylitis Disease
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Activity Index (BASDAI) 2) The Bath Ankylosing Spondylitis Functional Index (BASFI) 3) 
The Bath Ankylosing Spondylitis Global Score.
Statistical analysis was performed using the SPSS package. Paired t-tests or McNemar’s 
chi-squared tests were used in analysis.
Results : In total, 915 (21%) patients were in Group 0, 836 (20%) patients were in Group 
I, 1491 (35%) were in Group II, 647 (15%) were in Group III and 393 (9%) patients were 
in Group IV (see Figures 25 and 26). There were proportionally more men in the higher 
exercise groups and more women in the lower exercise groups.
Group II (2 to 4 hours exercise):
Group II [M:F = 408:145 (ratio 2.8:1)] when compared to matched controls (n = 553 pairs) 
had improved function and lower disease activity (p < 0.001 and 0.015 respectively, Table
24). There was no difference in the global well-being of the two groups.
Delay in diagnosis, family history, marital and employment status were comparable (Table
25). A significantly greater number of patients from Group II were followed by a 
rheumatologist (p < 0.001) , had a higher education level (p = 0.005), and took more 
medication (p < 0.001). Controlling for medication, disease activity and function were still 
significantly better for group II (p = 0.017 and p = 0.001 respectively).
Group IV  (10 or more hours exercise):
Group IV [M:F = 220:52 (ratio 4.2:1)] had improved functional status when compared to 
matched controls (p = 0.033, table 26). The delay in diagnosis was significantly greater in 
Group IV (p = 0.003), as was the number of non-married individuals (p < 0.04), and the 
number of patients followed by a rheumatologist (p < 0.001, table 27)
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Employment, education level, family history , medication, disease activity and global well­
being were comparable.
Interpertation o f study: This study assessed physical exercise of patients with AS and 
explored the impact in terms of disease activity, function and well-being. It identifed factors 
associated with adherence to long-term exercise.
One potential defect of the study is the cross-sectional design allowing assessment only at 
one point.
The definition of exercise was very general, including sports, specific AS exercises and 
hydrotherapy. However the accuracy of the self-reported exercise frequency is hard to 
judge, and the quality of the exercise is unknown. Some of the patients reporting no 
exercise would have performed regular housework, walked short distances, and helped with 
all the usual household tasks. All these activities, although not strictly classified as formal 
exercise, are in themselves forms of exercise and patients would in fact be stretching, 
bending and lifting. However, all the groups would be performing these daily activities.
Most of the subjects reported either 2 to 4 hours of exercise per week (35%) or no exercise 
(21%). There were more men in Group IV and predominantly more women in Group 0. 
Most of the research reported in the literature relating to exercise in AS has been carried 
out in Europe using in-patient programmes of 2-4 weeks [200], [202], [119],[204], [205], 
[206],[207]. The majority of these studies did not include functional measurements. 
However, they reported improvement in metrology and short-term benefits in symptom 
control . Those that used functional measures reported that after the in-patient programs 
those who continue exercising had improved function [180].
The present study found that individuals who do moderate daily exercise have lower disease 
activity and improved function. Patients who performed intensive daily exercise had 
improved function but the disease activity did not improve. This suggests an optimum 
exercise duration with most benefit being derived from moderate consistent exercise. This
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finding is encouraging as the majority of the AS patients were already in this moderate 
group.
Exercise has been reported to improve well being [210], However this study did not find an 
improvement in the patients global well-being with increased exercise. This was possibly a 
reflection of a difference in study design. Previous studies used an intensive course and 
assessed well being post treatment. Therefore there is a point of intervention against which 
patients can be assessed to improve or deteriorate. This study on the other hand asked 
patients for their subjective opinion of their day to day well being. Patients who exercise 
regularly will have a better function, but they may not report any improvement or change in 
global well-being.
It has been suggested that compliance to exercise may be influenced by unmarried status 
[211]. This study did not find marital status to influence regular moderate exercise, however 
the intensive exercise group were generally unmarried.
In our study, employment status and family history of AS did not influence adherence to 
exercise.
Adherence with a regular exercise regimen is associated with rheumatologist follow-up, 
beliefs in the benefits of exercise, and a higher education level (Degree, diploma, High 
National Diploma).
Rheumatologists may be more aware than general practitioners of the benefits of exercise 
and therefore encourage and motivate the patient in the importance of regular moderate 
exercise.
Patients who practice regular exercise had strong believe in its efficacy. This finding is 
supported by previous studies that suggest beliefs in the benefits of exercise would 
differentiate exercisers from non-exercisers [211].
Patients who performed moderate exercise had a higher education level. It has been 
suggested that higher occupational status, which is associated with higher education,
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correlates with lower disease severity. Education may have an effect on an individual’s 
sense of self-efficacy, encouraging the patients to play a more active role in the control and 
the treatment of their disease, by exercising, rather than relying purely on medical 
intervention [212].
Moderate, regular exercise is beneficial for both functional status and disease activity. 
However intensive long term exercise is not as valuable for function or disease activity. 
Therefore this study suggest there is an optimum to exercise. Consistency, not quantity is of 
most importance. Those individuals most likely to follow this regime attend a 
rheumatologist, believe that exercise is of benefit and are in the higher educated bracket. 
Therefore, the less educated and those followed by general practitioners, should be 
preferentially targeted.
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Figure 25 - Distribution o f  the number o f  hours o f  exercise in the all cohort (%).
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Figure 26 - Distribution o f  the number o f hours o f  exercise per week in men and women
(%).
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n=  1460 
n = 553**
Group 0* 
n = 893 
n = 553**
P
BASDAI 3.8 ±2.0 4.2 ±2.3 0.015
BASFI 3.9 ±2.5 4.5 ±2.8 <0.001
BAS-G (1 w) 4.2 ±2.6 4.3 ±3.6 0.686
BAS-G (6 m) 4.8 ±2.5 4.8 ±2.9 0.880
* Group 0: no exercise; Group II: 2 to 4 hours of exercise per week.
* * Matched for current age, sex, and disease duration.
Table 25 - Comparison of demographic and clinical variables between Group II and
Group 0.
Group II* Group 0*
Total n = 1460 n = 893
Study Group n = 553** n = 553** P
Current age, yrs Mean ± SD 47.3 + 11.6 47.2 ±11.6 0.150
Age at onset, yrs Mean ± SD 23.8 + 7.9 23.6 ±7.9 0.111
Duration of disease, yrs Mean ± SD 23.0 ±11.9 23.0 ± 11.9 0.157
Delay in diagnosis, yrs Mean ± SD 9.6 ±9.7 8.8 ±9.6 0.141
Married, n 391 368 0.200
Employed, n 332 330 0.725
Education level - High, n 231 151 0.005
Rheumatologist, n 515 474 <0.001
Family history of AS, n 139 158 0.222
Co-medication, n 454 404 0.001
Efficacy of exercise Mean ± SD 5.2 ±2.4 3.4 ±3.0 < 0.001
*Group 0: no exercise; Group II: 2 to 4 hours of exercise per week. 
** Matched for current age, sex, and disease duration.
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n = 381 
n = 272**
Group 0* 
n = 893 
n = 272**
P
BASDAI 4.3 ±2.2 4.1 ±2.3 0.394
BASFI 4.0 ±2.6 4.5 ±2.8 0.033
BAS-G (1 w) 4.7 ±2.7 4.3 ±3.0 0.148
BAS-G (6 m) 5.1 ±2.6 4.8 ±2.9 0.284
* Group 0: no exercise; Group IV: 10 or more hours of exercise per week.
* * Matched for current age, sex, and disease duration.





n = 381 
n = 272**
Group 0* 
n = 893 
n = 272** P
Current age, yrs Mean ± SD 46.4 ± 12.6 46.4112.6 1.00
Age at onset, yrs Mean ± SD 24.4 ± 8.5 24.118.5 0.422
Duration of disease, yrs Mean ± SD 22.0±12.9 22.0112.9 0.706
Delay in diagnosis, yrs Mean ± SD 9.6110.1 7.417.8 0.003
Married, n 174 189 0.040
Employed, n 141 159 0.118
Education level - High, n 88 84 0.389
Rheumatologist, n 250 227 0.001
Family history of AS, n 64 65 1.00
Co-medication, n 210 193 0.137
Efficacy of exercise Mean ± SD 6.812.3 3.413.2 < 0.001
* Group 0: no exercise; Group IV: 10 or more hours of exercise per week.
* * Matched for current age, sex, and disease duration.
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(b) Impact of intensive physiotherapy and education program on ankylosing spondylitis: A 
longitudinal study.
Objective: Ankylosing spondyltis is a chronic systemic and progressive disorder. To date 
there are no disease modifying drugs to halt the advance of disease. Short term 
improvement in function along with reduction in pain and disease activity can be achieved 
by inpatient and outpatient exercise programmes [192-203] However, it is unknown if 
these benefits remain over the long term. In addition to physical therapy, patient education 
is believed to benefit the patient in terms of symptoms, mood, physical and social activities.
The RNHRD runs a treatment programme which combines inpatient physiotherapy with a 
comprehensive patient education package. Over the short term this programme reduces 
disease activity and improves function by on average twenty five percent. This study aims 
to examine the long term affect of this course on disease progression over a 2 year follow- 
up period.
Methods:
Study population: Annually, the RNHRD runs 24 two week inpatient programmes, with 
on average 10 patients attending each course. The programme consists of daily group 
sessions in hydrotherapy, circuit training, neck and trunk exercises, stretches and relaxation. 
Patient education includes; pathology, physiology, anatomy relevant to the disease process, 
pain management, medication, posture and coping strategies. The course should increase 
understanding of the nature of the disease and encourage adherence to exercise therapy.
To examine the longitudinal benefits of the course patients who attended [n=216] were 
asked to complete functional, disease activity and global well-being assessments at baseline 
(before course), 3 months, 6 months, 12 months and 24 months. In addition, a random
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sample of patients who did not attend the course [n=216] were asked to also complete the 
questionnaires. These non-course subjects were members of NASS (National Ankylosing 
Spondylitis Society).
Statistical analysis: Matched pair t-tests were used to evaluate the status of the individual 
after 24 months. The baseline score of the subject was compared with the 24 month score.
A scenario analysis was then performed to account for drop-outs from the study. In this 
analysis the scenario is assumed that at the 24 month time period, the drop-out patient 
remains at same disease activity and functional score as given in last questionnare recieved. 
Thus, last available questionaire is used as the final two year measure for all drop outs. 
Finally, univarent analysis was used to evaluate the effect of baseline level of B ASDAI an 
BASFI (ie severity before course) on average change in score at the 3 month, 6 month and 
12 month time period.
Results:
Full records for a follow-up period of twenty four months was avaliable on 181 (84%) 
course patients and 179 (83%) non-course patients. Patients attending the course were 
referred by a rheumatologist. Thus, at baseline the course subjects were more severe for 
disease activity and functional scores than the non-course individuals [Table 26]. These 
patients had an older age at onset and shorter disease duration than the non-course subjects.
1. Change over 24 months - Individual measures fmatched pair T-Testsl :
For patients attending the course, function, disease duration and global well-being were 
comparable at baseline and after two years. There was no significant disease progression 
over a two year period.
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For non-course patients, function [p=0.006], disese activity [p<0.001} and global well­
being [p<0.001] scores were worse after 2 years.
Scenario analysis: To determine if patients droped out of the study because disease had 
deteriorated (failure) or improved substancially, the last available score received from the 
drop outs patients [from both the course and non-course groups] was used to represent the 
24 months score. Match-test analysis on this new data showed that results did not differ 
when drops-out patients were included. [Table 27]. The mean time point when patients 
failed to return the questionnaire was at 18 months in both the course and non-course 
cohorts.
2. Analysis of variance:
In univariant analysis attendence to the course was associated with amount of change in 
funtional (p=0.01), disease activity (p=0.002) and global well-being scores (p=0.012). At 
2 years those not attending the course poorer BASFI, BASDAI and BAS-G scores . 
However, base line severity score was also a factor in determining amount of change in 
outcome measures. When these factor was included in multivariable analysis the effect of 
the course was no longer significant. (Figures 27, 28, 29). Thus, milder non-course patients 
appear to deteriorate over a two year period while more severe course patients do not 
change.
Interpertation o f study:
Intensive physiotherapy and education has a long term benefit in slowing disease 
progression of ankylosing spondylitis. However, it is recognised that due to the nature of 
the referral process for the course only the more severe patients were allowed to attend the 
programme. It is possible that those patient who have already progressed to this level of 
severe disease may not alter greatly over a two year period. While, the milder non-course
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subjects have the potential and scope to get worse. Regression to the mean may explain the 
findings of this study.
Yet, the patients who attended the course had the disease for a shorter duration than the 
non-course cohort, and in this time the severity was worse. Therefore, it is likely that these 
subjects represent a group with more active and aggressive disease. The disease activity of 
AS is normally constant throughout the patients life [42] and function deteriorates with age 
and disease duration. It is unlikely that the progression and activity of the disease would 
slow down and change unless the intervention programme had an effect.
Thus, an intensive physiotherapy and educational programme can have a long term (2 year) 
effect on disease progression. With the lack of any disease modifying drugs or therapy to 
combat this condition the intervention programme represents an effective and long lasting 
form of treatment for those patients with aggressive and advancing disease.
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Table 26: Demographic Data
Course (n=l81) Non-Course (n= 179) p value
Age 47.3 (+/-11) 48.4 (+/-11) ns
Age onset 25.9 (+/-10) 23.1 (+/- 9) p=0.003
Disease duration 21.4 (+/-9) 26.3 (+/-12) p<0.001
Delay in diagnosis 8.3 (+/-8) 7.8 (+/-T.9) ns
M:F 142 : 39 147 : 32 ns
Iritis 38% 42% ns
Psoriasis 19% 17% ns
IBD 9.4% 7.8% ns
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Table 27 : Outcome of course vs non-course patients.
Course (n=187) Non-course (N= 179)
BASDAI
Baseline 4.7 (+/- 2.0) 3.5 (+/-2.1)
6 months 4.7 (+/- 2.2) 3.6 (+/-2.1)
12 months 4.5 (+/- 2.1) 3.8 (+/- 2.0)
24 months 4.5 (+/- 2.0) 3.9 (+/-2.3)
Scenario analysis 4.52 (2.25) 3.98 (2.26)
p value ns 0.001
BASFI
Baseline 4.8 (+/-2.1) 3.6 (+/-2.3)
6 months 4.9 (+/-2.S) 3.8 (+/-2.4)
12 months 4.8 (+/-2.4) 3.8 (+/-2.4)
24 months 5.0 (+/-2.4) 3.9 (+/-2.S)
Scenario 5.0 (2.4) 3.95 (2.5)
p value ns 0.006
BAS-G
Baseline 5.1 (+/- 2.3) 3.8 (+/-2.6)
6 months 5.2 (+/-2.2) 4.1 (+/-2.5)
12 months 5.1 (+/-2.6) 4.2 (+7-2.8)
24 months 5.0 (+/-2.5) 4.5 (+7-2.7)
Scenario 5.1 (2.45) 4.5 (2.7)
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(cl Predictors of outcome in ankylosing spondylitis
Objective: Many overlapping and interlinking variables have been shown to affect severity 
in AS. It has been suggested that disease severity is at least partially determined by genetic 
factors [Appendix 9] [186]. The relative contribution of genetic and environmental factors 
to disease severity has not, however, been elucidated.
In terms of environmental factors identified, it is difficult to separate the effects of one 
variable from another. For example, cigarette smoking has been associated with worse 
clinical, functional and radiological outcome [114], patients in the lower educational / socio­
economic groups have a poorer prognosis [115][116] and daily exercise has been shown to 
retard the progression of disease. However, it is unclear weather variables like smoking is 
actually associated with poorer outcome or instead is a reflection of social status and lack of 
exercise. Amor et al [121] have shown that clinical entry variables predicting severity 
include hip arthritis, ESR>30mm/h, sausage like finger toe, oligoarthritis, onset <16 years, 
limitation of the lumbar spine and poor efficiency of nonsteroidal antiinflammatory drugs.
In this study radiology was seen to represent an unbiased, fixed, ‘gold standard* for the 
measurement of disease status. Damage is irreversible and thus can reflect the cumulative 
natural history of disease in the individual patient. However, it was felt that radiological 
score may miss much of the change important in AS such as pain and soft tissue 
inflammation. Therefore, function was also used for the measurement of outcome as this 
should be a more accurate reflection of the quality of life of the individual and the ability to 
remain in employment.
Thus, this study soought to determine patient characteristics which might explain the 
variability in outcome in AS.
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Methods: All subjects (n=311) were patients at the Royal National Hospital for Rheumatic 
Disease and had been diagnosed according to the New York Criteria. Patient hospital notes 
were used to confirm all variables such as diagnosis of secondary diseases (psoriasis, iritis, 
inflammatory bowel disease), peripheral involvement, smoking etc. All patients had full sets 
of radiographs (Lx, Cx, SI and hip) scored using BASRI by 2 trained independent readers. 
Discrepancies between scores were rescored by a third trained reader and a consensus was 
reached. All patients completed disease activity (BASDAI) and function (BASFI) 
assessments in the same year as radiological assessment (BASRI is sensitive to change over 
2 years).
Univariate analysis followed by multivariate regression analysis using backward selection 
was performed using SPSS to identify and analyse the factors correlated with severity. 
Correlations were performed using Spearman rank correlation coefficient. SPSS was used 
for all analysis.
Results: Demographic data and distribution of the variables among the 311 patients are 
showen in Table 28. Of the 311 patients in the study, 254 (82%) were male and the average 
age at disease diagnosis was 22.9 years (SD 8.3).
1. Univariant analysis of factors influencing radiological status [BASRI] showed : Disease 
duration, sex, marital status, education level, iritis, psoriasis (and hip involvement in the 
case of spinal score) [Table 29] all impact on radiological change. Using these variables in 
multivariable analysis showed that disease duration , sex, marital status and iritis together 
explain 22.8% (p<0.001) of the variation seen in BASRI. [Hip involvement, disease 
duration, sex and iritis explain 29% (p<0.001) of variation seen in the spinal involvement]. 
These findings indicate that level of radiological change progresses with disease duration, 
men have more advanced change than women except when iritis is present (Figure 30) and
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married or widowed patients have less radiological change than single or separated subjects. 
The presence of hip involvement is associated with more severe spinal radiological change.
2. Univariant analysis showed that factors influencing BASFI were: Radiological status, 
disease activity, disease duration, smoking, peripheral involvement, psoriasis and hip 
involvement. [Table 30] Using these factors in multivarable analysis showed : radiological 
status, disease activity and smoking were all associated with function (p<0.001) accounting 
for 50% of the variation seen in BASFI. There was a relationship between smoking and 
psoriasis (p=0.001) . Those psoriasis patients who smoked had poorer function than either 
patients with psoriasis who did not smoke or smokers without psoriasis [Figure 31].
Factors not associated with outcome included: variables such as first symptom of AS, age at 
onset, delay in diagnosis, family history, NSAID ineffective, family history and exerciser vs 
non-exerciser.
Interperation o f study: Inherent characteristics such as iritis and the sex of the patients 
determine radiological outcome in AS. However, variables impacting on function such as 
smoking and disease activity (pain, fatigue, stiffness and discomfort) may be more easily 
altered or treated. Function is perhaps the most important outcome measure in allowing 
patients to maintain a quality of life at home and at work. Two of the three factors 
associated with functional outcome in this study are modifiable - disease activity and 
cigarette smoking. Thus, by targeting those individuals with peripheral involvement, 
psoriasis and hip involvement with aggressive treatment early on [such as physiotherapy, 
education (ie advice on smoking, drug treatments, pain management) and drug therapy] we 
may be better able to maintain function in the high risk individuals.
The criteria used by Amore et al to predict outcome were not all examined within this study 
(ie ESR was not included). However, this study support the previous findings that hip
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arthritis predicts a poor outcome both in terms of radiology and function. Only 16 patients 
(of 311) were identified who had evidence that NSAIDs were ineffective and no subjects 
with sausage-like fingers or toes were found. Age at onset was not found to be a predictor 
of outcome.
Some environmental variables impacting on radiological outcome may in fact be due to 
reverse correlation. Marital status and education level may be a reflection that those 
subjects with mild disease have less disruption to their life than those with severe arthritis. 
Alternatively, social support (from spouses) may play a role in outcome. An education 
beyond school leaving level may allow patients to manage their disease better.
The patients used in this study are those referred to a tertiary referral centre and therefore 
will be more severe than patients managed by their GP. It is therefore possible that 
environmental variables like occupation and exercise would become important in subjects 
who have milder disease. However, the population we examined were by selection (ie 
referral) a more inherently severe cohort.
Much of the variability in outcome is not accounted for by the models within this study. 
There still remains 80% of the variation in radiology and 50% of the variation in function 
unexplained. It is possible that genetic factors (as suggested by influence of iritis and 
psoriasis) and hormonal (as suggested by predictive value of sex) have a greater influence 
on outcome than environmental factors particularly in terms of radiology.
In conclusion, smoking, secondary diseases (iritis and psoriasis), hip involvement and male 
sex are important predictors of a poor outcome in ankylosing spondylitis. Individuals with 
these characteristics should be targeted for aggressive treatment early on in the disease.
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Table 28: Characteristics of AS study subjects/Demographic data (n=311)
Variable Mean years (sd)
Disease Duration 23.5(11.3)
Delay in Diagnosis 7.7 (7.7)
Age at onset 22.9 yrs (8.3)
Number (% of total)
Male sex 254 (82%)
Iritis present 120 (39%)
Psoriasis present 69 (22%)
IBD present 23 (7%)
Hip involvement 81 (26%)
Peripheral joint involvement 130 (42%)
Affected family member 70 (23%)
Ever cigarette smoker 120 (39%)
Area first symptomatic Low back 191 (61%) 
Hip /groin 46 (15%) 
Knee/ankle 31 (10%)





Education level (%) Primary school 11/ 217(5%)
O level 78/217(36%) 
A level 30/217(14%) 
3rd level 98/217(45%)
Occupational activity level (%) Active 66/283 (23%) 
Sedentary 164/283(58%) 
Manual 53/283 (19%)
Marital Status (%) Separated/Divorced 20 (6%) 
Married/Widowed 220 (70%) 
Single 71 (23%)
Social Status** A=15, B=105, C=74, D=23, E=35, F=59
*l=None; 2=<2 hours per week; 3=2-4 hours per week; 4=5-9 hours per week; 5=10+ hours per week 
** A=director; B=profesional; C=administrative; D=skilled; E=unskilled; F=farmer
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Table 29: Factors influencing outcome as defined by radiology [BASRI]
Predictor variable Correlation’s and Mean BASRI for each Univariant
subgroup Analysis
Correlation’s
Disease activity [BASDAI] -0.008 p=0.9
Disease duration 0.286 pO.0001
Delay in diagnosis -0.093 p=0.121
Age at onset -0.024 p=0.2
Means BASRI score Mean difference in 
BASRI (95% Cl)
Sex Male 9.3, female 7.8 1.5 (0.3-2.6) p=0.022
Iritis Present 10.2 absent 8.4 1.8 (0.9-2.8) pO.0001
Psoriasis Present 9.6 absent 8.8 0.8 (0-1.9) p=0.051
IBD Present 8.7 absent 9.0 0.3 (-1.5-2.1) p=0.7
Peripheral involvement Present 9.0, absent 8.9 0.1 (-1.1-0.9) p=0.9
Hip involvement Present 10.3 absent 7.4 3.0 (2.2-3.7) p<0.001
Family history Present 8.9 absent 10.5 0.6 (-0.4-1.4) p=0.6
Smoking Yes 9.1, no 8.9 0.3 (-0.7-1.2) p=0.6
NSAID ineffective Yes 9.5, no 9.0 0.5 (-1.5-2.6) p=0.6
First symptom LBP 9.1, hip 8.5, knee/ankle 9.2, groin 8.3 p=0.7
Sedentary/active/manual job Sed 9.4, active 8.5 manual 8.4 p=0.2
Marital status Married 8.7, single 9.7, separated/divorced 10.26 p=0.025
Education level School 11.0, O’level 8.0, A’level 9.5, univ. 9.5 p=0.034
Social status Director 11.5, Teacher 9.2, admin. 8.5, skilled 
labour 9.6, unskilled labour 6.9, Farmer 8.6.
p=0.2
Exercise 1. 10.5, 2. 8.6, 3. 8.4, 4. 9.5, 5. 8.9 p=0.3
1= None, 2= 1  hour per week, 3 = 2-4 hours per week, 4 = 5-9 hours per week, 5 = 10 + 
hours per week.
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Table 30: Factors influencing outcome as defined by function [BASFI]




Disease activity [BASDAI] 0.6 pO.OOl
Disease duration 0.1 p=0.06
Delay in diagnosis 0.1 p=0.2
Age at onset 0.1 p=0.4
Means BASFI score Mean difference in
BASFI (95% Cl)
Sex Male 4.8, female 4.8 p=0.8
Iritis Present 4.9 absent 4.7 0.2 (-0.4-0.8) p=0.5
Psoriasis Present 5.8 absent 4.5 1.3 (0.6-2.0) p<0.0001
IBD Present 5.0 absent 4.8 0.2 (-0.9-1.3) p=0.7
Peripheral involvement Present 5.4, absent 4.1 1.2 (0.7-1.8) pO.OOl
Hip involvement Present 5.9 absent 4.4 1.6 (0.9-2.1) pO.0001
Family history Present 4.5 absent 4.9 0.4 (-0.3-1.0) p=0.3
Smoking Yes 5.4, no 4.3 1.0 (0.5-1.6) pO.OOl
NSAID ineffective Yes 5.7, no 4.7 0.4 (-0.9-1.6) p=0.6
First symptom LBP 4.7, hip 4.9, knee/ankle 4.9, groin 4.7 p=0.9
Sedentary/active/manual job Sed 4.8, active 4.4 imanual 5.3 p=0.1
Marital status Married 4.5, single 4.8, separated/divorced 5.4 p=0.03
Education level School 5.7, O’level 4.7, A’level 5.0, univ. 4.4 p=0.3
Social status Director' 5.2, Teacher 4.5, admin. 4.6, skilled labour p=0.2
5.1, unskilled labour 2.3, Farmer 5.3.
Exercise 1.5.1, 2. 4.5, 3.4.8, 4.4.7, 5. 4.9 p=0.5
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(e) Birth Order and Ankylosing spondylitis
Objective : In the HLA-B27 transgenic mouse model the first litters have been shown to 
have a higher percentage of diseased offspring than later litters [195]. This could be 
explained either by : a) the age of the mother (older maternal age decreases transmission of 
disease to the next generation) or b) the birth order of the offspring (ie environmental 
influence) has an influence on susceptibility to disease. Previous work has shown, that in 
humans the maternal age does not appear to have an effect on inheritance of disease [217] 
However, it has been shown using 162 AS patients, that the number of first-born children 
with AS is significantly higher than would be expected. [218]. Herein, we examine this 
hypothesis, that birth order of the child may effect the prevalence of disease, using 2343 
patients. [Appendix 13]
Methods: The entire Bath ankylosing spondylitis database was used (n=5120). Patients of 
family size 2 -6 siblings were selected. When more than one sibling in the same family had 
AS, a random number table was used to select the child for inclusion and additional relatives 
were removed from the study. All adopted patients were removed from the study.
X2 was performed on position of birth compared to family size using SPSS. Patients were 
grouped as first-born versus not first-born. After stratification by family size, the number of 
children with AS who were expected to be first-born on the basis of an equal distribution 
within birth orders was computed.
Results:
Demographic date: The AS children bom into family sizes of 2,3,4,5, or 6 children were 
comparable for sex ratio and disease duration. [Table 33]. AS patients from families of five 
or six children were older than those from 2, 3, or 4 child families [47 vs 45 respectively
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p=0.026] and they therefore had the disease for longer. [25 vs 24 years respectively p=0.04]
[Table 33].
Birth Order: Chi squared test on first bom compared to later bom children: When 
observed values of AS for the first bom child were compared to those observed for later 
bom children, the first bom child is more likely to develop disease [p=0.025]. However, the 
first bom child was only 1% more likely to develop disease. [1351 (37% of children were 
expected to be first bom children and 1390 (38%) were bom first]. [Table 34].
Chi squared test on family size units: The birth order in families of 3, 4, and 6 children 
deviated from the expected. Fewer of the youngest children had AS in these families 
(however in families of 6 children more were fourth bom than expected). [Table 34 and 
Figure 35].
Interpretation o f study: Taking the AS population as a whole there is a statistically 
significant effect of birth order. However, this difference is 1% and is unlikely to be 
clinically relevant. In addition, there was no clear biological gradient observed among 
families of different sizes. For example, in a family of 3 and 4 children the first bom child is 
more likely to have AS than later bom children but this is not seen among families of 5 
children. In a family of 6 children there was no case of AS among the fifth or sixth bom 
child but more than expected among the fourth bom child. Factors which may be having an 
influence on birth order would obviously include abortion, miscarriage and stillbirth. Only 
live births are included in this analysis. It is possible that families of 5 or 6 children have 
more miscarriages and the children may be of a much later birth order (ie 7th or 8th) than 
recorded. There are many factors which make comparisons between families difficult. For 
example, we know that genetic susceptibility is required to develop AS and that women
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with early onset AS are more likely to pass on the disease to their children [152]. Logically, 
women who suffer symptoms of AS would be less likely to have a large family. Therefore, 
only women with no family history of AS will be likely to have families of 5-6 children. 
Thus, any child bom into a large family is automatically at a lower risk of AS than any child 
bom into a small family. This means that children bom 5th or 6th (higher birth order) appear 
to have a lower risk when compared to the population. However, when compared to first 
bom children in a larger family they do not actually have a lower risk [Table 34].
Recent research [218] shows an increased risk of AS among first bom children. In 40 
families with 2 children, 26 of the AS affected children were first bom, whereas the number 
expected was 20, a surplus of 30%. This study, does not substantiate these findings.
Birth order appears to have a statistically significant effect but the actual difference in this 
study between first bom and later bom children is only 1% and is unlikely to be clinically 
relevant. Thus, the effect of birth order needs to be interpreted with caution.
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Table 33 : Demographic data
Family size
Family of 2 Family of 3 Family of 4
Age of AS child (sd.) 45 (13) 45 (13) 45 (13)
Sex ratio of child 2.3 : 1 2.3 : 1 2.3 : 1
Disease duration of child (sd) 21 (14) 21 (13) 20(13)
Age at onset of child (sd.) 24(11) 24(11) 25(11)
Family of 5 Family of 6 p value
47 (12) 47(11) p=0.026
2.3 : 1 2.3 : 1 ns
22 (14) 22 (13) ns
25 (13) 25 (12) p=0.039
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Table 34 : Birth order of AS individuals within the family.
Family Size Total
Birth Order 2 3 4 5 6 Observed Expected
1 741 (49.8%) 385 (35.8%) 167 (28.8%) 75 (20.6%) 22 (9.7%) 1390 (38%) 1351 (37%)
2 747 (50.2%) 375 (34.9%) 157 (27.1%) 61 (16.8%) 27 (11.3%) 1367 (37%) 1351 (37%)
3 314 (29.2%) 144 (24.9%) 70 (19.2%) 38 (21.0%) 566 (26%) 607 (28%)
4 111 (19.2%) 75 (20.6%) 102 (50.1%) 288 (25%) 249 (22%)
5 83 (22.8%) 0 (0%) 83 (15%) 104 (19%)
6 0 (0%) 0 (0%) 32 (17%)
Total 1488 1074 579 364 189 3694 3694
AS child first bom 741 385 167 75 22 1390 (38%) 1351 (37%)
AS child not first bom 747 689 412 289 167 2304 (62%) 2343 (63%)
x 2 = 11.16*
p=0.025
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7 Conclusions
7.1 Summary of findings for nature of progression in AS
Radiology is fundamental to the diagnosis and evaluation of subsequent progression of AS. 
Apart from the New York criteria for the sacroiliac joints, no widely accepted radiological 
measure exist. The BASRJ index (for spine, hip and combined for total) is reproducible, 
disease specific, sensitive to change at two years, simple to use and explain. It has now been 
accepted under the OMERACT [Outcome Measures in Rheumatology] criteria for Truth (ie 
validity , does it measure what it reports to measure), Discrimination (ie reliability and 
sensitivity to change), Feasibility (ie can it be applied easily). [223]
In comparison to other radiology scoring methods used for AS, the Stoke Radiology Spinal 
Score [224] was found to be more reliable for scoring cervical and lumber spine (intraclass 
correlation coefficient between 0.87 and 0.97) [225] . BASRI for cervical and lumbar spine 
was found to be moderately reliable when scored by independent observers [225] . 
However, the Larsen hip score proved unreliable when used in AS (Kappa 0.47-0.58). 
Therefore the BASRI hip score would constitute the only measure of change in patients 
with hip involvement due to AS. It is simple to use and required minimal training. The 
BASRI-hip was found to be sensitive to change over a one year period.
Although the Stoke index showed better reliability, it has 72 domains and takes times to 
complete. It is much more detailed and slower to use than BASRI and only examines the 
spine and neck. The BASRI global index (spine and hip score together) will examine the SI 
joints, neck, spine and hips within 30 seconds. Thus, is an easier system to employ when 
grading large numbers of radiographs for study and can be used to give a more rounded 
picture of the AS individual.
The disease history of AS as described by BASRI shows a progressive disorder with a great 
deal of variation between individuals. Those subjects with severe disease in one area were
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destined to develop severe disease in other joints. Those with mild disease in one area (such 
as in the lumbar spine or no hip involvement) had milder disease in all other joints. As a 
group the rate of progression of AS is constant. However, among individuals there is a 
great deal of variation and definite subsets of patients exist. Some subjects do not progress 
at all in 10 years of disease and others show marked change in a short period. Male patients 
show worse axial disease than women, patients with hip disease (male or female) show 
more axial involvement and those subjects with iritis show more cervical involvement. Thus, 
males with hip disease and iritis should be seen as a high risk group compared to females 
without hip involvement or iritis.
The age of first radiographic change can be estimated to be before the age of 10 in those 
patients showing symptoms at the twenties. This extrapolation assumes that rate of change 
before symptoms (ie SI joints change) will be equivalent to rate of change after symptoms 
(ie axial change). If this assumption is true then the trigger of AS would be pulled in or 
before childhood.
Thus, BASRI spine and hip are reliable and valid measures. Disease duration, male sex, hip 
involvement and iritis are the main markers for severe radiological outcome. This is a 
progressive disease (with average 30% change every 10 years) which shows a great deal of 
variation between individuals and may begin as young as age 8.
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7.2 (i) Summary of finding for influence of genetic factors on AS
The susceptibility genes for inflammatory eye, skin, bowel and joint disease appear to 
overlap: these conditions are prevalent more often in the same individual, in the same 
families and do not appear to follow a temporal pattern in onset of symptoms. Those 
patients with AS and inflammatory bowel disease carry the greatest genetic load. Thus, it is 
possible that for AS to develop there needs to be a combination of susceptibility genes. 
These are either genes linked to iritis and AS (therefore family member also suffer from 
iritis or AS but not psoriasis or inflammatory bowel disease) or genes for IBD and psoriasis 
(therefore family members suffer from IBD, psoriasis and/or AS). These genes may be 
occult or expressed. (Figure 14). Iritis predicts a poorer radiological (AS specific) outcome 
and psoriasis and inflammatory bowel disease are associated with more disease activity and 
poorer function.
In the absence of susceptibility genes linked to iritis, psoriasis and bowel disease it appears 
that other susceptibility factors are required for AS to develop, such as the susceptibility 
gene B60 and B27 (ie 77% of patients with IBD carry B27 compared to 98% of non-IBD 
AS patients). However, HLA B60 and B27 do not affect AS disease activity or function, 
while the presence of psoriasis and inflammatory bowel disease do affect these outcome 
measures. It is possible that patients with these secondary conditions do not carry enough 
AS specific susceptibility genes but do carry a higher frequency of other pathogenic factors 
(as well as the iritis, psoriasis and inflammatory bowel disease genes) which influence 
disease activity (and therefore function). AS specific susceptibility gene such as B27 can be 
seen to cause a younger age at onset of disease in the individual. However, this younger 
age at onset does not affect outcome (ie radiological change, function and disease activity). 
Therefore, age of first onset of symptoms is not a factor of severity of disease (ie most 
severe present symptoms first) but may be related to genetic susceptibility load.
170
However, a young onset is associated with hip involvement and hip involvement is 
associated with more severe AS. Yet, young age at onset without hip involvement does not 
have a poorer outcome and adult onset with hip involvement is associated with more severe 
disease. Therefore, hip involvement may represent the phenotypic expression for a severity 
marker.
Women appear to be protected from AS and therefore those females that do suffer from the 
disease carry a higher susceptibility load than both men and women without the condition. 
This is seen in the finding that the children and siblings of women with disease are more 
likely to develop the condition and women with a young age at onset are more likely 
transmit the condition to their children. These results have also been confirmed by findings 
in a French cohort [226] It has been argued [227] that the women with a negative family 
history are underdiagnosed previously and were therefore underrepresented in our study in 
comparisons to males. However, data from the RNHRD database do not support this 
hypothesis. From the database, of 243 women diagnosed in 1970-79 62 (26%) had a 
positive family history (ie father/mother, aunt/uncle, brother/sister with disease). Of patients 
diagnosed in 1990-99, 213 (30%) had a positive family history. In addition, familial disease 
is thought to be less severe [167] than sporadic illness. Thus, women with a family history 
may have a greater delay in diagnosis.
The are two possible explanations for higher risks associated with maternal AS: 1. women 
with disease may require a higher genetic load or 2. they may pass on through the uterine 
environment or breast milk, disease inducing factors (ie pathogenic triggers). However, a X 
chromosome effect is clearly ruled out by findings here and by subsequent findings from 
Oxford [228] . Further evidence that the effect may be genetic comes from findings that 
offspring of mother with disease have more previous relatives with disease (grandparents, 
uncle/aunt). It is possible that a triggering pathogen is found to run in families and is passed 
on by females (thorough breast-feeding). However, the most likely explanation is probably
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the influence of genetic factors. However, disease inherited from the maternal side does not 
differ from that inherited from the paternal side. Susceptibility factors from the maternal 
side also have no impact on severity.
However, the inheritance of secondary disorders is dependent on sex of affected parent. 
Children of mothers with disease inherit more inflammatory bowel disease but sons inherit 
less psoriasis (than if the father has disease). However the genes for these conditions may be 
occult as only 7% of the mothers transmitting bowel disease also suffer from the disorder 
(93% did not have IBD). Parents who do suffer from secondary conditions do transmit 
them to their children. However expression of disease is not directly transmitted from 
diseased parent to child. Genetic information from the unaffected parent may modify the 
expression of disease. [As siblings have comparable disease].
There does appear to be a difference between familial and sporadic disease. Those patients 
with an affected parent have milder disease (and parents with AS have milder disease 
however we have shown that they also probably had a previous family history [20 % in 
females and 10% in males]). This may be a factor of selection that only those patients with 
milder disease have a family.
Finally, there is strong evidence that there is genetic control over the level of severity in AS. 
Genes contained in loci on chromosomes 18 and 20 may be involved in regulating disease 
activity and loci on chromosomes 2,9 and 11 may contain genes involved in regulating 
function. This shows that severity and susceptibility are controlled by separate determinates 
and that different aspects of severity (ie BASDAI and BASFI) may be regulated by 
different areas of the genome.
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7.2 (ii) Summary of influence of environmental factors:
Moderate daily exercise is associated with lower disease activity and improved function. 
Those patients who followed a regular exercise regimen were in the higher education 
bracket and under the care of a rheumatologist. However, in any test of this type it is 
difficult to rule out the possibility that milder patients are more able to exercise and have 
less disruption to their life. Milder patients have less fatigue naturally and therefore may be 
able to perform exercise and continue in education. However, those who do daily activities 
score highly in beliefs in the benefits of exercise. Therefore they themselves feel the 
exercise is having an influence on their disease activity and ability to function. Using these 
findings suggest that an physiotherapy and education intensive program should be a highly 
effective treatment for those with spondylitis. It does appear that a course of this type can 
reduce deterioration while controls not attending a program will change by on average by 
10% over 2 years. However, yet again it is difficult to rule out the possibility that this is 
simply regression to the mean. As patients referred to the program are by selection more 
severe than those not referred by their rheumatologist. However it could be argued that as 
these patients were more severe it would be expected that their disease would be more 
aggressive and more likely to deteriorate over time (than milder patients). The finding that 
the course may prevent advance of the disease demonstrates that this method of treatment 
works.
Determinants of outcome appear to be inherent to the individual. Male sex, iritis, peripheral 
involvement, hip disease and psoriasis all point to more severe disease. However, one 
environmental variable which did have a significant influence was smoking. Those patients 
with AS and especially those with psoriasis who do smoke have worse disease.
It is possible that the uterine environment has an influence on susceptibility to AS. In both 
the transgenic mouse and among the AS database there appears to be a lower birth order
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among those patients with AS. However, this birth order effect might be explained by the 
hypothesis that women with AS are less likely to have large families. It appears that the 5th 
or 6th bom child in a family is at a lower risk that first bom children but this may just be 
because these children are less likely to have and AS mother.
Thus, environmental factors do appear to play a role in severity to AS. Exercise, 
physiotherapy, smoking and education may aid in modifying the disease expression for the 
individual. Alterations in the uterine enviroment may play a role in susceptibility.
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7.3. What this study has shown which is new:
1. The validation of BASRI, an AS specific scoring system which meets the OMERACT 
criteria.
2. AS is a linearly progressing disorder which may begin as young as age 8 in patients with 
first symptoms age 25-28 years.
3. Inherent characteristics associated with worse disease are: hip involvement, iritis, male 
sex and peripheral involvement.
4. Environmental variables associated with worse disease are: smoking, poor education, and 
lack of regular exercise.
5. The susceptibility genes between AS, psoriasis, inflammatory bowel disease and iritis 
overlap.
6. Women with AS are associated with more heritable susceptibility factors.
7. Women transmit more bowel disease to children and men transmit psoriasis to sons.
8. Susceptibility does not influence severity.
9. Outcome is not comparable between affected parent and child but is comparable between 
siblings.
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10. Loci on chromosomes 18, 20 and 2,13,11 are linked to severity of disease.
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8. Discussion and future direction
8.1 Natural history of AS and factors modifying progression.
Results show that for the majority of patients, AS is a progressive disorder. The rate of 
progression of radiological change in an AS hospital population is 35% of available change 
(or 2.5 on the BASRI 2-16 scale) every 10 years. Thus, disease becomes more severe with 
progressing disease duration. However, although correlation with disease duration and 
severity of radiographs is significant it is still poor (r=0.3) and only describes 19% of the 
variation seen in BASRI. Thus, 80% of the variation must be accounted for by other 
determinants. Factors associated with severe disease (as measured either by radiographs, 
disease activity or function) are: hip involvement, iritis, psoriasis, inflammatory bowel 
disease, male sex, peripheral involvement, smoking, poor education, lack of regular 
exercise, genetic determinants on chromosomes 18, 20, 2 ,3 & 11, and finally siblings with 
severe disease.
These findings do aid understanding of AS but they may not be useful in identifying or 
predicting the individuals at risk of a severe outcome. For example, in terms of the 
environmental variables (education, exercise, smoking), it is very difficult to prove cause 
and effect. It is possible that the most severely affected individuals have greater disruption 
to their life, they may not continue their education and may not be able to do regular 
exercise. In addition, it is possible that those with severe disease are more likely to smoke 
because it psychologically helps to make them feel better. Moreover, the inherent factors 
(hip involvement, iritis, psoriasis, inflammatory bowel disease) associated with poor 
outcome may also not act as predictors to severity. Symptoms of AS occur on average at 
age 25 but first symptoms of hip involvement, inflammatory bowel disease or iritis do not 
occur until ages 30, 30 or 39 respectively. Therefore the patients with these disorders have 
had AS for at least 5-10 years before any development of the ‘predictors’ of severe disease.
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In this time it is possible to see that the disease is severe without needing to observe the 
presence of hip disease, iritis etc. This criticism will also apply to the criteria of Amor et al 
[117], who found that hip arthritis, sausage-like finger or toe, oligoarthrtis and poor 
efficiency of nonsteriodial anti-inflammatory drugs predict a poor outcome. These factors 
will all take time to develop and can not be used as entry variables to predict outcome. In 
addition, it is perhaps unsurprising that inflammation of the eye, skin, bowel, hip and 
peripheral joint are associated with worse disease in the spine, as they are simply reflections 
of inflammation in more areas of the body. The more severe the disease, the more areas of 
the body become affected. Thus, worse disease is associated with worse disease. The 
disease spreads and more areas are inflamed in those patients with severe disease (affecting 
the hip, eye, peripheral joints, bowel and skin), while in those with mild disease there is little 
inflammation even in the areas affected with disease. These are not predictors of outcome 
but are themselves part of the measure of the level of inflammation in the body.
Male sex has also been used as a predictor of radiological outcome in AS. However, it 
could be argued that AS has long been thought of as a disease affecting men more than 
women. Therefore, when describing the changes seen in AS in the past and today the focus 
has been on the changes seen in men (3:1, male :female) and these are mostly axial spine 
changes. There is more change in the axial spine in men compared to women. However, if 
women had been used to define AS specific measures there may be a different criteria and 
under these new scoring assessments women may appear more severe. For example, if 
peripheral joint damage was included as part of an AS specific measure, women may appear 
worse than men. Women do have poorer function and more disease activity than men as 
measured both from centile reference curves and among the offspring of parents with AS. In 
addition, hip disease is found as often in women as in men and severity of hip involvement is 
comparable between the two sexes Therefore, men do have more severe axial disease than 
women but that may not mean that they have more severe disease generally. This may be
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more a factor of how radiological outcome is defined and less that male sex really translates 
into more severe disease. Thus, it would appear that siblings level of disease is the only real 
predictor of outcome.
It is possible that in a few individuals an early prognosis of severe disease (eg as defined 
from figure 9), with early involvement in the neck or advanced disease in the spine could 
allow treatment with interventions such as anti-TNF and might prevent hip involvement 
occurring.
In 21% of patients with iritis [50/237], there is inflammatory eye involvement before the age 
of 25 [the average age of onset of symptoms of AS in these patients was 18.5 years (stdev : 
5.6)]. These patients, and any subjects from a eye clinic with iritis followed by arthritis 
should be flagged for early aggressive intervention treatment such as physiotherapy and 
disease modifying agents like anti-TNF. This may prevent severe axial involvement and hip/ 
peripheral disease in the future.
Finally, those with a severely affected sibling should be flagged for early treatment.
Any sign of severe early disease will suggest more widespread and advanced involvement in 
the future. This spread of disease may be prevented if treatment is give early. In addition, 
all patients should be encouraged not to smoke, to be educated about their condition and to 
do regular exercise.
8.2 Secondary disorders and AS
There are a number of interacting findings from this study regarding the relationship 
between AS and the secondary disorders:
1. The secondary disorders associated with AS are found more often than expected in the 
same individual. Relatives of patients with AS are also more likely to suffer from the
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secondary disorders than expected (in the absence of AS). Therefore, there does appear to 
be an overlap in the susceptibility genes of these conditions.
2. It has been shown that iritis is associated with more radiological involvement and 
psoriasis & bowel disease are associated with higher disease activity and poorer function.
3. In women, there appears to be more susceptibility genes than in men. Women have 
higher disease activity and poorer function but less radiological involvement of the axial 
spine.
4. The children of AS-women are more likely to develop inflammatory bowel disease and 
the sons of male patients more likely to develop psoriasis
Hypothesis : Susceptibility genes (ie inherited factors predisposing an individual to AS) do 
not affect the severity of inflammation. However, they may determine which regions of the 
body become susceptible to inflammation. Therefore, susceptibility genes for psoriasis 
bowel disease or iritis will make the skin, bowel or eye susceptible to inflammation. 
Severity genes determine the level of inflammation in susceptible areas.
For example, the genes linked to iritis may be present in all individuals with AS (eg the B27 
genes is linked to iritis and AS). If the disease is mild (ie few severity genes) there is a low 
level of inflammation in the body. The patient is susceptible to iritis but does not show 
clinical symptoms because the inflammation level is mild. If the patient has a large number 
of severity genes then areas prone to disease (ie susceptible) will show clinical symptoms of 
inflammation. Thus, the genes appear occult among patients with mild AS and appear 
expressed in those with more severe AS [Figure 36].
However, in the case of inflammatory bowel disease and psoriasis genes there appears to be 
an effect of sex on expression of the genes. When a women carries these genes they may 
make the bowel susceptible to inflammation. When a man carries these genes they may 
make the skin (psoriasis) susceptible to inflammation. Women generally , carry more
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susceptibility genes but not necessarily more severity genes. Therefore, more areas are 
prone to inflammation (areas susceptible) in women, but depending on the severity genes 
these areas may not become symptomatic. Thus, in women disease may appear to remain 
occult. For example only 7% of the AS mothers of children with AS-IBD also suffered from 
bowel disease.
Thus, the secondary disorders are controlled by related genes. These disorders control 
which areas of the body will become susceptible to inflammation. The sex of the individual 
will determine how many of these susceptibility genes are present and modify which areas 
are prone to inflammation. [Figure 36]
8.3 Interaction between susceptibility and severity factors.
This study has show that in addition to specific susceptibility genes such as B27 and B60, 
susceptibility is also associated with; sex, the secondary disorders (IBD, iritis, psoriasis), 
age at onset, and family history. Men show clinical symptoms of AS more often than 
women. Thus, women are thought to be protected in some way from developing AS. 
Those women who do suffer from the condition may have been exposed to higher levels of 
susceptibility than men. Evidence that they carry more susceptibility genes comes from the 
findings that they are more likely to have a previous family history of disease and more 
likely to pass the condition on to their children. Women also pass on bowel disease to their 
children even when they do not suffer from bowel disease. Thus, occult susceptibility 
genes exist and women may carry more of these genes.
Susceptibility is determined by genetics and bacterial triggers. Severity genes are 
independent from susceptibility genes and it is possible that men carry more severity genes 
(thus show more clinical symptoms than women). When disease is present the genes linked 
to IBD, psoriasis and iritis will determine which parts of the body become inflamed.
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However, these genes do not determine the severity of disease. Separate severity genes 
determine level of inflammation. Under higher levels of inflammation, the areas susceptible 
(eye, skin, bowel, peripheral joint or hip) become involved. Thus, without severity genes 
determining severe disease, the susceptibility genes (for hip, bowel etc) remain hidden (but 
may be involved in determining susceptibility to AS)
Patients with a young age at onset carry more susceptibility factors. Some of these factor 
such as B27 cause an earlier onset of disease. Hip disease genes will be a susceptibility 
factor, also making the hip susceptible to disease. If genes for severe disease are present 
then the hip susceptibility genes (leading to earlier onset of AS) may target the inflammation 
to the hip. However, if AS is mild (due to mild severity genes), then the hip does not 
become involved even though the factors targeting the hip are present.
Thus, susceptibility genes and severity genes are separate factors. Susceptibility genes 
determine what areas become ‘susceptible’ and severity genes determine whether these 
areas develop disease and to what extent.
8.4 Influence of environmental factors.
Of seven environmental variables examined (smoking, activity of job, marital status, 
education level, social status, exercise, birth order) only three were not associated 
pathogenesis of AS. The others (smoking, marital status, education and exercise) were 
associated with variation in disease expression.
As suggested earlier, it is difficult to prove cause and effect when discussing association 
between traits and variables. However, the finding that the majority of environmental 
variables examined were associated with severity of AS suggests that to an extent the 
progression of AS can be modified. If it was found that smoking, exercise, and education 
had no effect on outcome, this result would have implied that severity is totally inherent.
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Instead, these findings suggest that environmental factors may limit and moderate outcome, 
Patients themselves report a high belief in the effectiveness of exercise to relieve symptoms 
and those subject that attend the intensive education/physiotherapy course of the RNHRD 
report great benefits and often want to come back on repeat courses.
There were many other variables which may influence outcome but could not be examined 
within this study. For example, hormonal levels and bowel flora may be important 
determinants of severity of disease.
Thus, environmental variables do appear to play a role in pathogenesis of AS. However, 
much more work in this area is need to demonstrate and understand this role.
8.5 Future directions
Men are more susceptible to AS then women, and disease is transmitted more to the son 
than the daughter. One explanation for this has been that there may be a Y chromosome 
effect. In collaboration with Harvard University, where the entire Y chromosome has 
previously been mapped, possible susceptibility genes will be examined. Blood from 50 AS 
males and 50 normal males will be analysed to establish if a link does exist. To date the 
bloods of 36 affected AS males have been collected and analysed.
The targeting of patients with severe and active AS (i.e. those with bowel disease or hip 
involvement) for disease modifying drugs was attempted for this study. It was hoped that 
the anti-TNF drug Etanercept could be given in a pilot study. However , supplies of the 
drug were limited and all research was stopped by the company. However, it is planned 
that Infleximab may now be used on a sample of patients to establish the beneficial effects 
of this new treatment.
The radiographic database is currently being expanded so that concordance of disease 
among siblings and parent-child pairs can be compared for AS specific changes. The level 
of change in the axial spine is different between the sexes. Thus, concordance of disease will
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highlight how much radiological change is inherited and to what degree it is determined by 
sex of the patient.
The increased level of susceptibility to AS among the children of women with AS could be 
explained by transmission of the triggering agent through breast milk. A cohort study of 
breast feeding levels among those AS mothers with an affected child versus those with an 
unaffected child will be undertaken.
The effect of the X chromosome on severity of disease will be examined using similar 
methods to those used in the autosmal genome screen. In addition, in collaboration with 
The Wellcome Trust, Oxford more work will be undertaken to further focus in on the 
location of the severity genes.
To examine the age of first radiological change in the sacroiliac joints a study will be 
undertaken (if funding permits) examining by MRI the children (age 10-16) of women with 
young age at onset and the children of men with a strong family history. A cohort of B27 
negative children will be used as a control to examine if first changes can be observed in 
some of the B27 positive children of AS patients.
8.6 In Summary
Susceptibility to AS is determined by susceptibility genes and an environmental trigger. The 
trigger may be pulled in childhood and first radiological change may begin as young as age
8. Separate severity genes are involved in determining the rate of progression and the 
extent of inflammation of the disease. There are many interlinking susceptibility genes and 
these will determine the areas susceptible to AS. There are a number of severity genes and 
these will interact to determine outcome. The genetic load of susceptibility and severity 
genes is determined by both parents whether or not they are affected by AS. The activity 
level of the person will modify the activity of the disease. Smoking will make progression 
worse especially in those patients with psoriasis. Education may help a person deal better
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with their disease and perhaps adhere to the treatments prescribed. Further work should 
examine what genes are involved in susceptibility and severity and what the role or function 
is of these genes in the body. Drug therapy may then help modify the condition or in the 
long term prevent the disease in those most at risk.
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Figure 36: Susceptibility genes for psoriasis/ IBD and iritis in men and women with AS.
Susceptibility gene Severity gene Sex Outcome
Ps/IBD + mild Female AS Mild AS, No secondary disorder
Ps/IBD +++ severe Female AS Severe AS, IBD
Ps/IBD + mild Male AS Mild A S , No secondary disorder
Ps/IBD +++severe Male AS Severe AS, Ps
Iritis + mild Female AS Mild AS, No secondaiy disorder
Iritis +++ severe Female AS Severe AS, Iritis
Iritis + mild Male AS Mild AS, No secondary disorder
Iritis +++ severe Male AS Severe AS, Iritis
9. Final Statements.
1. BASRI is a valid measure to assess radiology in AS. It gives a description of the axial 
spine and hips. This constitutes the only rapid measure (ie 30 seconds to complete) which 
can give a global score of the radiographic status of the AS individual. Thus, it may be used 
both in research to compare large numbers of subjects rapidly, reliably and with minimal 
training, as well as in the clinic for routine follow-up .
2. The radiological progression of ankylosing spondylitis as a population is linear, 
progressing at a rate of 35% of available change every 10 years. It may begin as young as 
age 8 in the sacroiliac joints and then progresses up the spine to the lumbar and then 
cervical spine. A quarter of patients with severe disease will develop hip involvement. 
Factors associated with rate of progression of disease include sex of the patient, presence of 
iritis or hip involvement, education level and marital status.
3. Patients with severe disease (as determined by radiographs or disease activity or function) 
do not just have advanced disease in the spine but also suffer from inflammation in the hips, 
peripheral joints, skin, eye, bowel. Thus, severe AS is a more wide spread disease than mild 
AS. These additional areas become involved generally after the onset of the arthritis . Thus, 
with increasing disease duration the disease becomes more progressive. This level of 
severity appears to be inherit as siblings are concomitant for disease expression.
4. Susceptibility factors and severity factors are discrete. Susceptibility is determined by 
genetic load (which may include those genes determining inflammation of the eye, bowel 
and skin) and infective triggers which may take effect even in the uterine environment. 
Women with AS transmit the disease more often to their children, this may because they
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carry a higher susceptibility load (ie they have more diseased relatives) or there may be a 
uterine environmental effect. Severity genes and environmental factors may determine the 
level and nature of the inflammation but susceptibility factors may determine the areas 
‘susceptible’ to disease (ie bowel, eye skin, hip , peripheral joints etc).
5. Inherent severity level of disease may be modified by factors such as exercise, education 
and social support.
6. Future work should examine drugs specifically targeting the underlying inflammatory 
process involved in AS such as the drug anti-TNF. In addition, by targeting the genes 
involved in severity of AS and identify their protein products, it will be possible to develop 
disease modifying drugs and alter prognosis of disease for the first time.
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Appendix 1: The BAS indices
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Please place a mark on each line below to indicate your answer to each 
question, relating to the past week.








3. How would you describe the overall level of pain/swelling in joints other 
than neck, back or hips you have had?
NONE VERY
SEVERE
4. How would you describe the overall level of discomfort you have had from 
any areas tender to touch or pressure?
NONE VERY
SEVERE
5. How would you describe the overall level of morning stiffness you have 
had from the time you wake up?
NONE VERY
SEVERE
6. How long does your morning stiffness last from the time you wake up?
0 hrs l/2hr 1 hr 1 l/2hrs 2 or more hrs
[The VAS are scored in cm and the BASDAI score is calculated as :
the sum of question 1,2,3,4 + the average of question 5 and 6, all divided by 5.]
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Bath Ankylosing Spondylitis Functional Index  
(BASFI)
Please draw a mark on each line below to indicate your level of ability with 
each of the following activities, during the last week.
Note: An aid is a piece of equipment which helps you to perform an action or 
movement.
1. Putting on your socks or tights without help or aids (eg sock aids):
EASY IMPOSSIBLE
2. Bending forward from the waist to pick up a pen from the floor without an 
aid:
EASY IMPOSSIBLE
3. Reaching up to a high shelf without help or aids (eg helping hand):
EASY IMPOSSIBLE
4. Getting up out of an armless dining room chair without using your hands or 
any other help:
EASY IMPOSSIBLE
5. Getting up off the floor without help from lying on your back:
EASY IMPOSSIBLE
6. Standing unsupported for 10 minutes without discomfort:
EASY IMPOSSIBLE
7. Climbing 12-15 steps without using a handrail or walking aid (one foot each step):
EASY IMPOSSIBLE
8. Looking over your shoulder without turning your body:
EASY IMPOSSIBLE
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9. Doing physically demanding activities (eg, physiotherapy exercises, gardening, or 
sports):
EASY IMPOSSIBLE
10. Doing a full days activities whether it be at home or at work:
EASY IMPOSSIBLE
[The VAS are scored in cm and BASFI is calculated by taking the average of the 10 
questions. ]
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Bath Ankylosing Spondylitis Patient Global Score (BAS-G)
Please place a vertical mark on the scale below to indicate the effect your disease has 
had on your well-being over the last week.
NONE WORST
POSSIBLE
[BAS-G is calcuated by measuring the VAS scale in cm]
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TH E BATH ANKYLOSING SPONDYLITIS RADIOLOGY INDEX (BASRI)
A New, Validated Approach to Disease Assessment 
KIRSTEN MACKAY, CHRISTOPHER MACK, SINEAD BROPHY, and A N D REI CALIN
Objective. To develop a reproducible and simple 
radiologic scoring system for the spine in patients with 
ankylosing spondylitis (AS): the Bath Ankylosing Spon­
dylitis Radiology Index for the spine (BASRI-s).
Methods. Radiographs of 470 patients with AS 
were scored using the New York criteria for the sacro­
iliac joints and, similarly, grading the lumbar and 
cervical spine on a scale of 0-4 (for normal, suspicious, 
mild, moderate, and severe). These 3 scores were added 
together to produce the BASRI-s score (scored 2-12). 
Radiographs of 188 patients were used to test reproduc­
ibility. Blinded radiographs of 89 non-AS patients were 
included, randomly, to assess disease specificity. Sensi­
tivity to change was assessed using 177 radiographs 
from 58 AS patients.
Results. Intra- and interobserver variation 
showed 75-86% and 73-79% complete agreement at all 
sites, respectively. Specificities of 0.83-0.89 suggested 
that the lumbar and cervical spine BASRI scores were 
disease specific. Sensitivity to change became apparent 
at 2 years (P  < 0.001). Using a lateral view and an 
anteroposterior view of the lumbar spine was more 
sensitive than using a lateral view alone. Grading a set 
of radiographs (sacroiliac joints, lumbar spine, and 
cervical spine) took 30 seconds.
Conclusion. BASRI is a reliable method for grad­
ing radiographic changes in patients with AS. It is 
disease specific, sensitive to change, valid, simple, and 
rapid to perform.
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Ankylosing spondylitis (AS) is a chronic, progres­
sive condition with fluctuating disease activity. A num­
ber of measures are used simultaneously to monitor 
outcome (1-10), and these are fundamental in assessing 
the natural history of AS and the effectiveness of specific 
management strategies in terms of outcomes research 
(11). Characteristic radiologic change is essential for the 
diagnosis of AS and is considered the “gold standard'7 
for disease status, but little work has been done to assess 
disease progression in radiologic terms. Radiographs 
have the advantage over other measures of being objec­
tive and uncomplicated by diurnal variation (12).
No classification defining global radiologic 
change in AS exists. The New York (NY) criteria for AS 
include the only widely accepted radiology measure 
specific for the disease, but this refers purely to the 
sacroiliac (SI) joints (13-15). The Rome criteria use the 
presence of radiologic sacroiliitis to diagnosis AS but 
ignore the rest of the spine (16). End-slage cervical and 
lumbar spine disease may be readily recognizable in 
terms of a “bamboo spine,” but less severe changes have 
not been adequately described. A number of systems for 
scoring some part of the spine in AS have been pub­
lished (12,17-20), but these are not used widely. None of 
them score the whole spine. Some have poor reproduc­
ibility, are insensitive to disease progression, and are 
slow to use (21). All ignore the posterior structures of 
the spine, classifying those who have only posterior 
element fusion as normal or as having “mild77 radio- 
graphic changes when in fact the spine may be com­
pletely fused (see Figures 1A and B and Figure 2).
The Bath Ankylosing Spondylitis Radiology In­
dex for the spine (BASRI-s), a new radiologic scoring 
system, was designed to address these problems. This 
report describes the BASRI-s, its inception, and its uses. 
Radiologic changes in the hip have specifically been 
excluded from this study, since those AS patients who 
develop hip disease represent a small, distinct subset of
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T abic 1. Bath A nkylosing Spondylitis R adiology Index (B A SR I) for 
the spine*
Score G rade
Syslcm  app lies to both the lumbar and 
the cervical spine  
(grade each  as 0 - 4 )
0 Normal N o  change
1 Suspicious N o defin ite  change
2 Mild A ny num ber o f  erosions, squaring, or 
sclerosis, with or without 
syndesm ophytes, on  < 2  vertebrae
3 M oderate Syn desm op hytes on ^ 3  vertebrae, with 
or w ithout fusion involving 2 
vertebrae
4 Severe Fusion involving > 3  vertebrae
5 For the lumbar sp ine, exam ine both the anteroposterior and lateral 
radiographs together. T he score for the lum bar spine is a com posite o f  
the 2 views. If. as in Figures IA  and B, o n e  view  show s syndesm ophytes 
and fusion but the oth er view  show s lesser changes, the overall score 
will relate to the view show ing the m ore significant change. This system  
applies equally to the cervical sp ine, but only to the lateral radiograph. 
See Figures I and 2.
patients whose disease occurs at a younger age (22-26). 
An index documenting radiologic hip change is being 
developed.
PATIENTS AND METHODS
A consensus approach (27) was used to determine a 
suitable scoring system for radiographs of patients with AS. 
Radiographs of 470 patients who had been diagnosed accord­
ing to the NY criteria were scored openly and assigned to 1 of 
5 severity grades based on the NY grading of SI joint disease 
(0 = no disease, 1 = suspicious for disease, 2 = minimal 
disease, 3 = moderate disease, and 4 = severe disease). The 
radiographs used were an anteroposterior (AP) pelvis film, AP 
and lateral lumbar spine films, and a lateral cervical spine film. 
The SI joints, lumbar spine, and cervical spine were each 
assessed separately. The lumbar spine was defined as extend­
ing from the lower border of T12 to the upper border of SI, 
and the cervical spine as extending from the lower border of 
Cl to the upper border of Cl.
The discriminating features of each radiologic severity 
group were defined and used as the basis to describe a method 
of assessing the severity of radiologic change in AS! The system 
was then repeatedly tested in a blinded manner by 3 experi­
enced readers (KM, CM, and AC) and modified openly on 
several occasions before the final format was determined. 
Rules for scoring the lumbar and cervical spine are shown in 
Table I. The NY criteria were used to score the SI joints (15).
To assess whether an AP or lateral radiographic view 
was more appropriate for scoring the lumbar spine, 58 sets of 
lumbar spine radiographs with both AP and lateral views were 
scored using 1) the AP view alone, 2) the lateral view alone, 
and 3) the AP and lateral views combined. Sensitivity and 
specificity for each view was determined and compared with 
the score obtained with both radiographic views. A similar 
process was used for assessment of cervical spine radiographs.
Following definition of the scoring system, radiographs 
of 188 consecutive patients with AS and 89 without AS were 
scored randomly and blindly by the 3 readers to validate the 
BASRI. The mean (± S D )  age of this AS population was 
44.5 ± 10.9 years, and the sex ratio was 3:1 (males:females) 
Two hundred sixty-three SI joint, 160 lumbar spine, and 145 
cervical spine radiographs from the AS cohort were scored 
assessing intra- and interobserver variation. Because these data 
were nonparametrically distributed, tending, with increasing 
disease duration, to cluster toward a higher score (worse 
disease), a kappa statistic was used to determine the signifi­
cance of the intra- and interobserver variability.
Sensitivity to change over time was determined by 
scoring serial radiographs of 58 patients, assessing 177 time 
intervals of 1, 2, 3, and 4 years. Radiographs were obtained on 
2 occasions 12, 24, 36, and 48 months apart, and were available 
in 20, 31, 28, and 23 cases, respectively. The mean time from 
diagnosis of these 58 patients was 18 years (range 0-44 years). 
All radiographs were blinded as to the name and date of the 
radiograph, and a Wilcoxon signed rank test for nonparamctric 
data was used to determine the earliest point at which sensi­
tivity to change became apparent.
The specificity and positive predictive value against 
other rheumatic conditions was assessed using 305 radiographs 
from the AS cohort and 78 radiographs from the 89 non-AS 
patients. Radiographs of non-AS patients were interspersed 
with the AS patients’ films, such that readers were unaware of 
the diagnosis. A cutoff of grade 2 (definite) disease w-as used, 
and all radiographs were then classified into 1 of 2 groups: 
those with and those without AS changes. The SI joints were 
not viewed at this point.
The non-AS cohort we studied consisted of consecu­
tive outpatients who were attending the Royal National Hos­
pital for Rheumatic Diseases, a tertiary referral center, and 
who had had cervical or lumbar spine radiographs obtained for 
evaluation of symptoms. Their mean (± S D )  age was 57.9 ± 
16.8 years, and the sex ratio was 1:3 (males:females). This 
cohort included 41 patients with rheumatoid arthritis, 21 with 
mechanical back pain, 10 with fibromyalgia, 10 with osteo­
porosis, and 7 with psoriatic arthritis.
RESULTS
Lumbar and cervical spine: which film should be 
used? Using 58 sets of AP and lateral lumbar spine 
radiographs, 3 scores were derived as described above. 
This third, or combination, score differed from the AP 
or lateral scores if syndesmophytes or fusion were seen 
at different levels on each projection. This occurred in 3 
of the 58 patients. The “combination” score differed 
from the AP score alone in 9 of the 58 patients (15.5%) 
and from the lateral score alone in 21 (36%). Overall, 
the use of 2 projections changed the score 46% of the 
time. Assuming that the combination view gives the 
truest assessment, the sensitivity for the AP view alone is 
0.83 and that for the lateral view alone is 0.73 (see 
Figures 1A and B).
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A B
F igure 1. A, A n terop osterior  (A P ) and 8 , lateral radiographic views o f the lumbar sp ine o f  an ank ylosin g sp on d ylitis  patien t, ob ta in ed  on the sam e 
day. Syn d esm op h ytes and fusion can be seen  in the A P view  but not in the lateral view. In a scoring system  that uses on ly  the lateral radiograph, 
the findings on  the film in B could  be classified  as normal.
In the cervical spine,  this si tuation was not evi­
den t  ( see Figure 2). Only 20 cases were available in the 
popu la t ion  studied,  since AP views o f  the cervical spine 
were  rarely taken.  T h e  AP view influenced the overall 
s core  only once.
Validation of the BASRI. Intraobseiver variation. 
T wo  hu n dr ed  bl inded SI joint  r adiographs  were assessed 
twice by a single observer,  with 86% comple te  ag re e ­
ment ,  giving a kappa score of  0.69. Resul ts  for the 
lum ba r  and  cervical spine were similar,  with kappa 
scores  o f  0.65 (75% complete  ag reement )  and  0.73 (81%
complete ag re eme nt ) ,  respect ively (see Tables 2 and 3). 
The  main e r ror s  were  r ea d in g  the SI joints  as grade 3 
r ather  than g rade  4 in 12 o f  200 cases (6%) ,  scoring the 
lumbar  spine as g rade  4 r a th e r  than grade  3 in 7 of 97 
cases (7%),  and  in dis t ingui shing  suspicious (grade 1) 
f rom mild (grade 2) d i sease  in the cervical spine in 5 
cases. Var iat ion  o f  > 1  g r ad e  occ ur red  only twice when 
scoring the lumbar  spine a n d  never  when  scoring the SI 
joints or  the cervical spine.
Interobsen’er variation. Reproducibi l i ty  between 2 
r eader s was assessed us ing  263 SI joint  r adiographs
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Figure 2. C ervical sp in e  radiograph, sh ow in g  fusion o f  the posterior  
e lem en ts  hut no anterior fusion . Any scoring  system  that ignored the 
posterior e lem en ts  w ould  classify the findings on  this film as norm al.
scored by each assessor on separate occasions. There 
was 78% complete agreement between observers, with a 
kappa score o f  0.55. The 160 sets of lumbar spine 
radiographs used reached 73% complete agreement (k 
= 0.64), and the 145 cervical spine radiographs reached 
79% complete agreement (k = 0.69) (see Tables 2 and 
3). Both the lumbar and cervical spine scores ou tper­
formed the established NY criteria for SI joint assess­
ment. Considerable difficulty in separating grades 3 and 
4 existed in SI joint assessment (8 occasions), while
T able 2. Sum m ary o f  intra- and in lerohscrvcr variations at the 
various skeleta l sites scored  as part o f  the Bath A nkylosing Spondylitis  
R adiology Index















Sacroiliac joints 86 0.69 78 0.55
Lumbar sp ine 75 0.65 73 0.64
C ervical sp ine 81 0.73 79 0 .69
T able 3. Kappa statistics and strengths o f  agreem ent
Kappa
statistic Strength o f  agreem ent
< 0 .2  P oor agreem ent
0 .2 -0 .4  Fair agreem ent
0 .4 -0 .6  M oderate agreem ent
0 .6 -0 .8  G o o d  agreem ent
0 .8 -1 .0  V ery good  agreem ent
distinguishing mild from suspicious disease was the main 
problem for the lumbar and cervical spine scoring (5 
occasions). Discrepancies of >1 grade occurred while 
scoring the SI joints in 3 of 263 films, the lumbar spine 
in 5 of 160 films, and the cervical spine in 10 of 145 
radiographs.
Disease specificity. Specificity for the lumbar 
spine was 0.89, and that for the cervical spine was 0.83. 
The positive predictive value for the lumbar spine was 
0.97, and that for the cervical spine was 0.95.
Sensitivity to change. Using Wilcoxon’s signed 
rank test for nonparam etric  data, the BASRI-s dem on­
strated a significant change in radiologic score (P  <  
0.001) at 24 months for the SI joints, the lumbar spine, 
and the cervical spine. W here the time interval between 
radiographs was 12 months, 30% of cases showed 
changes of at least 1 grade within this period, but this 
was not statistically significant (P  <  0.07).
Scoring speed. T he  mean time taken to score 1 set 
of films (SI joints, lumbar spine, and cervical spine) was 
less than 30 seconds.
DISCUSSION
Any measure that documents disease status must 
be reproducible and sensitive to change. It should be 
disease specific and have both face validity and predic­
tive validity (11). To be clinically useful, it needs to be 
easy and quick to use, with few training requirements. 
The use of standard measures is essential to allow 
comparison of results between clinical studies (28). This 
is illustrated well in the rheum atoid  arthritis literature by 
the frequent use of radiologic grading systems, such as 
the Larsen and Sharp scores for the hand and the ACR 
(American College of Rheumatology) response criteria 
oi EU'LAR (European  League Against Rheumatism) 
Core Data Set (29-32). Using these criteria in epidemi­
ologic studies can improve knowledge of  disease and set 
a standard against which new treatments may be as­
sessed. Knowledge of the natural history of a disease 
such as AS, which has an unknown etiology, can provide
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insights into causal factors and provide patients with 
prognostic information and expectations (33). Distin­
guishing between markers of disease activity and those 
that attempt to measure damage and function is impor­
tant (11). T he BASRI was designed to fill a perceived 
gap in the range of outcome measures for AS.
Given that the NY criteria for the SI joints are 
well established, they were incorporated into the BASRI 
without change. To gain credibility, any newly developed 
score needs to perform as well as these criteria, and we 
have used the performance data for the NY criteria as 
the “gold standard.” The BASRI was reproducible, with 
intra- and interobserver variations equivalent to or bet­
ter than those of the NY criteria. The main problem for 
grading the lumbar and cervical spine was distinguishing 
suspicious disease from mild disease on 5 occasions 
because of difficulty in determining whether squaring 
was present. Difficulty in distinguishing between grades 
1 and 2 was not seen with the SI joints because bilateral 
grade 2 or unilateral grade 3 sacroiliitis was part of the 
entry criteria for the study. A potential method of 
overcoming this problem for the spine would be to 
measure each vertebra individually to determine the 
presence or absence of squaring compared with the 
population mean, as done in the method described by 
Ralston and colleagues (18). However, this would con­
siderably increase the time taken for scoring, thereby 
reducing the clinical usefulness of the BASRI.
The lumbar and cervical spine were shown to be 
disease specific, but the SI joints were excluded from this 
part of the study because the presence of sacroiliitis (as 
part of the NY criteria) was one of the entry criteria for 
the AS cohort. Since only 7 of the 89 non-AS cohort had 
psoriatic arthritis, further work is under way to deter­
mine whether the BASRI would be able to differentiate 
AS patients from those with Reiter’s disease or psoriatic 
arthritis.
Little information has been available regarding 
radiographic sensitivity to disease progression and the 
frequency with which repeat radiographs should be 
performed. The BASRI was found to be sensitive to 
change over a 2-year period, which suggests that radio­
graphs at intervals of < 2  years, for either routine or 
study purposes, are not warranted. The radiographs in 
the study were blinded for the date, confirming that the 
BASRI could determine “forward progression” (i.e., 
could identify the earlier of 2 radiographs performed on 
the same individual).
O ther radiologic scoring systems for the lumbar 
spine have used a single lateral radiograph to grade 
radiologic change (12,19). Although classic radiologic
features can be seen on this view, some changes, such as 
syndesmophyte formation and fusion between vertebrae, 
can be missed. The score generated using the AP view 
alone differed from the combined score (using both the 
AP and lateral views) 15% of the time but less frequently 
than with the lateral view alone, which differed 36% of 
the time. The best screening view for assessing the 
lumbar spine appears not to be the traditional lateral 
projection, but rather, the AP projection. If grade 4 
change is seen on this view, no further radiographs are 
required, but if lesser disease is evident, then both the 
AP and lateral views are essential to define fully the 
severity of change. This did not apply to the cervical 
spine. The combination of views therefore used to 
determine the BASRI for the spine was: a lateral 
cervical spine, an AP and lateral lumbar spine, and an 
AP pelvis.
The use of the AP lumbar spine radiograph does 
increase the radiation dose slightly. A lateral lumbar 
spine radiograph incurs a dose of 19.0 milliSieverts 
(mSv), the addition of an AP lumbar spine radiograph 
increases the dose by 7.0 mSv (34), which is equivalent to 
the radiation exposure incurred during a transatlantic 
flight. The total radiation exposure for AP pelvis and AP 
and lateral lumbar spine radiographs is 31.3 mSv (34). 
No data are available for the cervical spine, but the 
nearest comparable examination would be a lateral chest 
radiograph, incurring a dose of 0.66 mSv (34). The risk 
of death from a fatal cancer following a lumbar spine 
radiograph is —1:10,000 (35). The risk of dying in a road 
traffic accident in 1 year is 1:8,000 (35).
The thoracic spine has not been included in the 
BASRI-s because of technical difficulties and excessive 
radiation exposure. The scapulae and ribs tend to overlie 
the vertebrae, making a good view impossible. So, it is 
difficult to produce a well-penetrated radiograph. Lung 
disease will also add to any difficulties because the lungs 
overlie the thoracic spine in the lateral position. At­
tempts to improve the penetrance will increase the 
radiation exposure by an amount that is dependent upon 
the individual (e.g., muscle thickness affects penetra­
tion). Standard radiographs (as used by Larsen for other 
conditions) (29) have not been used since there are no 
available “gold s tan d a rd ” radiographs in AS. The 
BASRI was compared with the only other available 
index (21) and was found to be more reproducible, 
equally sensitive to change, and easier to use. Larsen 
scored only the hips in AS but found less reproduc­
ibility than in o ther  diseases, perhaps because new bone 
formation occurs in spondylarthropathies. He suggests
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that his index should be used with caution in these 
conditions (29).
The BASRI was easy to use and to explain. The 
mean time taken to score a set of radiographs for 1 
subject was <30 seconds, and the required training was 
minimal. Cross-sectional data generated using the orig­
inal cohort of 470 patients suggest that the disease 
ascends with time (36), which is consistent with many 
earlier studies and supports the instrument’s face valid­
ity. Additionally, these data suggest that radiology may 
help in defining subgroups of patients, especially if used 
in conjunction with a variety of o ther indices. Studies 
using longitudinal data to confirm the validity of the 
BASRI as a prognostic marker are in progress. A pilot 
study investigating the relationship between metrology 
and an earlier version of the BASRI revealed a good 
correlation between the 2 scores (37). Following from 
this, the relationships between radiology, metrology, 
function, and disease activity (3-5) are currently being 
investigated.
The BASRI, as described above, is a modified 
version of studies previously published in abstract form 
(38), involving the entire axial skeleton, including the 
hips. Further work has since been undertaken delineat­
ing the spinal score, or BASRI-s, allowing for a more 
precise interpretation of the grading system, and this 
system has been compared with o ther available radio­
logic scoring systems (20,21). The present study uses a 
separate cohort of patients from those used in the 
previous studies and was undertaken to validate the 
BASRI-s in a new AS population.
Hip changes have not been included in the 
BASRI-s because patients who develop hip disease 
appear to represent a distinct subgroup. Hip arthritis is 
associated with the age at disease onset, occurring at a 
younger age. Ascending spinal disease seems to be a 
product of time— the longer the disease, the greater the 
spinal change (22). The majority of patients with hip 
disease have developed some radiographic change by the 
age of 23 (23). In a prospective study begun in 1947, 150 
war veterans with AS were followed up for 33 years. 
Peripheral joint disease occurred early, and those whose 
hips were normal after 10 years of AS did not subse­
quently develop hip arthritis (24). O ther evidence has 
shown that hip disease is associated with a more severe 
outcome. Amor and colleagues (25) include hip arthritis 
as 1 of 7 entry variables correlating with disease severity 
(odds ratio 22.85; 95% confidence interval 4.43-118) 
(25). Because hip disease affects only 18-37% of the AS 
population (22), the use of a global score (BASRI-g) for 
every AS patient, with a maximum score of 16 rather
than 12, may inappropriately dilute the score of the 
majority of AS patients. Those with severe, or grade 4 
spinal disease without hip arthritis would rate only 12 on 
a 16-point global scale despite having a bamboo spine, 
poor metrology, and poor function. It may be better to 
grade these populations separately, using the BASRI-s 
for one and the BASRI-g for the other.
To maintain simplicity, the BASRI does not pick 
up minor radiologic change. The score does not change 
with each additional erosion. Evidence of squaring or 
sclerosis will always remain grade 2, or m ild  disease, 
until fusion between 2 vertebrae or the presence of >3 
syndesmophytes is identified. This is because spinal 
restriction in patients without bridging syndesmophytes 
may be related to soft tissue inflammation and poten­
tially reversible factors, and therefore should be classed 
as mild disease (12,22). As well as scoring the type of 
damage that occurs in AS (erosions, squaring, syndes­
mophytes), the BASRI also incorporates the extent of 
the involvement (i.e., number of vertebral levels with 
syndesmophytes or fusion). However, it does not differ­
entiate between those with a complete “bamboo spine” 
and those who have > 3  fused vertebrae. Both score a 
grade 4, or severe disease. This definition of severe 
disease has been used because fusion of ^ 3  vertebrae 
involves at least 60% of the lumbar spine, which limits 
spinal movement significantly. O ur preliminary work 
cori elating radiology with metrology supports this (37), 
but it does mean that the BASRI suffers from a ceiling 
effect. However, the same plateau effect and broad 
grading system are seen in the NY criteria, which have 
been widely accepted for scoring the SI joints and were 
the blueprint for the BASRI.
The limited scale of 1-4, necessitating fairly 
broad categories of radiologic grade, potentially explain 
why sensitivity to change for the BASRI is seen at 2 
years. However, it might be that relevant change is truly 
slow and can only be seen at 2 years whatever the design 
of the index. Thus, the 72-point scale of the Stoke 
Ankylosing Spondylitis Spine Score (SASSS) (12) was no 
more sensitive to change (21). Unlike rheumatoid arthri­
tis, where erosions tend to occur within the first few 
years, progression in AS appears to proceed quite slowly. 
Only 35% of a 470-patient cohort (mean disease dura­
tion 21 years, range 2-50 years) developed grade 4 
changes in the lumbar spine (36). It is likely that the 
majority are diagnosed with grade 4 SI changes because 
of the lateness of their presentation, not the speed of the 
radiologic change. This lack of radiologic progression to 
severe spinal disease in the majority suggests that the 
potential ceiling effect is of little consequence.
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Various other radiologic scores for AS have been 
published in the past 10 years (12,17-19). These have 
not attempted to define progression in the entire axial 
skeleton. The SASSS, as mentioned above, grades the 
lumbar spine alone, using a scale of 0-72. It scores the 
edges of each vertebral body from the lower border of 
T12 to the upper border of SI, using a 0-3  scale (1 for 
erosions, squaring, or sclerosis; 2 for syndesmophytes; 
and 3 for a total bony bridge). The maximum possible 
score is therefore 72, which represents a completely 
ankylosed spine. The SASSS does not take into account 
the posterior elements. This means that a subject with 
only posterior fusion would have a low score, and the 
low SASSS would be inconsistent with the clinical pic­
ture (see Figures 1A and B and Figure 2). Using the 
SASSS is slow, taking more than twice the time of the 
BASRI to grade just the lumbar spine (21). It does not 
use the AP lumbar spine film, which we have shown to 
be necessary (see Figures 1A and B). It is less reliable 
than the BASRI and is not sensitive to progression (21).
The Glasgow Radiological Index (G RI) (18-19) 
is a composite score. The SI joints are scored using the 
NY criteria, but a maximum score of 8 can be attained 
(unlike the NY criteria, the mean of the SI joints is not 
taken). The lumbar spine score includes the Vertebral 
Concavity Index, which measures the concavity of an 
individual vertebra, comparing it with a normal refer­
ence range. If the vertebra is squared, it is scored 1. The 
maximum concavity score is 5. In addition, each syndes­
mophyte identified is scored 1, allowing for a maximum 
possible score of 12. All 3 scores are added for a 
potential total of 25. The GRI applies only to the lumbar 
spine and SI joints. It is slow to perform, taking > 3  
minutes (18). It scores syndesmophytes but not fusion. It 
ignores erosions, the posterior elements, and uses only a 
lateral radiograph. The followup study (19) evaluated 41 
patients at 5-year intervals. The abstract states that 
progressive change was detected. There was no correla­
tion between the G R I and other clinical and laboratory 
parameters, namely, chest expansion, spondylometry, 
the erythrocyte sedimentation rate, and IgG levels.
In conclusion, radiology is fundamental to the 
diagnosis and tracking the subsequent progression of 
AS. Apart from the New York criteria for the SI joints, 
no  widely accepted radiologic criteria exist. The BASRI, 
as a radiologic classification system, aims to satisfy the 
O M E R A C T  (Outcome Measures in Rheumatoid A r­
thritis Clinical Trials) filter goal: specifically, one aspires 
toward truth, discrimination, and feasibility (39). The 
BASRI fulfills these criteria because it is reproducible, 
specific, sensitive to change at 2 years, simple and quick
to use, and easy to explain. It is a global index, scoring 
the SI joints and the lumbar and cervical spine.
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Erratum
In the article entitled ‘‘O utcom e of Renal Transplantation in N inety-Seven Cyclosporine-Era Patients with 
System ic Lupus Erythematosus and M atched Controls” published in the August 1998 issue of Arthritis & 
Rheumatism  (Stone et al, pp 1438-1445), the nam e of the third author of reference 4 w as listed incorrectly. 
The correct reference is Reveille JD, Bartolucci A, Alarcon GS. Prognosis in system ic lupus erythem atosus; 
negative impact of increasing age  at onset, black race, and throm bocytopenia, a s well a s  ca u se s  of death. 
Arthritis Rheum 1990;33:37-48. We regret the error.
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Appendix 3
The D evelopm ent and Validation of a Radiographic 
Grading System  for the Hip in A nkylosing Spondylitis: 
the Bath A nkylosing Spondylitis Radiology Hip Index
K IRSTEN  M ac KAY, S IN E A D  BROPHY, C H R IS T O P H E R  M ACK, M IC H E L E  D O R A N , and A N D REI CALIN
A B STR A C T  Objective. T o  d e v e lo p  a s im p le  but rep rod ucib le  rad io log ica l sco r in g  sy ste m  lor the h ip in a n k y ­
lo s in g  sp o n d y litis  (A S ) .
Methods. A  c o n se n su s  app roach  w a s  used to d e v e lo p  a grad ing sy ste m  w h ereb y  hip radiographs o f  
4 7 0  p atien ts w ith  A S  w ere  sco red  from  0  to 4 (n orm al, s u sp ic io u s , m ild , m od erate , and sev ere) , 
prod u cin g  the B ath A n k y lo s in g  S p o n d y lit is  R a d io logy  H ip Index ( B A S R I-h ip  or B A S R l-h ) . T h e  
sy ste m  w as d es ig n ed  to be s p e c if ic  for A S radiographic ch a n g e  at the h ip and in c lu d es  c ircu m fe ren ­
tial jo in t sp a ce  n arrow in g , o s te o p h y te s , e ro s io n s , and protrusio a cetab u lae . T h is  score  can then be 
added to the B A S R I-sp in e , form in g  the grading system  B A S R I-to ta l, scored  2 - 1 6 .  R adiograph s o f  
134 p atien ts w ere u sed  to le st rep rod ucib ility . B lind ed radiographs o f  100 n o n -A S  patien ts w ere  
in c lu d ed  ran d om ly  to  a s se ss  d is e a se  sp e c if ic ity . S en s itiv ity  to c h a n g e  w a s  d eterm in ed  u sin g  4j)8 radi­
ographs from  122 p atien ts, o v e r  2 1 9  tim e intervals.
Results. Inter and in traob server  variation for the right and left h ip  s h o w ed  8 3 -8 4 %  and 9 4 -9 6 %  
co m p le te  ag reem en t, r esp ectiv e ly . D isea se  sp e c if ic ity  w as 0 .7 6 . If n o n -A S  patien ts w ith  a total hip  
rep lacem en t w ere e x c lu d e d , d ise a se  sp e c if ic ity  w as 0 .8 3 . S e n s itiv ity  to ch a n g e  b eca m e apparent at 
on e  year (p  <  0 .0 0 1 ) .  G rad in g  the h ips u sin g  a s in g le  radiograph tak es sec o n d s .
Conclusion. B A S R I-h  is a r eliab le  m ethod for grading h ip radiographic ch a n g e  in A S . It is d isea se -  
s p e c if ic , s en s it iv e  to ch a n g e , s im p le  to use, and rapid to perform . (J R h eu m ato l 2 0 0 0 ;2 7 : 2 8 6 6 -7 2 )
Key Indexing Terms:
A N K Y L O S IN G  S P O N D Y L IT IS  R A D IO G R A P H IC  IN D E X  R A D IO L O G Y
BA TH  A N K Y L O S IN G  S P O N D Y L IT IS  R A D IO L O G Y  IN D E X  HIP
Ankylosing  spondylit is  (A S) is a chronic ,  progressive 
condition with fluctuating disease activity. A number of 
m e a s u re s 1 '0 can be used s im u l tan eou s ly  to monitor 
outcom e and these are fundamental in assessing the natural 
history o f  A S " .  Characteristic  radiological appearances at 
the sacroiliac (SI) joints are essential for the diagnosis of 
A S '-  ' \  but no classification completely  defining axial 
radiological change in AS exists. We developed the Bath 
Ankylosing Spondylitis  Radiology Index (BA SRI-spine or 
BASRI-s), which describes a system for scoring radiolog­
ical change in the AS sp in e 14. The hips were excluded from
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this score as those developing hip disease represent a small, 
distinct subset o f  patients, developing more severe disease, 
al a younger a g e 1*'19. Hip disease in AS has not been satis­
factorily defined. It is difficult to distinguish between AS 
hip changes and those o f  osteoarthrit is  (OA) in older 
patients with AS. The Larsen score [originally designed for 
grading radiological change in rheumatoid arthritis (RA)] 
has occasionally been applied to the hip radiographs of 
patients with AS, but is less reproducible if used to score 
conditions where there is increased bony deposition, as 
occurs in AS, with the developm ent of syndesm ophytes30.
T he  Bath Ankylosing Spondylitis Radiology Hip Index 
(B A SRI-hip  or BASRI-h) is a new radiological scoring 
system designed to address these problems. We describe the 
BASRI-hip  and its inception and uses. It can be used inde­
pendently or in conjunction with the B A SR I-sp ine14 to 
produce the BASRI-total (BASRI-t) score for the axial 
skeleton. No additional radiographs will be required to score 
the BASRI-hip  if an anteroposterior (AP) pelvic view has 
already been taken to review the SI joints .
MATERIALS AND METHODS
A co n s e n s u s  a p p r o a c h 21 w as  used  to d e t e r m in e  a su itab le  s cor ing  system  
for  h ip  r a d io g r a p h s  in pa t ien t s  with  A S .  F o u r  h u n d r e d  seven ty  A P  pelvic 
rad io g rap h s  o f  A S  pat ien ts ,  d ia g n o s e d  u s in g  the  N e w  York c r i t e r i a 12, were 
s co red  o p e n ly  by  3 e x p e r i e n c e d  read e rs  and  p la ced  in o ne  ol 5 severi ty
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grades: 0 = no d isease, I = suspicious disease, 2 = minimal disease, 3 = 
moderate disease, and 4 = severe disease. These were based on the New 
York grading o f  SI joint d isease, which was used as a “blueprint" in view  
o f  its widespread acceptance. The discriminating features determining the 
assignm ent o f  radiographs into different categories were used as the basis 
to describe the radiographic changes. The system  was repeatedly tested in 
a blinded fashion by 3 experienced readers (KM , CM. and AC) and m odi­
fied openly on several occasions before a final format was agreed on. 
Circum ferential joint space narrowing appeared to be the most important 
discrim inating feature and as such, differing degrees o f narrowing were 
used to distinguish between radiological grades. However, erosions, osteo­
phytes. and protrusio acctabulae were important in aiding the differentia­
tion between grades I, 2, and 3. Rules for scoring the hip radiographs are 
show n m Table I and illustrated in Figures I and 2.
Follow ing defin ition o f  the scoring system , radiographs o f  134 consec­
utive patients with AS and l(K) without AS were chosen to assess the relia­
bility o f  the scoring system , predict sensitivity to change, and determine 
disease specificity. The mean age o f  the AS population was 45.9 ± 10.6 
years and the sex ratio was 4.8:1 (m aleTem ale). The non-AS cohort were 
co n secu tiv e  outpatients attending the Royal National Hospital for 
Rheumatic D iseases (R N H R D ), a tertiary referral center. Pelvic radi­
ographs, in this group had been taken for the evaluation o f symptoms. Their 
mean age was 54.5 ± 17.5 years and the sex ratio was 1:2 (m aleTemale). 
The cohort included 48 with RA, 21 with OA or mechanical back pain, 7 
with fibrom yalgia. 3 with osteoporosis, 12 with psoriatic arthritis. 4 with 
polym yalgia rheumatica, 3 with inflammatory bowel disease, and 2 with 
trochanteric bursitis.
Table I. BASRI-hip scoring system . Increase BASRI-h grades I and 2 
(suspicious and m inim al) by one grade if 2 o f  the follow ing bony changes 
are present: erosions, osteophytes, or protrusio.
Grade Description
0 Normal N o change
1 Suspicious Possible focal joint space narrowing
2 Minimal Definite narrowing, leaving a circumferential
joint space > 2 mm
3 Moderate Narrowing but with circumferential joint space
< 2 111111 or bone-on-bone apposition o f < 2 cm
4 Severe Bone deformity or bone-on-bone apposition
> 2 cm or total hip replacement
Reliability. Two independent observers scored the 234 radiographs in a 
blinded fashion, on separate occasions, to assess interobserver variation 
All SI joints had been obscured and radiographs from the non-AS cohort 
interspersed such that the readers were unaware o f the diagnosis. One 
hundred o f  the AS radiographs were then randomly chosen, by a nonreader, 
and scored by a single observer on 2 consecutive days, assessing intraob­
server variation. A kappa statistic was used to determine the significance of 
inter and intraobserver variability.
Figure I. These pelv ic radiographs are o f  the same AS patient. The first was taken when he was age 25 and had had disease for 5 years. Shown here: a BASRI 
h score o f  grade 2 (m ild d isease) for the right hip with erosions (arrow I), osteophytes and focal joint space narrowing (arrow 2). BASRI-hip score for the 
left hip is grade I (suspicious d isease) with focal joint space narrowing only (arrow 3).
2 2 2
Figure 2. Same patient as Figure 1. Close up view o f the right hip taken 18 months later. The BASRI-h grade is 
now moderate (grade 3) because o f bone-on-bone apposition o f < 2 cm (broken arrow). An osteophyte can be 
seen at the acetabular margin (arrow 4).
Di.sea.se specificity. The specificity o f the BASRI-h against other rheumatic 
renditions was assessed using all 234 radiographs. A cutoff o f grade 2 
definite) disease was agreed upon and all radiographs were then classified 
into one o f 2 groups: those with and those without AS changes. 
Measurement o f disease specificity was undertaken to determine whether 
the BASRI-h measures AS-specific change.
Sensitivity to change. Sensitivity to change over time was determined by 
scoring 438 serial radiographs o f 122 patients, assessing 219 time intervals 
of 1, 2, 3, or 4 years. Patients were included if pelvic radiographs were 
available on 2 occasions 12, 24. 36, or 48 months apart. Pairs o f radi­
ographs were available in 60, 65, 55, and 55 cases, respectively. The mean 
time from diagnosis o f these 122 patients was 18 years (range 0-44). All
radiographs were blinded for name and date o f the radiograph and a 
W ilcoxon signed-rank test for nonparametric data was used to determine 
the earliest point at which sensitivity to change became apparent.
R ESU L TS
Intraobserver variation. One hundred pelvic (AP) radi­
ographs were assessed, on 2 occasions, by a single observer, 
with 94% complete agreement for the right hip and 96% 
complete agreement for the left hip. The kappa scores 
showed good and very good agreement at 0.86 and 0.91, 
respectively, for the right and left hips (Table 2). The main
Table 2. Intraobserver variation.
Right hip, K 0.86 (n = 100) Left hip. k  0.91 (n = 100)
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errors w ere  d is t inguishing between suspicious (grade 1) and 
fninimal (grade 2) d isease in 4%  of  cases.
Interobserver variation. Reproducibility between 2 readers 
was assessed using 134 pelvic (AP) radiographs scored by 
each o b se rv e r  on sep a ra te  occas ions ,  reveal ing  83%  
complete agreem en t between readers for the right hip and 
8^7o com ple te  agreem ent for the left hip. Kappa scores 
showed good  ag reem ent at 0.75 and 0.74, respectively 
(Table 3). D istinguish ing  minimal from suspicious disease 
was again the main problem, in 6%  o f  cases.
Sensitivity to change. Using a Wilcoxon signed-rank test for 
nonparametric data, the B A SRI-hip  showed a significant 
change in radiological score at one year (p < 0.001; Table 4). 
D’sease specificity. A BA SR I-h ip  score o f  grade 2 was used 
a. the cu toff  to de term ine  AS radiological change. Disease 
specificity is defined as “ the proportion o f  true positives that 
are correctly identified as such and is I minus the false 
negative rate” .22 Hence, the d isease specificity o f  the 
BASRI-hip in this study was I -  0.24 = 0.76 (76%). If non- 
AS patients with a  total hip replacement (THR) are excluded 
(because they au tom atically  score grade 4. whatever the 
i ason for their T H R ),  disease specificity becomes 0.83. 
lienee, 24 o f  the 200  hips studied in the non-AS cohort 
scored > 2.
Scoring speed. T he  mean time taken to score a pair o f  hips 
on a single A P  pelvic radiograph is 10 s.
DISCUSSION
The use o f  standard m easures  docum enting disease status is 
ssential to a llow com parison  o f  results between clinical 
studies, to im prove know ledge o f  disease natural history, 
and to set a standard against which new treatments may be 
assessed23. A ny such measure  must be reproducible, respon­
sive (sensitive to change),  disease-specific, and valid (i.e., 
measures what it cla ims to m easu re )1 l-24-2S. To be useful it 
must be clinically feasible, being simple to use with few 
training requirem ents24-23. T he  RA literature demonstrates 
.his well by the frequent use o f  the American College o f  
Rheumatology Response  Criteria, European League Against 
R heum atism  C o re  Data Set, and radiological scoring 
systems such as the Larsen and Sharp scores20-26'28. The only 
radiological scoring sys tem  currently  in use for the AS hip
Table 3. Interobserver variation.
has been the Larsen score, which was designed primarily to 
describe the hip in R A 20. Larsen states that the score is not 
as reliable when used to grade conditions, such as psoriatic 
arthritis or AS, w here  new bone formation is a prominent 
feature20. T he  B ASR I-hip , in conjunction with the BASRI- 
sp ine14, was designed to fill a perceived gap in the range of 
outcom e m easures  for AS.
As the New York c r i te r ia12 for the SI joints are well estab­
lished they w ere used as the basis for the BASRI scores. The 
BASRI-hip  was developed in an identical way to the 
BASRI-spine sc o re 14 and was equally reproducible, with 
kappa scores show ing  good agreement. In addition, it 
performed as well as the New York criteria for the SI joints 
when tested in the sam e patient cohort on a separate occa­
s ion 14.
Although the B A SR I-h ip  was shown to be disease- 
specific it did not perform as well as the B A SR I-sp ine14. 
This may have been caused by 2 principal factors. All 
patients in the non-A S group had pelvic radiographs taken 
because o f  hip pain, whereas those in the AS cohort had 
radiographs taken to visualize the SI joints and did not 
necessarily have hip pain. Additionally, a hip replacement 
always scores grade 4  whatever its cause. O f  the 100 
patients included in the non-AS cohort, 24 were graded as if 
they had AS (i.e., they had scores > 2), but 7 of the 24 scored 
grade 4 because o f  a hip replacement. If these 7 were 
excluded, only 17/100 scored > 2 (minimal disease),  giving 
a specific ity o f  83% . Thirteen o f  those 17 had severe RA. It 
is likely that the B A SR I-h ip  is describing aspects of inf lam­
matory arthritis, e.g., c ircumferential joint space narrowing, 
that are central to both RA and AS. During the validation of 
BASRI-hip, the SI jo in ts  were covered prior to scoring 
because sacroiliit is  (as part o f the New York cri ter ia12) was 
a necessary entry requirem ent for any patient with AS in the 
study.
Little information has been available regarding radi­
ographic sensitivity to disease progression and at what 
frequency repeat radiographs should be performed. The 
B ASRI-hip was sensitive to change over a one year period. 
Repeating radiographs at intervals of less than one year, for 
either routine or s tudy purposes, is therefore not warranted. 
By definition, the patients used to study sensitivity to
0
Right hip, ic 0.75 (n = 134)
0
Left hip, k 0.74 (n = 134)
41
1st Reader 




0 72 3 4 71 2 3
1 2 9 3 4 10 3
2 2 8 2 1 3 3
3 1 4 2 1 5 3
4 1 20 I 17
MacKay, et at: D evelopm ent o f  B A SR I-hip  2869
224
Table 4. I . Sensitivity to change: one year
0
Right hip, p < 0.001 (n = 60)
4





0 1 2 3
Baseline
0 29 4 1 34 4
1 7 4 3
2 3 1 5 2
3 2 1
4 8 12
2. Sensitivity to change: 2 years
Right hip, p < 0.0001 (n = 65) Left hip, p = 0 .006  (n = 65)
24 Months 24 Months
0 1 2 3 4 0 1 2 3 4
Baseline
0 29 3 2 26 2 1
1 9 4 1 2
3
2 2 2 6 1 2
3 1 3 1
4 10 11
3. Sensitivity to change: 3 years
Right hip. p < 0.001 (n = 60) Left hip, p = 0.0001 (n = 60)
36 Months 36 Months
0 1 2 3 4 0  1 2 3 4
Baseline
0 33 1 5 27 3 2 1
1 1 5 1 1 3 2 ■> 1
2 3 4 1 5 1
3 3 1 4
4 3 7
4. Sensitivity to change: 4 years
Right hip. p < 0.0001 (n = 56) Left hip, p < O.tXKIl (n = 56)
48 Months 48 Months
0 1 2 3 4 0  1 2 3 4
Baseline
0  26 1 4 23 3 2 i
1 1 1 1 2 3 2 ■> 1
2 8 1 1 5 1
3 3 3 1 4
4 5 7
change  each  had more than one  pelvic radiograph available. 
It is possib le ,  therefore,  they  had more severe hip disease 
than o ther  patients with only a single pelvic radiograph. 
T h is  c o u ld  m ean  that sen s i t iv i ty  to ch ange  becom es  
apparen t at one  year only in those with severe hip disease. 
However,  to reduce  radiation dosage, it is our policy to 
perform  a s ing le  A P  pelvic radiograph to assess both the SI 
jo in ts  and hips together. H ence , the additional pelvic radio­
graph m ay  have been taken to assess the SI jo in ts  rather than
the hips, and this was the case in at least ha lf  o f  the patients 
included. T he  rad iographs in the study w ere b linded for date 
and the B A S R I-h ip  w as able to identify the earl ie r  o f  2 radi­
og raphs  perform ed on the same individual,  de term ining 
“ forward  progress ion .”
It w ould  be quite feasible to use the index in routine 
m edical practice, s ince the B A SR I-h ip  w as  sim ple  to use 
and expla in , requiring  minimal training. M oreover,  scoring 
a pair o f  hips takes only seconds. The face and construct
2870  The Journa l o f  R h eu m a to lo g y  2000; 27:12
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l idity25 o f  the index is suppor ted  by cross sectional data 
nerated using the cohort  o f  47 0  patients29. These data 
ncur  with earl ier  stud ies  suggesting  that hip disease 
velops in those w hose  AS begins at a younger age and 
10 tend to have  m ore  severe  d is e a se 15' 19. Work with longi- 
dinal data is under  w ay  to confirm  the validity o f  using 
«th the B A SR I-h ip  and the BASRI-spine as prognostic 
arkers. To date, only limited data  are available deter- 
ining the rela tionship  be tw een  radiology, metrology, func- 
»n, and d isease activity, and w e  now plan to expand this to 
plore the in terre la tionsh ip  be tw een  these p h eno m en a’ \  
T he  B A SR I-h ip , as d escr ibed  above, is a modified 
:rsion o f  w ork  prev iously  published in abstract form, 
volving the w hole  axial sk e le ton 20. Further work has since 
:en undertaken d e linea ting  the hip score and allowing a 
o re  precise in terpre tation  o f  the grading system. The 
irrent study uses a separa te  cohort o f patients to the 
ev ious w ork  and was undertaken  to validate the BASRl- 
p in a new AS popula t ion . Hip changes have been 
jscribed separa te ly  from the BASRI-spine, as those devel- 
l in g  hip d isease  ap pea r  to represent a distinct cohort of 
sease affecting be tw een  18 and 37% of  the AS popula- 
o n |S and 22%  o f  the 4 7 0  patients with AS studied29. Hip 
thrit is is associated  with the age o f  disease onset, occur- 
ng by the age  o f  23 in the m a jo ri ty16. This is unlike 
scending spinal d isease , w hich  seem s to be a product of 
m e lxl7. Hip d isease  is also associated with a worse 
utcom e and has been included as one o f  7 entry variables 
orre la t ing  w ith  d is e a se  sev e r i ty  (odds ratio 22.85, 
.43— 118)IS. To avoid  inappropria te ly  diluting the overall 
jore  o f  patients with AS it is important to be able to sepa- 
ite the hip and spine sco res  as necessary. Additional radi- 
graphs are not necessary  to score the BASRI-hip if the 
lASRI-spine has already  been undertaken, since the AP 
iew o f  the pelvis shou ld  inc lude the hips when the SI joints 
re scored.
Radiology is fu n dam en ta l  to the diagnosis and subse- 
uent progression o f  AS. A part  from the New York criteria 
or the SI jo in ts ,  no w ide ly  accepted  radiological criteria 
xist. The B A S R I-h ip  is reproducible ,  disease-specific, 
ensitive to ch an g e  at o n e  year, and simple to use and 
xplain. It can be used in conjunct ion  with the BASRI- 
p ine14 to p roduce  a g lobal radiological index scoring the 
hole axial skele ton , w h ich  will be a valuable addition to 
ne range o f  o u tc o m e  m easu res  in AS.
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The Natural History of Ankylosing Spondylitis as 
Defined by Radiological Progression
SINEAD BROPHY1, KIRSTEN MACKAY142, AHMED AL-SAIDI1, GORDON 
TAYLOR3 and ANDREI CALIN1.
ABSTRACT. Objective. Radiological status is an important objective endpoint in the 
assessment of ankylosing spondylitis (AS). Herein we investigate the disease 
development of AS using radiological change.
Methods. The existing radiographs (n=2284) of 571 AS patients attending the Royal 
National Hospital for Rheumatic Diseases were scored retrospectively using the Bath 
Ankylosing Spondylitis Radiology Index. [1] Progression of disease was initially 
examined cross-sectionally. Univariant analysis was used to examine factors associated 
with joint involvement. [2]. Progression of disease was then examined longitudinally 
for those patients with films at time of symptom onset. [3] Rate of progression of 
radiological change was calculated using longitudinal data of two sets of radiographs 
taken 10 years apart [patient number = 54]. The results from this were used to 
extrapolate backwards to age at first radiological change.
Results. [1] Progression to cervical spine disease is a function of : disease duration, 
severity of hip and lumbar involvement and a history of iritis. [p<0.001]. Lumbar 
involvement was associated with disease duration, age now, and severity of cervical 
and hip involvement [p<0.001]. Hip involvement was a marker for cervical disease and 
associated with disease duration [p<0.001][2] Longitudinal analysis reveals marked 
variation among patients with a slow general rate of progression. [3] The progression 
of AS over any ten year period is linear [First 10 years = 30% (sd: 0.3) of potential 
change, 10-20 yrs = 40% (sd: 0.3) change, 20-30 yrs = 35% (sd: 0.4) change
1
(p=0.5)]. Backward extrapolation suggests that the approximate time of first 
radiological change is at the age of 8 years.
Conclusion. 1 AS is a linearly progressive disease with approximately 35% change 
every 10 years. Spinal involvement is largely an expression of disease duration while 
the hips become involved in about 25% of individuals and may predict a more severe 
outcome for the cervical spine. 2. Backward extrapolation shows that the disease 
process may start as young as 8 years of age. However, the time interval between the 
disease trigger and radiological change remains unknown.
Key words: ankylosing spondylitis, radiology, disease history ,BASRI
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A N e w  D im ension  toH utcom e: A pplication of The 
Bath A nkylosing Spondylitis R adiology Index
ANDREI CALIN, KIRSTEN MACKAY, HELENA SANTOS, and SINEAD BROPHY
A B STR A C T. O u r  a im  w a s  to d e v e lo p  a rep rod ucib le and s im p le  r a d io lo g ic a l s c o r in g  sy ste m  for a n k y lo sin g  
s p o n d y lit is  (A S )  to u se  in cross  section a l and p r o sp e ct iv e  s tu d ie s . R eg a rd in g  va lid ation  o f  the 
B A S R I  (B ath  A n k y lo s in g  S p o n d y lit is  R a d io lo g y  In d ex ), ra d io g ra p h s o f  4 7 0  p atien ts w ith  A S  w ere  
s c o r e d  u s in g  the N e w  York criteria for the sacro iliac  jo in ts . T h e  lu m b ar and c erv ica l sp in e , and h ips  
w e r e  s im ila r ly  graded  0 - 4 .  T h e se  scores w ere added to g e th er  to  g iv e  B A S R I - l  (to ta l) and if  the h ips  
are e x c lu d e d  to g iv e  B A S R I-s  (sp in e). R adiographs o f  188 p a tien ts  w e r e  u sed  to test r ep rod u c ib ili­
ty. B lin d e d  rad iographs o f  89  n o n -A S  patients w ere in c lu d ed  r a n d o m ly  to  a s se ss  d ise a se  sp e c if ic ity . 
S e n s it iv i ty  to ch a n g e  w as a sse ssed  using 177 radiographs fr o m  4 0  p a tien ts . R egard in g  the cro ss  s e c ­
t io n a l stu d y , 2 2 0 0  radiographs o f  5 5 0  (1 0 4  F :446 M ) p a tien ts  w e r e  ra n d o m ly  se le c te d  and scored  
u s in g  B A S R I. T h e  freq u en cy  d istribution o f  B A S R I-t and B A S R I - s  w e re  p lo tted  u sin g  a probit p lot. 
In ter and  in traob serva tion  sh o w ed  b etw een  73 and 82%  and  7 3  and 88%  c o m p le te  agreem en t, w ith  
s p e c if ic ity  o f  0 .7 8 - 0 .8 9 ,  su g g estin g  scores are d is e a s e -s p e c if ic .  S e n s it iv i ty  to  ch a n g e  b eca m e appar­
e n t at 2  years (p  <  0 .0 5 ) .  S co r in g  required 30  seco n d s  to c o m p le te .  B A S R I- t  w a s  found to be n or­
m a lly  d istr ib u ted  u sin g  a probit plot. T he m ean B A S R I s c o r e s  (to ta l, sp in a l, h ip ) in creased  w ith  d is ­
e a s e  d u ration . T h e  corre la tion , h ow ever, w as poor (r =  0 .2 9 3 ,  0 .3 4 7 ,  0 .2 6 3 ,  r e sp e c tiv e ly ) . T h o se  w ith  
h ip  in v o lv em en t had m ore sev ere  sp inal d isea se  (p  <  0 .0 0 0 1 ) .  M en  had m ore  sev e re  sp inal d ise a se  
than w o m e n  (p  <  0 .0 0 0 1 ) .  W e co n c lu d e  B A SR I is a re lia b le  and  rapid m e th o d  to grade rad iograp h ­
ic  c h a n g e s  in A S . U s in g  th is scor in g  sy stem  it can be see n  that A S  is a s lo w ly  p rogress ive  d isea se  
w ith  m u ch  in d iv id u a l variation . H ip patients have m ore s e v e r e  sp in a l d is e a s e  than th ose w ith ou t hip  
in v o lv e m e n t  and m en  have m ore sev ere  spinal d isea se  than w o m e n . (J R h eu m a to l 1 9 9 9 ;2 6 :9 8 8 -9 2 )
K ey Indexing Terms:
ANKYLOSING SPONDYLITIS RADIOLOGY BASRI OUTCOME
Ankylosing spondylitis (AS) is a chronic inflammatory pro­
gressive disorder mainly affecting the axial skeleton and the 
peripheral joints. The disease is a result of interaction 
between genetic and environmental triggers. A number of 
measures can be used simultaneously to monitor outcome 
and these are fundamental in assessing the natural history of 
AS1-6. Characteristic radiological appearances at the sacroil­
iac (SI) joints are essential for diagnosis of AS7, but no clas­
sification completely defining axial and hip radiological 
change exists in AS. The Bath Ankylosing Spondylitis 
Radiology Index-total (BASRI-t) is a new system for scor­
ing radiological change for the spine and hip in AS8. Results 
can be divided into Bath Ankylosing Spondylitis Radiology 
Index-spinc (BASRI-s), which combines the scores of the SI 
joints, lumbar spine, and the cervical spine, and the BASRI- 
hip (BASRI-h). We describe BASRI-t, BASRI-s, and
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B A SR I-h  and dem ons tra te  their value in a cross sectional 
study.
M ATERIALS AND METHODS
Validation o f  BA SRI. Existing Radiographs o f 470 patients, diagnosed 
using the N ew  York criteria for AS. were used to develop the method They 
were scored openly and placed in one o f 5 severity grades based on the NY 
scale for SI joint d isease. The radiographs were an anteroposterior (AP) 
pelvis, an AP and lateral lumbar spine, and a lateral cervical spine. The 
lumbar spine was defined as extending from the lower border o f Tl 2 to the 
upper border o f  S I , and the cervical spine from the lower border of Cl to 
the upper border o f  C7. The discriminating features o f each group were 
defined and used as the basis to describe a method o f  assessing seventy of 
radiological change in AS. The system was then repeatedly tested in a 
blinded fashion by 3 experienced readers and modified openly on several 
occasions before a final format was agreed on. Rules for scoring the lum­
bar, cervical and hip radiographs are shown in Table 1.
To assess whether AP or lateral radiograph was more appropriate. 58 
sets o f  lumbar and cervical spine radiographs with both AP and lateral 
view s were scored using (1) AP alone, (2) the lateral alone, and (3) both 
v iew s’ contribution (as a com posite score). Sensitivity and specificity for 
each v iew  was determ ined and compared to Score 3.
A fter definition o f  the scoring system, radiographs of 188 consecutive 
patients with AS and 89 without AS were scored randomly and blindly by 
the 3 readers to validate BASRI. The mean age o f  the population was 44.5 
± 10.9 years and the sex ratio 3:1 (M:F), disease duration = 23 years. 
A ssessm ent included inter and intraobscrver variation, sensitivity to change 
over a yearly period (1, 2. 3 yrs, etc.), and specificity (cutoff of grade 2 
definite d isease). T he non-AS cohort studies were consecutive outpatients 
attending the Royal National Hospital for Rheumatic Diseases and had
9<S<S 77 ,e Journal o f  Rheumatology 1999. 26:4
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Table /A .  BASRI-spine.
Score Grade System  Applies to Both Lumbar and Cervical Spine
0 Normal N o change
1 Suspicious No definite change
2 Mild Any number o f  erosions, squaring, sclerosis ±  syndesm ophytes  
on < 2  vertebrae
3 Moderate Syndesmophytes on t  3 vertebrae ± fusion involv ing 2 vertebrae
4 Severe Fusion involving > 3 vertebrae
Table IB. BASRI-hip.
Score Grade Description
0 . Normal No change
1 Suspicious Focal joint space narrowing
2 M ild Circumferential joint space narrowing >  2 mm
3 Moderate Circumferential joint space narrowing <  2 mm  or bone-on-Bone 
apposition o f  <1 cm
4 Severe Bone deformity or bone-on-bone apposition >1 cm
NB: Increase the grade by 1 if  2 o f  3 o f the following bony changes are present: erosions, osteophytes, protru­
sion.
pelvic radiographs taken. Their mean age was 57.9 ±  16.8 years, sex ratio 
1:3 (M :F). The cohort included 41 rheumatoid arthritis, 21 mechanical back 
pain, 10 fibrom yalgia, 10 osteoporosis, 7 psoriatic arthritis.
Cross sectional study. We randomly selected and scored 2200 sets o f  films 
o f  550  (4:1, M:F) patients with AS using BASRI-t. The frequency distrib­
utions o f  BASRI-t and BASRI-s were plotted using a probit plot to estab­
lish parametric distribution. The probit plot is a scatter diagram that is lin­
ear if  data are normally distributed and curved if  they are not. O f the 550  
patients, there were 423 with known disease duration.
Statistical methods. For validation o f  BASRI: The data were nonparamet- 
rically  distributed; therefore an unweighted kappa statistic was used to 
determ ine the significance o f  inter and intraobserver variability. The 
W ilcoxon  signed rank test was used to assess significance o f  change over 
tim e. For the implementation o f  BASRI: correlations were established 
using Pearson's correlation coefficient for normally distributed variables or 
Spearm an’s rank order for non-normally distributed variables. Independent 
t tests or W ilcoxon rank sum test and chi-squared were used to evaluate 
m ean scores. The SPSS software program w as used for all analyses.
RESULTS
Lum bar spine: which film  should be used. Using 58 sets of 
AP and lateral lumbar spine radiographs, 3 scores were 
derived as described above. The combination score differed 
from both the AP and lateral scores if syndesmophytes or 
fusion was seen at different levels on each projection and
occurred in 3/58 cases. The combination score differed from 
the AP alone in 9/58 (16%) cases and the lateral alone in 
21/58 (36%) cases. Over all, the use of 2 projections 
changed the score 46% of the time.
In traobserver variation. The complete agreement and kappa 
scores were (Table 2): 86% agreement (kappa 0.69) for the 
SI joints, 75% agreement (kappa 0.65) for the lumbar spine, 
81% agreement (kappa 0.73) score for the cervical spine, 
and 87 and 88% agreement (kappa 0.70 and 0.75) for the 
right and left hip.
Interobserver variation. Reproducibility between readers 
revealed 78% agreement (kappa 0.55) for the SI joints, 73% 
agreement (kappa 0.64) for the lumbar spine, 79% agree­
ment (kappa 0.69) for the cervical spine, and 82 and 78% 
agreement (kappa 0.64 and 0.57) for the right and left hip. 
D isease specificity. To validate lumbar and cervical spine, 
radiographs of 89 non-AS outpatients were scored. For the 
hip component 51 non-AS outpatients were scored. Grade 2 
was taken as the cutoff. A sample of 188 patients with AS 
was used (disease duration = 23 yrs; age 44.5 ± 10.9). 
Specificity for the lumbar spine was 0.89, for the cervical 
spine it was 0.83, and for the hips 0.78.
Table 2. Summary o f  inter and intraobserver variation in BA SR I-total.
Skeletal Site Intraobserver Variation Interobserver Variation
Com plete Kappa C om plete Kappa
Agreem ent, % A greem ent, %
SI joints 86 0.69 78 0.55
Lumbar spine 75 0.65 73 0.64
Cervical spine 81 0.73 79 0.69
Hips 87 0 .70 78 0.57
C alin. e t al: Validation o f  B A SR I 989
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Sensitivity to change. Serial radiographs of 40 patients were 
scored over 177 time intervals (4.4 intervals/patient). All 
radiographs were blinded for the name and date of radio­
graph. Scoring was performed by a single observer. The 
patients were assessed over a time period of one year [years 
between radiographs: 1 yr (n = 24), 2 yrs (n = 31), 3 yrs (n 
= 30), 4 yrs (n = 26)]. A significant change in radiological 
score (p < 0.05) at 2 years was observed for the SI joints, 
lumbar and cervical spine, and the hips. The magnitude of 
change for the BASRI-spine was from 7.0 to 7.9 in a 2 year 
period. Forty-two percent of patients had a change in 
BASRI-s score in a 2 year period. The smallest detectable 
difference between scores over a 2 year period is a change in 
BASRI-s of 0.5, i.e., 0.5 change in SI joints score, and a 
change in score of 1 for the lumbar spine and cervical spine.
Frequency distribution o f  BASRI-t and BASRI-s. BASRI-t 
was normally distributed using a probit plot. BASRI-s was 
not normally distributed.
Cross sectional study. The mean BASRI-t and BASRI-s 
scores over 5 year intervals were plotted against disease 
duration (Figure 1). Correlation was poor: r = 0.293, p < 
0.01 and r = 0.347, p < 0.01, respectively.
BASRI-s for those patients with hip disease (n = 101) and 
those without (n = 322) was plotted against disease duration 
(Figure 2). The BASRI-s was higher for those with hip dis­
ease (p < 0.0001). There was no difference in disease dura­
tion between the 2 groups (20 and 21 yrs, respectively; p <
0 .2 ).
The mean BASRI-t was higher for men (n = 351) than for 
women (n = 72) (8.9 vs 7.2, respectively; p < 0.0001). 
Disease duration was comparable (20 vs 21 yrs; p < 0.27) 
(Figure 3). More men than women had severe disease in the 
SI joints (odds ratio, OR = 1.74; 95% confidence interval, 
Cl, 1.1-2.7; p < 0.016). More men than women had severe 
lumbar spine disease (OR = 2.6, 95% Cl 1.4-4.6; p < 0.001). 
More men than women had severe cervical spine disease 
(OR = 2.3, 95% C l 1.3-3.9; p < 0.002). The numbers of men 
and women with severe hip disease were comparable at all 
stages o f disease.
D IS C U S S IO N
The BASRI is reproducible, with inter and intraobserver 
variation equivalent to or better than the NY criteria. The 
BASRI was found to be sensitive to change over a 2 year 
period, which suggests radiographs at intervals of less than 
2 years are not warranted. The BASRI was easy to use; the 
mean time taken to score a set of radiographs was less than 
30 seconds. To maintain simplicity, BASRI does not pick up 
minor radiological change. The score does not change with 
each additional erosion or sclerosis, and will always remain 
grade 2 or mild disease until there is fusion between 2 ver­
tebrae or > 3 syndesmophytes are identified.



































D ise a s e  duration
Figure I. BASRI-total and B A SR I-spine versus d isease duration (n =  423 ). ♦  B A SR I-t. r = 0 .293 . H BA SR I-s. 
r = 0 .347.















Figure 2. B A SR J-sp ine  —  patients  with hip d isease  (n =  101) versus  no  h ip  d isease  (n = 322). ■  BASRI-s  (H). 


























F igure 3. BASRI- to ta l —  radio logy o f  m en (n = 354) versus  w o m e n  (n =  72). ♦  Male. H  Female,  p < 0.0001.





indicate that AS is a slow progressive disease, or of course, 
that BASRI is too insensitive to pick up clinically relevant 
change. However, lack of correlation between BASRI 
scores and disease duration shows that outcome is extremely 
variable for different individuals. The change in BASRI-s in 
patients with and without hip involvement shows that 
patients with hip disease have more severe axial disease. 
This supports other studies that suggest hip involvement is 
predictive of more severe disease9. Comparison of male ver­
sus female has shown that men have more severe disease in 
the SI joints, lumbar spine, and the cervical spine, but not in 
the hips. Clearly, clinical significance does not equate with 
statistical significance. Further studies will be required to 
define the value of these findings.
The correlation of severity with disease duration is poor 
if taken individually. In the scoring of the lumbar spine, only 
half the patients develop severe disease after 45 years. For 
the cervical spine, 25% never develop any cervical involve­
ment.
In conclusion, radiology is fundamental to diagnosis and 
progression of AS. Apart from the New York criteria for the 
SI joints, no widely accepted radiological criteria exist. 
BASRI as a radiological classification system is a valuable 
tool that is reproducible, specific, sensitive to change at 2 
years, simple, and fast to use. Using the BASRI in cross sec­
tional study of AS shows that this is a slowly progressive 
disease with much individual variation. Some of this varia­
tion can be accounted for: patients with hip involvement 
have more severe spinal disease and men have more spinal 
involvement than women. In conclusion, BASRI is an
important outcome measure joining the metrology index 
(B A SM I)1, functional index (BASFI)3, disease activity 
index (BASDAI)5, and global score (BAS-G)6 in the assess­
ment of our patients.
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Inflammatory eye, skin and bowel disease in spondylarthritis : 
Genetic, phenotypic and environmental factors.
SINEAD BROPHY1, STEPHAN PAVY1, PETER LEWIS2, GORDON TAYLOR2, 
LINDA BRADBURY3, DUNCAN ROBERTSON4, CHRIS LOVELL5 and ANDREI
CALIN1
ABSTRACT. Objective: To explore the nature of the inter-relationship between 
inflammatory disease of the spine/ joints, skin, eye and bowel [i.e. ankylosing 
spondylitis (AS), psoriasis (Ps), iritis (I), inflammatory bowel disease (IBD)].
Methods: The study used four approaches: 1. Analysis of the prevalence of secondary 
disorders within the AS individual (x2 and matched pair analysis). 2. A study of the 
temporal relationship between the onset of the different conditions. 3. An evaluation of 
the prevalence of disease among first degree relatives and 4. The influence of 
secondary disorders on outcome of AS.
Results : 1. Among 3287 patients with AS, more than expected had either spondylitis 
associated with multiple co-disorders or pure AS (with no co-diseases) while fewer 
had AS plus one single co-disease than expected. (x2=32.2 p<0.001). In a matched pair 
analysis, patients with AS and a secondary disorder were more likely to have yet 
another additional concomitant disease, eg IBD-AS (n=335) patients had a higher 
prevalence of iritis [45.4% vs 36.7% O.R: 1.4 (1.1-2.0)] or psoriasis [23.9% vs 14.3%
O.R: 1.9 (1.3-2.8)] than controls. 2. Among our database subjects, the symptomatic 
onset of the spinal disease precedes or is contemporaneous with gut, skin and eye 
involvement (Matched pair T-test , p<0.001). 3. Patients with multiple disorders 
predict the highest prevalence of co-diseases (ie Ps, IBD, I or AS) within family 
members, followed by those AS patients with only IBD, Ps or iritis in descending 
order. 4. Both Ps and IBD increase severity in terms of function and disease activity of 
AS in the patient. Radiological change is greatest for those AS subjects with iritis. 
Conclusion: There is a striking overlap within patients and family members of 
rheumatological, dermatological and gastroenterological diseases. The susceptibility
1
genes of these co-disorders appear to overlap with each other and with AS : 1. A 
patient with two inflammatory conditions is at an increased risk of developing an 
additional related inflammatory disorder. 2. Those with enteropathic spondylarthritis 
would appear to carry the greatest genetic load in terms of first degree relatives 
developing inflammatory conditions (including Ps and I which are not seen in the index 
IBD-AS patient) 3. The secondary disorders do not precede AS (arguing against Ps 
and IBD allowing for an environmental conduit to pathogenic triggers in AS).
The susceptibility factors for these inflammatory conditions may be additive or have a 
synergistic effect on each other. There is evidence for a shared gene hypothesis.
Key words: Spondylarthritis, iritis, inflammatory bowel disease, psoriasis.
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INTRODUCTION
The spondylarthritides are a group of disorders characterised by involvement of the 
sacroiliac joints and peripheral inflammatory arthropathy together with target organs 
including the eye, bowel and skin1. Patients with ankylosing spondylitis (AS) can 
develop psoriasis (Ps) or inflammatory bowel disease (IBD), whereas those with 
psoriasis or enteropathy may develop joint involvement. The link between these 
diseases might be genetic, with shared susceptibility genes. This hypothesis is 
supported by the finding that B27 negative spondylitis patients are more likely to have 
secondary forms of disease linked to psoriasis or IBD2. Thus, in the absence of the 
B27 susceptibility effect, genes such as those for the other inflammatory conditions 
may be important in predisposing the individual to ankylosing spondylitis. 
Alternatively, these conditions may be linked by environmental factors, the inflamed 
gut and skin allowing the conduit of pathogenic triggers which induce AS. The HLA- 
B27 transgenic rat develops clinical features including: inflammatory gastrointestinal 
disease, skin lesions, spinal lesions and peripheral arthritis. These rats generally 
develop bowel inflammation which is then followed by arthritis. However, if the HLA 
B27 transgenic rat is maintained in a sterile environment neither the inflammatory 
gastrointestinal disease, nor the arthritis develop4
Thus there is evidence that the link between these inflammatory conditions could be 
genetic or environmental. How these diseases are linked will have an important impact 
on our understanding and treatment of AS and the associated risks to relatives of 
affected individuals5 . This study explores the nature of the inter-relationship between 
inflammatory disease of the spine / joints, skin, eye and bowel [i.e ankylosing 




The Bath RNHRD Ankylosing Spondylitis Database consists of 4953 patients. These 
subjects are defined as those with symptomatic disease and sacroiliitis diagnosed by x- 
ray, fulfilling the New York criteria for AS (ie all patients had at least sacroiliitis stage 
II bilateral or stage HI unilateral disease) and meeting the Amor (1991) and the 
European Spondylarthropathy Study Group diagnostic criteria for the 
Spondylarthropathies. These patients represent a sub-group of spondyarthritis as they 
only include patients diagnosed with Ankylosing Spondylitis. Subjects are either those 
referred to the Royal National Hospital for Rheumatic Diseases or are members of the 
National Ankylosing Spondylitis Society (NASS). Among the patients, 1915 (39%) 
have iritis, 811 (16%) psoriasis and 404 (8%) inflammatory bowel disease (IBD: 158 
Crohn’s disease and 246 ulcerative colitis). The diagnoses for iritis and psoriasis were 
ascertained by the GP, rheumatologist, ophthalmologist or dermatologist. A 
gastroenterologist was required for the diagnosis of inflammatory bowel disease. In 
each case the diagnosis was recorded as representing one point in time. Two studies 
have been performed to validate the diagnosis of ankylosing spondylitis in those 
patients recruited through NASS. 146 subjects were assessed by a rheumatologist and 
100% were confirmed as having AS according to the New York Criteria (personal 
communication, M. Brown, Oxford) The general practitioners of a further 240 NASS 
members were contacted to determine whether their patient’s AS had been confirmed 
radiologically. In 229 (95.4%) cases, AS with radiological evidence of sacroliitis was 
confirmed . We contacted the GP’s of 120 Ps-AS patients and 139 IBD-AS patients. 
Of these, 77 (64%) and 112 (81 %) replied confirming Ps in 65 (84%) of cases and
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IBD in 108 (96%) of cases. Iritis was diagnosed by an eye specialist in 1551 (81%) 
cases of 1915 reported with iritis (GPs or rheumatologist diagnosed 19%)
Data processing and statistical methods
1. Of the 4953 subjects on the database, 3287 had a complete data set with full family 
and personal data (the disease duration and sex ratio of those analysed compared to 
those without complete records was comparable : 21.3 yrs , 2.3:1 M:F and 20.0 yrs , 
2.1:1 M:F respectively). The prevalence of the three individual secondary disorders 
(psoriasis, IBD and iritis) was determined. From these data the expected numbers of 
patients with none, one, two or three of these conditions was established assuming 
independence between the diseases. The expected number was compared with the 
observed number using the x2 test. Patients with a secondary disorder were matched 
with an available and appropriate control (without the specific condition) for disease 
duration, age and sex ( ie psoriasis patients were matched with those without psoriasis 
[600 pairs of 811 Ps patients], IBD patients with those without IBD [335 pairs of 404 
IBD patients], and iritis patients matched with those without iritis [735 pairs]. All pairs 
were matched for exactly the same number of years of disease duration and age. 
These pairs were compared using McNemar’s %2 for prevalence of secondary disorders 
as outlined above.
2. Patients with a confirmed diagnosis for all reported secondary conditions and 
arthritis were asked to report when symptoms of each condition first began. Patient 
recollection was verified by GP reports.
3. Patients with a confirmed diagnosis of disease were asked ‘to your knowledge do 
any members of your family have a diagnosis of psoriasis, inflammatory bowel disease, 
iritis or ankylosing spondylitis’.
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4. Patients with multiple disease completed disease activity (Bath Ankylosing 
Spondylitis Disease Activity Index [BASDAI]6) and function (Bath Ankylosing 
Spondylitis Functional Index [BASFI]7) assessments (three assessments were made on 
each patient. The results of the last assessment were used as these were completed in 
the same month by all subjects) . The radiographs of RNHRD patients (n= 660) were 
blindly scored by two independent observers using the Bath Ankylosing Spondylitis 
Radiology Index [BASRI8] and then sub-grouped according to presence of secondary 
disorders. Matched pair T-test were used to compare groups.
RESULTS
1. Analysis of the prevalence of secondary disorders within the individual: There were 
more people with spondylitis and multiple co-diseases (ie more than one secondary 
disorder) than expected and more with pure ankylosing spondylitis (ie no secondary 
diseases) but there were fewer with spondylitis and only one single co-disease than 
expected. The observed /expected numbers for patients with no co-diseases were 2069 
/1973, with one co-disease 1722 /1872, with two co-diseases 454 /417 and with three 
co-diseases 42 /25. (x2 =32.2 p<0.001).
Psoriatic patients had a higher prevalence of iritis. 48% vs 40% [Odds Ratio : 1.4 
95% confid. (1.1-1.7)] and more IBD than controls [O.R: 1.3 (1.1-2.0)] 12.5% vs 
9.4%. (Demographic data: Ps & controls (number, sex ratio, disease duration (sd), age 
(sd)) n =600, M:F 3.2:1, dis dur = 22 (10) ys, age = 47 (11))
Iritis patients had a higher prevalence of psoriasis [OR: 1.4 (1.1-1.8)] 18.2 % vs 14% 
and IBD [OR: 1.5 (1.1-2.2)] 10.6% vs 7.3% than controls (Demographic data : Iritis 
& controls (number, sex ratio, disease duration (sd), age (sd)) n=735, M:F=2.3:1, dis 
dur = 21(10) yrs, age = 45 (11) yrs).
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IBD patients had a higher prevalence of iritis [O.R: 1.4 (1.1-2.0)] 45.4% vs 36.7% and 
psoriasis [O.R: 1.9 (1.3-2.8)] 23.9% vs 14.3% than controls (Demographic data : IBD 
& controls (number, sex ratio, disease duration (sd), age (sd)) n=335, M:F=2.3:1, 
disease duration =22 (10) yrs, age = 47 (11) yrs).
2. Temporal relationship between onset of the different conditions: Patient recollection 
of age of onset of symptoms and diagnosis was confirmed using GP reports. The GP 
and patients recollection was comparable for age/year in 95% of cases of ankylosing 
spondylitis, inflammatory bowel disease and psoriasis and 100% of those with iritis. 
[There were 47 patients with psoriasis were the GP had records of when the first 
symptoms were presented. Of these 45 (ie 95%) reported the same year of 
presentation as the patient recalled. There were 110 patients with IBD were the GPs 
had records and verified the patient recollection as correct in 105 (95%) of these cases. 
In the sample with iritis only 58 GPs had records (as patients may generally present 
directly to casualty or the eye department and not to the GP), of these all 58 were in 
the same year as given by the patient. However, many of the GPs for the non-included 
samples reported that results had been computerised and the data was not available or 
the patient was new and there were no backdated records]. Onset of AS symptoms 
occurs significantly before advent of iritis (p<0.001) and IBD (p<0.001) symptoms. 
Onset of Ps and AS symptoms occurs at comparable ages. Gut, skin and eye symptoms 
do not precede those of AS. [Table 1]
3. The prevalence of disease among first degree relatives: Relatives of patient with 
IBD-AS are at an increased risk of developing psoriasis and iritis. (Tables 2 and 3) 
Those with multiple disease predict the highest prevalence of co-diseases (ie Ps, IBD, I 
or AS) within family members, followed by those with IBD, psoriasis and lastly iritis.
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4. The influence of secondaiy disorders on outcome of AS: Disease activity and 
function are worse for patients with psoriasis and/or IBD. However, those with iritis 
are comparable to those with primary disease. [Table 4] Radiological change was 
worse for those with iritis than for patients with pure AS [Table 5].
DISCUSSION
Our data explore the nature of the inter-relationship between the spinal disease, AS, 
and the extra-spinal co-disorders. We are particularly intrigued by the relative role of 
environment and genetics in the inter-relationship of these inflammatory disorders. We 
have shown that: (1) in an individual with AS, the presence of one concomitant 
disorder enhances the probability of there being a second or third co-disease. (2) the 
symptoms of AS precede or are contemporaneous with the concomitant disorders (3) 
family members are at increased risk of secondary disorders even in the absence of 
their expression in the index case and finally (4) the expression of severity (ie BASRI, 
BASDAI, BASFI) in AS is influenced by the presence of the secondary conditions. 
Thus, it can be concluded that the susceptibility genes of these co-disorders overlap 
with each other and with AS and impact on disease severity.
This study is exploratory and there is no guarantee that clinical subsets will necessarily 
simplify the disease from a genetic perspective. In addition, in terms of the increased 
prevalence of secondary disorders within the individual, it is recognised that patients 
seen at a tertiary referral clinic may have more co-diseases than those seen in the 
general population. Similarly, patients who join a self help group (NASS) may be more 
likely to have multiple disorders. This suggests that a bias towards multiple disease 
(Berkson’s Bias) may be observed among the total sample. However, more patients 
than expected were found without a concomitant disease (pure AS) and fewer were
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found with AS and a single secondary disorder. This is not a finding predicted by the 
bias. In addition, the matched data used control and sample patients from the same 
population which were equally likely to have multiple disease as there were no 
selection differences between the subgroups (ie both entered the hospital/self help 
group system).
A link between the secondary disorders in the absence of AS has been previously 
described. Psoriatic patients suffer from IBD more than controls9, the prevalence of 
psoriasis is increased in Crohn’s disease10,11,12 and there is a higher incidence of iritis 
than expected among psoriasis patients13. Genes on chromosome 16 are associated 
with iritis14, psoriasis15 and Crohn’s disease16 . However, no gene has been identified 
from the region. These inflammatory disorders are linked to chromosome 6, perhaps 
through HLA-Cw6, in the case of psoriasis17, B62 in IBD18 and B27 for AS 19and 
iritis20. Thus, there is evidence to support the finding in this study that the genetic 
susceptibility to inflammatory bowel, skin, eye and joint disease overlaps and may be 
additive.
The suggestion that the triggering agent for AS may enter the body through the 
inflamed gut or skin (as proposed in the HLA transgenic rat) is not supported by our 
human data. There was little overt (symptomatic) inflammation due to IBD prior to the 
onset of symptomatic AS. However, we do appreciate that occult bowel involvement 
may occur early in AS21 and that the clinical expression of psoriasis varies, very mild 
disease (ie minor scalp involvement) could be overlooked by the patient and GP. In 
fact, it is not know when the actual onset of disease begins in any of these conditions. 
It is possible that the trigger is pulled in the womb and disease begins in the infant with 
age of symptom onset simply a reflection of severity of disease. However, this study 
has not found evidence that overt and symptomatic IBD or Ps are involved in
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triggering AS (ie allowing the conduit of environmental pathogens to induce AS). 
Conceivably, the results may be different in a population chosen from a 
gastroenterological or dermatological clinic22. For example, 7 of 19 patients with non 
AS spondylarthritis followed long term went on to develop AS, all had initially 
presented inflammatory gut lesions. Thus, evolution of non-AS-SpA to full blown AS 
was associated with gut inflammation at disease onset23. However, the finding that 
onset of bowel disease and the other inflammatory conditions do not follow a temporal 
pattern but may occur at any time (before or after the onset of arthritis), supports the 
hypothesis that susceptibility genes of inflammatory skin, eye and bowel disease may 
overlap with those for inflammatory joint disease.
The prevalence of disease among family members of the index case represents an 
estimate of the occurrence of disease within this population. The observation of 
familial aggregation has been previously identified. 9 Herein, we reinforce the previous 
observations and suggest that the strongest genetic load can be seen among the IBD- 
AS sufferers with the least observed among the iritis-AS patients (Table 3). The data 
from the relatives of the pure AS subjects suggest that occult genes associated with 
IBD & Ps and/or the presence of iritis genes may be required for the development of 
ankylosing spondylitis (see figure 1)
Patients with psoriasis and / or IBD had poorer function and greater disease activity. 
Psoriasis/IBD genes may have an additive effect on susceptibility to and severity of 
AS. Alternatively, an inflammatory/immunological response to a sizeable area of body 
(skin surface or bowel) may have an effect of potentiating inflammation elsewhere. 
Indeed, it is recognised that active inflammatory bowel disease can coincide with flares 
in peripheral joint disease23. Disease activity and function can be modified and 
therefore are measures of inflammation and soft tissue involvement. However,
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radiological assessment is measured in terms of disease specific change and is not 
directly related to the level of pain/fatigue (ie disease activity) nor poor function (as 
this can be due to pain or soft tissue damage). Ps /IBD does not appear to increase 
these disease specific radiological changes. Conversely, iritis appears to be a strong 
phenotypic marker for more severe radiological disease. Moreover, peripheral arthritis 
in a patient with ankylosing spondylitis enhances the likelihood that iritis will develop24. 
The secondary diseases do appear to have a genetic overlap with AS in terms of 
susceptibility genes. The susceptibility factors for these conditions may be additive or 
have a synergistic effect on each other. The presence of these conditions has a 
pronounced effect on the phenotypic expression. The patient is more likely to have 
multiple disorders, develop these disorders after the onset of AS and have a poorer 
outcome in terms of the spondylitis. These findings point to the striking overlap 
within the patient and their family of rheumatological, dermatological and 
gasteroentrological processes. The impact of a relevant family history is clearly 
demonstrated and the data enhance our understanding of how the shared gene 
hypothesis can have an impact on disease expression.
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Table 1: Mean age of onset of the inflammatory disorders [Iritis (I), psoriasis (Ps), inflammatory bowel (IBD)] compared to onset of AS [all 
cohorts are independent and do not include subsets of the same individuals].
AS (yrs) I (yrs) Ps (yrs) IBD (yrs) Mean difference (Confidence Intervals)
Pure AS (n=2221)* 25
AS I (n=151) 23 33 AS vs 1 : 10 (7.4-10.8)
AS Ps (n=40) 27 26 AS vs Ps : none
AS IBD (n=74) 24 30 AS vs IBD : 6 (3.4-9.7)
AS IPs (n = 30) 28 39 32 AS vs 1 :11 (6.6-15.2), AS vs Ps : 4 (0.5-8.8)
AS I IBD (n=66) 22 34 31 AS vs 1 :12 (9.6-15.8), AS vs IBD: 9 (5.1-12.2)
AS Ps IBD (n=18) 23 26 31 AS vs Ps : none, AS vs IBD : 6.6 (1.7-11.6)
AS IPs IBD (n=26) 23 32 33 33 AS vs 1 : 9 (4.5-14.8), AS vs Ps : 10 (2.5-16.9), AS vs IBD : 10 (3.6-16.1)
* Includes original 2069 and additional recruited subjects.
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Table 2 First degree relatives
Ps IBD Iritis AS Order
1. AS pure (n = 138) 10% 7% 6% 25% 1
2. AS + iritis (n=142) 5% 3% 13% 29% 2
3. AS + Ps (n=42) 33% 12% 0% 14% 3
4. AS + iritis + Ps (n= 26) 19% 8% 15% 19% 4
5. AS + IBD + Ps (n=17) 12% 24% 6% 24% 5
6. AS + iritis + IBD (n=63) 14% 14% 16% 29% 6
7. AS + IBD (n=76) 17% 24% 8% 24% 6
8. AS +IBD + Ps + Iritis (n=23) 17% 17% 26% 30% 8
Population Rate*. 1-2% 0.07- 0.2% 0.25 %
0.1%
• The Spondylarthritides Ed A. Calin, J Taurog. 1998 Oxford University Press and Linssen 
A, Rothova A, Valkenburg H, Dekker-Saeys A, Luyendiijk L, Kiilstra A, Feltkamp T.
The Lifetime cumulative incidence of acute anterior uveitis in a normal population and its 
relation to ankylosing spondylitis and histocompatibility antigen HLA-B27. Investigative 
Opthalmology & Visual Science, 1991; 32 (9): 2568-2578.
Based on patient recollection only.
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Ps Iritis Summary Ps Iritis Summary
AS + IBD 13/76 6/76 16/76 AS pure 14/138 8/138 21/138
AS + iritis + IBD 9/63 9/63 AS + iritis 7/142 7/142
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Relatives with:
IBD Ps Summary IBD Ps Summary
AS + iritis 4/142 7/142 11/142 AS pure 10/138 14/138 23/138
AS + iritis + IBD 9/63 9/63 AS + IBD 13/76 13/76









Table 4: Phenotypic expression of secondary disease
AS duration BASDAI BASFI Mean Difference between 1° AS vs 2° AS 
[BASDAI] (confidence interval of mean)
Mean Difference between 1° AS vs 2° AS 
[BASFI] (confidence interval of mean)
Pure AS (n=2221) 19.0 yrs 4.1 3.9
AS I (n=1342) 23.7 yrs 3.9 4.0 ns ns
AS Ps (n=389) 19.3 yrs 4.7 4.6 0.5 (0.3-0.7) 0.4 (0.2-0.7)
AS IBD (n=341) 25.7 yrs 4.5 4.8 0.4 (0.05-0.7) 0.8 (0.6-1.1)
AS I Ps (n=323) 25.6 yrs 4.6 4.8 0.4 (0.2-0.6) 0.8 (0.4-1.0)
AS I IBD (n=150) 25.3 yrs 4.3 4.6 ns 0.6 (0.2-1.1)
AS Ps IBD (n=44) 20.5 yrs 5.9 5.4 1.7 (1.2-2.4) 1.6 (0.9-2.4)
AS I Ps IBD (n=46) 23 yrs 4.5 5.4 ns 1.5 (0.8-2.3)
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AS I [mean (sd)] Pure AS [mean (sd)j 
143 143
3:1 3:1
22 (+/- 9) 21 (+/-10)
23.7 (+/- 8) 25.4 (+/-8)
9.2 (+/- 3.8)_______ 7.7 (+/- 3.4)_____________ p<0.001
AS Ps [mean (sd)] Pure AS [mean (sd)]
91 91
2 .5 :1  2.5:1
21.5 (+/-9.6) 21.7 (+/-10.24)
23.0 23.6
8.7 (+Z-3.5)________ 8.8 (+/- 3.7)_____________ Ns
Cohort comparison 
AS IBD [mean (sd)] Pure AS [mean (sd)]
23 151




3. AS Iritis1. AS Ps IBD
8 Phenotypes
AS (+Ps & IBD genes) 
AS Ps (+IBD genes) 
AS IBD (+Ps genes) 
AS IBD Ps
AS Ps I(+IBD genes) AS Iritis 
AS IBD Iritis(+ft genes)












Figure 1: Relationship between AS and secondary disorders
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Appendix 7 : In Press. Journal of Rheumatology
Ankylosing Spondylitis: Interaction between genes, joints, age at onset and 
disease expression.
SINEAD BROPHY, ANDREI CALIN.
ABSTRACT. Objective: Ankylosing spondylitis (AS) is a chronic inflammatory disorder with 
symptom onset generally occurring in the late teens/ mid twenties. We have shown that in 
women, a younger age at onset enhances disease susceptibility in the next generation. Herein, 
we examine the influence of the age at symptom onset on phenotypic expression.
Methods: Patients were divided into cohorts according to age of symptom onset. The primary 
outcome measure was radiological progression (BASRI). Secondary measures were disease 
activity (BASDAI), function (BASFI), numbers undergoing AS-related surgery and percentage 
with secondary disorders.
Results: Age at onset had no significant effect on radiological progression [Young onset vs 
Late onset; 8.0 : 8.6 respectively] disease activity [Young vs Late ; 4.4 :4.4], need for non­
hip surgical intervention [9% : 8% respectively] or prevalence of secondary disorders [Iritis ; 
40% :41%, Psoriasis ; 20% : 19% , IBD; 7.5% : 8.9%]. By contrast, there was a striking 
increase in prevalence of total hip replacement in those with juvenile onset [18% : 8% 
respectively (p<0.001)]. Regardless of age at onset, spinal progression determined 
radiologically, was greater in those with hip arthritis compared to those without [Young onset 
Hip invol vs non-hip invol. : 9.7 (2.4): 7.2 (3.0) respectively. p<0.001. Late onset. Hip invol 
vs non-hip invol. : 10.1 (2.5) :7.1 (3.0) respectively] . Function deteriorates with age [Young 
onset vs late onset; 3.7 : 4.5 respectively p<0.01].
l
Conclusion: 1) Hip disease (young or late onset) is a major prognostic marker for long term 
severe disease [Patients with hip disease have an increased spinal score by 2.5-3 points or 35%- 
40% more change]. 2) Hip involvement is more prevalent among patients with young age at 
onset. 3) Young onset patients without hip involvement do not have more severe disease. 
Thus, age at onset, itself, does not influence disease severity. 4) Since hip involvement and not 
age at onset is associated with worse outcome, patients with a young age at onset may be 
assumed to have an increased susceptibility load (ie genetic component or environmental 
trigger) rather than more severity genes. The lack of association between severity and age at 
onset implies that the determinants of susceptibility and severity are independent.
Key Indexing Terms: Ankylosing spondylitis, symptom onset, severity, outcome.
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Introduction
Ankylosing spondylitis is a chronic inflammatory disorder with symptom onset generally 
occurring in the late teens/ mid twenties. A juvenile age at symptom onset (less than 16 yrs) 
has been found to correlate with increased disease severity [1,2,3]. In addition, hip involvement 
(and need for total hip replacement) is more often seen in those with juvenile onset [3,4] and 
hip involvement itself is a marker for more severe axial involvement [2,5] However, late onset, 
(after age 55) has also been reported to affect the clinical pattern of disease. Such patients are 
said to have more cervical pain, anterior chest wall involvement, aseptic osteitis [6] and 
shoulder involvement [7]. It can be assumed that the expression of AS results from a 
combination of severity and susceptibility genes. In women, a younger age at onset enhances 
disease penetrance in the next generation [8]. Therefore, patients with a younger age at onset 
may have an increased number of susceptibility factors and perhaps a different disease 
expression from those with late onset. Late onset individuals may carry fewer susceptibility and 
a different array of severity genes.
This study aims to examine the influence of age at symptom onset on disease expression as 
measured by radiological change (BASRI) [9], disease activity (BASDAI) [10], function 
(BASFI) [11], percentage undergoing AS-related surgery, and prevalence of secondary 
disorders (iritis, psoriasis, inflammatory bowel disease)
Methods
The Bath Ankylosing Spondylitis Database consists of 4741 patients (2.5:1 M:F). All were 
out-patients of the Royal National Hospital for Rheumatic Diseases (n=851) or were members 
of the National Ankylosing Spondylitis Society. Patients referred to the RNHRD had their 
diagnosis confirmed according to the New York Criteria. The NASS members are those who 
have received a positive diagnosis of ankylosing spondylitis from a specialist rheumatologist as
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a result of an x ray. To validate the diagnosis in those patients recruited through NASS, one 
hundred and forty-six consecutive subjects were invited to attend an assessment clinic and all 
146 were confirmed as having AS according to the same criteria. In addition, for 240 patients a 
confirmation was sought from the GP, and confirmed in 229 cases (95.4%) [ie AS with 
radiological evidence of sacroliitis]. We contacted the GP’s of 120 Ps(AS) patients and 139 
IBD(AS) patients. Of these, 77 (64%) and 112(81%) replied confirming the diagnosis ofPs 
and IBD in 65 (84%) and 108 (96%) cases.
Independent samples of patients were divided into cohorts according to age of symptom onset 
and were controlled for a) age now and b) disease duration now (McNemar’s chi-squared). In 
addition, cohorts of juvenile onset (<16 yrs), teen onset (17-20 yrs), twenties (21-29 yrs), 
thirties (30-39) and late onset (40+ yrs) were compared. The primary outcome measure was 
radiological status as determined by BASRI. Secondary measures were disease activity 
(BASDAI), function (BASFI), numbers undergoing surgery and percentage with secondary 
disorders.
Results
Radiological progression [sacroiliac joints, hips, lumbar spine, cervical spine]; BASRI 
Age at onset has no significant effect on radiological progression [Table 1 & Graph 1]. 
Radiological change is a factor of disease duration ie those with a young age at onset have 
more severe disease when compared to like aged late onset patients [Young onset: Late onset; 
10.0: 8.0 respectively (p=0.02)] However, disease duration matched pairs are comparable for 
radiological change [Young onset: Late onset; 8.0 : 8.6]
Patients with hip disease and a young onset had comparable spinal disease to those with hip 
disease and a late onset [Table 1] . [Young : Late ; 9.0 :10.8 p=0.04 (corrected value not 
significant)]. Hip disease patients have more spinal change than non-hip patients [Table 2]
4
[Young onset - Hip disease : Non-hip disease ; 9.7 :7.2 respectively (p=0.0001). Late onset - 
Hip disease : Non-hip disease ; 10.13 : 7.1 p=0.0001]
Secondary outcome measures
Age at onset had no significant effect on disease activity, function, prevalence of secondary 
disorders, or need for surgery [Table 3 & Table 4]. At comparable age (ie age now [Table 2]), 
those with longer disease duration (ie young onset) have lower disease activity [Young onset: 
Late onset; 4.0 : 4.3 respectively p<0.02], more iritis [Young onset: Late onset; 50% : 40% 
p<0.01] and more surgical intervention [14% : 7% respectively p<0.01]. However, when 
matched for disease duration [Table 3], the disease activity [Young onset : Late onset; 4.4 : 
4.4], prevalence of secondary conditions and need for surgery [9% : 8%] were all comparable 
for those with a young age at onset vs late age onset. When matched for disease duration the 
function was worse for the delayed onset males (ie older aged men) [Young onset: Late onset 
; 3.6 : 4.5 respectively p<0.01]. However, at equivalent ages [Tablel] the function is 
comparable regardless of disease duration (ie between young age at onset and delayed onset 
individuals).
Cohorts of juvenile onset (<16 yrs), young onset (17-20 yrs), twenties (21-29 yrs), thirties (30- 
39) and late onset (40+ yrs) were comparable for disease activity [Graph 2], function [Graph 3] 
and surgery [Graph 4].
Discussion:
Our data examines young onset compared to late onset and was not intended to analyse 
juvenile ankylosing spondylitis (JAS) as a separate entity. However, reviewing graphs 1-5 
demonstrates that finding in young onset patients are applicable to juvenile AS subjects. The 
data suggest that age at first symptoms onset has no impact on disease severity. However, this 
must be seen in the context that hip disease is more prevalent among patients with juvenile
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onset [THR rate - Juvenile vs non-juvenile : 18% : 8% respectively, p<0.001, Graph 5] and 
this phenomenon is known to be a predictor of more severe spondylitis [2,5]. This paradox [ie 
a) there is a link between age at onset and hip disease, b) hip disease is linked to increased 
severity but c) there is no link between age at onset and increased severity] may be explained 
on the basis that only a subgroup of young onset patients develop hip disease and only this 
cohort is at risk of more severe spondylitis. [In our study 21/68 (31%) of the young onset 
subjects and 13/68 (19%) in of the late onset patients had hip involvement as assessed by a 
radiograph and THR occurred in 9% and 4% respectively].
It is possible that the young developing hip may be more at risk of becoming affected than the 
adult hip. Thus, patients with young onset are more at risk of hip involvement (because of the 
juvenile hip). However, patients with hip disease and a young onset do not have more severe 
disease than subjects with a late onset and hip disease [Figure 1]. Hip involvement per se 
appears to be the relevant factor contributing to outcome.
The trigger for AS is thought to be a ubiquitous bacterium [12]. If this is so, then the age of 
onset of disease should be related to the genetic susceptibility load. Yet, this enhanced genetic 
susceptibly in young onset patients does not influence outcome, implying that the contributing 
genes for susceptibility and severity are independent of one another. If by contrast, the age of 
onset of a patient is governed by the timing of contact with an environmental trigger, the age 
when this happens appears to have no influence on the later disease development. Separate and 
unrelated severity factors must influence disease progression. This hypothesis has been 
supported by early findings identifing from a genome screen at least one area of significant 
linkage between severity and genetic factors. [13] In conclusion, there are three clearly distinct 
independent factors: the environment and both susceptibility and severity genes.
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Table 1: Young onset compared to Late onset in terms of radiological progression [ie 
T otal= SI jo in t, Lumbar spine,Cervical spine and Hips, Spinal = SI jo in t, Lumbar 
spine and Cervical spine ].
Age onset 0-21 (young onset) Age onset 30+ (late onset) p value
(corrected)
Age Now (& Sex) Matched n=56 pairs
BASRI-total* [Scale 2-16] 10.0 8.0 p=0.02 (ns)
BASRI-spine** [Scale 2-12] 8.7 7.6 p=0.02 (ns)
With hip involvement (n= 19 , 10) 9.7 10.0 ns
Without hip involvement (n=37,46) 8.2 7.1 ns
Disease Duration (& Sex) Matched n=68 pairs
BASRI-total* 8.0 8.6 ns
BASRI-spine** 7.1 8.1 ns
With hip involvement (n=21, 13) 9.0 10.8 p=0.04 (ns)
Without hip involvement (n=47, 55) 6.3 7.5 p=0.06 (ns)
* including hips **without hips
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Table 2 : Radiological hip disease vs non-hip disease patients : spinal severity score and 
age at onset of AS
Hip disease Non-hip disease P value
(corrected)
Young onset n=81 n=148
Disease duration 22.1 yrs 22.7 yrs
Mean (sd) 9.7 (2.43) 7.2 (3.0) p<0.001
Late onset n=19 n=64
Disease duration 15.2 14.1
Means (sd) 10.13(2.5) 7.1 (3.0) p<0.001
10
Table 3: Influence of age at onset on outcome - Age Now and Sex matched
Age onset 0-21 (young onset) Age onset 30+ (late onset) p value$
BASDAI
Whole group (n=784) 4.0 4.3 p<0.02
Males (n=543 pairs) 3.7 4.2 p<0.01
Females (n=241 pairs) 4.5 4.4 Ns
BASH
Whole group (n=829) 4.4 4.3 Ns
Males (n=574 pairs) 4.3 4.3 Ns
Females (n=255 pairs) 4.8 4.3 p=0.03
Secondary Disorders
Iritis (n=829 pairs) 50% 40% p<0.01
Ps (n=807) 20% 20% Ns
IBD (n=828) 7.5% 7.6% Ns
Surgery
Total surgery n=991 140 (14%) 67 (7%) p<0.01
$ Corrected
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Table 4: Influence of age at onset on outcome - Disease Duration and Sex Matched
Age onset 0-21 (young onset) Age onset 30+ (late onset) P value$
BASDAI
Whole group (n=784) 4.4 4.4 Ns
Males (n=543 pairs) 4.2 4.1 Ns
Females (n=241) 4.6 4.5 Ns
BASH
Whole group (n=762) 3.7 4.5 p<0.01
Males (n=546 pairs) 3.6 4.5 pO.Ol
Females (n=216) 4.1 4.5 Ns
Secondary Disorders
Iritis (n=788 pairs)^ 280 (35.5%) 283 (36%) Ns
Ps (n=777 pairs)** 110(14.2%) 120 (15.4%) Ns
IBD(n=810 pairs)*** 61 (7.5%) 72 (8.9%) Ns
Surgery
Total surgery n= 924 86 (9%) 71 (8%) Ns
$ Corrected
♦Average age of onset of AS symptoms in iritis vs non iritis patients : 26,7 vs 26.9 (ns) 
♦♦Average age of onset of AS symptoms in psoriasis vs non-psoriasis patients : 27.7 vs 26.9 
(ns)
♦♦♦Average age of onset of AS symptoms in IBD vs non-IBD patients : 28.1 vs 27.0 (ns)
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ARTICLES
Impact of sex on inheritance of ankylosing spondylitis: a cohort 
study
Andrei Calin, Sinead Brophy, David Blake
Summary
Background Ankylosing spondylitis is a genetically 
determined and commonly familial disorder. Men and women 
differ in their susceptibility to ankylosing spondylitis, with 
about 2-5 men affected for every woman with the disease. We 
investigated the influence of the sex of the index case on 
disease penetrance within families.
Methods The ages at which 50% and 75% of patients were 
diagnosed with ankylosing spondylitis were ascertained from 
a database of 4400  cases. Index patients with children or 
siblings who were old enough to have obtained a diagnosis 
(50% and 75% rates) were assessed  for prevalence of 
disease among relatives. Confirmation of diagnosis for 
affected relatives was sought for all offspring and a random 
25% selection of siblings.
Findings Ankylosing spondylitis was more prevalent among 
children (odds ratio 1-9 [95% Cl 1-2-3-0], p<0-005) and 
siblings (1-5 [1-2-1-9], p<0-0001) of female index cases  
than among those of male cases. Analyses restricted to index 
cases with a young age at onset (*£21 years) indicated that 
children of women had an even higher incidence of ankylosing 
spondylitis (7-2 [1-5-34], p=0-013) than did children of men 
at similar age at onset. 38% of children of female cases had 
disease compared with 8% of male cases. There was no 
difference in sex distribution among affected children or 
siblings of female patients with ankylosing spondylitis. By 
contrast, the sons and brothers of male patients had a higher 
prevalence of the disease (odds ratio 2-6 [1-4-5-2], 
p=0-003) than did daughters and sisters (1-7 [1-3-2-2],
p<0-0001).
Interpretation The influence of female sex is greater than that 
of male sex in determining increased susceptibility to 
ankylosing spondylitis in children. The striking maternal effect 
is greatest for women with young age at onset, which is not 
seen in men. The sex ratio of affected children depends on 
the sex of the affected parent.
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Introduction
The genes of the HLA region control a variety of functions 
involved in immune responses and influence susceptibility 
to more than 40 diseases. Many HLA-associated diseases 
clearly involve heterogeneity in HLA components, as well 
as non-HLA genetic factors.1 In the case of ankylosing 
spondylitis, susceptibility genes in the HLA region include 
B27, B60, and DR1. However, familial studies show that 
the HLA region explains only a third of the genetic 
influence on ankylosing spondylitis2 and that other non- 
HLA genes are involved. Moreover, concomitant disorders 
associated with ankylosing spondylitis have been linked to 
different chromosomes, including chromosome 16, 
implicated in Crohn’s disease,3 uveitis,4 and psoriasis.5
Disease expression differs in men and women, with 
about 2-5 men affected for every woman with the disease.6 
Men develop more severe spinal disease.7 Women have 
more peripheral joint involvement.8 These differences may 
be due to genetic factors in the sex chromosomes,9 which 
would lead to a difference in the sex ratio of children and 
siblings who inherit the disease.
We investigated the influence of the sex of the index 
case of ankylosing spondylitis on disease inheritance 




We studied 4400 individuals with ankylosing spondylitis (3143 
men, 1257 women), who were outpatients of the Royal National 
Hospital for Rheumatic Diseases (RNHRD) or members of the 
National Ankylosing Spondylitis Society (NASS) and had been 
recorded on our database. Patients referred to the RNHRD had 
their diagnosis confirmed according to the New York criteria.10 All 
NASS members who completed our questionnaire were asked to 
complete the form only if they had received a positive diagnosis of 
ankylosing spondylitis by radiography from a specialist 
rheumatologist. To validate the diagnosis in patients recruited 
through NASS, 146 consecutive patients were invited to attend an 
assessment clinic. All 146 were confirmed as having ankylosing 
spondylitis according to the same criteria.10 The family physicians 
of a further 330 NASS members were contacted to check whether 
their patient’s disease had been confirmed radiologically. Of these, 
306 (93%) had definite ankylosing spondylitis, 15 had arthritic 
diseases other than ankylosing spondylitis, three showed 
suspicious change on radiography, and for five patients the 
primary source material was unclear.
Analysis
The frequency distributions of age of onset and age at diagnosis of 
the 4400 individuals were calculated so that we could identify the 
ages at which 50% (ie, 30 years) and 75% (ie, 39 years) of patients 
should have obtained a diagnosis of ankylosing spondylitis (figure 
1). The study then focused on 1192 individuals (879 men, 313 
women) who had children and were older than 50 years (to select 
those with older children), and 2222 individuals (1615 men, 
607 women) with siblings older than 39 years. Where there 
were several family members with ankylosing spondylitis, only 
one sibling per family was selected. The patients were asked
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Figure 1: Frequency distribution o f a g e  of o n s e t  and a g e  of d ia g n o sis  o f ank ylosin g  spondylitis  (ac tu a l data)
by postal questionnaire whether any member of their family 
had ankylosing spondylitis and to state which relatives were 
affected. In each sample the sexes were compared to investigate 
transmission of the disease to sons and daughters or brothers and 
sisters.
All patients who had children older than 39 years who had 
ankylosing spondylitis were contacted to ensure that the child 
had a radiographically validated diagnosis. Of 29 families with a 
child older than 39 years with ankylosing spondylitis, all the 
affected offspring provided confirmation of diagnosis (ie, they 
were asked to confirm that a rheumatologist had made the 
diagnosis based on pelvic radiography). 100 (25%) patients who 
reported a sibling with ankylosing spondylitis were contacted to 
provide medical confirmation of diagnosis. We selected these 
patients using a random numbers table. Of those chosen, 18 
could not be contacted (moved or died). 82 individuals were 
traced, of whom 78 (95%) had ankylosing spondylitis confirmed, 
two had no formal diagnosis but were still in the process of 
investigation for ankylosing spondylitis, and two did not have the 
disease.
The age of disease onset of fathers and mothers with ankylosing 
spondylitis was compared with the percentage of children with 
disease. To investigate the possibility of a uterine effect (eg, 
passage of pathogens or other agents across the placenta) in 
mothers with ankylosing spondylitis, we assessed whether the 
affected child was born before or after disease onset in the parent. 
The results for affected fathers were used as a control for when no 
uterine effect is present.
Statistical analysis
We analysed the data using \ 2 tests with Yates’ continuity 
correction on SPSS (version 7.0). We used Fisher’s exact test for 
small entries.
Results
The frequency distribution of age of diagnosis showed a 
mean 10-year delay from onset of symptoms to diagnosis 
(figure 1). Men and women did not differ in mean age at 
onset (24-5 [SD 10-1] vs 24-4 [10-5] years) or mean age at 
diagnosis (31-7 [11-5] vs 33-2 [11-4] years). The sex ratio 
of sporadic (simplex family) cases (74%) was 2-8, whereas 
the male/female ratio of familial (first-degree relatives, 
multiplex family) cases (22%) was 1-7 (p<0-0001). 
Further relatives (ie, second and third degree; 4%) had a 
ratio of 2-3.
The inheritance of ankylosing spondylitis among 
children of affected patients is shown in table 1. Overall, 
sons of men with ankylosing spondylitis were 2-5 times 
more likely than daughters to inherit the disease, and 
children of women with the disease were more likely to 
develop ankylosing spondylitis than were children of male 
patients (table 1). Women with a young age at onset were 
more likely to have children with disease than were men or 
women with older age at disease onset (table 1). Women
Index case n Sons Daughters Rate of inheritance 
(sons vs daughters)




Odds ratio (95% Cl) P Odds ratio (95% Cl) P
For children >30 years (50% diagnosis)
Father 354 35/396 (8-8%) 








40/375 (10-7%) 1-9 (1-2-3-0) 0-005
2-5
1-4
For children >39 years (75% diagnosis)
Father 101 11/90 (12%) 








16/93 (17%) 2-1 (1-0-4-5) 0-063
2-25
1-4
Age of onset € 2 1  years and children >30 years
Father 90 11/105 (10%) 








13/93 (14%) 2-0 (0-9-4-5) 0-086
2-6
1
Age of onset € 2 1  years and children >39 years
Father 22 2/20 (10%) 








6/16 (38%) 7-2 (1-5-34) 0-013
1-9
2-6
Table 1: Inheritance of an k y lo sin g  sp o n d y litis  am o n g  s o n s  and d a u g h ters  of p a tien ts
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Figure 2: Proportion of children older than 3 9  years with  
ank ylosin g spondylitis accord in g  to  a g e  of o n s e t  of parent
aged 21 years or less at disease onset had a much higher 
proportion of affected children (38%) than women who 
were at least 25 years at disease onset (13%; odds ratio 4-0 
[95% Cl 1 1 -1 4  0]; figure 2).
For women with an affected child, 74 (43%) mothers 
had onset of ankylosing spondylitis before birth of the 
affected child, whereas 48 (28%) women had onset of 
disease after birth of child and 26 (15%) had child and 
onset of disease in the same year (onset unknown in 25 
[15%] cases). For men with an affected child, 205 (58%) 
had onset of ankylosing spondylitis before birth of an 
affected child, 103 (29%) had onset of disease after birth 
of an affected child, and 46 (13%) developed ankylosing 
spondylitis at the same time as the birth of their child 
(p=0-712).
For siblings older than 39 years of men with ankylosing 
spondylitis, brothers were 1-6 times more likely to have 
inherited the disease than sisters (table 2). For siblings 
older than 39 years of men with ankylosing spondylitis 
with young age of onset (=s21 years), brothers were twice 
as likely to have inherited the disease as sisters. In all cases, 
siblings of women were more likely to have the disease 
than siblings of men (table 2).
Discussion
Our study may have been biased because patients who 
have a relative with ankylosing spondylitis are more likely 
to join a self-help group, resulting in a greater number of 
patients with a positive family history. However, this 
would apply irrespective of the sex of the relative and 
should not influence the comparison of ratios for each sex 
affected by ankylosing spondylitis. The proportion of 
affected relatives in this study (11%) is similar to that of 
other studies.11 13 A further issue is that certain subsets of 
individuals (ie, offspring of mothers with young age at 
onset) were small.
We did not systematically type patients or relatives for 
HLA-B27 status. Nevertheless, of the children randomly 
reviewed for HLA-B27 status, 92% (34 of 37) and 96% 
(113 of 118) of first-degree disease-concordant relatives of
patients were HLA-B27 positive. Moreover, over 95% of 
patients carry this antigen and B27 is inherited as a co­
dominant factor.14 About 50-56% of siblings and children 
of patients are expected to be H1A-B27 positive. Thus, 
the risk for those carrying HLA B27 will be twice that of 
our estimates. The prevalence of ankylosing spondylitis 
among relatives may be a conservative estimate. Clearly, 
individuals with ankylosing spondylitis cannot be included 
in the study if they are undiagnosed, misdiagnosed, or 
have clinically silent disease. Although we ascertained 
whether patients had a diagnosis from their rheumatologist 
after pelvic radiography, we did not always review source 
material.
With rheumatoid disease, female susceptibility 
predominates. The patient’s sex seems to be an important 
risk factor, with relatives of male patients having the 
greatest cumulative risk of rheumatoid arthritis.15 
However, we have shown that the opposite seems to be 
true for ankylosing spondylitis, which mainly affects men 
with relatives of female patients being more at risk.
Women have a greater family history of ankylosing
spondylitis than do men and this finding is reflected by our 
findings, which shows the sex ratio of sporadic (simplex 
family) cases compared with that of familial disease.
Where the index case is male, female relatives are less
susceptible than men to ankylosing spondylitis. By 
contrast, there is no significant difference in prevalence of 
ankylosing spondylitis among the relatives of either sex of 
female patients. The genetic load passed on by women 
with young age at onset seems to be even more striking. 
However, this finding is not seen among siblings. There 
are at least four possible explanations for these findings, 
none of which are mutually exclusive.
First is the genetic load effect. In general, women are 
less likely than men to develop ankylosing spondylitis. 
Thus, it remains possible that women with ankylosing 
spondylitis have to have a higher genetic load to develop 
the disease. A woman with ankylosing spondylitis has 
sufficient genetic susceptibility factors for disease 
expression. This could explain why her male and female 
children will have an equal chance of developing disease. 
By contrast, daughters of men with ankylosing spondylitis 
may not inherit enough genetic material to present clinical 
symptoms.
The second possibility is a uterine effect. The overall 
male/female sex ratio for ankylosing spondylitis is 2-5. 
However, 80% of these individuals have sporadic disease. 
For those with familial disease, a similar distribution is 
observed among the offspring of affected fathers. By 
contrast, the sex ratio for offspring of maternal cases is 1 -0. 
Moreover, children of affected mothers have a higher risk 
of disease than do children of affected men. Mothers with 
ankylosing spondylitis may pass an environmental disease- 
inducing factor across the placenta. Such a uterine effect 
(ie, environmental overlay) may increase the risk of disease 
susceptibility in children who would not normally have
Index case n Brothers Sisters Rate of inheritance 
(brothers vs sisters)























^ 2 1  and siblings >39 years









64/461 (13-9%) 1-5 (1-0-2 0) 0-029
2-0
1-6
Table 2: Inheritance o f an k y lo sin g  sp on d y litis  am o n g  broth ers and s is t e r s  o f p a tien ts











50% diagnosis^ 9% 4% 12% 9%
75% diagnosis! 12% 5% 20% 15%
Extrapolated data
100% diagnosis! -15% -6% -30% -20%
HLA-B27 positive! -30% -12% -60% -40%
♦Age at which 50% of patients are assumed to have received a diagnosis of ankylosing 
spondylitis. fAge at which 75% of patients are assumed to have received a diagnosis of 
anklyosing spondylitis. ^ Percentage of sons or daughters who will develop ankylosing 
spondylitis eventually based on linear extrapolation from actual data of 50% and 75%. 
§100% diagnosis based on HLA-B27 positive and negative cases; 100% diagnosis 
underestimates the value of HLA-B27-positive children by 50%.
Table 3 : Data and extrapolation of inheritance of ankylosing 
spondylitis to children
developed ankylosing spondylitis. This effect may explain 
how the disease develops in female offspring. Women with 
a young age at onset may have a greater genetic 
susceptibility load than women developing the disease later 
in life. Therefore, children exposed to a uterine effect and 
carrying this larger genetic susceptibility factor would have 
an even higher prevalence of disease. Indeed, in the small 
number of women with a young age of onset, no less than 
38% of children developed disease (ie, about 70-80% of 
HLA-B27-positive individuals; table 3). Nevertheless, for 
28% of women onset of disease had not occurred before 
the birth of the affected child. Indeed, there is no 
difference in numbers of affected children bom  before, 
after, or during onset of ankylosing spondylitis among 
fathers and mothers. However, the time at which disease 
development is triggered remains unknown, and there may 
be many years of latency between precipitation of disease 
and symptom onset.
A third explanation is the influence of cytoplasmic or 
mitochondrial DNA. Children of affected fathers normally 
inherit disease at a male/female ratio of 2-5. That mothers 
with ankylosing spondylitis have more offspring with the 
disease than do men could be explained in part by 
additional non-nuclear cytoplasmic or mitochondrial 
genetic material that is operative only in women. Sons and 
daughters of affected mothers inherit susceptibility to 
ankylosing spondylitis equally because they both receive 
maternal mitochondrial DNA.
Finally, the susceptibility genes might be on the X  or Y 
chromosome. The X  chromosome may carry susceptibility 
or protective genes and influence disease. Sons of affected 
mothers with early onset of disease have a 50% chance of 
developing ankylosing spondylitis, irrespective of HLA- 
B27 status. The healthy sons are probably those who have 
not inherited their mother’s HLA B27. Of those with the 
antigen, there may be nearly 100% penetrance of disease. 
These sons will have inherited their mother’s X  
chromosome. Daughters who develop disease may receive 
an X  chromosome from their healthy father who carries 
the same recessive susceptibility gene. However, with an 
X-linked disease daughters of affected fathers should have 
a higher risk than sons, which is not supported by our data.
Alternatively, if the Y chromosome is involved, some of 
the susceptibility to ankylosing spondylitis may come from 
the Y chromosome. Therefore, men with this factor would 
have an extra susceptibility gene that cannot be inherited 
by women. The sons of affected men would be more likely 
to develop disease and the children of affected women 
would be equally likely to develop disease. This suggestion 
is supported by the finding that, in mice, the Y
chromosome interacts with the HLA-B27 gene.16 Peptides 
encoded by the Y chromosome are believed to be 
presented by the HLA-B27 gene.
Environmental and genetic factors are required in the 
pathogenesis of ankylosing spondylitis.17 N o doubt genes 
affect susceptibility and severity, and may influence onset 
and course of disease by way of negative or positive effects 
(protective genes). HLA and non-HLA genes are relevant. 
Herein, we show an important influence of the sex of the 
index case and suggest that additional factors are 
operative. These could include a uterine (environmental) 
effect and influence from either or both the X and Y 
chromosomes. Meanwhile, the role of protective genes, 
particularly in women, and the relation between such 
putative genes and sex remains an enigma.
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Is Disease Severity in Ankylosing Spondylitis 
Genetically Determined?
J. Hamersma,1 L. R. Cardon,2 L. Bradbury,2 S. Brophy,3 I. van der Horst-Bruinsma,1 
A. Calin,3 and M. A. Brown1
Objective. To assess the role of genes and the 
environment in determining the severity of ankylosing 
spondylitis.
Methods. One hundred seventy-three families 
with >1 case of ankylosing spondylitis were recruited 
(120 affected sibling pairs, 26 affected parent-child 
pairs, 20 families with both first- and second-degree 
relatives affected, and 7 families with only second- 
degree relatives affected), comprising a total of 384 
affected individuals. Disease severity was assessed by 
the Bath Ankylosing Spondylitis Disease Activity Index 
(BASDAI) and functional impairment was determined 
using the Bath Ankylosing Spondylitis Functional Index 
(BASFI). Disease duration and age at onset were also 
studied. Variance-components modeling was used to 
determine the genetic and environmental components 
contributing to familiality of the traits examined, and 
complex segregation analysis was performed to assess 
different disease models.
Results. Both the disease activity and functional 
capacity as assessed by the BASDAI and the BASFI, 
respectively, were found to be highly familial (BASDAI 
familiality 0.51 IP =  10-4], BASFI familiality 0.68 [P =  
3 x 10-7]). No significant shared environmental com­
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ponent was demonstrated to be associated with either 
the BASDAI or the BASFI. Including age at disease 
onset and duration of disease as covariates made no 
difference in the heritability assessments. A strong 
correlation was noted between the BASDAI and the 
BASFI (genetic correlation 0.9), suggesting the presence 
of shared determinants of these 2 measures. However, 
there was significant residual heritability for each mea­
sure independent of the other (BASFI residual herita­
bility 0.48, BASDAI 0.36), perhaps indicating that not 
all genes influencing disease activity influence chronic- 
ity. No significant heritability of age at disease onset 
was found (heritability 0.18; P  — 0.2). Segregation 
studies suggested the presence of a single major gene 
influencing the BASDAI and the BASFI.
Conclusion. This study demonstrates a major 
genetic contribution to disease severity in ankylosing 
spondylitis. As with susceptibility to ankylosing spondy­
litis, shared environmental factors play little role in 
determining the disease severity.
It is well established that genetic factors play a 
m ajor role in susceptibility to ankylosing spondylitis. 
H eritability  in twins is estim ated to be > 90%  (1), and 
genes of the m ajor histocom patibility complex, in p ar­
ticular H LA -B 27, have been dem onstrated, by both 
linkage and association m ethods, to be heavily involved 
(2-5).
V ery little is known about the genetic control of 
disease severity in ankylosing spondylitis. G reater simi­
larity of disease severity was observed in monozygotic, 
com pared with dizygotic, twins, although no individual 
severity m easure achieved statistical significance (1). A  
study of 42 sibling pairs revealed greater familiality of 
disease severity m arkers, including pain and disability 
indices and abnorm alities on pelvic and spinal rad io­
graphs, bu t did not differentiate shared environm ental 
factors from genetic factors (6). Few association studies
1396
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of candidate genes and disease severity in ankylosing 
spondylitis have been perform ed, and to date, all have 
yielded negative results. G enetic associations with par­
ticular disease characteristics have been reported, al­
though no reported  association has been widely repli­
cated (for review, see ref. 7).
In recent years, specific disease activity and ou t­
come m easures have been designed for ankylosing spon­
dylitis, to allow easy and reproducible assessment of 
disease severity. In particular, Calin and colleagues have 
deve'oped a suite of validated, self-administered m ea­
sures of ankylosing spondylitis disease activity and func­
tional effects. These include the Bath Ankylosing Spon­
dylitis Disease Activity Index (BASDAI) (8), Bath 
Ankylosing Spondylitis Functional Index (BASFI) (9), 
Bath Ankylosing Spondylitis Global Index (10), Bath 
Ankylosing Spondylitis M etrology Index (11), and Bath 
Ankylosing Spondylitis Radiology Index (12). The aim 
of the current study was to test the hypothesis that 
disease severity, as assessed by the indices BASDAI and 
BASFI, is genetically determ ined.
PATIENTS AND METHODS
Patients. Probands of families with >1 m em ber af­
fected with ankylosing spondylitis were recruited from the 
Royal National H ospital for R heum atic Diseases Ankylosing 
Spandylitis database. Ankylosing spondylitis was defined ac­
cording to the modified New Y ork diagnostic criteria (13). 
Alfecied family m em bers were contacted by telephone and the 
diignosis confirm ed by a sem istructured interview that was 
conducted by 1 of us (JH , LB, o r MAB). All patients were then 
sent a self-report questionnaire  to com plete, which included 
scores for disease activity and function on the BASDAI and 
BaSFI; in addition, patients w ere asked to detail the date  at 
onset of the ankylosing spondylitis symptoms and the date of 
diignosis. M ore than 90%  of the individuals who were ap ­
proached to participate in the study com pleted the question- 
nare.
O ne hundred seventy-three families were identified 
will 384 affected family m em bers. O f these families, 146 had 
affceted first-degree relatives only, including 120 sibling pairs 
an! 26 paren t-ch ild  pairs. Twenty families had affected first 
aid second-degree relatives, and 7 families had affected 
second-degree relatives.
Blood sam ples w ere obtained from 240 of the 384 
afbeted family m em bers, and these were typed for H LA -B 27 
bypolvmerase chain reaction/sequence-specific prim er analysis
(IT ‘
Statistical m ethods. Fam iliality and heritability of the 
trats evaluated quantitatively on the BASDAI and BASFI 
w ee assessed using the Pedigree Analysis (PA P) statistical 
paikage (15). Fam iliality refers to the proportion of the overall 
trat variance due to  shared  environm ental and genetic factors. 
Heritability refers to the  proportion  of the overall trait vari- 
ame ascribable to the genetic variance. PAP uses a variance-
com ponents approach to assess the relative con tributions of 
genetic and environm ental effects in the tra it studied. Using 
the known genetic relationship between family m em bers, and 
assum ing greater environm ental sharing betw een first-degree 
relatives than with more distantly related individuals or with 
unrelated  individuals, the genetic and environm ental variances 
o f the tra it are calculated. The total trait variance is assumed 
to be the sum of the genetic variance and shared and random  
environm ental variances. The correlations betw een genotypic 
and environm ental factors and the gene-env ironm ent in terac­
tion are  assum ed to be negligible; violation o f these assum p­
tions could lead to over- or underestim ation o f heritability, 
respectively.
Potential covariates studied included age at onset of 
sym ptom s, age at diagnosis, and disease duration  from  age at 
sym ptom onset. The heritability of the BASDAI independent 
o f the BASFI, and vice versa, was assessed by calculating 
BA SD A I or BASFI heritability estim ates with BASFI or 
BASDAI incorporated as a covariate.
A scertainm ent differences betw een closely and dis­
tantly related  affected individuals were assessed by analysis of 
covariance using the program SuperAnova, version 1.11 (A ba­
cus C oncepts, Berkeley, CA) to com pare the age at disease 
onset, diagnostic delay, BASDAI scores, and BASFI scores 
betw een probands and non-probands. The linear association 
betw een variables was studied by correlation coefficient ana­
lysis, using the same software package.
Complex unified segregation analysis (16,17) was per­
form ed using the package PAP. A unified m odel consisting of 
environm ental effects and a genetic com ponent consisting of a 
biallelic m ajor gene and polygenes was fitted to the family 
data, against which o ther genetic and environm ental models 
were com pared. Param eters estim ated in this m odel included 
the frequency of the m ajor gene alleles, f(A) and f(B), the 
m ean tra it values associated with the m ajor gene genotypes, 
l±(AA), /x(AB), and /a(BB), 3 transmission param eters, tA A , 
tA B , and tB B , which represent the probability o f transm ission 
of the m ajor gene genotypes, a single standard deviation, cr, for 
all genotype means, and a residual m ultifactorial familial 
com ponent, h2. Environm ental covariates w ere no t included in 
this analysis because they had been shown to have no signifi­
cant influence on the BASDAI or BASFI heritability  (see 
below).
Com parisons of models were perform ed by likelihood 
ratio tests, in which the difference of the —2 X logc likelihood 
of the m odels was asymptotically distributed as the  ) f  value 
(with degrees of freedom  equal to the difference in the  num ber 
of param eters estim ated in the 2 models). A significant value 
of this statistic indicates that a m ore general m odel provides a 
b e tte r fit to the data than does the com parison m odel. Sub­
models of the unified model fitted to the data  included a 
codom inant/M endelian model (rA A , tA B , and tB B  set to 1.0,
0.5, and 0.0, respectively, with genotypic m eans independently  
estim ated), dom inant and recessive models (bo th  models, 
tAA, tAB, and tBB set to 1.0, 0.5, 0.0, respectively; recessive 
m odel, ju[AA] and m[AB] equal, jLi[BB] fixed; dom inan t model, 
/x[AA] free, ju[AB] and /x[BB] equal), and polygenic and 
environm ental models (estim ated by equating all transm ission 
probabilities and all genotypic means, and setting the  residual 
familial com ponent h2 to zero for the environm ental m odel). 
B ecause the M endelian/codom inant, dom inant, and  recessive 
models fitted the observed data, the presence o f a residual
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T ab le  1. S egregation  m od els o f  the Bath A nkylosin g  Spondylitis D isea se  A ctiv ity  Index*
M odel f( A ) m(A A ) P-(AB) M B B ) a h 2 -2 1 n L x 2 df P
1. G en era l 0.371 2.775 2 .337 5 .7 9 2 1.432 0.681 1,650.178
2. M en d elian  codom in ant 0 .730 2.227 5.251 6 .962 1.378 0 .024 1,653.893 3.715 3 0.3
3. D om in an t 0.765 2.405 5.679 5 .6 7 9 1.464 0.181 1,654.694 0.801 1 0.4
4. R ecess iv e 0 .370 2.439 2.439 5.738 1.462 0.251 1,655.160 1.267 1 0.3
5. R estr ic ted  M en d elian /cod om in an t 0.729 2.220 5.240 6.961 1.377 0 1,653.9 0.007 1 0.9
6. R estr ic ted  dom inant 0.760 2.379 5.647 5 .647 1.642 0 1,655.23 1.57 1 0.2
7. R estr ic ted  recessive 0.359 2.400 2.400 5 .679 1.460 0 1,656.264 1.104 1 0.3
8. P o lygen ic - 3.758 3.758 3 .758 2.178 0 .512 1,673.368 23.19 3.7 x  10 5
9. E nvironm enta l - 3.769 3.769 3 .769 2.179 0 1,687.843 37.665 4 1.3 x  1 0 - 7
* M od el 2 is com pared  w ith m od el I, m od els 5 -7  are com pared  w ith m o d els  2 - 4 ,  respectively , and all o th er m od els  are com p ared  with m od el
2. f  =  frequency; A  and B =  m ajor genes; /a =  m ean trait value; a  =  standard d eviation; h2 =  residual m ultifactoria l fam ilial com p on en t; —21nL =  
lik elih ood  ratio; d f =  d eg rees  o f  freedom .
polygenic contribution  was investigated by com paring these 
m odels with m odels fitted with no residual polygenic con tribu ­
tion (restric ted  models).
RESULTS
O f the 384 affected individuals studied, 36% were 
fem ale. The m edian age was 50 years (range 18-86 
years) and the m edian age at onset of symptoms was 21 
years (range 7-63 years). The median disease duration 
was 24 years (range 1-64 years). The m ean (± S D ) 
BASDAI was 3.8 ± 2.2 and the BASFI was 3.8 ±  2.7. 
Psoriasis was reported  by 13% of the affected individu­
als, and inflam m atory bowel disease by 8%. O f the 240 
patien ts typed for H LA -B 27, all were found positive.
T here was no evidence of ascertainm ent bias. 
P robands and non-probands had similar disease severity 
as assessed by either the BASDAI or the BASFI (con­
trolled for disease duration). T here was no difference in 
the m ean diagnostic delay (probands mean ±  SD 7.6 ± 
0.6 years, non-probands 9.1 ±  0.6 years).
N o c o rre la tio n  was o b served  b etw een  the 
BASDAI apd disease duration, whereas a significant 
correla tion  was observed betw een the BASFI and dis­
ease duration  (r =  0.18, P  = 0.0004). No correlation was 
observed betw een the age at disease onset and either the 
BASFI or the BASDAI. T here was no effect of sex on 
the age at disease onset, the BASDAI, or the BASFI.
M arked fam iliality and heritability were observed 
for both  the BASFI and the BASDAI. For the BASFI, 
fam iliality was 0.68 (P  =  3 X 10~7, 95% confidence 
interval [95% Cl] 0.42-0.94) and heritability was nearly 
identical (0.68; P  =  3 X 1(T 7, 95% Cl 0.44-0.92). This 
indicates virtually no shared environm ental effect on the 
BASFI. The BASDAI similarly showed high familiality 
(0.51; P  =  1(T4, 95%  Cl 0.25-0.77) and identical
heritability. N either familiality nor heritability estim ates 
for the age at disease onset were significant (0.2 \P =  
0.14] and 0.18 [P =  0.2], respectively). Inclusion of age at 
sym ptom  onset and disease duration  as covariates, either 
singly or together, m ade no difference to these assess­
m ents, with negligible correlation (0.00 for BASDAI 
versus e ither age at symptom onset or disease duration, 
0.01 for BASFI versus age at symptom onset, 0.04 for 
BASFI versus disease duration).
A strong genetic correlation was observed b e­
tween the BASDAI and the BASFI (correlation  coeffi­
cient 0.9), suggesting the possibility of shared determ i­
nants of these 2 m easures. The presence of significant 
residual heritability for each m easure independent of 
the o th er (BASDAI residual heritability [considering 
BASFI as a covariate] 0.36; BASFI residual heritability 
[considering BASDAI as a covariate] 0.48) suggests that 
som e genes influence disease activity and function dif­
ferentially.
Results o f the segregation analyses are presented 
in Tables 1 and 2. These results show that for both the 
BASDAI and the BASFI, the polygenic and environ­
m ental m odels are strongly excluded (m odels 8 and 9). 
For both the BASDAI and the BASFI, the codom inant, 
dom inant, and recessive m odels could not be rejected 
(m odels 2, 3, and 4), and these m odels are therefore 
considered to be consistent with the observed data. Note 
tha t m odels 3 and 4 produced conceptually equivalent 
findings, with the m ajor gene allele B being either rare 
and dom inant (m odel 3— equivalent to allele A being 
com m on but recessive) or com m on and recessive (m odel 
4— equivalent to allele A being rare but dom inant). 
Considering the m ajor gene effect observed in the 
absence of residual polygenic contribution (m odels 5 -7  
com pared with m odels 2 -4 , respectively, in Tables 1 and 
2), there was no significant evidence of a residual
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T abhle 2. S egregation  m od els  o f  the Bath A nkylosin g  Sp ondylitis F u nctional Index*
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M odel f(A ) m(A A ) M A B ) M(B B ) a h2 - 2 ln L r df P
1. G Jeneral 0.793 2.041 6.526 8.708 1.387 0.290 1,756.948
2. IvU endelian/codom inant 0 .797 2.066 6.607 8.731 1.406 0.247 1,757.533 0.585 3 0.9
3. D o m in a n t 0 .812 2.152 6.949 6.949 1.496 0.332 1,760.659 3.126 1 0.08
4. R e c e s s iv e 0 .420 2.151 2.151 6 .940 1.496 0.378 1,757.972 0 .439 1 0.5
5. R e str ic te d  M en d elian /cod om in an t 0 .214 2.058 6.579 8.813 1.393 O.(KK) 1,758.787 1.254 1 0.3
6. R e str ic te d  dom inant 0 .815 2 .164 6.991 6.991 1.497 0.000 1,763.805 3.146 1 0.08
7. R e s tr ic te d  recessive 0 .425 2 .162 2.162 6.995 1.493 0 .000 1,761.733 3.761 1 0.052
8. P folygen ic - 3 765 3.765 3.765 2.724 0.681 1,833.563 76.030 3 2 X 10 16
9. E n v iro n m en ta l - 3 .782 3.782 3.782 2.726 O.(KK) 1,859.927 102.394 4 3 x  10 21
* M oodel 2 is com p ared  with m od el I, m o d els  5 -7  are com p ared  with m o d els  2 - 4 ,  respectively , and all o th er  m od els are com p ared  with m od el 2. In 
e s t in m tin g  the param eters o f  the gen era l m od el, the value o f  tA A  always hit the bou ndary  o f  1.0, and w as th erefore fixed at this value to  estim ate  
the o t h e r  param eters. S ee  T ab le  1 for d efin ition s.
poly/genic com ponent for e ither the BASDAI or the 
B A SFI, with m odels including such a com ponent not 
beimg significantly different from  those w ithout.
DISCUSSION
This study dem onstrates that in ankylosing spon- 
dylittis, disease severity is largely genetically determ ined, 
and that shared environm ental factors play little role in 
de term in ing  e ither disease activity m easured at any one 
poimt in time or functional incapacity. A lthough the 
gene tic  factors involved in determ ining disease activity 
and functional im pairm ent overlap, some genes affect 
e ith e r  disease activity or functional im pairm ent, hut not 
bothi. This is similar to the findings from twin studies of 
d isease susceptibility, which have also shown that heri- 
tabillity of ankylosing spondylitis itself is extrem ely 
h ig h . However, those studies were not sufficiently pow­
erful! to dem onstrate the heritability of disease severity 
scores (1).
Q uestionnaire-based assessm ent of disease sever­
ity is clearly subject to many potential sources of error, 
w hich would diminish the power of heritability studies 
and lead to underestim ation of familiality and heritabil­
ity. M ore objective m easures, such as m etrology (11) and 
radiology indices (12), have been developed, but insuf­
ficient family data are currently  available for use in such 
a study. This study indicates, however, that the BASDAI 
and the BASFI are sufficiently robust to detect signifi­
cant genetic effects, and therefore  could be used for 
gene-m apping studies.
The results of the segregation analysis suggest 
that there is a m ajor genetic effect influencing both the 
BASDAI and the BASFI. The codom inant, dom inant, 
and recessive m odels could not be d ifferentiated and 
w ere all quite sim ilar, with significant dom inance- 
variance apparent. For all M endelian models, exclusion
of a residual polygenic com ponent did not significantly 
a lter the model likelihood. Estim ated genotypic m eans 
and allele frequencies for the major gene m odels are 
given in Tables 1 and 2. The polygenic and environm en­
tal m odels were strongly excluded for both disease 
severity m easures.
Few candidate gene association studies have been 
perform ed for disease severity or disease features in 
ankylosing spondylitis, in contrast to an abundance of 
genetic studies on disease susceptibility. A study of 
British Caucasian cases (18) found no association b e­
tween H LA -B 27, -B 60, o r -D R 1 and disease severity 
assessed by a com posite disease severity index (the  Bath 
Ankylosing Spondylitis Disease Severity Index [19]). 
O ther studies have addressed associations with H L A - 
B27 (20) and L M P 2  (21), and similarly reported  no 
association with disease severity scores. Homozygosity 
for H L A -B 27 also appears not to significantly influence 
the severity of ankylosing spondylitis (22). T hese nega­
tive findings suggest that the genes determ ining the 
severity of ankylosing spondylitis may be encoded o u t­
side of the m ajor histocom patibility complex. In the 
current study, it is known that all typed cases w ere B27 
positive, but w hether they were B27 heterozygotes or 
hom ozygotes is unknown. It is unlikely that m ore than a 
small proportion  of the cases would be B27 hom ozy­
gotes, since the allele frequency of B27 in this popu la ­
tion is only 4% , and therefore, unless B27 hom ozygosity 
had a m arked influence on disease severity, it would be 
unlikely to explain the segregation study findings. The 
findings of previous association studies suggest that if 
B27 has any effect on  disease severity, it is likely to be 
small. T herefore, although the current findings may be 
explained by an effect of B27 homozygosity on disease 
severity, it is more likely that ano ther gene is involved.
No o ther studies have addressed the heritability
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of disease activity or functional impairment. Several 
associations with complications of ankylosing spondylitis 
have been reported, such as associations with iritis and 
peripheral arthritis and with the age at symptom onset 
(for review, see ref. 7), but there is little consensus 
among these studies and no gene has conclusively been 
dem onstrated to be involved. The current study suggests 
that further studies of the genetic determination of 
disease severity are indicated, and that significant ge­
netic effects can be assessed using the easily adminis­
tered self-report questionnaires, the BASDAI and the 
BASFI. Practically, this study also indicates that because 
disease severity and functional impairment show a con­
sistent pattern within families, the severity of disease in 
secondarily affected family members can be roughly 
predicted from the severity of previously affected family 
members. Identifying the actual genes involved would 
obviously improve the precision and reliability of such 
predictions.
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Whole-Genome Screening in Ankylosing Spondylitis:
Evidence of Non-MHC Genetic-Susceptibility Loci
S. H. Laval,1'* A. Timms, 1 S. Edwards,1 L. Bradbury,1 S. Brophy,2 A. M ilicic,1 L. Rubin,3 
K. A. Siminovitch ,4 D. E. W eeks,5 A. Calin,2 B. P. W ordsworth ,1 and M. A. Brown1
'Spondyloarthritis and Bone D isease Research Group, W ellcom e Trust Centre for Human Genetics, Headington, United Kingdom; 2Royal 
National Hospital for Rheumatic D iseases, Bath, United Kingdom; 3Division of Rheumatology, St. M ichael's Hospital, and 4Mount Sinai 
Hospital, Department o f M edicine, University of Toronto, Toronto; and d ep a rtm en t of Human Genetics, University o f Pittsburgh, Pittsburgh
Ankylosing spondylitis (AS) is a common inflammatory arthritis predominantly affecting the axial skeleton. Sus­
ceptibility to the disease is thought to be oligogenic. To identify the genes involved, we have performed a genomewide 
scan in 185 families containing 255 affected sibling pairs. Two-point and multipoint nonparametric linkage analysis 
was performed. Regions were identified showing "suggestive” or stronger linkage with the disease on chromosomes 
lp , 2q, 6p, 9q, lOq, 16q, and 19q. The MHC locus was identified as encoding the greatest component of suscep­
tibility, with an overall LOD score of 15.6. The strongest non-MHC linkage lies on chromosome 16q (overall LOD 
score 4.7). These results strongly support the presence of non-MHC genedc-susceptibility factors in AS and point 
to their likely locations.
Introduction
Ankylosing spondylitis (AS) is the second-most-common 
cause of inflammatory arthritis worldwide, with a prev­
alence of 1/1,000-3/1,000 in white populations (Calin 
1998). It is characterized by inflammation in the spine 
and sacroiliac joints, causing initial bone and joint ero­
sion and subsequent ankylosis. Arthritis affecting pe­
ripheral joints, particularly the hips, occurs in 40% of 
cases, and inflammation may also involve extraarticular 
sites such as the uvea, tendon insertions, aorta, lungs, 
and kidneys. Genetic factors were implicated in the eti­
ology of the disease long ago, with the demonstration 
of high disease familiality (de Blecourt et al. 1961). The 
sibling recurrence-risk ratio is 82 (Brown et al. 2000b), 
and heritability, assessed by twin studies, is >90% 
(Brown et al. 1997). The recognition of the association 
of B27 with AS confirmed the importance of heritable 
factors in the disease (Brewerton et al. 1973; Schlosstein 
et al. 1973) and remains one of the strongest disease 
associations of any inflammatory human disease. In 
most populations that have been studied, the prevalence
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of AS is strongly correlated with the prevalence of the 
main disease-susceptibility gene, HLA-B27 (B27). Only 
a few families have been reported in which AS segregates 
independently from B27 (van der Linden et al. 1975; 
Gladman et al. 1986; Deshayes et al. 1987; Woodrow 
1988; Brown et al. 1996; Said-Nahal et al. 2000) and 
only rare cases of familial B27-negative AS have been 
reported (Rubin et al. 1994; Skomsvoll et al. 1995), 
suggesting that B27 is almost essential for the inheritance 
of AS within families. However, only l%-5% of B27- 
positive individuals develop AS, and there is increasing 
evidence to suggest that other genes must also be in­
volved. B27-positive relatives of AS patients have a re­
currence risk of the disease that is 5.6-16 times greater 
than that of B27-positive individuals in the population 
at large, implying the presence of non-B27 shared fa­
milial risk factors (Calin et al. 1983; van der Linden et 
al. 1983). Recurrence-risk modeling in AS rejects single­
gene and polygenic models. Oligogenic models with be­
tween three and nine genes operating in addition to B27 
fit the observed pattern of recurrence risks in relatives 
of patients with AS (Brown et al. 20006). A major non- 
B27 contribution to susceptibility to AS is suggested by 
the greater concordance rate in MZ twins (63%) than 
in B27-positive DZ twin pairs (23%) (Brown et al. 
1997).
A preliminary whole-genome screen in 105 affected- 
sibling-pair families with AS demonstrated strong link­
age to the MHC locus (LOD 8.1) but also identified 
several other regions with moderate evidence of linkage 
(Brown et al. 1998). Six regions lying on chromosomes 
2p, 2q, 3p, lOq, l ip ,  and 16q achieved LOD scores 
>1.0, with the peak non-MHC linkage occurring on
000
000
chromosome 16q (LOD 2.6). Candidate-gene studies 
have also implicated the gene cytochrome P450 2D6, 
lying on chromosome 2 2 q l3 .1 , in susceptibility to AS 
(Beyeler et al. 1996; Brown et al. 2000#) and suggest 
the involvement of more than one M HC gene (Hohler 
et al. 1998; Laval et al. 2000).
Since this preliminary study, we have continued to 
recruit additional families (screen 2) and have reinves­
tigated our initial families (screen 1) with a denser 
marker map. The results of these screens have been an­
alyzed both separately and as a combined cohort con­
sisting of 185 families containing 255 affected sibling 
pairs (see table 1). Results of the X-chromosome m ap­
ping have been presented elsewhere (Hoyle et al. 2000).
Subjects and Methods
Families with AS
This project was approved by the Central Oxford Re­
search Ethics Committee (approval CM 95.061) and the 
University of Toronto Ethics Committee. AS was defined 
according to the modified New York diagnostic criteria 
(van der Linden et al. 1984). All patients had been seen 
by a qualified rheumatologist, and the diagnosis of AS 
had been confirmed. To further confirm the diagnosis, 
all cases either were examined or were interviewed by 
telephone by one of us (L.B., M.A.B., or L.R.). In pa­
tients with atypical histories or for whom radiographs 
had not been performed previously, pelvic and lumbos­
acral spine radiographs were obtained, and attending 
physicians were contacted to confirm the diagnosis. All 
family members were typed for HLA-B27 (see below), 
and all the affected individuals were B27-positive. All 
family members were of white descent. Among partici­
pants affected with AS, the mean age at time of recruit­
ment was 46 years (range 16-86 years), 63%  were male, 
and 44%  reported having had iritis, 16% psoriasis, and 
9%  inflammatory bowel disease.
Two cohorts of families were recruited (screens 1 and 
2—see table 1 for family details). Six families included 
in our initial publication have been excluded from the 
current study because of changes of diagnosis or pater­
nity (outlined below). Although both screens have sim­
ilar numbers of affected sibling pairs, there are signifi­
cant differences between the two cohorts. Screen 2 has 
fewer families (86) than screen 1 (99) and fewer affected 
individuals (210) than screen 1 (235). Blood samples 
were available from a higher proportion of parents in 
screen 1 families (62% of all parents) than of parents 
in screen 2 families (51% of all parents). Thus, it is likely 
that the power to detect linkage was higher for the screen 
1 families than the screen 2 families.
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Table 1
Summary of Families Included in G enom e Screen
N o . OF 1
Sc r e e n  
2 1 and 2
Families:
Overall 99 86 185
With two affected sibs 87 69 156
With three affected sibs 7 9 16
With four affected sibs 2 1 3
With five affected sibs . . . 1 1
With sibling pairs in two generations 2 5 7
With a sibling trio in one generation 
and a sibling pair in another 1 1
With sibling trios in two generations 1 1
With other first- or second-degree 
relatives 21 18 39
With both parents 50 29 79
With one parent 22 29 51
With no parents 27 28 55
Sibling pairs overall 130 125 255
Affected individuals 235 210 445
Unaffected individuals 187 186 373
C enotyping
All individuals were typed for HLA-B27 by PCR-SSP 
(Brown et al. 1996). Screen 1 families were genotyped 
for 505 autosomal microsatellite markers, including 259 
markers from the Medical Research Council (United 
Kingdom) set (Reed et al. 1994), 5 markers lying within 
the M HC locus (62A, 82-1, 82-2, T2, and D3A) (Hsieh 
et al. 1997), and 241 additional markers from the Ap­
plied Biosystems Prism Linkage M apping Set Version 2 
(LMSv2) marker set (PE Biosystems). Screen 2 families 
were genotyped for 367 markers from the LMSv2 
marker set (not including markers excluded by error- 
checking procedures). The markers were amplified by 
methods reported elsewhere (Brown et al. 1998), pooled 
in sets of 15-20 markers, and products were separated 
by electrophoresis in 6%  polyacrylamide gels using ABI 
373 semiautomated sequencers. Products were sized us­
ing the program GENESCAN 672, version 1.1 (PE Bios­
ystems), and genotypes were assigned semiautomatically 
using the program  GENOTYPER, version 1.1 (PE 
Biosystems).
Statistical Analysis
To minimize data errors, extensive checking proce­
dures were employed. Mendelian inheritance of markers 
was checked manually within GENOTYPER, and the 
program GAS, version 2.0 (A. Young, unpublished), was 
used to convert the size data into discrete allele numbers. 
Consistency of allele assignment was ensured by use of 
a control sample on each gel and by comparison of allele 
distributions between screens. The program  PED- 
CHECK (O’Connell and Weeks 1998) then was used to
Laval et al.: Ankylosing Spondylitis Genome Screening 000
screen all data for previously undetected inconsistencies 
of Mendelian inheritance. The relationship between ped­
igree members was then examined, using the results of 
>90 markers, by means of the program SIBERR (Ehm 
et al. 1998). This program identifies misspecification of 
probable MZ twins, half-siblings, and unrelated indi­
viduals as full sibling pairs by comparison of the number 
of alleles shared IBD at unlinked loci with null hypoth­
esis expectations. One previously unrecognized MZ twin 
pair was identified by this program and was removed 
from the analysis. This pair was identical at 181 of 182 
alleles checked (0.5% genotyping-error rate). Excess re­
combination events between markers, a finding sugges­
tive of genotyping error, was screened for, by calculation 
of recombination distances, using the program SIM- 
WALK2 (Sobel and Lange 1996). Of the 527 markers 
used, 3 were removed from the screens as a result of this 
analysis. Finally, non-Mendelian errors were investi­
gated further using the program SIBMED (Douglas et 
al. 2000). SIBMED identifies likely genotyping errors 
and marker mutations by calculating the posterior prob­
ability of an error for each sibling-pair-marker combi­
nation. The prior probability of genotype error was set 
at 1%, and genotypes of sibling-pair-marker combi­
nations with a posterior probability of error of >50% 
were checked. Among the 614,929 genotypes scored, 51 
genotype errors (0.008%) were identified by this pro­
gram and were removed from the analysis.
Allele frequencies were calculated, from all scored 
genotypes, by means of the program DOWNFREQ (J. 
Terwilliger). Marker positions were obtained from pub­
lic databases (either the Whitehead Institute for Bio­
medical Research database or GeneMap’99).
Multipoint analysis theoretically is more accurate in 
identifying the position of maximum linkage and has 
greater power to identify linkage but is susceptible to 
biases that are less important in two-point analysis. Mul­
tipoint analysis depends critically on the correct marker 
order and intermarker distances. Genotyping errors in 
two-point analysis affect only the marker involved, 
whereas, in multipoint analysis, they can also affect 
surrounding markers. Therefore, both analyses are 
presented.
Two-point nonparametric affected-sibling-pair link­
age analysis was performed using the program ANA­
LYZE (Satsangi et al. 1996). Multipoint nonparametric 
linkage analysis was performed using the ALL statistic 
of the program GENEHUNTER-PLUS (Kong et al. 
1997). IBD sharing by affected sibling pairs was deter­
mined using GENEHUNTER, version 2.0 (Pratt et al. 
2000), and confidence intervals for locus-specific X 
values were determined by methods reported elsewhere 
(Cordell and Olson 1997). The contribution of each lo­
cus to the overall sibling recurrence risk was calculated 
assuming a sibling recurrence-risk ratio of 82 (Brown et
al. 2000b) and either additive (Norman et al. 1998) or 
multiplicative (Risch 1987) interaction between loci. 
“Suggestive” and “significant” linkage are defined, ac­
cording to published recommendations for affected-sib- 
ling-pair nonparametric analysis, as LOD 5= 2.2 and 
LOD 5* 3.6, respectively (Lander and Kruglyak 1995).
Results
Two-point results for markers achieving LOD scores of 
1.0 in screens 1 and 2 and the combined results are listed 
in table 2. Twenty-eight markers from 14 regions 
achieved LOD scores of 2=1.0 in screen 1. Among these, 
three markers (D6S276, D10S185, and D16S422) from 
three regions achieved LOD scores of 5*1.0 in screen 2. 
Strong linkage with the MHC locus in this set was ob­
served, with a peak LOD score of 6.9. Outside of the 
MHC locus, “significant” linkage was observed with 
marker D9S1826 (LOD 3.9). “Suggestive” linkage was 
observed for markers D10S597 (LOD 2.4) and D16S289 
(LOD 2.7). In screen 2, 22 markers from 11 regions 
achieved LOD scores of 2*1.0. Of these, three markers 
(D6S276, D10S185, and D16S422) from three regions 
achieved linkage with LOD 1.0 in screen 1. Strong link­
age was again observed with the MHC locus (LOD 4.8). 
“Significant” linkage was only observed with the mi­
crosatellites in the region of the MHC locus. Outside of 
the MHC locus, “suggestive” linkage was observed with 
markers D7S519 (LOD 2.6), D19S414 (LOD 2.5), and 
D19S420 (LOD 3.58). Considering the combined data 
across both screens, 34 markers from 14 regions 
achieved LOD scores of 2*1.0. Five markers from four 
regions achieved “suggestive” linkage (markers D1S255 
[LOD 2.2], D9S288 [LOD 2.3], D9S1682 [LOD 2.3], 
D9S1826 [LOD 2.8], and D16S422 [LOD 3.3]).
The results of the multipoint analysis are given in 
figure 1. For most loci, there are only minor differences 
between the two-point and multipoint LOD scores, but, 
for a small number of loci, quite marked differences 
were observed. For the MHC locus, the peak LOD 
scores obtained in screen 1,2, and the combined screen, 
respectively, were 7.8, 8.1, and 15.6. The X value for 
this locus overall was 5.2 (z0 = 0.048, z x — 0.5, 
z 2 =  0.45, where z„ is the probability of sharing n al­
leles identical by descent). The contribution of the MHC 
locus (X =  5.2, 95% Cl 3.0-9.0) to the recurrence-risk 
ratio in AS is either 37%, under a multiplicative disease 
model, or 6.8%, under an additive disease model. Mul­
tipoint analysis demonstrated greater evidence of link­
age on chromosomes 2, 5, and 16 than did two-point 
analysis and showed less evidence of linkage on chro­
mosomes 1 and 7. On chromosome 1, the peak mul­
tipoint linkages were at 60 cM from the p telomere, 
with LOD scores in screens 1 and 2 and the combined 
analysis being 0.6, 1.1, and 1.7, respectively. On chro-
Table 2
Two-Point Linkage Results for Screens t and 2 and the Com bined Data Set, Using the Program ANALYZE
C h r o m o s o m e D i s t a n c e  F r o m  p  T e l o m f r e
Sc r e e n  1 S c r e e n  2 Sc r e e n s  1 a n d  2
a n d  M a r k e r (cM) LOD P LOD P LOD P
1:
D1S199 47.7 1.2 .01 .0 .41 .5 .07
D1S255 66.6 1.7 .0029 .6 .046 2.2 .0007
D1S197 78.3 1.0 .014 .0 .5 .5 .074




290.1 .6 .045 .7 .032 1.3 .007
73.8 1.0 .017 .4 .083 1.3 .0073
D2S337 84.1 1.3 .0079 .1 .23 1.1 .014
D2S160 127.4 1.1 .011 .2 .18 1.1 .011
D2S347 135.7 .7 .034 .4 .076 1.2 .011
D2S335 182.5 1.2 .0083 .0 .5 .5 .069
D2S1572. 212.6 1.6 .0034 1.6 .0034■J.
D3S1300 79 1.1 .012 .0 J .4 .092




174.3 .0 .5 1.4 .0056 .6 .044
13.6 .0 .5 1.5 .0043 .8 .026
D6S470 17.7 .1 .26 3.1 .000079 2.2 .00066
D6S289 29.55 .8 .028 T79~ .0017 IX .00033
D6S422 35.7 .9 .02 2.9 .00012 3.6 .000023
D6S276 44.8 1.8 .0022 4 T .0000013 6.5 <10 ‘
8211 44.95 6.9 <10 * 6.9 <10 *
HLADRA 46.05 3.9 .OOOOtl ... 3.9 .000011
D6S291 49.8 1.2 .0097 13. .0097
D6S1610 53.9 1.5 .0042 1.5 .0042




90 .6 .045 2.0 .0012 2.4 .00041
70.5 .0 .5 2.6 .00025 .6 .045
o:




128.9 .5 .068 .6 .054 1.0 .014
8.8 1.6 .003 .7 .037 2.3 .00058
D9S286 16.8 .5 .066 1.0 .014 1.5 .0044
D9S161 50.3 .6 .043 .7 .032 1.4 .006
D9S283 93.2 .7 .039 1.2 .01 1.8 .0019
D9S1682 132.9 .5 .068 2.1 .001 2.3 .0006
D9S1826
10:
160.2 3.9 .000013 .0 .33 2.8 .00016
D10S185 123.3 1.0 .016 1.1 .012 2.1 .0009
D10S192 131.2 1.5 .0041 .2 .2 1.1 .011




147.2 1.0 .015 .1 .29 .8 .025
3.2 1.1 .014 1.1 .014
D11S935 49.6 1.1 .011 .0 .5 .6 .054
15:
D15S165 20.2 .0 .5 1.6 .003 .4 .078
16:
D16S3068 46.6 1.3 .0068 .0 .5 .0 .39
D16S515 90.2 1.8 .0022 .0 .5 1.1 .014
D16S516 98.3 .8 .028 .4 .095 1.1 .012
D16S422 109.1 1.4 .0049 1.9 .0015 3.3 .000044
D16S289 122.1 2.7 .0002 2.7 .0002
17:
D17S831 6.6 .0 .32 1.2 .0093 1.0 .014
19:
D19S226 41.7 .3 .14 1.2 .009 1.3 .0065
D19S414 53.2 .0 .5 2.5 .00037 .7 .042
D19S220 61.4 .0 .48 1.8 .0021 1.1 .013
D19S420 66 .0 .44 3.58 .000025 2.0 .0012
D19S902 76.2 .4 .096 1.7 .0025 1.9 .0016
D19S571 87.7 .3 .13 1.4 .0058 1.4 .0057
21:
D21S266 49.9 1.1 .011 .4 .092 1.4 .0052
N o t e .—Markers scoring LOD 3= 1 .0  in any screen are presented. Results achieving “significant” linkage (LOD s= 3 .6 )  are indicated in boldface italics, and those 
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Figure 1 Multipoint results for screens 1 and 2 and the combined data set using the program GENEHUNTER PLUS. Screen 1 results 
are given with a dotted line, screen 2 with a dashed and dotted line, and the combined results with an unbroken line.
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from the p telomere. The IL-l/IL-1 RA complex is 
encoded in this region, and association studies of the 
IL-1 RA gene previously have reported association of 
alleles of an IL-1 RA VNTR with AS (McGarry et al. 
2000; Van der Paardt et al. 2000). On chromosomes 
9q and lOq, there were substantial differences in max­
imum points of linkage for screens 1 and 2. On chro­
mosome 9q, although the maximum points of linkage 
by multipoint analysis were similar for screens 1 and 2, 
by two-point analysis there were substantial differences. 
In screen 1, marker D9S1826 achieved significant link­
age (LOD 3.9; position 160.2 cM), with no support in 
screen 2. In screen 2, marker D9S1682, located at 132.9 
cM, achieved a LOD score of 2.1 in screen 2, but a 
LOD of only 0.5 in screen 1. On chromosome 10, the 
peak position of linkage differed in screens 1 and 2 by 
25 cM. By two-point analysis, one marker lying in this 
region (D10S192, at 131.2 cM) had good support in 
both screens, achieving LOD scores of 1.1,1.0, and 2.1 
in screens 1 and 2 and in the combined data set, re­
spectively. It is a well-recognized characteristic of link­
age analyses that the maximum position of linkage may 
vary between genome screens (Roberts et al. 1999), and, 
therefore, one locus may produce the different point of 
maximum linkage results in this region in the two 
screens. Further linkage mapping on chromosomes 9 
and 10 may help define better the true regions of linkage 
in the different data sets. The region on chromosome 
19 that achieved “suggestive” linkage in screen 1 
(marker D19S420; LOD 3.58) achieved only minor sup­
port in screen 2 (peak multipoint LOD score 0.5), and 
further studies will be required to confirm this finding.
Replication of linkages in complex genetic diseases 
has often proved unreliable, resulting in confusion as 
to which linkages are true- or false-positive findings. 
Reasons for this include use of insufficiently stringent 
thresholds for identification of loci, genetic heteroge­
neity, and inadequate power of replication studies. To 
achieve 80% power to detect a locus of magnitude 
X = 1.8 in a complex genetic disease (equivalent to the 
magnitude of the chromosome 16q locus in this screen), 
even at a low significance threshold of LOD 1.0, will 
require studying 200 affected sibling pairs (with both 
parents available for genotyping, using a 10-cM marker 
map). The low power of linkage studies to replicate 
small genetic effects must be considered in comparisons 
between the results of future genetic studies and those 
presented here.
No other genomewide scans have been reported in 
AS, but scans have been completed in both psoriasis 
and inflammatory bowel disease, which are clinically 
related to AS. AS frequently complicates inflammatory 
bowel disease, and subclinical bowel inflammation is 
present in the majority of AS cases (Mielants et al. 
1991). Strong linkage of chromosome 19 similar to that
observed in our screen 2 was recently identified in a 
genomewide screen in inflammatory bowel disease 
(Rioux et al. 2000). The two other main IBD linkages 
(IBD1, located in the pericentromeric region of chro­
mosome 16, and IBD2, located on chromosome 12) 
showed no evidence of linkage with AS in this study. 
Genomewide linkage studies in psoriatic skin disease 
have identified replicated linkages on chromosomes 
lcen-q21, 3q21, 4q, 6p (PSORS1, the MHC region), 
17q, 19pl3, and 20p (Enlund et al. 1999; Samuelsson 
et al. 1999; Lee et al. 2000). Of these regions, we iden­
tified strong linkage at the MHC locus and on chro­
mosome 19, weak linkage in chromosome lq, and no 
linkage on chromosomes 3q21, 4q, and 17q. The peak 
linkage in both psoriasis and inflammatory bowel dis­
ease lies on chromosome 19p (Lee et al. 2000; Rioux 
et al. 2000), but, as in our own study, the area of linkage 
is quite broad, and considerable overlap exists. A ge­
nomewide screen has recently been reported in families 
with psoriatic arthritis (Samuelsson et al. 1999). Ar­
thritis in psoriasis is clinically heterogeneous, and only 
a proportion of cases suffer from a spondyloarthritis 
similar to AS. Nonetheless, there are some overlaps with 
the findings presented here. Specifically, regions on chro­
mosomes lq , 5q, and 15p showed evidence of linkage 
to both diseases, adding support to our findings.
The ultimate proof that genes other than HLA-B27 
are involved in AS awaits identification of the actual 
genes involved. The linkage results presented in this 
study represent an important advance in that search. 
This study presents strong evidence of the involvement 
with AS of genes localized on chromosomes lp , 2q, 6p, 
9q, lOq, 16q, and 19q. Further linkage mapping, po­
sitional candidate, and linkage disequilibrium studies 
are under way to define these regions better and to iden­
tify the actual genes involved.
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Exercise in  A nkylosingspond ylitis:  
H ow  M uch Is Optimum?
HELENA SANTOS, SINEAD BROPHY, and ANDREI CALIN
A B S T R A C T  O bjective. T o  ev a lu a te  h o w  m u ch  e x er c is e  pa tien ts w ith  a n k y lo s in g  sp o n d y lit is  perform  on a r eg u ­
lar b a s is , to  a n a ly ze  d em o g ra p h ic  and c lin ic a l var iab les that m igh t in f lu e n c e  a d h eren ce  to e x e r c is e ,  
an d  to d e term in e  the e ffe c t  o f  e x e r c is e  o n 'd ise a s e  a c tiv ity  and fu n ctio n .
M ethods. W e an alyzed  4 2 8 2  pa tien ts w h o  c o m p le te d  a s e lf -a d m in is te r e d  q u estion n a ire  regard ing  
p h y s ic a l e x e r c is e . T o d e term in e  the re la tio n sh ip  b e tw een  e x e r c is e , d e m o g r a p h ic  data, and c lin ic a l  
v a r ia b le s , p atien ts w h o  e x e r c is e  2  to  4  hou rs and 10 or m ore  h ou rs  p er w e ek  w ere  co m p a r ed  to  
n o n e x e r c is in g  con tro ls  m atch ed  for a g e , s e x , and d ise a se  duration .
R esults. M o st o f  the patien ts reported  2  to  4  h ou rs o f  e x e r c is e  or  n o  e x e r c is e .  T he grou p  w h o  p er­
fo rm e d  m od erate  e x er c ise  had im p roved  fu n ctio n  and lo w e r  d is e a se  a c tiv ity  (p  <  0 . 0 0 1, p <  0 .0 1 5 ,  
r e s p e c t iv e ly ) .  T h e  group  w h o  perform ed  in ten siv e  e x er c is e  had im p ro v e d  fu n c tio n , but no d if fe r e n c e  
in  d is e a se  a c tiv ity  w as fou n d  (p  =  0 .0 3 3 . p =  0 .3 9 4 ,  r e sp e c tiv e ly ) . A d h e r e n c e  to a regu lar e x e r c is e  
r eg im e  is  a s so c ia ted  w ith  rh eu m a to lo g ist fo llo w u p . b e lie fs  in the b e n e f it s  o f  e x e r c is e , and a h ig h er  
e d u c a tio n  le v e l.
Conclusion. T h is  study su g g e sts  there is an o p tim u m  du ration  for  e x e r c is e  p erform ed  o v e r  a w e e k ­
ly  p er io d . C o n s isten cy , rather than qu antity , is o f  m ost im p ortan ce. In d iv id u a ls  m ost lik e ly  to fo llo w  
th is  r eg im e  attend a rh eu m a to lo g ist, b e lie v e  that e x er c ise  is o f  b e n e fit , and  are in the h ig h er  e d u c a ­
tio n  c a te g o ry . T h o se  w h o  are le ss  ed u cated  and fo llo w e d  b y  g en era l p ra ctitio n ers  sh ou ld  be targeted . 
(J R h eu m a to l 1 9 9 8 :2 5 :2 1 5 6 -6 0 )
Key Indexing Tentts:
A N K Y L O S IN G  S P O N D Y L IT IS  
F U N C T IO N
Ankylosing spondylitis (AS) is a chronic progressive 
inflammatory disorder mainly affecting the axial skeleton 
and the peripheral joints. For the individual, the natural his­
tory of the disease is poorly defined. Some have minimal 
symptoms with only pelvic involvement, while others have 
widespread disease that results in poor functional outcome1.
There is no cure for the disorder. Moreover, we are uncer­
tain whether the longterm course of the disease can,.be 
altered but, despite this, most patients can be adequately 
managed2-4.
Drug therapy for symptom control in patients with AS 
has largely been confined to the use of nonsteroidal antiin­
flammatory drugs (NSAID) and second line agents like sul­
fasalazine, which have some activity on peripheral joints but 
less effect on the spine itself. Although drug therapy with 
NSAID can be effective, the cornerstone of medical man­
agement is therapeutic exercise with the prime objective of 
maintaining normal posture and activity. This is now an 
essential part of a patient’s treatment1.
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E X E R C IS E  A D H E R E N C E
D IS E A S E  A C T IV IT Y
Many kinds of physical therapy can be considered fo 
patients with AS: supervised individual therapy, unsuper 
vised self-administered individual exercise, and supervise 
group therapy5. Short term improvement, following inpr 
tient and outpatient treatment regimes, has been observed i 
a number of centers4’ 16. There remains some doubt wheiht 
this improvement is sustained in the longer term. In add 
tion. there is the bias that the act of followup may create th 
Hawthorne effect17, encouraging patients to do more exe: 
cise.
Our aim was to evaluate how much exercise patients pe 
form on a regular basis, to analyze demographic and clinic 
variables that might influence adherence to exercise, and 1 
assess the effect of exercise on disease activity and functio
M ATERIALS AND METHODS
The database. The Bath Ankylosing Spondylitis Data Base consisted 
4365 subjects. T hese were outpatients referred to the Royal Natiot 
Hospital for Rheumatic D iseases or members o f  the National Ankylosi 
Spondylitis Society. The diagnosis o f  AS has been substantiated in a se[ 
rate study1*.
Study population. A ltogether. 4282 patients (M :F = 3057:1221: dise; 
duration = 21.3 ±  0 .2  years) completed a self-adm inistered questionna 
regarding physical exercise. Patients were asked “For how many hours | 
week on average have you taken part in sports, AS exercises or hydroth 
apy during the last three months?" Patients were given 5 options: 0 ho 
(Group 0), I hour (Group I), 2-4 hours (Group II). 5-9 hours (Group I 
10 or more hours (Group IV). Those who did not answer the question w 
excluded from the study (n = 83). The tim e delay between diagnosis ;
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siurt o f  exercising w as very varied and ranged from im m ediately at tim e o f  
diagnosis (for som e younger patients), to not follow ing any form o f  exer­
cise after 50 years o f  d isease.
D a ta  p r o c e s s i n g  a n d  s t a t i s t i c a l  m e th o d s . To determine the relationship  
between physical exercise, dem ographic data, and clin ical variables, 
patients who exercised  2 to 4 hours and 10 hours were com pared to the 
nonexercising group. Group II (2  to 4  hours exercise) was matched for sex , 
age, and d isease duration w ith Group 0 (n = 553). Group IV (10  or more 
hours exercise) was m atched for sex , age, and disease duration with Group 
0 (n = 272). The m atched pairs were analyzed for dem ographic and crini- 
cul status. T his included marital status, em ploym ent status, education level, 
m edical follow up (rheum atologist or general practitioner), delay in d iagno­
sis, m edication/no m edication, and fam ily history o f  AS. B eliefs in the ben­
efits o f  exercise were assessed  by asking the patients to record on a sepa­
rate 10 cm  visual analog scale (V A S) the effectiveness that exercise has on 
relieving their sym ptom s. C lin ical status was assessed by self-adm inistered  
validated instrum ents: (1 ) the Bath A nkylosing Spondylitis D isease  
A ctivity Index (B A S D A I) con sists  o f  6 VAS (each 10 cm ) referring to 
sym ptom s o f A S related to the previous week: fatigue, spinal pain, periph­
eral join t pain or sw ellin g , tender areas, and morning stiffness (quantity and 
• quality"). A mean o f  the 2 stiffness VAS are added to the other 4 values 
and the overall mean represents the final B A SD A I score19; (2) the Bath 
A nkylosing Spondylitis Functional Index (B A SFI) consists o f 10 questions  
assessing functional ability related to the previous w eek and recorded on a 
10 cm  VAS. A final score is obtained by calculating the mean o f  the 10 
responses20; (3) the Bath A nkylosin g Spondylitis Global Score is a single  
item question regarding a patient's sense o f  w ell being over the last w eek  
and the last 6 m onths, a lso recorded on a 10 cm  V A S21.
Statistical analysis was perform ed using the SPSS package. Paired t 
tests or M cN em ar’s chi-squared tests were used in analysis.
RESULTS
In total, 915 (21%) patients were in Group 0, 836 (20%) 
were in Group I, 1491 (35%) were in Group II, 647 (15%) 
were in Group III, and 393 (9%) patients were in Group IV
(see Figure 1). There were proportionally more men in the 
higher exercise groups and more women in the lower exer­
cise groups.
Group II (2 to 4 hours exercise). Group II [M:F = 408:145 
(ratio 2.8:1)] compared to matched controls (n = 553 pairs) 
had improved function and lower disease activity (p < 
0.001, p < 0.015, respectively; Table 1). There was no dif­
ference in the global well being between the 2 groups.
Delay in diagnosis, family history, and marital and 
employment status were comparable (Table 2). A signifi­
cantly greater number of patients from Group II were fol­
lowed by a rheumatologist (p < 0.001), had a higher educa­
tion level (p = 0.005), and took more medication (p < 
0.001). Controlling for medication, disease activity and 
function were still significantly better for group II (p = 
0.017, p = 0.001, respectively).
Group IV (10 or more hours exercise). Group IV [M:F = 
220:52 (ratio 4 .2 :1)] had improved functional status com­
pared to matched controls (p = 0.033; Table 3). The delay in 
diagnosis was significantly greater in Group IV (p = 0.003), 
as was the number of nonmarried individuals (p < 0.04) and 
the number of patients followed by a rheumatologist (p < 
0.001; Table 4).
Employment, education level, family history, medica­
tion. disease activity, and global well being were compar­
able.
DISCUSSION
We assessed physical exercise of patients with AS and 
explored the effect in terms of disease activity, function, and
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F igure 1. Distribution o f  the number o f hours o f  exerc ise  per w eek in men and w om en (7c).
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Table 1. Comparison o f  self-assessm ent outcom e measures betw een Group 0  and Group II measured on a 0 -1 0  
sca le .
Group II Group 0 P M ean d iffem ce ± SEM
(95%  C l)
Total, n 1460 893
Study group, n 553* 553*
B A S D A I 3.8 + 0 .09 4.2 ± 0 .1 0.015 0.33  ± 0 .1 3  (0 .2 -0 .6 )
B A S F ! 3 .9 +  0.1 4.5 ± 0 .1 2 < 0 .0 0 1 0.59  ± a  1 6 (0 .3 -0 .9 )
B A S -G  (1 week) 4.2 + 0.17 ' 4 .3  ± 0 .1 2 0.686 0 .08  ± 0 .2 1  ( -0 .3 -0 .4 )
B A S -G  (6 months) 4.8 ± 0 .12 4^ .8 ± 0 .1 3 0.880 0 .004  ± 0 .1 8  ( -0 .3 -0 .3 )
G roup 0: no exercise; Group II: 2 to 4 h o f  exercise per week.
* M atched for current age, sex, and d isease duration.
Table 2. Comparison o f  demographic and clinical variables between Group II and Group 0.
Group II Group 0 P
Total, n 1460 893
Study group, n 553* 553*
Current age, yrs, mean ± SD 47.3  ± 1 1 .6 47 .2  ± 1 1 .6 0.150
A ge  at onset, yrs, mean + SD 23.8 ± 7 .9 23 .6  ± 7.9 0.111
Duration o f  disease, yrs, mean + SD 23.0  ±  11.9 23 .0  ± 1 1 .9 0.157
D elay in diagnosis, yrs, mean + SD 9.6  ± 9.7 8.8 ± 9 .6 0.141
Married, 9c 71 67 0.200
Em ployed, 9c 60 60 0.725
High education level, 9c 42 27 0.005
R heum atologist care. 9c 93 86 < 0 .0 0 1
Fam ily history o f A S, 9c 25 29 0.222
C o-m edication. % 82 73 0.001
E fficacy o f  exercise, mean ± SD 5.2 ± 2.4 3.4 ± 3.0 < 0 .0 0 1
Group 0: no exercise: Group II: 2 to 4 h o f  exercise per week. 
^Matched for current age, sex, and d isease duration.
Table 3. Comparison o f self-assessm ent outcom e m easures between Group 0  and Group IV measured on a 0 -1 0  
scale.
Group IV Group 0 P Mean difference ± SEM  
(95%  C l)
Total, n 381 893
Study group, n 272* 272*
B A SD A I 4.3 ± 0 .1 3 4.1 ± 0 .1 4 0 .3 9 4 0.18 ± 0 .2  ( -0 .6 -0 .2 )
B A SFI 4 .0  ± 0 .1 7 4.5  ± 0 .1 7 0 .0 3 3 0.56 ± 0 .2  (0 .0 2 4 -1 .0 )
B A S-G  (1 w) 4.7 ± 0 .1 8 4.3  ± 0 .2 0 .1 4 8 0.44 ± 0 .3  ( - 0 .1 3 -1 .0 )
B A S-G  (6 m) 5.1 ± 2 .6 4 .8  ±  2.9 0 .2 8 4 0.34 ± 0 .2 8  ( -0 .2 -0 .9 )
Group 0: no exercise; Group IV: 10 or more h o f  exercise per week. 
*M atched for current age, sex, and d isease duration.
The Jou rn a l o f  R heum ato logy  1998; 2
294
Table 4. C om parison o f  demographic and clinical variables between Group IV and Group 0.
Group IV Group 0 P
Total, n 381 893
Study group, n 272* 272*
Current age, yrs, mean ± SD 46.4 ±  12.6 46.4 ±  12.6 1.00
A ge at onset, yrs, mean ± SD 24.4 ±  8.5 24.1 ± 8.5 0 .422
Duration o f  d isease, yrs, mean ± SD 22.0 ± 12.9 22.0 ±  12.9 0 .706
D elay in d iagnosis, yrs, mean ± SD 9.6 ±r 10.1 7 .4 ±  7.8 0 .003
Married, % 64 70 0 .040
E m ployed, % 52 59 0 .118
High education level, % 32 31 0 .389
R heum atologist care, % 92 84 0.001
Fam ily history o f  A S, % 24 24 1.00
C o-m edication , % 77 71 0 .137
E fficacy o f  exercise, mean ± SD 6.8 ± 2.3 3.4 ±  3.2 < 0 .0 0 1
Group 0: no exercise; Group IV: 10 or more h o f  exercise per week. 
* M atched for current age, sex, and disease duration.
well being. We also tried to identify factors associated with 
adherence to longterm exercise. The response rate was 
excellent in this study. However, we do recognize that the 
patients were from a highly motivated group and many were 
members of the national self-help group, the National 
Ankylosing Spondylitis Society.
One potential defect o f the study is the cross sectional 
design allowing assessment at only one point. As with all 
studies of this design it is impossible to show a specific 
group has improved in any aspect.
Our definition of exercise was very general, including 
sports, specific AS exercises, and hydrotherapy. However, 
the accuracy of the self-reported exercise frequency is hard 
to judge, and the intensity is unknown. The relative value of 
different forms of exercise cannot be determined. Some of 
the patients reporting no exercise would have performed 
regular housework, walked short distances, and helped with 
all the usual household tasks. All these activities, although 
not strictly classified as formal exercise, are in themselves 
forms of exercise and patients would in fact be stretching, 
bending, and lifting. However, all the groups would be per­
forming these daily activities.
Most of the subjects reported either 2 to 4 hours of exer­
cise per week (35%) or no exercise (21 %). There were more 
men in Group IV and predominantly more women in Group 
0 (Figure 1). Most o f the research relating to exercise in AS 
has been carried out in Europe using inpatient programs of
2-4 weeks2-810-1216. The majority of these studies did not 
include functional measurements. However, they reported 
improvement in metrology8' 10-13' 16 and short term benefits in 
symptom control7. Those that used functional measures 
reported that after the inpatient programs those who contin­
ue exercising had improved function7-22.
We found that individuals who do 2-4 hours of exercise 
a week have lower disease activity and improved function in 
comparison to nonexercising patients. This may imply that
exercise improves disease activity and function or it may 
show that patients with lower disease activity and good 
function are able to do more exercise. It may be that the 
amount of time spent exercising during a weekly period can 
be used as a rough indicator for disease activity. The study 
also found that patients who performed intensive daily exer­
cise had improved function, but the disease activity did not 
improve. This suggests an optimum exercise duration, with 
most benefit being derived from moderate consistent exer­
cise. However, further study would be needed to investigate 
which comes first, whether the improved disease activity 
means there is less discomfort and pain when moving, there­
fore improving function. Or exercise improves function 
first, and from this, disease activity is improved. If the for­
mer is true then better medical control of the disease may 
enhance exercise adherence.
Exercise has been reported to improve well being23. 
However, this study did not find an improvement in the 
patients’ global well being with increased exercise. This was 
possibly a reflection of a difference in study design. 
Previous studies used an intensive course and assessed well 
being post treatm ent12. Therefore there is a point of inter­
vention against which patients can be assessed to improve or 
deteriorate. This study, on the other hand, asked patients for 
their subjective opinion of their day to day well being. 
Patients who exercise regularly will have a better function, 
but they may not report any improvement or change in glob­
al well being.
It has been suggested that compliance to exercise may be 
influenced by unmarried status24. This study did not find 
marital status to influence regular moderate exercise; how­
ever, the intensive exercise group were generally unmarried.
In our study, employment status and family history of AS 
did not influence adherence to exercise.
Adherence with a regular exercise regimen is associated 
with rheumatologist followup, beliefs in the benefits of
Santos, e t a l: E xerc is ing  in A S  2159
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exercise, and a higher education level (degree, diploma, 
higher national diploma).
Rheumatologists may be more aware than general practi­
tioners of the benefits o f exercise and therefore encourage 
and motivate the patient in the importance of regular mod­
erate exercise.
Patients who practice regular exercise had strong belief 
in its efficacy. This finding is supported by studies- that sug­
gest beliefs in the benefits of exercise would differentiate 
exercisers from nonexercisers24.
Patients who performed moderate exercise had a higher 
education level. It has been suggested that higher occupa­
tional status, which is associated with higher education, cor­
relates with lower disease severity. Education may have an 
effect on an individual’s sense of self-efficacy, encouraging 
the patients to play a more active role in the control and the 
treatment of their disease by exercising, rather than relying 
purely on medical intervention25.
This study suggests that moderate, regular exercise may 
be beneficial for both functional status and disease activity. 
However, intensive longterm exercise may not be as valu­
able for function or disease activity. Therefore there may be 
an optimum duration for exercise over the period of a week; 
however, this study does not attempt to identify where this 
optimum level lies. It appears that consistency, not quantity, 
is of most importance. Those individuals most likely to fol­
low this regime attend a rheumatologist, believe that exer­
cise is of benefit, and are in the more highly educated cate­
gory. Therefore, the less educated and those followed by 
general practitioners should be preferentially targeted.
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Predictors of Long-term Outcome in Ankylosing Spondylitis
Michele Doran, Sinead Brophy, Kirsten MacKay, Gordon Taylor, Andrei Calin.
ABSTRACT
Objective: To determine predictors of long-term outcome in ankylosing spondylitis 
(AS).
Methods: Data were collected on constitutional and environmental factors that may 
predict outcome in AS in 311 patients (252 (81%) male). Univariate statistics and 
multivariable regression analysis were used to identify factors correlated with disease 
outcome, which was defined in terms of radiological (Bath Ankylosing Spondylitis 
Radiology Index (BASRI)) and functional status (Bath Ankylosing Spondylitis 
Functional Index (BASFI)).
Results: Disease duration, sex and iritis are independently associated with BASRI and 
account for 23% (p<0.001) of variation in radiological scores (BASRI-t), a measure 
which includes the hip joint in the score. Radiological hip involvement is significantly 
associated with higher scores of spinal radiological change (BASRI-s) (p<0.001). 
Cigarette smoking, radiological status and Bath Ankylosing Spondylitis Disease 
Activity Score (BASDAI) are independently associated with and account for 50% of 
variability in functional status (p<0.001).
Conclusions: Much of the variability in disease severity in AS remains unexplained. 
Furthermore, all but one of the factors associated with outcome in this study are 
inherent. This suggests that genetic factors have a greater influence than environmental 
factors on radiological progression and disability in AS. It may, however, be possible
to improve long-term functional outcome in AS by targeting of high-risk individuals 
early in the disease course with more aggressive management strategies and 
encouraging smoking cessation in all AS patients.
Key indexing terms: ankylosing spondylitis; outcome; radiology; function
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Birth Order and Ankylosing spondylitis : no increased risk of 
developing ankylosing spondylitis among first-born children.
SINEAD BROPHY1, GORDON TAYLOR1+2, ANDREI CALIN1
Abstract: Objective In the HLA-B27 transgenic mouse model the first litters have 
been shown to have a higher percentage of diseased offspring than later litters. In 
addition, first bom children (n=162) have also been shown to have a higher risk of AS 
than later bom children. Our study aims to examine this effect of birth order using 
similar methods but larger numbers.
Methods’. Patients from the Bath AS database [n=4517 (M:F 2.5:1)] were examined 
according to position of birth within the family unit. Chi-squared analysis was used to 
examine if AS was more prevalent among first bom children than later bom children. 
Results : The first bom child was not significantly more likely to suffer from AS than 
later bom children (p=0.295). [Observed compared to expected : 1607 (36%) 
compared to 1641.13 (36%) for first bom children and 2910 (64%) compared to 
2876.3 (64%) for later bom children, respectively]. There was no biological gradient 
(ie inverse correlation between birth order and disease risk).
Conclusion : There was no statistically significant effect of birth order based on our 
data. Findings suggesting a birth order effect may be skewed as it is possible that 
those parents who do have AS will be less likely to have a large family and yet it is 
their offspring who will be at greatest risk of developing disease. This will affect the 
data as those children bom into a large family (ie high birth order children) will be at 
a lower risk of AS than any child bom into a small but family history positive unit.
Key words : Birth order, ankylosing spondylitis.
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Birth order and AS
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INTRODUCTION:
Ankylosing spondylitis is a systemic disease occurring in genetically predisposed 
individuals exposed to specific environmental triggers. In the HLA-B27 transgenic 
mouse the first litters have a higher percentage of diseased offspring than later litters 
[1]. This could be explained either by: a) the age of the mother (older maternal age 
decreases transmission of disease to the next generation) or b) the birth order of the 
offspring (ie environmental influence) has an influence on susceptibility to disease. 
Previous work has shown, that in humans the maternal age does not appear have an 
effect on inheritance of disease [2]. (Maternal age of onset of symptoms of AS, on the 
other hand, does influence prevalence of AS among the children of women [3]). 
However, it has been shown using 162 AS patients, that the number of first bom 
children with AS is significantly higher than would be expected. [4]. Herein, we 
examine this hypothesis , that birth order of the child may effect the prevalence of 
disease, using the similar methods on 4313 patients.
METHODS:
The Bath ankylosing spondylitis database of 5623 patients was used (M:F 2.5:1). 
These patients were either out-patients of the Royal National Hospital for Rheumatic 
Diseases (RNHRD) or were members of the National Ankylosing Spondylitis Society 
(NASS). Patients referred to the RNHRD (n=1874) had their diagnosis confirmed 
according to the New York Criteria. To estimate the validity of the diagnosis of 
ankylosing spondylitis among the 3749 patients recruited through NASS, several 
samplings were performed. First, 146 consecutive patients were invited to attend an 
assessment clinic. All 146 were confirmed as having ankylosing spondylitis 
according to the same criteria. Second, the family physicians of a further 330 NASS
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members were contacted to check whether their patient’s disease had been confirmed 
radiologically. Of these 307 (93%) had definite ankylosing spondylitis, 15 had 
arthritic diseases other than ankylosing spondylitis, three showed suspicious change 
on radiograph, and for 5 patients the primary source material was unclear. Thus, of 
5623 patients on the database 264 (4.7%) individuals [ie a maximum of 7% of 3764 
NASS patients] may not have had definite AS. Thirdly, the radiographs of the SI 
joints were requested and scored on 90 subjects, all of whom were found to have 
evidence of sacroliitis of grade 2 or more. Taken together, the various samplings 
suggest that approximately 4% (ie 23 of 566 patients sampled using the three 
methods) of NASS recruits may not actually have AS.
All adopted patients were removed from the study (n=54) and patients from one child 
families (n=1013) were not included.
X2 was performed on position of birth compared to family size using SPSS. Patients 
were grouped as first-born versus not first-born. After stratification by family size, the 
number of children with AS who were expected to be first-born on the basis of an 
equal distribution within birth order was computed.
In the first analyses only confirmed cases of AS (ie Royal National Hospital for 
Rheumatic Diseases patients) were analysed. Of 1874 subjects; 670 were not included 
due to adoption/only child/incomplete data.
In the second analysis all confirmed or possible AS (ie 4% of the sample may not 
have definite AS) were included. Of 5623 subjects : 1013 were single child families/ 
56 incomplete data/ 37 adopted.
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RESULTS:
Demographic date: The AS children, bom into family sizes of 2-9 children were 
comparable for sex ratio and disease duration. [Table 1]. AS patients from families of 
seven or eight children were older than those from 2, 3, or 4 child families [50 vs 45 
respectively p=0.001] and they therefore had the disease for longer. [22.5 vs 21 years 
respectively p=0.001] [Table 1]. Of the 4517 patients studied 741 (16.4%) had a 
sibling with AS.
Birth Order: Chi squared test on first bom compared to later bom children: When 
observed values of confirmed AS patients who were first bom were compared to 
those observed for later bom children, the first bom child is not more likely to 
develop disease [p=0.9]. [Table 2].
When all patients were included (confirmed AS and not confirmed) there was still no 
effect of birth order [p=0.3] [Table 3]
DISCUSSION:
Taking the AS population as a whole there is no significant effect of birth order. 
Factors which may have an influence on birth order would obviously include 
abortion, miscarriage and stillbirth. Only live births are included in this analysis. It is 
possible that families of 4 or 5 children have more miscarriages and the children may 
be of a much later birth order (ie 6th or 7th) than recorded. In addition, this study did 
not attempt to validate the absence of AS in apparently unaffected siblings and it is 
possible that asymptomatic AS is present among some of the sample. However, it is 
unlikely to affect the results of the study unless first bom child were more likely to 
have milder (asymptomatic) disease.
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Recent research by Baudoin et al [4] shows an increased risk of AS among first bom 
children. In 40 families with 2 children , 26 of the AS affected children were first 
bom, whereas the number expected was 20, a surplus of 30%. This study, does not 
substantiate these findings. It is possible that the discrepancy between the Baudoin 
findings and those present here are due to the difference in numbers. The difference 
of 6 children in the expected compared to the observed translates to 3.7% of the total 
patient sample being first bom instead of later bom. This difference seems to 
disappear with larger number. In addition, there are many factors which make 
comparisons between families difficult. For example, we know that genetic 
susceptibility is required to develop AS and that women with early onset AS are more 
likely to pass on the disease to their children [3]. Logically, women who suffer 
symptoms of AS would be less likely to have a large family. Therefore, only women 
with no family history of AS will be likely to have families of 4-5 children. Thus, any 
child bom into a large family is automatically at a lower risk of AS than any child 
bom into a small family. This means that children bom 4th or 5th (higher birth order) 
may appear to have a lower risk when compared to the population. However, when 
compared to first bom children in a larger family they do not actually have a lower 
risk [Table 2 and 3].
Both this study and Baudoin et al only examined multi-sibling families. Future work 
may examine if AS is more prevalent in ‘only* children (by definition first bom, with 
no sibs) than expected. This could be done by estimating how many only children 
with HLA-B27 there are in the population (ie HLA frequency X only child frequency) 
and then compare the prevalence of AS in this group with the prevalence of AS in the 
entire HLA B27 positive population.
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In summary, previous work using a mouse model and examining 162 patients 
suggested a birth order effect in AS. However, using similar methods on 4517 patients 
we were not able to substantiate these findings. Thus, there does not appear to be a 
birth order effect operable in AS.
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Family of 2 
(n=1785)
Family size
Family of 3 Family of 4 
(n=1330) (n=706)
Family of 5 
(n=492)
Family of 6 
(n=106)




Family of 9 
(n=14)
p value
Age of AS child (sd.) 45 (13) 45 (13) 45 (13) 47 (12) 45 (10) 51(11) 49(11) 45(9) p=0.001
Sex ratio of child 2.3 :1 2.3 : 1 2.3 : 1 2.3 : 1 2.0:1 3.0:1 1.5:1 1.8:1 Ns
Disease duration of child (sd) 21 (14) 21 (13) 20 (13) 21 (13) 20 (11) 23 (13) 22 (13) 23(12) Ns
Age at onset of child (sd.) 24(11) 24(11) 25(11) 25 (10) 25 (9) 27 (10) 27 (10) 22 (10) p=0.001
Table 2 : Birth order of confirmed AS individuals within the family.
Family Size Total
Birth Order 2 3 4 5 6 7 8 Observed Expected
1 215 (48%) 127 (36%) 54 (27%) 30(18%) 2 (6%) 1 (11%) 1 (20%) 430 429.23
2 232 (52%) 110(32%) 55(28%) 27(17%) 9 (27%) 2 (22%) 0 435 429.23
3 112(32%) 40 (20%) 32(20%) 5(15%) 2 (22%) 0 191 205.73
4 48 (24%) 41(25%) 10(30%) 1 (11%) 0 100 89.43
5 34(21%) 4 (12%) 0 (0%) 2 (40%) 40 40.18
6 3(9) 1 (11%) 1 (20%) 5 7.38
7 2 (22%) 1 (20% 3 1.88
8 0 0 0.6
Total 447 349 197 164 33 9 5 1204 1203.66
AS child first bom 215 127 54 30 2 1 1 430 (35.7%) 429.23 (35.6%)
AS child not first bom 232 222 143 134 31 8 4 774 (64.3%) 774.43 (64.4%)
X2 =  0.006*
p=0.967
* First bom child compared to later bom 
children
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Table 3 : Birth order o f  AS individuals (confirmed and suspected) within the family.
Birth Order 2 3
Family Size 
4 5 6 7 8 9 10 11
Total
Observed Expectet
1 865 (49%) 447 (34%) 186 (26%) 92 (19%) 7 (7%) 4 (9%) 5 (16%) 1 (7%) 0 0 1607 1641.13
2 920 (525%) 462 (35%) 176 (25%) 84 (17%) 20 (19%) 9 (20%) 1 (3%) 1 (7%) 1 (33%) 0 1674 1641.13
3 421 (32%) 190 (27%) 86 (18%) 16(15%) 9 (20%) 5 (16%) 2 (14%) 0 1(33%) 730 748.63
4 154 (22%) 104 (21%) 26 (25%) 10 (22%) 2(6%) 2 (14%) 0 0 298 305.33
5 126 (26%) 21 (20%) 7 (15%) 5 (16%) 0 1 (33%) 0 160 128.83
6 16 (15%) 5 (11%) 3 (9%) 1 (7%) 0 0 25 30.43
7 2 (4%) 5 (16%) 4 (29%) 1 (33%) 1 (33%) 13 12.77
8 6 (19%) 2 (14%) 0 0 8 6.17
9 1 (7%) 0 0 1 2.17
10 0 1 (33%) 1 0.57
11 0 0 0.27
Total 1785 1330 706 492 106 46 32 14 3 3 4517 4517.43
AS child first 865 447 186 92 7 4 5 1 0 0 1607 1641.13
bom (36%) (36%)
AS child not 920 883 520 400 99 42 27 13 3 3 2910 2876.3




* First bom child compared to later bom children
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Appendix 14
Recurrence risk modelling of the genetic
susceptibility to ankylosing spondylitis
M  A Brown, S H Laval, S Brophy, A Calin
Abstract
O bjectives—It has long been suspected  
that susceptibility to ankylosing spondyli­
tis (AS) is influenced by genes lying  
distant to the major histocom patibility  
com plex. This study com pares genetic 
m odels o f  AS to assess the m ost likely 
m ode o f inheritance, using recurrence  
risk ratios in relatives o f affected subjects. 
M ethods—Recurrence risk ratios in d if­
ferent degrees o f relatives were deter­
m ined using published data from studies 
specifically designed to address the ques­
tion. The m ethods o f  Risch were used to 
determ ine the expected recurrence risk  
ratios in different degrees o f relatives, 
assum ing equal first degree relative re­
currence risk between m odels. Goodness 
o f  fit was determ ined by x* com parison o f  
the expected num ber o f  affected subjects 
with the observed number, given equal 
num bers o f each type o f  relative studied. 
R esults—The recurrence risks in different 
degrees o f  relatives were: m onozygotic  
(MZ) twins 63% (17/27), first degree 
relatives 8.2% (441/5390), second degree 
relatives 1.0% (8/834), and third degree 
relatives 0.7% (7/997). Parent-child recur­
rence risk (7.9%, 37/466) was not signifi­
cantly different from  the sibling  
recurrence risk (8.2%, 404/4924), exclud­
ing a significant dom inance genetic com ­
ponent to susceptibility. Poor fitting 
m odels included single gene, genetic het­
erogeneity, additive, two locus m ultiplica­
tive, and one locus and residual polygenes 
(XJ >32 (two degrees o f freedom ), p<10~4 
for all m odels). The best fitting m odel 
studied was a five locus m odel with m ulti­
plicative interaction between loci (xJ=1.4 
(two degrees o f  freedom ), p=0.5). O ligo­
genic m ultiplicative m odels were the best 
fitting over a range o f  population preva­
lences and first degree recurrence risk 
rates.
Conclusions—This study suggests that o f  
the genetic m odels tested, the m ost likely 
m odel operating in AS is an oligogenic  
m odel with predom inantly m ultiplicative 
interaction between loci.
(Ann Rheum Dis 2 0 0 0 ;5 9 :8 8 3 -8 8 6 )
The importance of genes encoded within the 
major histocompatibility complex (M HC) in 
the aetiology o f ankylosing spondylitis (AS) has 
been well established by association12 and 
linkage studies.3 4 Few families have been  
reported in which AS has occurred in the 
absence o f HLA-B27 (B27) or in which AS
segregates separately from B27, suggesting that 
the inheritance of AS depends on the presence 
of B27.
There are considerable data suggesting that 
B 27, though essential, is not sufficient to 
explain the genetic epidemiology o f AS. Only a 
small proportion of B27 positive subjects 
develop AS, suggesting the presence of other 
susceptibility factors. Twin studies demonstrat­
ing high heritability o f susceptibility to AS 
(97%) indicate that these factors are primarily 
genetic.5 The concordance rate for B27 positive 
dizygotic twin pairs (24%) is considerably 
lower than for MZ twins (63%), suggesting the 
presence of other genes influencing disease 
susceptibility. Gene mapping studies have 
implicated other genes, both within the M HC  
(for example, HLA-B60 and HLA-DR1) and 
distantly encoded (CY P2D 6), which are likely 
to have small effects on disease susceptibility.4 7 
Linkage studies in affected sibling pair families 
have also identified several non-M H C  regions 
likely to contain further susceptibility genes.3
The recurrence risk in relatives o f affected 
subjects (the proportion o f relatives o f an 
affected subject who develop the disease them­
selves) is determined by the number of genes 
involved, the magnitude o f their individual 
effects, and the manner o f their interaction. 
Risch has reported a non-parametric approach 
to studying different genetic models to assess 
likely modes o f inheritance in genetic diseases 
employing familial recurrence risk ratios.8 In 
this study Risch’s approach has been used to 
investigate the likely genetic models operating 
in AS.
M ethods
Recurrence risk rates in different degrees of 
relatives of white patients with AS were deter­
mined using the results o f all studies published 
in peer reviewed journals. Studies were in­
cluded if they had either complete ascertain­
m ent of a population or proband ascertain­
ment with careful control against 
ascertainment bias. Case reports or studies 
without specific measures to avoid ascertain­
m ent bias were not included. Table 1 outlines 
the studies meeting these criteria and their 
findings.
T he population prevalence o f AS was set at 
0.1% (95% confidence interval 0.03 to 0.24%) 
from the studies o f van der Linden and 
colleagues.’ This study was used because it was 
determined using screening methods similar in 
sensitivity to those employed by the recurrence 
risk studies. Alteration in the population preva­
lence directly influences the recurrence risk 
ratio (recurrence risk/population prevalence),
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Table 1 Recurrence risk o f ankylosing spondylitis in different degrees o f probands o f affected subjects
Study Relationship M Z twins Siblings Parent-child First degree Second degree Third degree
de Blecourt18 Number affected — 24 5 29 8 7
Number studied — 401 191 592 834 997
Recurrence risk (%) — 6.0 2.6 4.9 1.0 0.7
Brown5 Number affected 6 4 — 4 — —
Number studied 8 32 — 32 — —
Recurrence risk (%) 75 12.5 — 12.5 — —
Calin" Number affected — 363 32 363 — —
Number studied — 4298 275 4298 — —
Recurrence risk (%) — 8.4 11.6 8.4 — —
Carter'" Number affected — 10 — 10 — —
Number studied — 169 — 169 — —
Recurrence risk (%) — 5.9 — 5.9 — —
Emery50 Number affected 1 0 — 0 — —
Number studied 2 4 — 4 — —
Recurrence risk (%) 50 0 — 0 — —
Jarvinen21 Number affected 3 3 — 3 — —
Number studied 6 20 — 20 — —
Recurrence risk (%) 50 15 — 15 — —
Moesman20 Number affected 7 — — — — —
Number studied 11 — — — — —
Recurrence risk (%) 63.6 — — — — —
Total Number affected 17 404 37 441 8 7
Number studied 27 4924 466 5390 834 997
Recurrence risk (%) 63.0 8.2 7.9 8.2 1.0 0.7
(95% Cl) (42 to 81) (7.4 to 9.0) (5.6 to 10.7) (7.4 to 8.9) (0.2 to 1.7) (0.1 to 1.4)
Recurrence risk ratio 630 82 79 82 10 7
and different studies have reported different 
population prevalences. A recent study report­
ing a population prevalence of 1.0% used mag­
netic resonance imaging (MRI) scanning to 
screen for cases, a considerably more sensitive 
method than has been used previously in stud­
ies either of population prevalence or recur­
rence risk.1" It would be expected that the use 
of M RI scanning, or a similarly sensitive 
screening modality, in studies of recurrence 
rates would observe higher recurrence rates 
than those previously reported. Therefore 
models using prevalences in the range 0 .1% - 
0.5% were tested against the observed data, but 
not as high as 1.0% as no comparable 
recurrence risk data are available.
Risch defines the recurrence risk ratio in 
relatives of type R (XR) as X.R=recurrence risk in 
relatives of type R/population prevalence. In 
single gene models, XR- 1 falls by half with each 
increase in distance of relationship to the 
proband, such that:
>0,-1 = 2(X,2—1) = 4(X3-1 ) .
Where there is no dominance variance com ­
ponent to disease susceptibility (see below), 
this relation can be extended to MZ twins, such 
that:
XMZ- \  = 2 ( X - l ) .
This relation is also true for polygenic m od­
els with additive interaction between loci, and 
approximately for genetic heterogeneity m od­
els (where the same phenotype may result from 
different susceptibility genes).
In polygenic multiplicative models, in which 
there is multiplicative interaction between large 
num bers of loci, the recurrence risk ratio falls 
by the square root with each increase in 
distance of relationship, such that:
^MZ =  Vk = xr
5 _  1 0.5   5 0.25
A<j A>2 j
Dominance variance is the com ponent of 
genetic susceptibility due to interaction be­
tween alleles of a particular locus. W hereas 
there is a dom inance variance com ponent to 
the genetic correlation between siblings, this is
not the case between parents and children, who 
can only share one copy of any gene identical 
by descent. No significant difference was noted 
between parent-child and sibling recurrence 
risks (7.9% v  8.2%, x2“ 0, odds ratio = 1.0, 
95% confidence interval 0.7 to 1.4), indicating 
that any dominance variance com ponent in AS 
m ust be small. In the largest study examining 
both types of first degree relatives, the parent- 
child rate was actually greater than the sibling 
recurrence rate, a finding not consistent with 
any genetic m odel." The dominance and addi­
tive variance com ponents to susceptibility can 
be calculated from the parent-child and sibling 
recurrence risk ratios assuming a single locus 
model, the model most affected by mis- 
specification of dominance variance. The 
dom inance variance com ponent is calculated 
to be only 4% of the total variance. The 
estim ated M Z recurrence risk ratio for a single 
locus model assuming dominance variance is 
130, not significantly different from the figure 
estim ated assuming no dominance variance 
(125). Therefore for all further calculations it 
was assumed that there is no significant dom i­
nance variance com ponent in AS.
W hen a combination of these equations is 
used, any variety of genetic model can be stud­
ied. T he models studied were single locus/ 
additive/genetic heterogeneity, polygenic mul­
tiplicative, two locus multiplicative, one locus 
and residual polygenic multiplicative compo­
nent, and five loci with multiplicative interac­
tion and residual polygenic multiplicative com­
ponent. M ore complex models of genetic 
interaction may exist but are not considered in 
this study. T he models considered broadly 
reflect the likely models operating, and greater 
definition of the models, though increasing the 
precision of the estimates would not add 
greatly to the findings presented.
For the two locus multiplicative and one 
locus with residual polygenes models, one 
locus was assumed to be HLA, which in AS has 
a recurrence risk value (XHLA) of 3 .6 .12 Oligo­
genic models using X.HLA of 3.6, and 2-10 loci 
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Table 2 Observed and expected recurrence risk ratios for different genetic models assuming no dominance variance 










MZ twins 630 163 6694 282 3202 780
First degree relatives 82 82 82 82 82 82
Second degree relatives 10 41 9 27 11 15
Third degree relatives 7 21 3 11 4 5
with equal X and a residual polygenic com po­
nent were fitted against the observed data. The 
best fitting oligogenic models had no residual 
polygenic component, and the best fitting such 
model had five genes, consisting o f HLA and 
four genes each with X -2 .2 .  The first degree 
relative recurrence risk ratio was fixed at the 
observed figure o f 82 for all models.
Goodness o f fit o f models was compared 
with the observed data by x 2 analysis compar­
ing the expected and observed number of 
affected M Z, second and third degree relatives 
for each model. For each model, the expected 
number o f  affected subjects for each degree of 
relationship was calculated from the predicted 
recurrence risk ratio and the number o f  
subjects with that degree o f relationship 
actually studied.
There is a clear bias in AS between the sexes, 
with men more commonly affected than 
women. M ost available recurrence risk data are 
not specific for one sex, and therefore the 
effects o f  the sex o f the subject were not 
considered in this study. It is assumed that the 
inheritance of AS in men and women follows 
similar genetic models, an assumption sup­
ported by the available recurrence risk data."
Results
Table 2 shows the expected recurrence risk 
ratios for each genetic model. The results 
clearly demonstrate that single gene, polygenic 
multiplicative, one locus (HLA) with residual 
polygenes models, and the two locus multipli­
cative m odel match the observed data poorly 
(X2=129, 90, 32, 36; p <10'6, <10"6, <10"6, 
<10~6) respectively. The expected recurrence 
risk ratios for M Z twins under the polygenic 
multiplicative and one locus (HLA) are ex­
tremely high, but these models accurately esti­
mate the recurrence risk ratio in more distant 
relatives. The single gene and two locus multi­
plicative models underestimate the M Z recur­
rence risk ratio and greatly overestimate the 
second degree relative recurrence risk ratios.
The best fitting model is an oligogenic mul­
tiplicative model with a small residual poly­
genic effect. T he five locus with residual poly­
genes is not significantly different from the 
observed data (x2= 1.4 , p=0.5), and estimates 
the recurrence risk in MZ twins, second and 
third degree relatives quite closely. Models with
3-9  genes fitted the observed data (p<0.05), 
but three gene models can be excluded as the 
magnitude o f the genes involved (A,=4.8) would 
be larger than the M H C (A=3.6). The presence 
o f genes o f this magnitude has been excluded 
by whole genom e linkage studies, which clearly 
indicate that the M H C  is the major susceptibil­
ity locus in AS.3
T hese findings were largely unaffected by the 
population prevalence chosen. Increasing the 
population prevalence alters the recurrence 
risk ratios for all types o f relatives, but the 
m odels fitting the data were similar for a range 
of population prevalences. Oligogenic multipli­
cative m odels o f 2 -6  loci in addition to the 
M H C  fit the observed recurrence risk rate data 
for population prevalences from 0.1 to 0.2% 
(data not shown). With a population preva­
lence o f 0.5% , non-oligogenic models (mono­
genic, HLA and polygenic residual genes, and 
the polygenic model) were rejected, but the 
ability to differentiate between oligogenic 
m odels with different numbers of genes was 
poor, and m odels with 20 genes fitted the data 
similarly to those with only two (data not 
shown). T he first degree relative recurrence 
risk rate varies between 0% and 25% in various 
studies, but in studies including more than 100 
relatives, the rate is between 4.9% and 8.4%. 
Oligogenic multiplicative models are still fa­
voured where lower first degree relative recur­
rence risk rates are chosen, but models with a 
larger number o f genes are permitted. For 
example, if  the true first degree relative 
recurrence risk is 50, then only oligogenic mul­
tiplicative m odels with two to 14 loci fit the 
observed data. Conversely, where higher first 
degree relative recurrence risk rates are em­
ployed, m odels with fewer genes are permitted. 
Overall, however, the finding that oligogenic 
multiplicative models are the best fitting is sus­
tained over a range o f population prevalence 
and first degree recurrence risk rates.
D iscu ssion
This study suggests that the likely genetic 
m odel in AS is an oligogenic model with mul­
tiplicative interaction between loci. The 
number o f  loci involved and their individual 
magnitude is o f  great importance in determin­
ing the feasibility o f mapping such genes. 
Genes of magnitude X.^1.3 require extremely 
large sample sizes to be identifed by either 
linkage studies in affected sibling pair families 
or by linkage disequilibrium mapping.13 The 
finding that single gene and polygenic models 
(with or without a contribution from the M HC  
region) were excluded by this study is therefore 
of great relevance. The data predict the 
existence o f  genes lying distant to the M HC of 
sufficient m agnitude to be tractable to posi­
tional cloning.
T he precise number o f genes involved 
cannot be accurately modelled by such studies, 
particularly where the population prevalence 
increases relative to the recurrence rate, as the 
power to discriminate between multilocus 
m odels is small, with all such models giving
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similar predictions. However, a model with 
only five genes models the observed data quite 
closely, and models with three to nine genes 
were consistent with the observed data. Models 
with 10 or more genes interacting multiplica- 
tively fail to model accurately the observed 
recurrence risks, significantly overestimating 
the M Z twin recurrence risk ratio and underes­
timating the third degree relative recurrence 
risk ratio (data not shown). Oligogenic multi­
plicative models with two to four loci model the 
observed data closely, but only if the recurrence 
risk for each locus is fairly high (non-HLA loci 
X^ 2 .8 ). Five locus models estimated the 
recurrence risk well with non-M HC loci o f  
magnitude X=2.2. Genes of this magnitude are 
sufficiently large to be identified by current 
linkage-mapping techniques.
Although there are data supporting the 
autosomal dominant role o f B27 in A S,1415 the 
finding that the sibling recurrence risk ratio is 
not significantly greater than the parent-child 
recurrence risk ratio suggests that there is not a 
great dominance variance component to sus­
ceptibility to AS. This might be explained if 
there was a substantial non-M HC genetic 
com ponent to AS, or, alternatively, if the M H C  
acted codominantly. If the latter situation is the 
case, then either B27 does not act dominantly, 
or there are other M HC susceptibility genes 
either operating in trans relative to B27, or act­
ing recessively. HLA-B60 is one gene that in 
white populations acts in trans with B27 to 
increase susceptibility to AS,2 16 but there is 
increasingly strong evidence of other M HC  
susceptibility genes in AS, which may explain 
the apparent lack of a strong dominance 
genetic effect in this disease.17
Although this study supports the presence of 
non-M H C  genetic susceptibility in this com ­
m on rheumatic condition, the ultimate proof of 
this theory will be the isolation of the genes 
involved. Perhaps the most important conclu­
sion from the modelling presented here is that 
the genes involved are likely to be o f sufficient 
magnitude to be identifiable by current gene 
mapping techniques.
This study was funded by the Arthritis Research Campaign. 
Steven Laval is funded by the Oliver Bird Fund, Nuffield Foun­
dation; Sinead Brophy by the Colonel WW Pilkington Charita­
ble Trust; and Dr Andrei Calin by the Royal National Hospital 
for Rheumatic Diseases NHS Trust.
1 Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC,
Sturrock RD. Ankylosing spondylitis and HL-A27. Lancet 
1973;i:904-7.
2 Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell 
J, et al. HLA class I associations of ankylosing spondylitis in 
the white population in the United Kingdom. Ann Rheum 
Dis 1996;55:268-70.
3 Brown MA, Pile KD, Kennedy LG, Campbell D, Andrew L,
March R, et al. A genome-wide screen for susceptibility loci 
in ankylosing spondylitis. Arthritis Rheum 1998;41:588- 
95.
4 Rubin LA, Amos Cl, Wade JA, Martin JR, Bale SJ, Little
AH, et al. Investigating the genetic basis for ankylosing 
spondylitis. Linkage studies with the major histocompat­
ibility complex region. Arthritis Rheum 1994;37:1212-20.
5 Brown MA, Kennedy LG, MacGregor AJ, Darke C,
Duncan E, Shatford JL, et al. Susceptibility to ankylosing 
spondylitis in twins: the role of genes, HLA, and the envi­
ronment. Arthritis Rheum 1997;40:1823-8.
6 Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Rela­
tionship between genotype for the cytochrome P450 
CYP2D6 and susceptibility to ankylosing spondylitis and 
rheumatoid arthritis. Ann Rheum Dis 1996;55:66-8.
7 Brown MA, Campbell S, Pile KD, Calin A, Ebringer A,
Weeks DE, et al. Polymorphisms of the CYP2D6 gene 
increase susceptibility to ankylosing spondylitis [abstract]. 
Arthritis Rheum 1998;41:S355.
8 Risch N. Linkage strategies for genetically complex traits. I.
Multilocus models. Am J Hum Genet 1990;46:222-8.
9 van der Linden S, Valkenburg H, Cats A. The risk of devel­
oping ankylosing spondylitis in HLA-B27 positive 
individuals: a family and population study. Br J Rheumatol 
1983;22:18-19.
10 Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M,
Distler A, et al. Prevalence of spondylarthropathies in 
HLA-B27 positive and negative blood donors. Arthritis 
Rheum 1998;41:58-67.
11 Calin A, Brophy S, Blake D. Impact of sex on inheritance of
ankylosing spondylitis: a cohort study. Lancet 1999;354: 
1687-90.
12 Laval S, Timms A, Bradbury L, Edwards S, Rubin L, Simi-
novitch K, et al. Whole genome screening in ankylosing 
spondylitis confirms presence of major non-MHC suscep­
tibility loci on chromosomes 7, 10, 16 and 19 [abstract]. 
Rheumatology 2000;suppl 1:83.
13 Risch N, Merikangas K. The future of genetic studies of
complex human diseases. Science 1996;273:1516-17.
14 Suarez AM, Russell AS. B27 homozygosity and ankylosing
spondylitis. J Rheumatol 1987;14:302-4.
15 Arnett FC Jr, Schacter BZ, Hochberg MC, Hsu SH, Bias
WB. Homozygosity for HLA-B27. Impact on rheumatic 
disease expression in two families. Arthritis Rheum 
1977;20:797-804.
16 Robinson WP, van der Linden S, Khan MA, Rentsch HU,
Cats A, Russell A, et al. HLA-Bw60 increases susceptibility 
to ankylosing spondylitis in HLA-B27+ patients. Arthritis 
Rheum 1989;32:1135—41.
17 Hohler T, Schaper T, Schneider PM, Meyer zum Buschen-
felde KH, Marker-Hermann E. Association of different 
tumor necrosis factor alpha promoter allele frequencies 
with ankylosing spondylitis in HLA-B27 positive individu­
als. Arthritis Rheum 1998;41:1489-92.
18 de Blecourt J, Polman A, de Blecourt-Meindersma T.
Hereditary factors in rheumatoid arthritis and ankylosing 
spondylitis. Ann Rheum Dis 1961;20:215-23.
19 Carter N, Williamson L, Kennedy L, Brown M, Words­
worth B. Sibling recurrence risk in ankylosing spondylitis. 
Rheumatology (Oxford) 2000;39:445.
20 Lawrence J. Rheumatism in populations. London: Hein-
emann, 1977:282-324.
21 Jarvinen P. Occurrence of ankylosing spondylitis in a
nationwide series of twins. Arthritis Rheum 1995;38: 
381-3.
302
